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Abstract 
 
Monoclonal antibodies (MAbs) have emerged as an important therapeutic 
modality for the treatment of cancer, due to their high specificity, low toxicity, 
and the ability to activate components of the immune system. The research 
carried out in this thesis aims to identify novel antigens associated with cancer 
invasion, that could form the basis of anti-invasive therapeutic targets, through 
the generation of MAbs directed against the highly invasive MiaPaCa-2 clone 3 
pancreatic cell line, and the MDA-MB-435-SF breast cancer cell line.  
 
Two MAbs were identified that could successfully block cancer invasion in vitro. 
MAb 7B7 G5 (2) significantly reduced invasion in the MiaPaCa-2 clone 3 
pancreatic cell line; the SKBR-3 and MDA-MB-231 breast cancer cell lines; the 
DLKP-M and H1299 lung cancer cell lines; the SNB-19 glioma cell line and the 
HCT-116 colon cancer cell line. Inhibition of invasion was also observed in the 
Lox IMVI melanoma cell line, but not significantly so. This MAb also 
significantly decreased cell motility in the MiaPaCa-2 clone 3 cell line. MAb 
9E1 24 (6) significantly decreased cell invasion in the MiaPaCa-2 clone 3, 
MDA-MB-231, DLKP-I, DLKP-M, H1299, C/68 and Lox IMVI cell lines. 
Invasion was also inhibited in the SKBR-3 cell line, but not significantly so. 
Surprisingly, invasion was increased in the HCT-116 colon cancer cell line, 
following incubation with this MAb.  
 
Other invasion-related processes were also decreased following incubation with 
the MAb 9E1 24 (6) and 7B7 G5 (2); MiaPaCa-2 clone 3 adhesion to fibronectin, 
and MMP-9 activity in the MDA-MB-231 breast cancer cell line. 
Immunohistochemical analysis of 9E1 24 (6) revealed that its target antigen is 
expressed to varying degrees in a wide range of tumour types (colon 
adenocarcinoma, pancreatic, breast, B-Cell lymphoma, Retinoblastoma and 
Glioma). Weaker staining was observed in normal colon, liver and prostate 
tissues. 
 
MAb 9E1 24 (6) was shown to react with a 75kDa protein band on Western blot 
analysis. Immunoprecipitation studies, followed by LC-MS/MS analysis, 
revealed that its target antigen was Annexin A6, a 75kDa cellular calcium and 
phospholipid binding protein. This was further corroborated by decreased 
expression of the reactive 9E1 24 (6) band in Annexin A6-silenced cells. siRNA 
silencing of Annexin A6 significantly reduced invasion in the MiaPaCa-2 clone 3 
and DLKP-M cell lines, suggesting a role for this protein in the invasion process. 
 
A cross-linked immunoprecipitation approach with MAb 7B7 G5 (2) revealed 
two bands at approximately 70 and 80kDa. LC-MS/MS analysis identified these 
as Ku70 and Ku80 respectively, two subunits of the Ku heterodimer, which is 
involved in DNA double strand break repair. siRNA silencing of these two 
subunits in the MiaPaCa-2 clone 3 and DLKP-M cell lines significantly reduced 
levels of invasion and motility, indicating that they play a role in both processes. 
Immunofluorescence analysis on Ku70 and Ku80 silenced MiaPaCa-2 clone 3 
cells revealed a significant decrease in MAb 7B7 G5 (2) reactivity on Ku80, but 
   XII 
not Ku70, silenced cells, suggesting that the Ku80 subunit is the main target 
antigen for MAb 7B7 G5 (2).  
 
The research presented in this thesis is proof of principle of how MAbs can be 
successfully generated that specifically target invasion-related proteins, and can 
block cancer invasion in vitro. The identified proteins may have the potential to 
become useful therapeutic targets for the treatment of invasive cancers, and could 
lead to the development of new drugs that specifically target metastatic cancer 
cells. 
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CHAPTER 1  
INTRODUCTION 
   2 
1.1  Cancer Metastasis 
 
Metastatic disease – the spread of cells from the primary neoplasm to distant 
organs, and their relentless growth - is the primary cause of death for most cancer 
patients. The development of invasion, which initiates the metastatic cascade, is 
comprised of a series of biological processes that move tumour cells from the 
primary site to a distant location. Each of these processes can potentially be 
targeted by therapeutic agents; however, the molecular events of metastasis are 
highly complex, and not fully understood. This is reflected in the fact that there 
are currently no effective treatments available that target invading tumour cells. 
Understanding these molecular mechanisms, and the role of the numerous 
proteins involved, is of crucial importance in the development of novel therapies 
for use in the treatment and diagnosis of cancer.  
 
1.1.1  Mechanisms of Invasion/Metastasis 
 
The ability of cancer cells to acquire a metastatic phenotype represents one of the 
most dangerous aspects of tumour progression. Normal cells are anchorage 
dependent and are designed to commit "suicide" by apoptosis if detached from 
cells of their own kind. This is a measure that prevents cancer and other 
abnormal growths from arising in most cases. However, in tumour cells, this 
regulatory process is disrupted, through accumulation of genetic changes, 
allowing for the survival of the tumour cell. Metastasis is the spread of these 
malignant tumour cells from their primary site to a distant, secondary site. The 
process of metastasis occurs in a series of discrete steps, termed the “metastatic 
cascade”.   
 
Firstly, the tumour cells undergo a transformation known as the epithelial-
mesenchymal transition, or EMT, which is a typical feature of aggressive, 
invasive and metastatic cancer cells (de Wever et al., 2008). This is followed by 
invasion, which initiates the metastatic process. This consists of (1) changes in 
tumour cell adherence to cells and the extra cellular matrix (ECM), (2) 
proteolytic degradation of the surrounding tissue and (3) motility to physically 
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propel a tumour cell through tissue. These metastatic cells are then transported 
around the body, where they can then colonise distant organs and establish 
secondary tumour sites. 
 
 
Figure 1.1: - The main steps involved in the formation of metastasis (Fidler, 
2003) 
 
EMT is a program of development of biological cells characterised by loss of cell 
adhesion, repression of E-cadherin expression, and increased cell mobility. It is 
normally observed in tissue morphogenesis during embryonic development and 
in fibrosing conditions succeeding tissue injury. During EMT, non-motile, 
polarised epithelial cells, embedded via cell-cell junctions in a cell collective, 
dissolve their cell-cell junctions and acquire characteristics similar to 
mesenchymal cells - non-polarised, motile and invasive (Yilmaz et al., 2009). 
Although the molecular basis of EMT are still not fully understood, several 
interconnected pathways and signalling molecules involved have been identified 
(growth factors, receptor tyrosine kinases, GTPases, β-catenin and integrins). 
Most of these pathways converge on the down regulation of the epithelial 
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molecule E-cadherin, an essential event in tumour invasion. (Guarino et al., 
2007). 
 
Once a cell undergoes EMT, it now has the ability to change its position within 
the tissue. Neoplastic cells are able to enter lymphatic and blood vessels through 
ECM invasion, allowing for the dissemination into the circulatory system, and 
finally, to undergo metastatic growth in distant sites. The process of tumour 
spreading within tissues uses migration mechanisms that are similar, if not 
identical, to those that occur in normal, non-neoplastic cells during physiological 
processes (Friedl et al., 2003). 
 
In order for migration to occur, the cell body needs to alter its shape and 
stiffness, thus allowing it to interact with the surrounding tissue structures. 
Hereby, the ECM is the environment in which tumour cells proliferate and 
provides the substrate, along with a partial barrier towards the advancing cell 
body. Cell migration through the tissue results from a continuous cycle of 
interdependent steps:  
 
(1) Polarisation and elongation of the cell body 
(2) Formations of a pseudopod, through extension of the cell’s 
leading edge 
(3) Contraction of regions on the leading edge, or the entire cell 
body, thus generating traction force 
(4) Cell body and trailing edge glides forward (Friedl et al., 2003).  
 
 
Figure 1.1.1: - Side view diagram of retrograde flow in lamillopodia in a 
motile/locomoting cell (Cramer, 1997) 
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Cell motility is also mediated by adhesion molecules. Cell adhesion molecules 
(CAMs) can be divided into 5 major families: the immunoglobulin superfamily, 
the integrins, selectins, cadherins and CD44 (Dowling et al., 2008).  
 
Intravasation, or penetration of the basement membrane barrier by tumour cells, 
is achieved through the release a variety of proteases, glycosidases, and 
collagenases, thus allowing for the degradation of various components of the 
matrix and resulting in tumour cell invasion through tissue barriers, blood 
vessels, and lymph channel. Matrix metalloproteinases (MMPs) are a family of 
membrane-anchored proteolytic enzymes that can remodel the ECM by acting on 
a relatively broad range of targets including collagen, plasminogen, elastin, 
fibronectin and laminin (Dowling et al., 2008). Tumour cells may also release 
polypeptide factors that can modulate the type of proteoglycans produced by host 
mesenchymal cells (Kufe et al., 2003). 
 
Once the tumour cell has detached from the primary site, and successfully 
invaded through the ECM, it then has several other phases to complete before it 
can colonise a second tumour site.  
 
⇒ Survival & Arrest in the Bloodstream 
Once the tumour cell invades through the ECM, it then enters the circulatory or 
lymphatic system, allowing it to travel to a new location. However, the 
bloodstream is a harsh environment for metastasising tumour cells because of 
velocity-induced shear forces and the presence of immune cells. Once the tumour 
cells have gained access to the blood system, they may be swept away to distant 
sites, which they can colonise. Within the bloodstream the tumour cells may 
interact with host components such as lymphocytes, monocytes and platelets 
through heterotypic adhesion. This may lead to larger clumps incorporating the 
tumour cells, lending them protection from mechanical stress and immune attack. 
Despite this, the chances of a cancer cell surviving circulation and establishing a 
new site is fewer than 10,000 to 1 (Zhao et al., 2010). 
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⇒ Lodgement at a Distant Site 
The circulation of the blood plays a significant role in determining where cancer 
cells travel. The cancer cells usually get trapped in the first set of capillaries, they 
encounter downstream from their point of entry. Frequently these are in the 
lungs, since returning deoxygenated blood leaving many organs is returned to the 
lungs for re-oxygenation. Once in a new site, the cells must again penetrate the 
basement membrane of the blood vessel and establish themselves in the new 
tissue.  
 
⇒ Extravasation  
After tumour cells enter the systemic circulation, and in order for a metastatic 
tumour to develop, the cells must extravasate from the blood supply, invade local 
stroma, and develop their own microenvironment (Small et al., 2002). The 
formation of new blood vessels (angiogenesis) is stimulated, so that oxygen and 
vital nutrients can reach the growing tumour.  
 
⇒ Growth 
Proliferation of the cancer cells at their new site is dependant on a number of 
factors including the nature of the environment it finds itself in and the nature of 
the tumour itself. These factors include resistance to host defence mechanisms of 
humoral and cellular nature and response to or requirement for specific growth 
factors. Failure in any one of these steps results in the death of the cancer cell, 
making this process highly inefficient. Millions of tumour cells can be shed into 
the circulatory system daily, with few secondary tumours forming (Kufe et al., 
2003).   
 
As has been shown, there are a multitude of factors involved in the metastatic 
process. Several key stages in the metastatic process have been shown to be 
controlled, directly or indirectly, through the cell surface, so the identification of 
these proteins that are preferentially expressed on the membrane of metastatic 
tumour cells is of fundamental importance in cancer research. The following 
sections will focus on various cell surface proteins, proteoglycans and 
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proteolipids that play a role in the metastatic process, including adhesion, ECM-
degradation and cell motility. 
 
1.1.2.  Cell Surface Proteins in Invasion/Metastasis 
 
Membrane proteins play a key role in cellular processes such as migration, 
adhesion, and cell survival. However, during transformation from a normal cell 
into a tumour cell, specific defects appear in these proteins, resulting in the loss 
of tumour suppressor genes, and alteration of cell cycle control. The cells 
become growth-factor independent, losing contact inhibition and features of 
differentiation (Chow, 2010). These transformed cells are a pre-requisite for 
metastasis, but they still need to acquire a wide range of molecular properties in 
order to complete the whole metastatic process, most of which are likely to be 
mediated by cell-surface proteins. Three different groups of molecules are 
essential for the metastatic cascade to occur: 
 
1. Proteases: - The proteolytic breakdown of proteins of the ECM is an 
essential step in the metastatic process. Several classes of proteases 
contribute to the breakdown and remodelling of the ECM, most of which 
are up-regulated in the course of metastatic cancer progression in 
different types of cancers. When invasive cells migrate through the ECM, 
proteases such as MMPs, serine proteases and cathepsins are utilised to 
proteolytically cleave and remove different ECM substrate types at cell-
ECM interface. These proteases can originate from the cell surface, 
intracellularly or can be secreted (Friedl et al., 2008).  
 
2. Cellular Adhesion Molecules (CAMs): - CAMs are glycoproteins 
expressed on the surface of cell membranes. In normal cells, they are 
involved in numerous cell processes such as cell proliferation, migration 
and differentiation. In tumourigenic cells, they have been reported to 
function as oncogenes or tumour suppressors, as well as regulators of 
tumour progression and metastasis. CAMs interact with other CAMs, as 
well as with multiple intracellular proteins and ECM components 
(Kerrigan et al., 1998).   
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The Cadherins, a type-1 transmembrane family of proteins, play an 
important role in cell adhesion, ensuring that cells within tissues are 
bound together. Loss of E-cadherin gene expression or of the E-cadherin 
protein, through EMT, is frequently found during tumour progression in 
most epithelial cancers (Vernon et al., 2004). Other membrane proteins 
involved in cellular adhesion include the immunoglobulin superfamily, 
selectins, and CD44. Integrins are also involved in adhesion, binding to a 
wide range of ECM molecules (Karmakar et al., 2003).  
 
3. Cell surface and cytoskeletal proteins: - mediate directional cell 
movement. This involves regulation of the actin cytoskeleton; an essential 
step for tumour cell migration, adhesion and invasion.   
 
1.1.2.1  Cadherins 
 
The cadherins are a family of homophilic, cell surface membrane glycoproteins 
capable of mediating cell-cell adhesion. Their extracellular regions consist of 
five tandemly repeated domains that require Ca2+ binding for their adhesiveness, 
rigidity and stability. The three most common cadherins are E-, N- and R- 
cadherins (based on the tissue from which they were first derived; epithelial, 
neural and retinal tissues respectively) (Baranwal et al., 2009).  
 
E-cadherin, one of the most widely studied of the cadherins, is a single-span 
transmembrane glycoprotein of five repeats and cytoplasmic domain. It mediates 
homotypic adhesion in epithelial tissue, bonding epithelial cells together and 
relaying signals between the cells (Dowling et al., 2008). Down-regulation of E-
cadherin reduces the cell-cell adhesion, facilitating detachment from the primary 
tumour and subsequent invasion into the surrounding tissue and environment. It 
has been suggested that loss of E-cadherin mediated cell-cell adhesion is a 
necessity for tumour cell invasion and metastasis formation (Heuberger et al., 
2010).  
 
Loss of E-cadherin function during tumour development can be caused by a 
variety of genetic or epigenetic mechanisms. Strathdee et al., showed that in a 
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panel of cancer cell lines, E-cadherin expression is downregulated at the 
transcriptional level through the binding of proteins, such as Snail and Slug, to 
the E2 boxes in the promoter of the E-cadherin gene (Strathdee, 2002). It has also 
been shown that engagement of integrins α1β1 and α2β1 by collagen type I 
results in a loss of E-cadherin mediated cell-cell contacts, along with the 
activation of the β-catenin/TCF (T cell factor) pathway in pancreatic cancer cells 
(Yilmaz et al., 2009). In adheren junctions, the intracellular domain of E-
cadherin binds directly to -catenin, that, in turn, associates with -catenin, which 
links cadherin complexes to the actin cytoskeleton. There are a number of 
stimulations, such as growth factor stimulation, which results in E-cadherin-
associated β-catenin tyrosine phosphorylation, and this phosphorylation 
destabilizes the E-cadherin complex and actin linkage. This causes loss of 
homophilic E-cadherin-dependent adhesion and induction of cell motility (Abe et 
al., 2008). 
 
An important molecular event in cancer progression is the switching of the 
expression of E-cadherin to N-cadherin, a process that takes place through the 
EMT. N-cadherin expression has been shown to promote aggressive behaviour of 
tumour cells, ranging from interacting with receptor tyrosine kinases at the cell 
surface to encouraging the activation levels of Rho-GTPases in the cytosol. 
(Baranwal et al., 2009). N-cadherin has also been implicated in promoting cell 
motility and migration – an opposite effect to that of E-cadherin. This switch in 
cadherins may provoke the tumour cell to migrate into different surroundings. E-
cadherin is expressed by epithelial cells, whereas mesenchymal cadherins are 
found in stromal cells such as fibroblasts (Cavallaro et al., 2004).  
 
1.1.2.2  Integrins 
 
Integrins are a diverse family of glycoproteins that serve as the main link 
between a cell and the ECM, forming heterodimeric receptors for ECM 
molecules. Containing 18 α-subunits and 8 β-subunits, integrins are able to form 
at least 25 distinct pairings, each of which is specific for a unique set of ligands. 
Each integrin generally consists of a non-covalently linked α- and β- subunit, 
each of which consists of a large extracellular domain, a single membrane-
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spanning domain, and a short, non-catalytic cytoplasmic tail (Gerger et al., 
2009).  
 
 
Figure 1.x: - Structure of integrin (Brooks et al., 2010)  
 
Altered expression of integrins in tumour cells promotes metastasis through the 
following mechanisms: 
 
(1). Integrin-mediated tumour cell de-adhesion to the surrounding ECM, thus 
enabling tumour cells to detach from the primary tumour: Integrins function as 
both mechanical adhesion and signalling molecules. For example, integrin αvβ3 
binds a wide variety of ECM molecules, including fibronectin, fibrinogen, 
vitronectin and proteolysed forms of collagen and laminin (Brooks et al., 2010).  
 
(2). Tumour cell migration into the ECM and surrounding stroma involving 
integrin-mediated adhesion/de-adhesion events:  
Integrins are vital for cell migration and invasion, not only because they directly 
mediate cell-ECM adhesion, but also because they regulate intracellular 
signalling pathways that control cytoskeletal organisation and force generation 
and survival. These pathways typically involve phosphorylation of focal 
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adhesion kinase (FAK), a cytoplasmic protein kinase that is localised at 
structures called focal adhesions (Brooks et al., 2010).  FAK has been shown to 
promote cell migration through direct modulation of key proteins involved in the 
remodelling of the actin cytoskeleton, including the Rho subfamily of small 
GTPases (Hsia et al., 2003), N-WASP (Wu et al., 2004), and the Arp2/3 
complex (Ichikawa et al., 1991).  
 
(3). Release of proteolytic enzymes induced by integrin-mediated intracellular 
signalling events:  
The integrins not only mediate cell-ECM adhesion; ligand binding can also result 
in the activation of further intracellular signalling pathway, which then stimulates 
proteolysis. Degradation or disorganisation of the basement membrane is a key 
feature of a tumour’s transition to a metastatic carcinoma (Egeblad et al., 2002). 
Cancer cells produce, activate and release several different types of proteases that 
specifically cleave ECM molecules. One family of proteases activated by up-
stream stimulation of integrin receptors are the MMPs. There are a number of 
reports demonstrating that co-localisation of β1-integrin and MT1-MMP1 is a 
requirement for cancer cell invasion into a collagen matrix and that both MT1-
MMP and β1-integrins have important roles in EMT (Cao et al., 2008). Work 
done by Brookes et al., have shown that MMP-2 can be localised in a 
proteolytically active form on the surface of invasive cells, through its direct 
binding of the αvβ3 integrin. This allows for facilitation of cell-mediated collagen 
degradation and directed cellular invasion (Brooks et al., 1996). Numerous other 
studies have also shown increased activation of MMPs during expression of 
integrins (αvβ1 and MMP-3; αvβ6 and MMP-9 in colon carcinoma cells (Werb et 
al., 1989)). 
 
1.1.2.3  Regulation of the Actin Cytoskeleton 
 
The formation of protrusive structures is a necessity for tumour cell movement 
and invasion. This is achieved through regulation of actin polymerisation. These 
protrusions, termed filopodia, lamellipodia and invadopodia, are driven by 
spatially and temporally-regulated actin polymerisation at the leading edge of the 
cell (Yamaguchi et al., 2007). Stabilisation of the protrusive structures is 
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achieved through integrin-mediated binding to the ECM of the actin 
cytoskeleton. This serves the additional role of co-ordinating signal transduction 
events that regulate cell movement (Kelley et al., 2008).  
 
Lamellipodia are the major organelles involved in cell movement, building upon 
highly branched dendritic actin networks. They interact with their surrounding 
environment through N-cadherin, β1-1 integrin or the hyaluronan receptor CD44, 
(which is also important for the correct positioning of the membrane-bound 
MT1-MMP) (Yilmaz et al., 2009). Lamellipodia protrusion is initiated by 
localised polymerisation of actin, which in turn requires the generation of free 
barbed ends of actin filaments at the leading edge. There are three major 
mechanisms for generation of free barbed ends: 
 
(1). de novo nucleation by Arp2/3 complexes and formins: 
Actin polymerisation occurs by coupling to the actin-nucleating Arp2/3 
complex, an activator of actin filament nucleation and branching (Yamaguchi 
et al., 2007), which in turn binds to a multifunctional adaptor protein, known 
as the Wiscott-Aldrich syndrome protein (WASP). This Arp2/3/WASP 
complex then connects to the inner leaflet of the plasma membrane via 
clustered phosphoinosites (PIPs) inserted therein. Arp2/3 can further interact 
laterally with established actin filaments to induce branching of pre-existing 
filaments to actin networks (Friedl et al., 2003). 
   
(2). severing of pre-existing actin filaments by cofilin: 
The severing of existing actin filaments is carried out by cofilin in response 
to epidermal growth factors (EGF) and other growth factor stimuli. This 
severing activity has a dual effect on actin dynamics to promote cortical 
actin-based protrusions: the number of available barbed ends increase, thus 
allowing for rapid actin polymerisation at the cell cortex, independent of 
Arp2/3 complex activity. It also serves to boost F-actin depolymerisation, 
therefore utilising G-actin monomers in a further round of polymerisation 
(Kelley et al., 2008). 
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(3). uncapping of barbed ends on pre-existing actin filaments: 
At the trailing edge, focal contact disassembly occurs through several 
mechanisms. Actin binding and severing proteins (Cofilin) cap actin 
filaments and cause actin filament strand breakage, respectively, and focal 
contact components are cleaved through the cytoplasmic protease calpain 
(Friedl et al., 2003).  
 
Cortactin is an adaptor protein that is present in lamellipodia and invadopodia 
that plays a role in stimulating actin nucleation and subsequent polymerisation by 
binding to F-actin and the Arp2/3 complex (Weed et al., 2001). In addition to 
regulating actin polymerisation within lamellipodia, cortactin also plays a role in 
the stabilisation of the actin networks formed by Arp2/3-driven polymerisation, a 
process congruent with the requirement for cortactin to maintain lamellipodia 
persistence. While not essential for lamellipodia formation, Cortactin is a crucial 
requisite for the creation of (matrix degrading) invadopodia. Invadopodia consist 
of an outer adhesive ring and a central actin-rich core. Cortactin, along with the 
non-receptor tyrosine kinase Src, and the membrane bound MT1-MMP plays an 
essential role in the formation and function of invadopodia. Integrins, such as 
αvβ3, in conjunction with their cytoplasmic interaction partners, are situated in 
the adhesive ring where they can mediate adhesion (Kelley et al., 2008).  
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Figure 1.4: - Various proteins involved in lamillopodia/filopodia and 
invadopodia formation (Yilmaz et al., 2009). 
 
1.1.3  Proteoglycans 
 
Proteoglycans (PGs) are ubiquitous biomolecules located in the ECM, on the cell 
surface and within cells that are heavily glycosylated. They consist of a core 
protein with one or more covalently attached glycosaminoglycan (GAG) chain(s) 
(Braga, 2008). These chains are long, linear carbohydrate polymers, and due to 
the occurrence of sulphate and uronic acid groups, they are negatively charged 
under physiological conditions.  
 
Located at the cell-tissue-organ interface, PGs are thought to govern crucial 
regulatory roles in cellular control, including cell movement in various 
physiological and pathological contexts, such as:  
 
• binding together ECM components such as hyaluronic acid, collagen, 
laminin and fibronectin.  
• mediating cell-ECM adhesion.  
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• acting as a reservoir for growth factors.  
• presentation of growth factors to growth factor receptors on cells; 
(Cattaruzza et al., 2006). 
 
PGs also act as cell adhesion factors by encouraging the organisation of actin 
filaments in the cells cytoskeleton (Kufe et al., 2003). The complex nature of 
PGs on the tumour cell surface allows for modulation, directly or indirectly, of 
several facets of the tumour cell phenotype, including growth kinetics, 
invasiveness and metastatic potential (Rossi, 2009). There are a number of 
examples of PGs involved in the metastatic cascade. 
 
1.1.3.1  Heparan Sulphate proteoglycans (HSPG): - Syndecan 
 
HSPGs on the tumour cell surface have been shown to play an important role in 
many aspects of tumour phenotype and development, including cellular 
transformation, tumour growth, invasion and metastasis. Due to their negative 
charge, the heparin sulphate (HS) chains bind to a very wide variety of proteins, 
including the members of the fibroblast growth factor (FGF) family and their 
receptor tyrosine kinase, transforming growth factors (TGFs) (Rossi, 2009).  
 
Over the past 30 years, substantial evidence has been gathered pointing to the 
role cell surface HSPGs play in inhibiting tumour invasion through the 
promotion of tight cell-cell and cell-ECM adhesion. There are numerous studies 
showing weak expression of heparin sulphate (HS) isolated from tumourigenic 
cells, when compared to normal cells. Alterations in HS have been shown to 
reduce the adhesive capacity of transformed cells. Low levels of cell surface HS 
also correlates with high metastatic activity of many tumours (Rossi, 2009). The 
most widely studied cell surface HSPG is the Syndecan family. Syndecans are a 
family of highly conserved type I transmembrane HSPGs and are expressed on 
virtually all cell types throughout development and adulthood. Syndecan-1 
regulates cell behaviour by binding ECM molecules such as growth factors types 
I, III, and V collagen, fibronectin, thrombospondin, and tenascin, via its HS 
chains. It also binds to basic fibroblast growth factor (bFGF/FGF-2), a member 
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of the heparin-binding growth factor (Anttonen et al., 1999). In a range of 
epithelial tumours including colon (Levy et al., 1996), mesothelioma (Kumar-
Singh et al., 1998), lung (Anttonen et al., 2001), hepatocellular carcinoma 
(Matsumoto et al., 1997), infiltrating ductal carcinoma of the breast (Stanley et 
al., 1999), and head and neck carcinoma (Anttonen et al., 1999), syndecan-1 
expression on the tumour cell surface decreases with increasing metastatic 
potential. Thus, decreased expression of syndecan-1 on tumour cells parallels 
with a decrease in overall HS expression (Mennerich et al., 2004). This data 
suggests that HSPGs and syndecan-1 in particular, play an important role in 
helping to block metastasis. 
 
Syndecan-1 has also been found to play an important role in supporting α2β1 
integrin-mediated adhesion. Work done by Vuoriluoto et al., has shown, through 
overexpression and knock-down experiments, that syndecan-1 enhances binding 
of α2β1 to collagen. Moreover, they showed that Syndecan-1 co-localises with 
α2β1 integrin and contributed to proper organisation of the cortical actin. 
Crosstalk between syndecan-1 and α2β1 integrin resulted in enhanced 
transcription of MMP-1 in response to collagen binding. These findings suggest 
that the α2β1/syndecan-1 complex is important in regulating cell adhesion to 
collagen and in triggering integrin downstream signalling (Vuoriluoto et al., 
2008). 
 
Syndecan-2, also called fibroglycan, has been observed to participate in diverse 
biological processes, including matrix assembly, cell adhesion and signalling 
(Tkachenko et al., 2005). In work carried out by Choi et al., overexpression of 
syndecan-2 was shown to enhance adhesion to collagen, cell migration and 
invasion in normal rat intestinal epithelial cells. Increased integrin α2β1 
expression levels were also observed. When α2β1 integrin expression was 
knocked down in colon cancer cells, levels of syndecan-2 were also diminished, 
resulting in decreased adhesion and migration, suggesting a relationship between 
syndecan-2 and α2β1 integrin in adhesion-mediated cell migration and invasion 
(Choi et al., 2009). Co-operation between syndecan-2 and the α5β1 integrin has 
also been shown in adhesion of lung carcinoma cells to fibronectin substratum, 
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along with regulation of the actin cytoskeleton organisation (Kusano et al., 
2004).       
  
1.1.3.2  Melanoma Chondroitin Sulphate Proteoglycan 
 
Melanoma chondroitin sulphate proteoglycan (MCSP) represents a unique 
glycoprotein–proteoglycan complex, with a 250 kDa core glycoprotein attached 
to a larger, 450 kDa proteoglycan component, via serine residues. It is a cell 
surface proteoglycan expressed relatively early in melanoma progression, and 
has been implicated in the malignant properties of advanced melanoma (Erfurt et 
al., 2009). Work done by Iida et al., have shown that MCSP interacts with a 
member of the MT-MMP family, allowing for the invasion of melanoma cells 
through type I collagen and degradation of type I gelatine (Iida et al., 2001).  
 
MT3-MMP has been shown to be specifically localised with MCSP to ECM 
adhesion sites on the surface of melanoma cells. This interaction requires the 
expression of an intact chondroitin sulphate proteoglycan (CSPG). Work done by 
Iida et al., suggests that the invasion of aggressive primary tumours within the 
dermis may be facilitated by MCSP enhancing the local concentration and/or 
activation of specific MMPs at contact sites between melanoma cells and the 
underlying ECM (Iida et al., 2001). 
 
1.1.3.3  Versican 
 
Versican is a CSPG consisting of a core protein with 12-15 chondroitin sulphate 
(CS) side chains covalently attached. It belongs to a family of extracellular 
proteoglycans (hyalectins) that bind to hyaluronan (HA) (Ricciardelli et al., 
2007). Versican (which possesses four isoforms) regulates many diverse cellular 
processes, including adhesion, proliferation, apoptosis, migration and invasion 
through the highly negatively-charged chondroitin/ dermatan sulphate side 
chains. High levels of versican expression have been observed in a wide range of 
cancers, including; melanomas, osteosarcomas, lymphomas, breast, brain, 
prostate, colon, lung, pancreatic, endometrial, oral, and ovarian cancers 
(Ricciardelli et al., 2009), suggesting that it is important in promoting cancer cell 
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motility and invasion. Work carried out by Riccaedelli et al., has shown that 
versican-treated cancer cells incorporate versican and hyaluronic acid into a 
prominent pericellular matrix that promotes their motility. Following versican 
treatment, a pericellular sheath of defined polarity is constructed by motile 
prostate cancer cells. The ability to construct this pericellular sheath correlated 
with the expression of the membranous HA receptor, CD44. All this suggests 
that tumour cells can form a polarised pericellular sheath through 
compartmentalised cell surface CD44 expression and ensuing assembly of 
HA/versican aggregates. The lack of a pericellular sheath at the leading edge of 
the cell may facilitate the attraction and binding to ECM components such as 
fibronectin, whilst at the trailing edge of the cell, the presence of a pericellular 
sheath inhibits cellular binding to ECM components, thus allowing for forward 
locomotion of the cell (Ricciardelli et al., 2007). 
 
In work done by Kim et al., (2009), the molecular pathways that link tumour 
cells, macrophages and metastasis was explored. Using the Lewis lung 
carcinoma cell line, components from the media, in which the cells were grown 
in, were purified, allowing for the identification of a factor that induced cytokine 
production by macrophages. This tumour-derived macrophage activator was 
ascertained as versican. It was also found that versican was recognized by TLR2 
and TLR6, two receptor proteins that belong to a family of cellular sensors of 
microbially derived molecules and tissue damage. Using small interfering RNAs, 
they went on to silence versican in tumour cells, and used TNF and TLR-null 
mice. On the basis of the evidence obtained, it was proposed that in the Lewis 
lung carcinoma model, tumour-derived versican acts on macrophages through 
TLR2/TLR6, leading to the production of inflammatory cytokines which enhance 
metastasis (Kim et al., 2009; Mantovani et al., 2009). 
 
1.1.3.4  HSPG: - Perlecan 
 
Although HS acts as an inhibitor against the metastatic cascade, it may also play 
a role in promoting metastasis. HS present in the ECM is thought to be involved 
in this, although there is some evidence that cell surface HSPGs may also 
contribute to metastatic behaviour. HSPGs present in the ECM can originate 
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from cellular secretions (Perlecan) or from cell surface HSPGs, which are then 
proteolytically shed from the cell surface (Syndecans) (Reiland et al., 2004). 
 
Perlecan is a major HSPG that is an important component of epithelial and 
endothelial basement membranes. Perlecan has recently been shown to support 
tumour progression and vascularisation in colon carcinoma (Sharma et al., 1998). 
Increased Perlecan levels have also been demonstrated in breast carcinomas 
(Iozzo et al., 1994) and in metastatic melanomas (Cohen et al., 1994) and 
correlated with a more aggressive phenotype (Savore et al., 2005). One way in 
which Perlecan and other HSPGs in the ECM may promote metastasis is through 
the binding of chemokines or growth factors within close proximity to migrating 
tumour cells. Through this, haptotactic-gradients could be formed, providing 
specific stimuli for migrating cells. For example, hepatocyte growth factor 
(HGF) binds to HS, and this may be a means to create a reservoir of HGF within 
matrices adjacent to tumours. Date et al., have shown that when HGF activity is 
interrupted, carcinoma cell invasion is blocked, highlighting the relevance of this 
to metastasis (Date et al., 1998).  
 
Along with its role in influencing cytokine activity, HSPG, when bound to the 
ECM, could also regulate cell migration, by providing an adhesive tract to 
facilitate movement. HS interactions with other molecules are usually of a weak 
affinity, thus allowing for cells to move along paths of HS. Additionally, HSPGs 
present in the ECM may bind to other molecules, thus masking them (e.g. 
collagen, fibronectin) resulting in a decrease in cell adhesion to the ECM. This 
possibility is supported by studies analysing tumour invasion through type I 
collagen gels. Non-invasive cells show substantial increases in invasion when 
heparin or heparan sulphates are added to the gels, and this is likely due to 
heparin binding to collagen and blocking adhesive interactions between the cell 
surface HSPGs and collagen (Savore et al., 2005). However, Perlecan may not 
always act to promote invasion, as it suppresses the growth and invasion of 
fibrosarcoma cells. This disparity in results suggest that Perlecan has a complex 
and wide ranging role in cell-ECM interaction; however, this may be due to the 
fact that Perlecan is part of the extracellular matrix in mesenchymal tissue, and 
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cells undergoing EMT may up-regulate Perlecan expression as part of their EMT 
programming (Date et al., 1998).  
 
1.1.3.5  CD44-Related CSPG 
 
Melanoma cells can express the CD44 core protein as a cell surface Chondroitin 
Sulphate Proteoglycan (CSPG) (Faassen et al., 1992). The CD44 proteoglycan 
forms a ubiquitously expressed family of cell surface adhesion molecules 
involved in cell-cell and cell-matrix interactions. CD44 proteins are composed of 
single chain molecules, containing an N-terminal extracellular domain, a 
membrane proximal region, a transmembrane domain, and a cytoplasmic tail. 
The primary ligand of CD44 is hyaluronic acid, a vital component of the 
extracellular matrix. Other CD44 ligands include osteopontin, serglycin, 
collagens, fibronectin, and laminin (Goodison et al., 1999). 
 
Over expression of CD44 is conventionally believed to be detrimental for cancer 
patients because it may reflect the presence of more malignant metastatic 
tumours. Work done by Iida et al., have shown that CD44, expressed as a CSPG, 
acts in unison with α2β1 integrin to support melanoma cell migration on type IV 
collagen and invasion for basement membranes. The integrin functions as the 
primary adhesion molecule for type IV collagen, while the CD44/CSPG mediates 
some aspect of melanoma cell migration that occurs as a post adhesion event 
(Iida et al., 1996).  
 
Bourguignon et al., have shown that CD44 plays a role in structuring the 
lamellopodial membrane extensions of the leading front of migrating cells. It was 
shown that the interaction of CD44 with Src kinases affected the cytoskeletal 
rearrangements at the filopodial-lamellopodial cell membrane protrusions by 
acting upon the underlying cortactin adaptor protein (Bourguignon et al., 2008). 
 
1.1.4.  Proteolipids 
 
The term proteolipid is used to define all proteins containing covalently bound 
lipid moieties, including fatty acids, isoprenoids, cholesterol and 
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glycosylphosphatidylinositol. Examples of proteolipids include the tetraspanin 
family and GPI-anchors (lipidlibrary.aocs.org).  
 
Human tetraspanin proteins are composed of 33 highly hydrophobic cell surface 
proteins that can form complexes in cholesterol-rich micro-domains, distinct 
from lipid rafts, on the cell surface in a dynamic reversible way. A core of 
several tetraspanin proteins form these complexes, which then organise other 
membrane proteins such as integrins, human leukocytes antigen (HLA) antigens 
and some growth factor receptors (Lazo, 2007). They consist of four conserved 
transmembrane domains, with characteristic extracellular loops, and short 
cytoplasmic domains. With a molecular weight range of 22–30 kDa, these 
relatively small proteins generally do not play the role of classical cell surface 
receptors. Instead, they function as molecular organisers of multi-protein 
membrane complexes, influencing a number of cellular functions, including 
proliferation, fusion, signalling, and migration (Stipp et al., 2003). As well as 
their role in cellular function, tetraspanins can form tetraspanin-enriched-micro-
domains, or TEMs, through associations with each other, and other proteins, 
including integrins, immunoglobulin (Ig) superfamily members, proteoglycans, 
ligands, and growth factor receptors (Lafleur et al., 2009). The tendency of 
different tetraspanins to associate closely within TEMs probably underlies the 
ability of distinct tetraspanins to provide functional compensation for each other 
(Lazo, 2007). 
 
1.1.4.1  Tetraspanins and Cell Adhesion: CD82 & CD151 
 
The tetraspanin protein superfamily member CD82 (KAI-1, kangai, or CD33) is 
a member of the 4-span transmembrane super family (TM4SF) of type III 
membrane proteins, specifically of the tetraspanin subgroup.  It is localized on 
the cell membrane and functions as a link between the actin cytoskeleton and 
membrane raft domains, inducing stable adhesion, spreading and development of 
membrane extensions (Lazo, 2007). KAI1/CD82 is a wide-spectrum tumour 
metastasis suppressor associated with proteins important for cell migration, such 
as cell adhesion molecules, growth factor receptors, and signalling molecules. 
Expression of CD82/KAI-1 in cancer patients correlates with a better prognosis, 
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while down-regulation of KAI-1/CD82 is commonly associated with clinically 
advanced cancers (Guo et al., 2009). 
 
KAI-1/CD82 has been shown to stabilise E-cadherin– β -catenin complexes 
through inhibition of β-catenin tyrosine phosphorylation. This results in 
induction of homocellular adhesion and prevents cancer cell dissemination from 
primary cancer sites. A shift in Protein-Localisation of KAI-1/CD83 from the 
membrane in grade 1 ovarian tumours to the cytoplasm in grade 3 tumours may 
be a mechanism by which tumour cells lose their adhesive properties during 
malignant transformation (Houle et al., 2002). 
 
Work done by Goa et al., suggested that synergism between wild-type p53 and 
JunB is involved in regulating the expression of KAI-1/CD83. When p53 
dysfunction coincides with low expression of JunB, they may play an important 
role in down-regulating the expression of KAI-1 through synergism in human 
hepatocellular carcinoma (Guo et al., 2009). From all of this, it is apparent that 
KAI-1/CD82 is a pivotal molecule in the regulation of cancer cells behaviour and 
has important clinical and therapeutic implications in cancer. 
 
CD151 is widely expressed on the surface of many cell types, where it associates 
strongly with laminin-binding integrins. Whereas other tetraspanins suppress 
tumour cell invasion and metastasis (Wright et al., 2004), CD151 promotes 
tumour malignancy (Testa et al., 1999), and its expression correlates with poor 
prognosis, enhanced metastasis, or increased motility in several cancer types 
(Yang et al., 2008). The best-known function of CD151 is its engagement of 
integrins in basal lateral cell surface complexes, such as α3β1 and α6β4, to 
facilitate cell-cell and cell-matrix adhesions (Chien et al., 2008). Lammerding et 
al., have shown that CD151 plays a key role as a regulator of α6β1 integrin 
adhesion strengthening. They proposed a “transmembrane linker” model in 
which (i) the integrin contacts laminin, (ii) CD151 forms an extracellular contact 
with the α subunit of laminin-binding integrins, and (iii) CD151 uses its short 
cytoplasmic tail to engage as yet unidentified membrane-proximal elements, thus 
strengthening integrin-mediated adhesion (Yang et al., 2008).  
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1.1.4.2  Tetraspanins and MMP Regulation 
 
Work done by Penas et al., have shown that tetraspanins tend to localise into 
cellular lamillopodia and filopodia, thus their location at the cell surface allows 
them to orchestrate events such as pericellular proteolysis by membrane-
anchored proteases (Penas et al., 2000). Along with β1- integrins and CD44, 
tetraspanin proteins such as CD63 and CD81 are associated with MT1-MMP (in 
human embryonic kidney cells, over-expression of CD63 correlates with a 
decrease in cell surface levels of MT1-MMP). MT1-MMP binds to the N-
terminal region of CD63, leading to endocytosis and degradation of MT1-MMP 
in lysosomes. This suggests that CD63 seems to promote lysosomal degradation 
of MT1-MMP (Huang et al., 2006).  Work carried out by Jang et al., showed that 
reduced CD63 expression contributes to the invasive and metastatic ability of 
human melanoma cells, and knockdown in MelJuso cells resulted in an increase 
in cell motility and activity of matrix-degrading enzymes such as MMP-2/-9 
(Jang et al., 2003). CD63 has also been shown to associate with other tetraspanin 
proteins, (CD9 and CD81), and with β1 integrins in human melanoma cells (Iida 
et al., 2001). 
 
CD151 has also been shown to associate with members of the MMP family. In 
human lung adenocarcinoma tissues, proMMP-7 is captured and activated on the 
cell membranes through interaction with CD151, while the activity was 
eliminated by their treatment with MMP inhibitors, anti-MMP-7 or anti-CD151 
antibodies. This suggests that MMP-7, mediated by CD151, is involved in the 
pericellular activation mechanism, a crucial step in proteolysis on the tumour cell 
(Shiomi et al., 2005). 
 
1.1.4.3  Tetraspanins and Cell Motility 
 
Down regulation of the tetraspanin CD82 is a frequent occurrence in advanced 
stages of cancer, and has been strongly associated with a poor prognosis in 
patients with prostate, gastric, colon, cervical, ovarian, breast, skin, bladder, 
endometrial, lung, pancreatic, liver and thyroid cancer, melanoma and myeloma 
(Tonoli et al., 2005). It is known to inhibit migration and invasion by associating 
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directly, or through integrins, with a variety of different molecules. CD82, in 
conjunction with the α6 integrin chain and the epidermal growth factor receptor 
(EGFR), is accompanied by impaired laminin adhesion and migration, due to co-
internalisation with CD82. Furthermore, the association of CD82 with EWI-2 
strengthens the motility-inhibitory activity of EWI-2 on laminin and fibronectin. 
CD82 has also been shown to interfere with hepatocyte growth factor receptor 
(HGFR) signalling such that when bound by its ligand HGF, HGFR induces 
proliferation but is unable to stimulate lamellipodia formation and therefore, cell 
migration in a non-small-cell lung cancer line (Zoller, 2009).  
 
CD151 has also been shown to play a role in cell motility. Overexpression of 
CD151 has been shown to result in increased motility, along with enhanced 
expression of MMP-9 and invasiveness (Hong et al., 2006). This has been shown 
to activate GTPase mediated pathways, which increases GTP binding to Cdc-42 
and Rac, two proteins involved in the organisation of the cell cytoskeleton 
(Shigeta et al., 2003). As stated previously, CD151 forms complexes with the 
major laminin-5 receptors, α3β1 and α6β4 integrins, in lateral cell surface 
membranes. Its dissociation from laminin-binding integrins permits the migration 
of epithelial cells (Chometon et al., 2006).  
 
CD9 is a 21-24 kDa surface molecule, and its down regulation is associated with 
tumour progression in numerous cancer types. In ovarian carcinoma cells, there 
is a correlation between expression levels of CD9 and β1, α2, α3, α5 and α6 
integrin chains, and down-regulation of CD9 is associated with weaker matrix 
adhesion and diminished growth in vivo (Furuya et al., 2005). Work carried out 
by Huang et al., have shown that expression of CD9 is accompanied by the 
transcriptional down-regulation of WASF2, a member of the WASP family of 
proteins (Huang et al., 2006). WASF2 serves as a scaffold that links upstream 
signals to the activation of the Arp2/3 complex, which in turn mediates actin 
polymerisation. WASF2 is also crucial for the formation of filopodia and 
lamellipodia (Takenawa et al., 2007).   
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1.1.4.4  GPI-Anchored Proteins 
 
Glycosylphosphatidylinositol (GPI-anchor) is a proteolipid that can be attached 
to the C-terminus of a protein during posttranslational modification. It is 
composed of a phosphatidylinositol group linked through a carbohydrate 
containing linker to the C-terminal amino acid of a mature protein. Many cell 
surface proteins are attached to the cell membrane through GPI-anchorage 
(Mayor et al., 2004). The presence of a GPI-anchor serves the following four 
functional roles: (1) the apical targeting of proteins in polarised cells, (2) GPI-
anchors mediate the cell surface organisation of attached proteins through 
association with specialised cholesterol and sphingolipid-rich micro-domains, 
commonly known as "lipid rafts", (3) endocytosis of GPI-anchor proteins, 
leading to downstream signaling and, (4) cleavage of GPI-anchors by 
phospholipases to release soluble protein for signaling (for example, Cripto-1) 
(Lakhan et al., 2009).  
 
GPI-anchored proteins usually lack a cytoplasmic domain, which results in the 
inhibition of direct intracellular protein signalling. In spite of this, many GPI-
anchored proteins have been implicated in signalling (Ilangumaran et al., 2000) 
and different models for the underlying mechanism have been suggested (Simons 
et al., 2000).  
 
GPI-APs are involved in a diverse range of functions, including cell migration 
and wound healing (uPAR) and protease regulation (RECK) 
 
1.1.4.4.1 Urokinase – Type Plasminogen (uPA)  
 
Urokinase (uPA) is a serine protease with a molecular weight of approximately 
54 kDa. It is composed of two disulfide-linked chains, A and B, of molecular 
weights 18 kDa and 33 kDa, respectively. 
 
The uPA system consists of:  
- the plasminogen activator of the urokinase-type (also called “urokinase“ or 
“uPA“); 
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- its physiological inhibitor (PAI-1);   
- and the uPA-receptor (uPAR), which is over-expressed on tumour cells (Gondi 
et al., 2009).  
 
Figure 1.5: - The uPA system (www.wilex.com) 
 
When uPA binds to its receptor, uPAR, a series of proteolytic processes occur, 
facilitating the conversion of plasminogen to plasmin (figure 1.5). This allows 
degradation of the ECM and activation of matrix metalloproteinases, which aids 
in tumour cell invasion into adjacent tissue, and eventually into the bloodstream 
(Aznavoorian, et al., 1993). uPAR also interacts functionally with matrix 
vitronectin, adhesion receptors of the integrin family, and G protein-coupled 
receptors. Its overexpression has also been reported in several types of human 
adenocarcinomas, including pancreatic cancer, gastric cancer, and colorectal 
cancer (Hildenbrand, et al., 2010). 
 
1.1.4.4.2 RECK 
 
RECK (REversion-inducing Cysteine rich protein with Kazal motifs) is a GPI-
anchored membrane bound protein involved in mediating tissue remodelling. Its 
primary role is in suppressing MMP-2, MMP-9 and MT1-MMP post-
transcriptionally (Zambuzzi et al., 2009). RECKs inhibition of MMPs, secreted 
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by tumour cells, occurs through a glycosylation mechanism. In normal cells, four 
separate asparagine residues in the RECK protein sequence are N-glycosylated. 
In work carried out by Simizu et al., (2005) mutated RECK proteins were 
produced, where Asn residues were replaced with Glu in certain positions. The 
effect of absent glycosylation was then observed on MMP-2 and MMP-9 
expression. It was found that glycosylation of the Asn297 was needed to inhibit 
MMP-9 secretion, while Asn352 glycosylation was required to inhibit MMP-2 
activation. To confirm these observations, invasion assays were carried out on 
HT1080-RECK mutants (no glycosylation of Asn297 and Asn 352). This showed 
an increase in tumour cell invasion when compared to HT1080 cells expressing 
wild-type RECK (Clark et al., 2007). 
 
1.1.4.4.3 Glypicans 
 
Glypicans are a family of heparan sulfate proteoglycans that are linked to the 
exocytoplasmic surface of the plasma membrane by a GPI anchor. They are 
involved in cell growth, invasion and adhesion. Six members of the Glypican 
family have been identified in mammals, termed GPC1 to GPC6 (Nakato et al., 
1995).  Glypicans role in tumour progression involves its ability to regulate the 
activity of growth and survival factors. Work carried out by Kleef et al., showed 
that expression levels of GPC1 are significantly increased in a large number of 
pancreatic cancers (Kleeff et al., 1998). It was also shown that transfection of 
antisense GPC1 inhibited the mitogenic response of pancreatic cancer cells, in 
vitro, to FGF2 and heparin-binding EGF-like growth factor and decreased the 
tumorigenicity of the transfected cells (Kleeff et al., 1999).  
 
GPC3 has also been observed in tumour progression. Work carried out by Lin et 
al., showed that GPC3 expression is downregulated in a majority of ovarian 
cancer cell lines. However, in all cases where GPC3 expression was lost, no 
mutations were found in the coding region of the gene; the promoter region of 
the GPC3 gene was hypermethylated. GPC3 expression was restored by 
treatment with a demethylating agent. In addition, the authors demonstrated that 
ectopic expression of GPC3 inhibits colony-forming activity in several ovarian 
cancer cell lines (Filmus et al., 2001). 
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1.1.5  Non-Cell Surface Proteins Involved in Invasion & Metastasis 
 
1.1.5.1  Semaphorins 
 
Semaphorins are a large family of conserved, secreted and transmembrane 
proteins that are involved in a variety of tumourigenic processes such as cell 
adhesion, migration and proliferation. Semaphorin receptors, the neurophilins 
and the plexins, are expressed by a wide variety of cell types, including 
endothelial and cancer cells. It is through these that semaphorins mediate 
crosstalk between tumour cells and multiple stromal cell types in the surrounding 
tumour microenvironment (Capparuccia et al., 2009).  However, semaphorin-
mediated signals have been shown to have both an anti-and pro-tumourigenic 
effect on cells. Work done by Barberis et al., have shown that following plexin 
activation by semaphorins, integrin-based focal-adhesive structures are rapidly 
disassembled, followed by actin depolymerisation and cytoskeletal remodelling, 
resulting in cellular collapse. Plexin activation can also inhibit the development 
of new adhesive complexes, and block the formation of lamellipodia, thus 
disrupting directional migration, by uncoupling cell-substrate adhesion from the 
cytoskeletal dynamics that are essential for cell migration (Barberis et al., 2004).  
 
However, contrary to this, Swiercz et al., have shown that the same receptor-
ligand interaction can promote chemotaxis and maintain invasive growth, 
depending on whether plexin-B1 was associated with the oncogenic receptor 
tyrosine kinases (RTKs), Met and HER2 (Swiercz et al., 2008). This paradoxical 
effect is supported by expression levels in a range of tumour cells e.g. plexin-B1 
over-expression correlates with increased invasiveness and metastatic 
progression in prostate cancer (Wong et al., 2007), whereas loss of plexin-B1 
expression was found to correlate with poor prognosis in estrogen-receptor-
positive breast cancer (Rody et al., 2007). This paradoxical effect is probably due 
to the multiple signalling cascades semaphorins stimulate in different tumour 
cells and in cells of the tumour microenvironment (Capparuccia et al., 2009). 
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1.1.5.2  Aquaporins 
 
The aquaporins (AQPs) represent a ubiquitous family of small, integral-
membrane proteins, which selectively transport water across cell plasma 
membranes (Andrews et al., 2008). A subset of AQPs, the aquaglyceroporins, 
also transport glycerol. AQPs are highly expressed in a variety of tumour cells, 
especially those with an aggressive phenotype. They have been proposed to play 
an important role in tumour biology, with recent observations showing them to 
be involved in cell proliferation and migration (Auguste et al., 2007; Hara-
Chikuma et al., 2008). In tumour vascular endothelium cells, AQP1 is 
universally expressed. Work done using wild type and AQP1-null mice showed a 
tumour reduction in the AQP1-null mice, due to impaired endothelial cell 
migration. AQP-expressing cancer cells also show enhanced migration in vitro, 
along with greater local tumour invasion, cell extravasation, and metastases in 
vivo. This may be due to AQP-facilitated water influx into lamellipodia at the 
leading front of migrating cells (Hu et al., 2006). AQP3 is an aquaglyceroporin 
that is expressed in basal cells in human skin squamous cell carcinomas, which 
facilitates cell proliferation in different cell types. Mice without the AQP3 
protein have been shown to be resistant to skin tumourigenesis, possibly due to 
reduced tumour cell glycerol metabolism and ATP generation. This data suggests 
that AQP expression in tumour cells facilitates cell growth and spread, and thus 
could be an important target for anti-tumour therapy (Verkman et al., 2008). 
 
1.1.5.3  ADAMs 
 
A disintegrin and metalloproteinases (ADAMs) are a family of proteins that 
share the metalloproteinase domain with matrix metalloproteinase’s (MMPs). 
They can be divided into two structural groups: (1) membrane-anchored ADAMs 
and (2) ADAM with thrombospondin motifs (ADAMTS) (Takeda et al., 2006). 
Both groups of ADAMs are involved in diverse roles such as cell adhesion, cell 
migration, cell fusion, membrane protein shedding and proteolysis. Many 
tumourigenic cells have a high expression of ADAMs, which direct activities 
such as regulation of growth factor activities (EGF, Heparin Binding-EGF and 
TGF-α, and cytokines e.g. TNF-α) and integrin functions, leading to promotion 
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of cell growth and invasion (Mochizuki et al., 2007). Work done by Ishikawa 
et al., have shown that transfection of ADAM8 into lung cancer cells enhanced 
their invasive activity (Ishikawa et al., 2004), while Wildeboer et al., 
demonstrated that ADAM8 is highly regulated in human primary brain tumours 
such as astrocytomas, and the expression levels and activity are associated with 
invasiveness (Wildeboer et al., 2006).  
 
One member of the ADAM family that has been proposed to play a role in the 
metastatic cascade is ADAM9, through its modulation of growth factor activity 
and integrin function. Secreted by activated stromal cells, ADAM9 is known to 
induce colon carcinoma cell invasion in vitro through binding to α6β4 and α2β1 
integrins. It also improves cell adhesion and invasion of non-small cell lung 
carcinoma (NSCLC) cells via modulation of α3β1 integrin and sensitivity to 
growth factors, resulting in promotion of brain metastasis of the carcinoma cells 
(Mazzocca et al., 2005). 
 
1.1.6  Therapeutic Targeting of Proteins 
 
There are currently no clinically approved, anti-metastasis therapies available, 
therefore, the identification and validation of novel proteins involved in cancer 
metastasis is an essential first step in developing new and effective therapies 
against this process. Membrane and membrane-associated proteins show great 
promise as therapeutic targets because of their easy accessibility. Many of the 
new therapies being developed include antibody targeting of the protein of 
interest. Antibodies have the ability to recognise native proteins expressed on the 
tumour cell surface, allowing for receptor binding, and the blocking of ligand 
interaction. They can bind to proteins and recruit complement or immune 
effector cells, thus eliciting antibody-dependent cellular cytotoxicity (ADCC). 
They also have the ability to neutralise growth factors or cytokines by binding to 
them and forming immune complexes, allowing for there removal (Durrant et al., 
2009). These factors make antibodies ideal agents for targeting cell surface 
proteins. 
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The αvβ3 integrin is an important receptor affecting tumour growth, local 
invasiveness, and metastatic potential. This integrin is expressed on various 
malignant tumours and mediates adhesion of tumour cells on a variety of 
extracellular matrix proteins, allowing these cells to migrate during invasion and 
extravasation (Felding-Habermann, 2003). Work carried out by Landon et al., 
have shown that etaracizumab, a fully humanised monoclonal antibody that 
targets the αVβ3 integrin, has been successful in decreasing ovarian cancer 
proliferation and invasion (Landen et al., 2008). The αvβ1 integrin is also being 
used for the development of targeted antibody therapy. Volociximab, a chimeric 
(82% human) antibody that specifically binds to αVβ1 integrin, blocks the 
integrins fibronectin binging site, leading to inhibited cell migration and the 
growth of new blood vessels. Testing is currently in the Phase I stage (Ricart et 
al., 2008).  
 
The heparan sulfate proteoglycan syndecan-1 is highly expressed by myeloma 
cells and is shed into the myeloma microenvironment. Tests carried out in animal 
models have shown that high levels of shed syndecan-1 promote tumour growth 
and invasion, while in myeloma patients, high levels are associated with a poor 
prognosis.  These findings suggest that syndecan-1 has the potential to be target 
for myeloma therapy (Yang et al., 2007).  
 
There are numerous monoclonal antibodies (MAbs) available that specifically 
target the Syndecan-1 proteoglycan. Furthermore, antibody-drug conjugates 
(ADCs), cytotoxic drugs chemically linked to antibodies, can enhance the 
efficiency of chemotherapy drugs. An anti-CD138-maytansinoid conjugate has 
been shown to target the Syndecan-1 protein, inhibiting the growth of multiple 
myeloma (MM) tumour cells in vitro and in vivo (Ikeda et al., 2009). 
 
As discussed, the tetraspanin transmembrane protein family have emerged as key 
players in the metastatic process, and as such, can be used as potential targets for 
cancer therapies. Several MAbs that target tetraspanins have an agonist effect. 
For example, an anti-CD151 antibody has been shown to stimulate cell adhesion, 
thereby preventing de-adhesion and immobilising tumour cells (Zijlstra et al., 
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2008). In addition, anti-CD9 MAbs amplify the inherent tumour suppressor 
function of CD9 (Ovalle et al., 2007). 
 
Cell surface proteins, proteoglycans and proteolipids play an integral part in the 
function of many cellular processes. Many of these proteins play a role in the 
different stages of tumour progression, carrying out a variety of complex 
functions. The interaction of these proteins with their environment and each other 
are varied, and to a large extent, still unknown. Some even seem to have a 
contradictory role in cancer progression. Understanding how these pathways 
contribute to the metastatic process, and what proteins play a critical role, is 
essential if we are to develop new cancer therapies. 
 
The ability of MAbs to target these, and other, cell surface proteins involved in 
the invasion process makes them ideal candidates as therapeutic tools for the 
treatment of metastasis. They possess many clinically relevant properties, 
including high specificity, low toxicity, and the ability to activate components of 
the immune system. For these reasons, MAbs have become an integral part in 
studies to treat metastatic cancers.  
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1.2  Monoclonal Antibodies 
 
Antibodies are proteins called immunoglobulins, produced by a biological host 
against the presence of a foreign molecule known as an “antigen”.  Antibodies 
occur in two forms: a soluble form secreted into the blood and tissue fluids, and a 
membrane-bound form attached to the surface of a B cell that is called the B cell 
receptor (BCR). The BCR allows a B cell to detect when a specific antigen is 
present in the body and triggers B cell activation. Activated B cells differentiate 
into either antibody generating factories called plasma cells that secrete soluble 
antibody, or into memory cells that survive in the body for years afterwards, 
allowing the immune system to remember an antigen and respond faster upon 
future exposures (www.chemprep.com). The antibodies produced recognise the 
antigen, and by cross reaction with other immune proteins, initiate an 
immunological response, thus destroying the invading presence.  
 
In mammals, there are five antibody isotypes or classes, each designated by an 
“Ig” prefix (Immunoglobulin), known as IgA, IgD, IgE, IgG and IgM. These 
antibody classes differ in their biological properties, functional locations and 
their ability to deal with different antigens (Woof et al., 2004). The antibody 
isotype can undergo changes during development and upon activation of B cells. 
Immature, or naïve, B cells that have never been exposed to antigen only express 
cell surface bound IgM. These cells begin to express both IgM and IgD isotypes 
when reaching maturity – the co-expression of both these isotypes renders the B 
cell “mature” and ready to react to antigens. Once the cell bound antibody 
molecule engages with the antigens, the B cell is activated, leading to cell 
division and differentiation into an antibody-producing plasma cell. In this 
activated form, the B cell produces antibody in a secreted, rather than a 
membrane-bound, form. A proportion of daughter cells of the activated B cells 
undergo isotype switching, inducing production of the other antibody isotypes 
(IgE, IgA or, more commonly, IgG), that have defined roles in the immune 
system (www.immunoportal.com). 
 
Antibodies are comprised of two antigen-binding fragments (Fabs), which are 
connected, via a flexible region (the hinge) to a constant, crystallisable fragment 
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(Fc). This structure is comprised of two pairs of polypeptide chains, each pair 
containing a heavy and light chain of dissimilar sizes (Chan et al., 2009). Both 
heavy and light chains are folded into the immunoglobulin domains. The variable 
regions in the amino-terminal part of the molecule t recognise and bind antigens; 
the remaining part of the molecule consists of constant domains that vary among 
immunoglobulin classes. The Fc portion serves to bind a variety of effector 
molecules of the immune system, as well as molecules that establish the 
biodistribution of the antibody (Binyamin et al., 2006).  
 
 
Figure 1.2: - Antibody Structure. www.mhhe.com.  
 
1.2.1  Hybridoma Technology 
A major milestone in antibody production occurred in 1975 when Kohler and 
Milstein successfully fused an antibody-producing B cell with an immortalised 
myeloma cell line resulting in a hybridoma. These hybridoma cells could then be 
cloned and screened for large-scale production of monoclonal antibodies 
(MAbs). This work, which was reported in Nature and eventually earned the two 
scientists the Nobel prize in 1980, allowed for the production of virtually 
unlimited quantities of antibody molecules, in which all antibodies were identical 
and of the same precise specificity for a given epitope (Kohler & Milstein, 1975).
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Figure 1.2.1: - Production of Monoclonal Antibodies. (www.uccs.edu) 
 
1.2.2  Development of Therapeutic Antibodies 
A major factor limiting the use of mouse MAbs in humans is the fact that the Fc 
region of the immunoglobulin structure is murine in origin. After intravenous 
administration of these MAbs patients developed human-antimouse antibodies 
(HAMAs) that were shown to complex with murine MAbs upon repeat 
administration. It has been demonstrated that HAMA responses were detected in 
approximately 50% of patients after a single injection of murine MAbs, and 
   36 
greater than 90% of patients develop HAMA following two or three repeated 
injections (Sears et al., 1984; Jaffers et al., 1986). Therefore, it is desirable to 
convert the clinically interesting MAbs of murine origin into those that are 
physically or functionally more human Ig alike. Molecular engineering 
techniques have achieved this by grafting critical sequences in the human heavy-
chain backbone onto the xenogeneic murine antibody structure, allowing for the 
retention of the Ag-binding specificities. This also imparts other attributes 
essential to enhanced clinical utility, such as decreased immunogenicity, longer 
serum half-life in humans, and the ability to recruit effector functions. Both 
chimerised and humanised MAb can be successfully administered to patients for 
prolonged treatment duration without inducing a clinically meaningful immune 
response (Binyamin et al., 2006).    
 
Figure 1.2.2: - Schematic representation of the development of therapeutic 
antibodies.    www.4-antibodies.com 
 
Chimeric Antibodies: - a chimeric antibody (cAb) is constructed by fusing the 
light and heavy chain variable regions (VL and VH respectively) of a murine 
MAb to the corresponding human constant regions.  Approximately 70% of the 
structure of a cAb is of human origin (Qu et al., 2005). The anti-CD20 MAb 
Rituximab, and the anti-EGFR Cetuximab are examples of a chimeric antibodies. 
 
Humanised Antibodies: - in a humanised antibody, the VL and VH domains of the 
original murine MAb are further engineered so that only the complementarity-
determining regions (CDRs), approximately 25% of the sequences, are grafted 
onto the scaffolds of corresponding human V region frameworks (termed CDR-
grafting). A humanised MAb has less than 10% amino acid sequences of murine 
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origin (Qu et al., 2005). Humanised antibodies are usually denoted by the 
addition of –zumab at the end of their name. Examples of humanised antibodies 
include the anti-HER2 Trastuzumab (Herceptin), and the anti-VEGF-A 
Bevacizumab (Avastin).  
 
Fully Human Antibodies: - the derivation of fully human antibodies can be 
accomplished in vitro using the phage display technique. Amino acid sequences 
of heavy and light chain variable regions of the MAb must first be elucidated. 
This is accomplished by molecular cloning. Second, the humanised MAb is 
designed and the plasmid vector for mammalian expression of the humanised 
MAb is constructed. Third, the humanised MAb is expressed and produced in 
cell cultures. Fourth, the immunological and biochemical characteristics of the 
humanised MAb are examined and compared with those of the parent murine 
MAb (Qu et al., 2005). The application of phage display technology has 
permitted the generation of human MAbs which encompass a wide range of 
specificities against hitherto refractory antigens.  
 
A second method for producing fully human antibodies is through the use of 
xenomouse© technology. Xenomice are developed when heavy and light IgG 
chains are inactivated in mouse embryonic stem (ES) cells by gene-targeting 
technology. These cells are then used to generate mice with homozygous 
deletions, in which mouse antibody production is disrupted. Human heavy and 
light IgG chain loci are introduced into ES cells, which are used to generate mice 
containing human Ig loci, thus producing fully human antibodies in the presence 
of mouse antibodies. Breeding of these mice with immunoglobulin-inactivated 
mice generate xenoMice (Jakobovits et al., 2007). 
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Figure 1.2.3: - Creation of Xenomouse strains (Jakobovits et al., 2007). 
 
The Xenomouse platform has been  used for the development of at least 18 
human MAbs;  Two (the anti-EGFR Panitumumab, and the anti-RANK 
Denosumab, used for the treatment of osteoporosis) are approved, nine are in 
clinical study (two at Phase II, five at Phase II and two at Phase III) and seven 
are discontinued (Nelson et al., 2010). 
 
1.2.3  Monoclonal Antibodies as Cancer Therapeutics  
The concept of using antibodies in cancer treatment was first proposed over a 
century ago by the German scientist Paul Ehrlich. He hypothesised that a “magic 
bullet” could be developed, based on an antibody, to selectively target disease; 
however, it was not until the advent of hybridoma technology that their use as a 
therapeutic agent became fully realised. A variety of mechanisms are thought to 
govern the anti-tumourigenic effects of MAbs. These include blocking of an 
activation signal that is necessary for continued cell growth, antibody-dependent 
cellular cytotoxicity (ADCC), complement dependent-cytotoxicity (CDC) and 
the ability of MAbs to alter the cytokine milieu or enhance development of an 
active anti-tumour immune response. Additionally, MAbs are also known to 
target the tumour microenvironment, which can result in inhibited tumour growth 
through restriction of pro-tumourigenic factors produced in the tumour stroma. 
(Weiner et al., 2010).  
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 1.2.3.1  ADCC 
ADCC occurs when antibodies bind to antigens on tumour cells, resulting in the 
antibody Fc domain engaging with Fc receptors (FcR) present on the surface of 
immune effector cells (see figure 1.2.4).  FcRs can activate downstream 
signalling through immunoreceptor tyrosine-based activation motifs (ITAMs) or 
deliver inhibitory signals through immunoreceptor tyrosine-based inhibitory 
motifs (ITIMs) (Ivashkiv et al., 2010). The main inhibitory FcR is the single 
chain CD32, whereas most Fc-dependent stimulatory signals are transduced by 
CD64 and CD16A. CD64 is a high-affinity receptor expressed by macrophages, 
dendritic cells (DCs), neutrophils and eosinophils (Weiner et al., 2010).  
 
Trastuzumab (Herceptin) has been shown to activate an ADCC response in 
multiple breast cancer cell lines. Natural killer (NK) cells, a chief immune cell 
type involved in ADCC, express the Fc gamma receptor, to which the Fc domain 
of t binds, activating NK-mediated cell lysis. In mice bearing BT474 HER2 
overexpressing xenografts, a tumour regression rate of 96% was observed 
following treatment with Herceptin. In contrast, mice lacking the Fc receptor lost 
much of the protective effect of Herceptin, with only 29% tumour growth 
inhibition observed (Clynes et al., 2000) 
 
After tumour cell lysis occurs, antigen-presenting cells can present tumour-
derived peptides on MHC (major histocompatibility complex) class II molecules, 
thus promoting CD4+ T-cell activation. Additionally, tumour-derived peptides 
can be presented on MHC class I molecules (cross-presentation), leading to 
CD8+ cytotoxic T cell activation (Flynn et al., 2003).  
 
Therefore, binding of MAbs to tumour cells enables the recognition of these 
targets by immune effector populations that express FcR receptors, such as NK 
cells, neutrophils, mononuclear phagocytes and dendritic cells (Weiner et al., 
2010).  
 
1.2.3.2  CDC: Blocking Ligand Binding & Signal Disruption 
CDC is another method antibodies can us to direct cell kill (see figure 1.2.4). For 
example, the binding of two or more IgG molecules to the cell surface leads to 
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high-affinity binding of complement component 1q (C1q) to the Fc domain. This 
is followed by the activation of C1r enzymatic activity and subsequent activation 
of downstream complement proteins. The complement cascade results in the 
formation of pores by the membrane attack complex (MAC) on the tumour cell 
surface, leading to tumour cell lysis (Weiner, et al., 2010). The anti-CD20 MAb 
Rituximab has been found to depend in part upon CDC, as well as ADCC, for its 
in vivo efficacy (Adams et al., 2005).  
 
Many of the most commonly targeted tumour-associated antigens are growth 
factor receptors, which are frequently over-expressed in a number of solid 
tumours. Overexpression of these receptors has been linked to tumour cell 
growth and survival, through desensitising against chemotherapeutic agents. By 
blocking signalling through these receptors, MAbs have the capability to 
decrease growth rates and re-sensitise cells to cytotoxic agents. Members of the 
EGFR family are the target of many therapeutic antibodies, and are thus among 
the most potent inhibitors of signal transduction. Cetuximab and Panitumumab 
(anti-EGFR MAbs, FDA-approved in 2006 (Nelson et al., 2010)) function by 
blocking the interaction between the receptor and its activating ligand, and by 
sterically preventing the receptor from assuming the extended conformation 
required for dimerisation (Li et al., 2005). Pertuzumab (anti-HER2, awaiting 
FDA approval) allows ligand binding to occur, but sterically inhibits the 
subsequent receptor heterodimerisation required for signal transduction (Franklin 
et al., 2004). (Pertuzumab binds to domain II of HER2, whereas Trastuzumab 
binds to domain IV (deVita et al., 2008)). Almost all unconjugated antibodies 
used as therapeutic agents disrupt the signals used by tumour cells for 
proliferation and survival (Weiner et al., 2010). 
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Figure 1.2.4: - MAb mediated ADCC and CDC (Carter, 2001) 
 
1.2.3.3  Targeting the Tumour Microenvironment  
The targeting of critical steps in the tumour microenvironment has shown 
therapeutic benefits in both preclinical and clinical settings. For example, many 
solid tumours express vascular endothelial growth factors (VEGFs), which bind 
to its receptor on the vascular endothelium, and thus stimulating angiogenesis. 
Bevacizumab, a VEGF-specific humanized MAb, blocks binding of VEGF to its 
receptor, resulting in hypoxia of the tumour. Cetuximab is also used as an anti-
VEGF MAb (Weiner et al., 2010).  
 
The tumour stroma consists of numerous matrix proteins, along with blood 
vessels, and fibroblasts. These tumour-associated fibroblasts express FAP 
(fibroblast activation proteins), and are both functionally and phenotypically 
different from normal fibroblasts. FAP is thought to play a crucial role in tumour 
formation and metastasis, and is thus an attractive target for MAb therapy. Work 
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carried out by Scott et al., have shown that an anti-FAP MAb (Sibrotuzumab) 
can successfully target this protein, with their study showing excellent tumour 
uptake and no localisation to normal tissue (Scott et al., 2003). However, this 
MAb has undergone no further development, and no clinical trials involving its 
use are currently taking place.   
 
 
Table 1: - Therapeutic monoclonal antibodies approved for use in oncology 
(Weiner et al., 2010) 
 
1.2.4  Anti-Invasion/Metastasis MAbs 
While current FDA-approved MAbs have greatly enhanced the field of cancer 
therapeutics, the majority of them are directed towards the treatment of primary 
and advanced cancers, and not metastatic disease. Metastatic cells pose the most 
dangerous threat to patient well-being; however, effective targeting of these cells 
remains an underdeveloped strategy when it comes to monoclonal antibody 
therapy. There are a number of studies taking place, in which MAbs are being 
generated against targets involved in the invasion process; however, none, as yet 
have received FDA approval for clinical use. 
 
Gamma secretase (GS) is a unique multi-protein complex with activity as a cell 
surface protease that directly cleaves a variety of transmembrane proteins to 
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modify their function. Nicastrin is an essential component of the GS enzyme 
complex, required for its synthesis and recognition of substrates for proteolytic 
cleavage. (De Strooper, 2005). Work carried out by Filipović et al., (2010) 
revealed marked upregulation of nicastrin in human breast cancer compared to 
normal breast tissue. Nicastrin silencing in invasive breast MDA-MB-231 cells 
resulted in a marked reduction in both cell motility and invasion. A rabbit 
polyclonal antibody (PcAb) was then produced, raised against the extracellular 
domain of human nicastrin protein. This PcAb significantly reduced invasion 
levels in the MDA-MB-231 cell line by 70%. Mouse MAbs were also generated 
using the same method, and produced results similar to those seen with the PcAb. 
This proof of principle study suggests that developing MAbs against nicastrin 
could aid in future therapeutic treatments for invasive breast cancers.   
 
A MAb generated against uPAR (Bauer et al., 2005), was shown to significantly 
decrease cell invasion and migration in the prostate cancer cell line, PC-3 in 
vitro, and caused a significant decrease in tumour volume in vivo. A humanised 
version of this MAb is expected to enter a Phase I clinical study shortly (Rabbani 
et al., 2010). 
 
Axl is a member of a family of receptor tyrosine kinases that also includes Tyro3 
and Mer (O’Bryan et al., 1991; Lai and Lemke, 1991). Originally identified as a 
transforming gene in haematological malignancies (O’Bryan et al., 1991; Janssen 
et al., 1991), its dysregulation (or that of its ligand, Gas6) is implicated in the 
pathogenesis of a variety of human cancers. Its overexpression has been reported 
in a multitude of human cancers (Berclaz et al., 2001; Sun et al., 2004; Shieh et 
al., 2005) and is associated with invasiveness and metastasis in lung (Shieh et al., 
2005), prostate (Sainaghi et al., 2005), breast (Zhang et al., 2008), gastric (Wu et 
al., 2002) and pancreatic (Koorstra et al., 2009) cancers, renal cell carcinoma 
(Chung et al., 2003) as well as glioblastoma (Hutterer et al., 2008). Generation of 
an anti-Axl MAb was achieved using phage-display antibody libraries (Li et al., 
2009). Antibody YW327.6S2 recognizes both human and murine Axl. In vivo 
testing with this MAb reduced metastasis of MDA-MB-231 breast cancer cells to 
distant organs. In NSCLC models, YW327.6S2 also enhanced the efficacy of 
Erlotinib and chemotherapy in reducing tumour growth (Ye et al., 2010). 
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There are a number of clinical trials taking place involving MAbs that have 
shown show anti-invasive characteristics. Intetumumab, a fully human anti–αv 
integrin monoclonal antibody, has been shown to inhibit both migration and 
invasion of MDA-MB-231 breast cancer cells (Chen et al., 2008). It underwent 
Phase I clinical trials in combination with docetaxel in patients with metastatic, 
castration-resistant prostate cancer, and is now in Phase II clinical trials for the 
treatment of a variety of malignancies (Ning et al., 2010). A fully human, anti-
HGF MAb, designated AMG-102, has shown anti-invasive effects in a 
leiomyosarcoma tumour-derived cell line, and is undergoing Phase I trials in 
combination with Bevacizumab/Motesanib in patients with advanced solid 
tumours (Rosen et al., 2010). In addition, the fully human monoclonal antibody 
AMG-102 was generated against HGF (Burgess et al., 2006). Subsequent testing 
of this MAb showed that it decreased invasion levels in SK-LMS-1 cells (a cell 
line derived from a leiomyosarcoma tumour). This MAb is undergoing Phase II 
clinical trials for patients with recurrent glioblastoma multiforme (Reardon et al., 
2008), and Phase I trials in combination with Bevacizumab/Motesanib in patients 
with advanced solid tumors (Rosen et al., 2010). 
 
There are also a number of MAb (and non-MAb therapeutic agents) in late stage 
clinical trials that are targeted against proteins involved in the invasion process: 
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Table 2: - Select agents in late-stage development that target 
aggressive/metastatic cancers (Mack & Marshall, 2010) 
 
1.2.5  Engineering MAbs 
 
As stated previously, MAbs can be engineered in order to overcome 
immunogenicity problems associated with their murine origin (section 1.8.2). 
However, engineering techniques can also be employed to increase the efficacy 
of MAbs, through increased antigen binding, enhancement of its natural effector 
functions and increasing serum half life.    
 
• Bispecific Antibodies 
The ability of tumour cells to appropriate multiple mediators, which allow them 
to proliferate and spread, is one of the reasons why it is so difficult to treat. 
Therefore, simultaneous blocking of several targets would greatly enhance 
therapeutic efficacy. This is the reasoning behind bispecific antibodies (BsAb). 
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BsAb are antibody-based molecules that can simultaneously bind two separate 
and distinct antigens (or different epitopes of the same antigen). This is achieved 
through the presence of two distinct binding specificities, which are combined to 
an antibody by (1) chemically cross-linking two antibody molecules or antibody 
fragments, (2) fusion of two different cell lines to form a quadroma or trioma, or 
(3) recombinant DNA based approaches (Cao et al., 1998). BsAbs are mainly 
used to redirect cytotoxic immune effector cells, thus enhancing tumour cell kill 
through ADCC. One arm of the BsAb binds a tumour-associated antigen, while 
the other binds a determinant expressed on effector cells, e.g. CD3, which is 
expressed on T cell receptors (Willems et al., 2005). By facilitating this cross-
linking, the BsAb triggers the activation of the effector cell, while bringing it into 
close proximity to the tumour cell, thus leading to effective tumour cell-killing 
(Shen et al., 2006).  The first bsAb, Catumaxomab, which binds to both epithelial 
cell adhesion molecule (EPCAM) on tumour cells and CD3 on effector immune 
cells, received approval from the European Medicines Agency (EMA) in 2009 
for the treatment of malignant ascites (Linke et al., 2010) 
 
• Single Chain Antibodies 
The conventional antibody (150 – 160kDa) is made up of two identical variable 
heavy chains (VH) and two identical variable light chains (VL) held together by 
interchain disulfide bonds. To improve the therapeutic value of antibodies, 
protein-engineering endeavours reduced the size of the antigen-binding moiety to 
a single-domain unit. Single chain antibodies, or single-chain Fvs (sFvs) are 
antibody fragments (25kDa) produced using phage display technology (Ohshima 
et al., 2010), that consist of only one VL and one VH domain, covalently 
connected to one another by a polypeptide linker. Their advantage over 
conventional antibodies lies in their ability to retain the specific, monovalent, 
antigen binding affinity of the parent Ab, while showing improved 
pharmacokinetics for tissue penetration (Harmsen et al., 2007).  
 
• Single Domain Antibodies/Nanobodies 
Single domain antibodies (sdAb), like sFvs, consist of antigen-binding fragments 
of the immunoglobulin, however, there are significantly smaller (11-15kDa). 
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Early work by Ward et al., (1988) showed that mouse sdAbs were able to 
function successfully, and it was proposed that, due to their smaller size, they 
could potentially penetrate tissues more effectively than conventional antibodies 
(Ward et al., 1989). However, work on them was limited due to their poor 
solubility, their propensity to aggregate, and because they rarely retained the 
affinity of the parent. Interest in sdAbs was rekindled with the discovery of 
naturally occurring, single V-like domains in camelids (dromedary, camel, llama, 
and alpaca) (Hamers-Casterman et al., 1993). These peculiar heavy chain 
antibodies (hcAbs) lack light chains. Therefore, the antigen-binding site of hcAbs 
is formed only by a single domain that is linked directly via a hinge region to the 
Fc-domain. The variable domain is designated VHH or nanobody) (Wesolowski et 
al., 2009). With this discovery, nanobodies specific for a given antigen could be 
generated though camelid immunisation, and subsequent cloning of its VHH 
repertoire in phage display vectors (Arbabi Ghahroudi et al., 1997; Roodink et 
al., 2010) 
 
Conventional antibodies have many advantageous features, such as their high 
affinity and selectivity for a target, their ease of discovery and production, and 
their low inherent toxicity. With nanobodies, not only are all this features 
present, they have other technological and biophysical advantages: they are 
highly stable to heat, retaining over 80% of their binding activity after 1 week of 
incubation at 37°C, thus indicating that they have a good shelf life; melting 
points of Nanobodies are in the range of 67- 78°C. They have also been shown to 
be stable in the presence of extremes of pH (Revets et al., 2005), allowing for 
their survival in harsh conditions such as the stomach. All these features make 
nanobodies as being potentially successful therapeutic agents for the treatment of 
cancer. 
 
1.2.6  Conjugated MAbs 
As described previously, MAbs attach to antigens on the cancer cell, inducing 
ADCC, CDC, or block ligands and signalling. These types of MAbs are known 
as “unconjugated” monoclonal antibodies. In addition to these mechanisms, 
increasing attention has turned to the possibilities of using antibodies as a 
delivery method for other, anti-cancer agents. By selectively targeting a drug to 
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the tumour site, an antibody can induce the desired biological effects with 
improved therapeutic index (McCarron et al., 2005). These drug-carrying 
antibodies are known as “conjugated” antibodies. To date, three antibody 
conjugate therapies have received FDA approval; the radioimmunoconjugates 
Ibritumomab tiuxetan (Zevalin) and [131I]-tositumomab (Bexxar) for the 
treatment of lymphoma, and the drug conjugate Gemtuzumab ozogamicin 
(Mylotarg) for the treatment of acute myeloid leukaemia (FDA approval for this 
conjugate was withdrawn by the FDA in 2001, due to lack of data proving its 
efficacy. It is no longer available for use outside of a clinical trial (Ricart et al., 
2007). Conjugation of a drug to an antibody makes it possible to achieve 
excellent localization of the drug at the desired site within the body (Senter et al., 
2001). This increases the effective drug concentration within this target area, 
thereby optimizing the therapeutic effect of the agent. 
 
Antibody Drug Conjugates (ADC): Standard cancer treatment regularly involves 
administering a regime of chemotherapeutic drugs that results in the death of 
actively dividing cells within the body, specifically cancer cells, but also healthy 
tissue. Selective targeting of these agents by conjugation to MAbs can improve 
efficacy and reduce side effects. Gemtuzumab ozogamicin was the first FDA-
approved drug immunoconjugate targeting CD33 and carrying the highly toxic 
calicheamicin, a highly potent apoptotic antibiotic. Its use in patients with acute 
myeloid leukaemia resulted in a median of 6.8 months relapse-free survival and a 
30% remission rate (Linenberger, 2005). However, this result could not be 
repeated, and FDA-approval was soon withdrawn. There are currently no FDA-
approved ADCs on the market.  
 
In July of this year, Genentech submitted a biologic license application to the US 
FDA for the ADC Trastuzumab–DM1 (T–DM1). This antibody conjugate 
combines the anti-HER2 Trastuzumab with the cytotoxic agent DM1. The 
application is based on the results of a Phase II trial that assessed the efficacy of 
T–DM1 in 110 women with HER2-positive advanced breast cancer whose 
disease had worsened after receiving at least two prior HER2-targeted 
treatments: Trastuzumab and lapatinib, as well as an anthracycline, a taxane and 
capecitabine (Hughes, 2010). (DM1 is a semi synthetic ansamacrolide, and 
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belongs to the maytansinoid class of anti-microtubular cytotoxic agents 
originally defined by the natural compound Maytansine (Cassady et al., 2004)). 
Radioimmunotherapy (RAIT): involves the application of radioactive MAbs for 
targeted radiotherapy. 131I-Tositumomab (Bexxar) and 90Y-Ibritumomab tiuxetan 
(Zevalin) are the two FDA-approved radiolabeled anti-CD20 murine antibodies 
that have shown significant overall and complete response rates in patients with 
non-Hodgkin lymphoma, a disease that is quite radiosensitive as well as readily 
accessible to the antibody conjugates (Goldsmith, 2010).  
Antibody-directed enzyme prodrug therapy (ADEPT): involves the application of 
antibody-enzyme conjugate, which then localises to its tumour-associated 
antigen. A suitable, non-toxic prodrug is then administered, which can be 
converted to its active cytotoxic form by the antibody-enzyme conjugate. The 
activated drug penetrates the tumour cells, destroying it in a localised manner. A 
Phase I clinical trial was carried out in 2006, with an antibody-enzyme conjugate 
on patients with nonresectable, locally recurrent, or metastatic histologically 
proven colorectal or other carcinoembryonic antigen-expressing cancer, 
however, there are no clinical trials currently taking place at time of writing. 
1.2.7 MAb Therapy in Combination with Other Anti-Cancer 
Agents 
Due to the highly complex nature of cancer, and the fact that a myriad of proteins 
are involved in its generation and progression, it is unlikely that any single agent 
will prove successful in treating it. For this reason, combination studies are 
carried out in order to investigate the potential of multi-drug therapies for the 
treatment of cancer. For example, in order to increase ADCC, Rituximab has 
been used in combination with cyclophosphamide, doxorubicin, vincristine, and 
prednisone in the treatment of patients with diffuse large B-cell lymphoma (Kim 
et al., 2006). Combination studies involving Trastuzumab with lapatinib 
(Blackwell et al., 2010), docetaxel (Sawaki et al., 2010), vinorelbine (Heinemann 
et al., 2010) and INCB7839, a potent and selective ADAM inhibitor (Newton et 
al,. 2010) are also taking place. Current clinically available drugs, which have 
shown some potential anti-tumourigenic properties are also being tested for any 
potential synergistic effect with standard cancer drugs. 
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1.2.7.1  Statins 
The statins are a group of drugs commonly used for the treatment of lipid 
disorders, including hypercholesterolemia. They function by inhibiting 3-
hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase). HMG-
CoA reductase catalyses the conversion of HMG-CoA into mevalonate in the 
mevalonate biosynthetic pathway (Graaf et al., 2004; Brown, 2007). 
 
 
Figure 1.10: - Overview of the mevalonate pathway and targets for inhibition by 
statins, farnesyltransferase inhibitors and geranylgeranyltransferase inhibitors 
(Graaf et al., 2004). 
 
In addition to the cholesterol lowering effects of statins, a number of studies 
suggest that cancer incidences may be lower in patients receiving statins. Trials 
carried out by the Air Force/Texas Coronary Atherosclerosis Prevention Study 
(AFCAPS/TexCAPS) examining the use of Lovastatin for preventing coronary 
events, found the rates of new melanomas were significantly lower in the 
Lovastatin arm compared with the placebo arm. Furthermore, among the 41 
participants who developed melanoma, there was a trend, although not 
statistically significant, toward earlier stage at diagnosis in the Lovastatin group 
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(Downs et al., 1998). A meta-analysis carried out described the incidence of 
melanoma in 12 qualifying randomised controlled statin trials, with 39,426 
participants. They reported that 127 melanomas occurred, 59 among the 19,872 
statin group participants and 68 among the 19,554 control group participants. 
The reported odds ratio for melanoma was in the direction of a protective effect, 
but did not reach significance. As the number of incident melanoma cases was 
low, a specific study to address the role of statins in preventing melanoma would 
need to be designed, with the required power to provide answers (Freeman et al., 
2006). 
 
Studies carried out by the Veterans affairs Health Care System showed that lung 
cancer incidences rates in statin users were also found to be significantly reduced 
(55% risk reduction) (Khurana et al., 2007). Several studies have also suggested 
that colorectal cancer rates are reduced amongst statin users, including the 
Molecular Epidemiology of Colorectal Cancer study (Poynter et al., 2005), and 
in the Rhine-Neckar-Odenwald population case-control study (Hoffmeister et al., 
2007). Graaf et al., (2004) also reported that statin use was associated with a risk 
reduction of cancer of 20%. However, other studies have shown no benefit for 
statin use with respect to cancer prevention. Jacob et al., (2006) examined the 
association between use of cholesterol-lowering drugs and colorectal cancer 
incidence among 132,136 men and women in the Cancer Prevention Study II 
Nutrition Cohort. Current or 5 year use of cholesterol-lowering drugs was not 
associated with colorectal cancer incidence. A recent meta-analysis study 
including 6662 incident cancers and 2407 cancer deaths showed that statins did 
not reduce the incidence of cancer or cancer deaths and there was no reduction in 
any individual cancer type (Dale et al., 2006). These conflicting reports highlight 
the need for further studies on the effects of statins on cancer cells. 
 
A number of studies have been carried out investigating the effects of statins on 
melanoma cells. Lovastatin was observed to induce apoptosis in A375 melanoma 
cells (Shellman et al., 2005), while enhancing responses to chemotherapy drugs 
in the B16 mouse model of melanoma (Feleszko et al., 1998, 2002). Atorvastatin 
was shown to inhibit invasion in vitro and metastasis in vivo in the A375M 
melanoma cells (Collisson et al., 2003); and work done by Depasquale and 
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Wheatley showed that Lovastatin reduced both melanoma cell growth and 
angiogenesis in an in vitro co-culture model angiogenesis system (Depasquale et 
al., 2006). These studies indicate that statins may play a role in melanoma 
prevention or treatment. However, the conflicting evidence from the 
chemoprevention studies suggests that further investigation is required to 
determine if standard cholesterol-lowering doses of statins will inhibit the growth 
of melanoma cells. 
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1.3  Aims of Thesis: 
 
The aims of this thesis are as follows: 
 
1. To generate monoclonal antibodies (MAbs) directed against the highly 
invasive MiaPaCa-2 clone 3 pancreatic cancer cell line, and the invasive MDA-
MB-435-SF breast cancer cell line.  
 
2. To develop a high throughput invasion assay system to screen resultant 
hybridomas directly for effects on invasion in vitro. 
 
3. To identify MAbs that can significantly block cancer invasion in vitro, and to 
functionally characterise these MAbs in a range of invasive cancer models 
(pancreatic, breast, melanoma, lung, prostate, colon, and glioma). To investigate 
their effect on a number of related cellular processes, including motility, 
proliferation, MMP activity and adhesion in vitro.   
 
4. To identify the antigens recognised by direct and cross-linked 
immunoprecipitation and proteomic analysis (mass spectrometry – LC-MS/MS). 
 
5. To establish if the target proteins identified are involved in invasion by siRNA 
silencing of their respective genes. 
 
6. To evaluate the expression of MAb targets in a range of human cancer cell 
lines, and normal and tumour tissues (breast, glioma, pancreatic, haematological 
malignancies). 
 
7. To investigate the effect of Lovastatin, Mevastatin and Simvastatin on the 
invasion and motility levels in human melanoma cell lines, and to investigate any 
possible synergy between the developed MAbs and statins, in relation to 
inhibition of invasion in human cancers. 
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CHAPTER 2  
MATERIALS & METHODS 
   55 
2.1  Cell Culture 
 
2.1.1 Cell Culture  
Cell culture procedures were strictly adhered to as outlined in NICB SOP. 
 
2.2. Cell Lines 
 
Details of all cell lines used for the experiments detailed in this thesis are 
provided in Table 2.1. Cell lines were maintained in T25cm3 (Costar 3056), 
T75cm3 (Costar 3290) or T175cm3 (Nunc, 156502) tissue culture flasks at 5% 
CO2, 37°C and fed every 2-3 days. Cell lines were cultured through 7-10 
passages before being discarded and replaced by new cultures grown from frozen 
stocks at an earlier passage.  
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Cell Line Details-Histology Invasion 
Status 
Basal Medium,  
with Additions 
BT20 Ductal Carcinoma of the breast Invasive DMEM; 10% FCS 
BT474 Ductal Carcinoma of the breast Non-Invasive RPMI; 10% FCS, 1mM Na-
pyruvate 
BxPc-3 Pancreas, adenocarcinoma Invasive RPMI; 10% FCS 
C/68 
(Bright et al., 1998) 
Prostate Cancer Invasive Keratinocyte; 25µg/ml BPE, 
11 µg/ml EGF, 5% FCS * 
DLKP Poorly Differentiated Squamous 
Cell Lung Carcinoma 
Low Invasion ATCC; 5% FCS 
DLKP-A 
(Clynes et al., 1992) 
Adriamycin Resistant Variant of 
DLKP 
Invasive ATCC; 5% FCS 
DLKP-I 
(McBride et al., 1998) 
Intermediate Sub-Population 
Cloned from DLKP 
Highly Invasive ATCC; 5% FCS 
DLKP-M 
(McBride et al., 1998) 
Mesenchymal-Like Sub-
Population Cloned from DLKP 
Highly Invasive ATCC; 5% FCS 
DLKP-SQ 
(McBride et al., 1998) 
Squamous Sub-Population 
Cloned from DLKP 
Low Invasion ATCC; 5% FCS 
DLKP-SQ-Mitox-6p 
(Joyce, H., unpublished) 
Mitoxanthane Resistant Variant 
of DLKP-SQ after 6th pulse of 
drug 
Invasive ATCC; 5% FCS 
HCT-116 Colon Cancer Highly Invasive DMEM; 10% FCS 
HT144 Human Melanoma Invasive McCoys 5A Media; 10% 
FCS 
Lox IVMI Human melanoma Invasive RPMI; 10% FCS 
MCF-7 Breast carcinoma (ER +, PR +) Non Invasive RPMI; 10% FCS 
MDA-MB-157 Triple Negative Breast 
carcinoma 
Low Invasion RPMI, 10% FCS 
MDA-MB-231 Triple Negative Breast 
Adenocarcinoma 
Highly Invasive RPMI; 10% FCS 
MDA-MB-361 HER2 positive Breast 
Adenocarcinoma 
Invasive RPMI; 10% FCS 
MDA-MB-435-SF 
(Glynn et al., 2004) 
Clonal subpopulation of human 
melanoma MDA-MB-435S 
(HER2 positive) 
Invasive RPMI; 10% FCS 
MDA-MB-435-SF-Taxol-
10p4p 
Taxol Resistant varient of 
MDA-MB-435-SF  
Invasive RPMI; 10% FCS 
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(Glynn et al., 2004) (HER2 positive) 
MDA-MB-453 HER2 positive Breast 
Carcinoma 
Non-Invasive RPMI; 10% FCS 
MiaPaCa-2 clone 3 
(Walsh et al., 2009) 
Invasive clonal subpopulation of 
pancreatic cell line MiaPaCa-2 
Invasive DMEM; 5% FCS 
MiaPaCa-2 clone 8 
(Walsh et al., 2009) 
Non-Invasive clonal 
subpopulation of pancreatic cell 
line MiaPaCa-2 
Low Invasion DMEM; 5% FCS 
NCI-H1299 Large Cell Lung Carcinoma Highly Invasive RPMI, 1mM Na pyruvate, 
5% FCS 
SK-Mel-28 Human Melanoma Invasive RPMI; 10% FCS 
SKBR-3 HER2 positive  Breast 
Carcinoma 
Low Invasion RPMI; 10% FCS 
SNB-19 Glioma Highly Invasive DMEM; 10% FCS 
 
Table 2.2: - Cell lines used during the course of this thesis 
ATCC: - American Tissue Culture Collection, Rockville, MD, USA. 
• BT20, BT474, BxPc-3, HCT-116, MCF-7, MDA-MB-157, NCI-H1299 
 
NICB: - National Institute for Cellular Biotechnology, D.C.U., Dublin, Ireland. 
• DLKP, DLKP-A, DLKP-I, DLKP-M, DLKP-SQ, DLKP-SQ-Mitox-6p, 
MDA-MB-435-SF, MDA-MB-435-SF-Taxol-10p4p, MiaPaCa-2 clone 3, 
MiaPaCa-2 clone 8 
 
NCI: - National Cancer Institute, Washington, D.C., USA 
• SK-Mel-28 
 
DSMZ: - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH 
(German Collection of Microorganisms and Cell Cultures) 
• SNB-19 
 
MDA-MB-157, MDA-MB-361: - Berlex 
Lox IMVI: - Radium Hospital, Norway. 
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2.3  Monoclonal Antibody Production 
 
2.3.1  Immunogen for MAb Generation 
The immunogen chosen for the generation of the 7B7 G5 (2) MAb was 
MiaPaCa-2 clone 3, an invasive clonal variant of the pancreatic cell line 
MiaPaCa-2. The immunogen chosen for the generation of the 9E1 24 (6) MAb 
was MDA-MB-435-SF, an invasive clonal variant of the melanoma cell line 
MDA-MB-435-S. Cells were detached from flasks using a non-enzymatic, cell 
dissociation solution (Sigma, C5914) to ensure that cell surface proteins remain 
undamaged.  
 
2.3.2 Immunisation Regime 
Using three BALB/c mice per immunisation, a primary immunisation with 2 X 
106 cells (50µl volume), plus an equal volume of lipopeptide adjuvants, 
Pam3Cys-SKKKK (EMC microcollectors), Germany; L2000) was administered 
intraperitoneal; four booster immunisations were similarly administered at three 
weekly intervals. Polyclonal serum was obtained from tail bleeds of animals 
following the third and fourth booster injections; this was tested for reactivity 
against each respective target immunogen by immunofluorescence analysis.  
Serum from the tail bleed of a non-immunised mouse was used as a negative 
control. 
 
• All experiments on animals were carried out under license and in compliance 
with the rules of The Cruelty to Animals Act, 1876, E.C. Directive 86/609EC 
 
2.3.3 Fusion Procedure 
The fusion procedure used for the production of monoclonal antibodies was a 
modification of the protocol outlined by Kohler and Milstein (1975). Prior to the 
removal of the spleen from the sacrificed mouse, SP/2/O-Ag 14myeloma cells 
(Shulman et al., 1978) were prepared for cell fusion by harvesting 2 x 75cm2 
flasks and centrifuging at 1000 rpm for 5 minutes in HEPES Buffered Saline 
Solution-serum free medium (Lonza, CC-5022). This step was repeated twice. A 
cell count was then performed and the cells kept at 37°C. 
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A BALB/C mouse was then sacrificed by cervical dislocation. The animal was 
swabbed with 70% IMS and the spleen removed in a laminar flow cabinet with 
sterile instruments. Single cells were obtained by forcing the spleen through a 
sterile Falcon cell strainer (BD FalconTM, 352360) using the plunger from a 
sterile 10ml syringe into serum free DMEM (the DMEM referred to in this 
section is DMEM with Glutamax I (high glucose concentration – 4.5mg Gibco 
61965-026)) containing pyridoxine and without sodium pyruvate or HEPES. This 
cell suspension was placed in a universal and the volume adjusted to 10mls. 
Large clumps of cells were allowed to pellet by standing at room temperature for 
2-3 minutes. The supernatant was then transferred to a fresh centrifuge tube and 
centrifuged at 1000 rpm for 5 minutes. A cell count was performed as before. 
 
Splenocyte and SP/2/O-Ag myeloma cells were mixed in a universal at a ratio of 
10:1 (a minimum of 1 x 107 SP/2 are required for this procedure), centrifuged at 
12,000 rpm for 5 minutes and resuspended in serum free medium. This step was 
repeated twice. Following the final washing step, 1ml of PEG (polyethylene 
glycol, Roche Diagnostics GmbH, Germany, 10783641001) (pre-warmed to 
37°C) was added to the cell pellet with a Pasteur pipette using a gentle swirling 
and aspirating action for 30 seconds. After 30 seconds the aspiration was 
discontinued. 75 seconds after the start, 0.5ml of planting medium (DMEM with 
Glutamax I, 10% heat inactivated FCS (Gibco, 10108165), 5% Briclone (NICB 
Ltd., Ireland) and 1% HAT (Hypoxanthine, Aminopterin, Thymidine) (Gibco, 
21060) was added slowly down the side of the universal while continuing to 
swirl gently. 5mls of planting medium was added over the next 5 minutes (at 1 
minute intervals followed by the addition of 5mls). Following this step, the cell 
suspension was centrifuged at 500 rpm for 5 minutes. The supernatant was 
removed and the cells were resuspended in 10ml of plating medium and 
incubated at room temperature for 15 minutes.  
 
Immunisation regimes and fusion procedures were kindly carried out by Dr. 
Anne-Marie Larkin.  
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2.3.4  Screening of Hybridomas  
Generated hybridomas were screened directly for function on cell invasion 
against their parent immunogen. This was done using a 96-well invasion assay 
(see section 2.5.2). Hybridomas that produced an effect on cell invasion, either 
an increase or decrease, where chosen for further subculturing.  
 
2.3.5  Subculture of Hybridomas 
Positive clones were further sub-cultured to 6 well plates (Costar, 3335) and 
gradually transferred (fed 2x in HAT medium (Gibco, 21060-017), followed by a 
gradual change into HT (Hypoxanthine, Thymidine) medium (Gibco, 41065) – 
50:50 HAT:HT. Eventually (within 2 weeks) hybridoma clones were weaned off 
HT (by decreasing HT gradually in feeds every three days) and fed with DMEM 
medium supplemented with 5% Briclone (NICB., Ireland) and 10% heat 
inactivated FCS (Invitrogen, BD Biosciences, 10082147). 
 
2.3.6  Single Cell Cloning by Limiting Dilution 
Using a multi-channel pipette (eppendorf), 100µl of DMEM growth medium was 
pipetted into each well of a sterile 96 well tissue plate. 100µl of cell suspension 
from the rapidly growing hybridomas at a concentration of 1 X 104 cells/ml was 
added to the top left hand well and mixed by pipetting. 1 in 2 doubling dilutions 
were performed down the left hand row of the plate (8 wells, 7 dilution steps) 
and mixed by pipetting, ensuring to change the pipette tip each time. 1 in 2 
dilutions were also performed across the plate using a multi-channel pipette. 
Plates were then incubated for 7-10 days at 37°C, 5% CO2. Wells with 1 or 2 
cells were chosen. Hybridomas were cultured in T25cm2 flasks and the procedure 
repeated. The selected clones were screened by Invasion assays (section 2.5.2) 
and immunofluorescence (section 2.9.2 & 2.9.2), and frozen stocks made of 
positive clones. 
 
2.3.7  Isotype Analysis 
Isotyping was carried out using The Isostrip Mouse Monoclonal Antibody 
Isotyping Kit (Roche Diagnostics GmbH, 1493027).    
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2.3.8  Purification of MAbs 
Purified MAbs are required for cross linked immunoprecipitations (section 
2.11.2), due to the presence of gelatin/carrier proteins in unpurified MAbs 
competing for coupling sites on the gel. Purification of MAbs was carried out 
using the Pierce NAbTM Spin Purification Kit (Pierce, 20530). 200µl of 
ImmunoPure® Immobilised Protein-L Plus gel slurry was dispensed into a 
HandeeTM Spin Cup Column, along with 300µl of Binding Buffer, and 
centrifuged at 5000 x g for 1 minute (all subsequent centrifuges were at this 
speed and duration). Excess solution was discarded, leaving the gel in the spin 
cup. This was washed twice with 0.4ml of Binding Buffer, centrifuged and 
excess solution discarded. 250µl of antibody was dispensed into the spin cup, 
along with 250µl Binding Buffer, and incubated at 4°C overnight on a rocking 
platform. The following day, the solution was centrifuged, and the non-bound 
sample was retained, to analysis the efficiency and capacity of the binding. 0.4ml 
Binding Buffer was added to the spin cup, followed by centrifugation and 
discarding of the excess solution. This step was repeated twice. 0.4ml of 
IgM/IgG Elution Buffer was added to the solution, followed by 5 minute 
incubation at room temperature. This was repeated twice more, with each 0.4ml 
fraction being retained (the purified MAb should be eluted within the first 3 
fractions). The high pH of the fractions were neutralised with the addition of 
10µl of a Tris-HCl, pH 8.8, solution. The gel was then regenerated by washing in 
0.4ml PBS, 3 times, centrifuging between every wash, and stored at 4°C in 0.5ml 
PBS. The immobilised protein can be re-used up to 10 times without significant 
loss in binding capacity.  
 
2.3.9  Dialysis of MAbs 
Dialysed MAbs are required for cross linked immunoprecipitations, due to the 
presence of amines in unpurified MAbs competing for coupling sites on the gel. 
Dialysis of MAbs was carried out using the Pierce Slide-A-Lyzer MINI Dialysis 
Units (Pierce, 69576). 100µl of MAb was dispensed into the Dialysis cup which, 
was placed in a floatation device, in PBS for a minimum of 15 minutes, allowing 
for buffer exchange to take place. 
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2.4  In Vitro Proliferation Assay 
 
Cells were harvested at a concentration of 2 X 104 cells/ml in media. Volumes of 
100µl/well of these cell suspensions were added to a 96 well plate (Costar, 3596) 
using a multichannel pipette. Plates were gently agitated to ensure an even 
dispersion of cells over a given plate. Cells were incubated at 37°C, 5% CO2 
overnight. Following this, 100µl of antibody was added to each well. Control 
wells were those with 100µl hybridoma media added to cell suspension. Plates 
were gently agitated, as above, and incubated at 37°C, 5% CO2 for 6/7 days, until 
the control wells have reached 80-90% confluency. Assessment of cell survival 
in the presence of the antibodies was determined by the acid phosphatase assay.  
 
2.4.1 Acid Phosphatase Assay 
Following the incubation period of 6-7 days, media was removed from the plates.  
Each well on the plate was washed twice with 100µl PBS.  This was then 
removed and 100µl of freshly prepared phosphatase substrate (10mM p-
nitrophenol phosphate (Sigma 104-0) in 0.1M sodium acetate (Sigma, S8625), 
0.1% triton X-100 (Sigma, X100), pH 5.5) was added to each well.  The plates 
were then incubated in the dark at 37°C for 2 hours.  Colour development was 
monitored during this time.  The enzymatic reaction was stopped by the addition 
of 50µl of 1N NaOH.  The plate was read in a dual beam plate reader at 405nm 
with a reference wavelength of 620nm 
 
2.5  Extracellular Matrix Studies 
 
2.5.1   Reconstitution of ECM proteins 
Matrigel (Sigma, E-1270) was diluted to a working stock of 1 mg/ml in serum 
free DMEM. Fibronectin (Sigma, F-2006) was reconstituted in PBS to a stock 
concentration of 500 µg/ml. Aliquoted stocks were stored at -20°C.  
 
2.5.2  Invasion Assays 
This assay was set up using a Costar 24 well plate (Costar, 3524), containing 
8.0µm pore sized inserts (BD Biosciences, 353097). For invasion (but not 
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motility) assays, a layer of Matrigel (BD Biosciences, 354234) was dispensed 
into the insert. Matrigel was diluted to 1mg/ml in serum-free DMEM medium. A 
volume of 100µl of this Matrigel was dispensed into each insert, and the plate 
was incubated overnight at 4°C.  The following day, any excess Matrigel was 
removed from the inserts. Cells were harvested at a concentration of 1 X 106 
cells/ml in media, and 100µl was added to each insert, along with 100µl of 
antibody/media (cells invading in the presence of hybridoma media were taken 
as 100%). A volume of 500µl media was added to each insert well. Cells were 
incubated at 37°C for 24 - 48hrs, depending on the cell line used.  
 
Cell Line Seeding Density Incubation Time 
MDA-MB-157 1 x 106 48hr 
MDA-MD-231 1 x 106 24hrs 
SKBR-3 1 x 106 48hrs 
DLKP-I 1 x 106 48hrs 
DLKP-M 1 x 106 24hrs 
H1299 5 x 105 24hrs 
MiaPaCa-2 clone 3 1 x 106 48hrs 
BxPc-3 1 x 106 48hrs 
Lox IMVI 1 x 106 24hrs 
SNB-19 1 x 105 24hrs 
C/68 1 x 106 48hrs 
HCT-116 1 x 106 24hrs 
 
Following this, the inner area of each insert was wiped with a cotton bud soaked 
in PBS, to remove any cells, while the outside of the insert was stained with 
0.25% crystal violet. Staining of the inserts was sustained for a period of 10 
minutes, followed by a gentle rinse, done in triplicate, in UHP and then allowed 
to dry. Quantification of the cells was achieved by doing a cell count per area per 
view at 20X magnification using a light microscope. 10 fields of view were 
counted per insert. A minimum of 2 inserts were used per sample tested.     
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For 96 well invasion assays, a Millipore 96 well invasion plate (Millipore, 
MAMIC8S10) was used. An identical procedure was followed, with the 
exceptions that 50µl Matrigel was dispensed into each insert, a cell suspension of 
2.5 X 104 cells/ml was used, 50µl of antibody/media was added to each insert, 
and 150µl media was added to each insert well.  
 
2.5.3  Motility Assays 
Motility assays were carried out in an identical manner to invasion assays, as 
described in section 2.5.2, with the exception that the inserts were not coated in 
Matrigel. 
 
2.5.4  Adhesion assay 
Adhesion assays were performed using an adapted method of Torimura et al., 
(1999). 250µl aliquots of ECM proteins were placed into wells of a 24-well plate. 
The plates were gently mixed to ensure the base of each well was completely 
covered with the solution. The plates were then incubated overnight at 4°C. The 
excess solution was then removed from the wells and washed twice with sterile 
PBS. To reduce nonspecific binding, 0.5 ml of sterile 0.1% BSA/PBS solution 
was dispensed into each well. The plates were incubated at 37°C for 20 minutes 
and then rinsed twice again with sterile PBS. 
 
Cells were harvested and resuspended in media at a concentration of 2.5 X 104 
cells/ml. 1ml of cells were plated onto 24 wells plates in triplicate and incubated 
for 60 minutes. Wells that had been coated with ECM proteins but contained no 
cells were used as blanks. Wells containing cells but not coated with ECM 
proteins were used as positive controls. After 60 minutes, the medium was 
removed from the wells and rinsed gently with sterile PBS. Cell number attached 
was assessed using the acid phosphatase assay (section 2.4.1). 
 
2.5.5   Pre-incubation of cells with Matrigel coated flasks 
Matrigel was coated onto flasks (1 ml/T25 cm2) at a concentration of 1 mg/ml. 
Flasks were shaken gently to ensure complete coverage of the bottom of the 
flask. The coated flasks were then placed at 4°C overnight to allow the Matrigel 
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to settle. Before seeding flasks with cells, the flasks were placed into an 
incubator at 37°C for approximately 1 hours to allow the Matrigel polymerise. 
The excess media in the flasks was then removed and fresh complete media 
containing the cell suspension was added. Cells attached to the Matrigel on the 
bottom of the flask and after 70-90% confluency was achieved, were removed 
with 0.5ml/T25 cm2 Dispase (BD Biosciences, 354235). Dispase is a bacillus 
derived neutral metalo protease that recovers cells cultured on Matrigel. 
 
2.6   Anoikis assay 
 
Poly- (2-hydroxyethyl methacrylate) (poly-HEMA, Sigma, P3932) was dissolved 
at 12 mg/ml in 95% ethanol. To coat 24-well plates, 100µl of poly-HEMA 
solution was added and allowed to dry in a laminar flow cabinet. After full 
evaporation, the coating step was repeated. Once evaporation was complete, 
wells were washed twice with sterile PBS. Cells (1 X 105cells/ml/well) were then 
plated onto standard 24-well tissue plates (adherent controls) or poly-HEMA-
coated plates (non-adherent) and incubated for 24 hrs at 37°C in 5% CO2. After 
this time, 100µl of alamar blue vital dye (Serotec, BUF012B) was added to the 
24-well plates to quantitatively measure cell survival. The plate was read in a 
dual beam plate reader at 570 nm with a reference wavelength of 600 nm. The 
level of anoikis was assessed as the percentage cell death relative to adherent 
controls over 24 hours.  
 
2.7  Zymography Assay 
 
2.7.1  Collection of Conditioned Media 
Cells were cultured until 50-60% confluent. Cells were washed x3 in serum-free 
(SF) media. Cells were incubated in SF media (12 ml/T75 cm2 flask) for 60 min. 
After this time, cells were washed again x3 in SF media. 12mls of 1:1 SF 
media/MAb/Hybridoma media was added to the cells and incubated for 72 hrs. 
After such time, conditioned media was collected, centrifuged for 5 min at 1000 
rpm, filtered through 0.22µm filter and stored at –80°C. 
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2.7.2  Zymography of Matrix Metalloproteinases 
Conditioned media supernatants were prepared in a 4X non-reducing loading 
buffer (Invitrogen, NP0007) before being separated on a 10% zymogram 
(gelatin) gel (Invitrogen, EC61752BOX). This gel allows for the visualisation of 
MMP-2 and MMP-9. The gels were run at a constant voltage of 125V, 45mA for 
90 minutes, or until the bromophenol blue dye front reached the end of the gel, in 
a 1X Tris-Glycine SDS running buffer (Biorad, 161-0732). After electrophoresis, 
the gel is incubated with a 1X Zymogram Renaturing Buffer (Invitrogen 
Developing buffer (LC2671) containing 2.5% Triton-X 100 (BDH, 30632), for 
30 minutes at room temperature. The Renaturing Buffer is decanted, and 1X 
Zymogram Developing Buffer is added, followed by an addition 30 minute 
incubation at room temperature. Fresh Developing Buffer is added, and the gel is 
incubated at 37°C overnight. The gel is then stained with Brilliant blue G 
Colloidal Coomassie (Sigma, B2025).  
 
2.8  Morphology Studies 
 
Cells were grown to 70-80% confluency in a T75 cm2, at which point a total 
volume of 12mls, 1:1 ratio fresh media:MAb is added. Cells are incubated for 
24hrs at 37°C, and cell morphology is assessed visually. 
 
2.9    Immunocytochemical Analysis 
 
2.9.1  Immunofluorescence Studies on Live Cells 
Viable MiaPaCa-2 clone 3 & clone 8 cells were tested for reactivity with 
antibodies by indirect immunofluorescence studies. When immunofluorescence 
studies are performed on viable cells only cell surface antigens are recognised 
(Schachner et al., 1977). Cells were suspended to a concentration of 2 X 106 
cells/ml in DMEM. 30µl of this cell suspension was added to a 10 well, 7mm 
microscope slide (Erie Scientific Company, 465-68X), and was incubated 
overnight at 37°C.  After 24hrs, excess supernatant was tapped off, and the 
microscope slides were rinsed gently with warm PBS. Primary antibodies were 
added to each well (PBS was added to one well as a negative control), and were 
incubated overnight at 4°C. Primary antibodies were removed by washing in 
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PBS 3 times, at 3-minute intervals. 30µl of secondary antibody, fluorescein 
isothicyanate-linked (FITC) rabbit anti-mouse IgG (Dako, F0261), diluted 1/40, 
was added to each well, followed by a 30-minute incubation at room 
temperature. Secondary antibody was removed by PBS washing as mentioned 
above. Excess PBS was drained of with filter paper, and each slide was mounted 
using vectashield mounting medium (Vector, H-100) and coverslips, and sealed 
with nail varnish. Slides were viewed using a Nikon phase contrast microscope 
fitted with an FITC filter.  
 
2.9.2  Immunofluorescence Studies on Fixed Cells 
Cell suspension, volume added to slides and incubation is as described (2.9.1). 
After 24hrs, excess supernatant was tapped off, and the microscope slides were 
rinsed gently with PBS. Slides were then air dried overnight, wrapped in tin foil, 
and stored at -80°C. Slides are then removed from -80° C freezers, and left for 15 
minutes prior to immunstaining. Cells were fixed in ice-cold acetone for 2-4 
minutes.  
 
2.10  Western Blot Analysis 
 
2.10.1  Preparation of Whole Cell Lysates 
Cells were grown to 80-90% confluency in culture flasks (T175cm2 flask),  
media was removed, cells were trypsinised, pelleted and washed three times in 
ice cold PBS. Cells were resuspended in 1.5mls (per T175cm2 flask) NP/40 lysis 
buffer (Appendix I, Table 1), RIPA lysis buffer (Sigma, R0278) or Lysis buffer 
C (Appendix I, Table 2) containing 1X protease inhibitor (Complete MiniTM, 
04693124001, Roche Diagnostics, GmbH). Cell suspensions were homogenised 
by passing through a 21 G syringe. Sample lysates were sonicated for 5 minutes 
and centrifuged at 14000 rpm for 10 minutes at 4°C. Supernatants containing 
extracted protein were transferred to fresh chilled eppendorf tubes in 250µl 
aliquots, and stored at -80°C. Protein concentration was quantified using the Bio-
Rad or BCA assay as detailed in Section 2.10.2.  
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2.10.2  Protein Concentration Determination 
Protein-Levels were determined using the Bio-Rad (for lysis buffer C cell lysates 
- Bio-Rad, 5000006) or BCA (for RIPA buffer cell lysates – Bio-Rad, 500-0001) 
protein assay kit.  
 
2.10.3  Gel Electrophoresis 
Proteins for Western blotting were separated by SDS-PAGE gel electrophoresis 
(Laemmli et al., 1970), using 4-12% gradient gels (NP0335, NP0321). 
Approximately 15-30 µg of protein was applied to each well of the 
polyacrylamide gel. Pre-stained molecular weight markers (Invitrogen, LC5800) 
were also loaded onto the gel for the determination of the molecular weight of 
the unknown protein samples. Gels were run at 200 volts and 250 milliamps for 
1-1.5 hours with 1X MOPS, Tris/ Glycine/ SDS running buffer (Invitrogen, 
NP0001). When the dye front of the molecular weight markers had reached the 
end of the gel, electrophoresis was stopped.  
 
2.10.4  Western Blotting 
Following separation on SDS gels, protein samples/immunoprecipitated sample 
were transferred to PVDF membranes (Roche Diagnostic GmbH, 03-010-040-
001) using a semi-dry apparatus (Trans-Blot SD semi-Dry Transfer Cell, Bio-
Rad, USA). Proteins were transferred at 15V, 34 milliamps, for 45 minutes 
 
2.10.5 Development of Western Blots by Enhanced 
Chemiluminescence (ECL) 
Following Western blotting, the filter paper was removed and the membrane 
blocked for non-specific binding by incubation for 1-4 hours on a rocking 
platform with Starting BlockTM (TBS) Blocking Buffer (Pierce, 37542). After the 
blocking step was complete, the blot was rinsed once in TBS, and incubated with 
the primary antibody optimally diluted in TBS/0.1% (v/v) Tween 20 overnight at 
4°C or 2 hours at R.T. on a rocking platform (MAbs generated in this study were 
used neat). The following day blots were washed 3 times within 90 minutes with 
TBS/0.5% (v/v) Tween 20. Blots were then incubated with an anti-mouse HRP-
conjugated secondary antibody diluted in TBS/0.1% (v/v) Tween 20 for 1 hour at 
   69 
room temperature on a rocking platform (See Appendix I, table 4, for full list of 
secondary Abs used and the dilutions). The blots were washed as before, laid on 
a glass plate covered in parafilm and incubated with ECL reagents (Amersham, 
RPN 2105) for 1 minute at room temperature. Following this, the solution was 
tapped off, the blot laid between two sheets of cling film, and exposed to 
Amersham HyperfilmTM, chemiluminescence film (GE Healthcare, 28906837) 
for various time periods and processed using standard x-ray developing 
procedures. Dried film was aligned with pre-stained molecular weight markers 
for molecular weight determination. 
 
2.11   Immunoprecipitation Studies 
 
2.11.1  Direct Immunoprecipitation 
Protein was isolated from a number of cell lines, as described in section 2.10.1. 
250µl test aliquots of supernatant were pre-cleared by incubation with protein-L 
(P3351, Sigma, UK), or Protein G (Pierce, 22852), 50µl of which was added to 
all test samples. All samples were incubated with two changes (2 x 2 hours) of 
protein-L/G agarose beads at 4°C on a rocking platform. Beads were removed by 
spinning at 2500rpm for 10 minutes at 4°C. Supernatants were removed to clean 
eppendorf tubes and 75µl of antibody (concentrated 5X supernatant, using 
Millipore Ultrafree-15 centrifuge filter units (Millipore, Z-36436-0) was added to 
250µl lysate samples. 50µl of control mouse IgM (Chemicon, PP50) or control 
mouse IgG (Sigma, I5381) (used at a concentration of 22µg/ml) was added to 
250µl negative control lysates. Antibody/lysate mixtures were incubated at 4°C 
overnight on a rocking platform. The following day, in order to precipitate the 
antibody-antigen complex, protein-L/G agarose was added to the antibody-
antigen complex samples as before and incubated at 4°C for 4 hours on a rocking 
platform. Beads were removed by spinning at 2500rpm for 10 minutes at 4°C, 
and the supernatant discarded. The beads were then washed for 3 x 15 minute 
periods with buffers as described in Appendix III and pelleted at 2500rpm for 10 
minutes. Following the final wash and spin, as much liquid as possible was 
removed from all samples. 75µl of 2X laemmili sample buffer was added to 
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original 250µl lysates and control sample beads. All samples were boiled for 10 
minutes and stored at -80°C until required for SDS-PAGE/Western blot analysis. 
 
2.11.2  Cross Linked Immunoprecipitation  
Cross Linked I.P.s were carried out using the Seize ® Primary 
Immunoprecipitation Kit (Pierce, 45335). 200µl of AminoLink® gel slurry was 
added to a HandeeTM Spin cup Column, and spun down at 5000 x g for 1 minute 
(all subsequent centrifuges were at this speed and duration). Excess slurry was 
discarded, leaving the gel in the spin cup. This was washed twice with 0.4ml of 
Coupling Buffer, centrifuged and excess solution discarded. 200µl of affinity-
purified antibody (section 2.3.8, 2.3.9) was added to the gel, along with 200µl of 
Coupling Buffer. 4µl of Reducing Agent (Sodium Cyanoborohydride) was added 
to the mixture (1µl/100ul diluted antibody), which was then incubated over night 
at 4°C. This step is to facilitate cross-linking of the antibody to the gel. The gel 
was then centrifuged and washed with 0.4ml Coupling Buffer, followed by 
another centrifugation step. Excess solution was discarded. Following this, 0.4 
ml of Quenching Buffer was added to the suspension, centrifuged, and excess 
solution discarded. 0.4ml of Quenching Buffer was then added to the 
gel/antibody complex, along with 4µl of Reducing Agent. This suspension was 
incubated with end-over-end mixing, for 30 minutes at room temperature, 
followed by centrifugation and discarding of any excess solution. The gel was 
then washed 6 times with 0.4ml Wash Buffer, followed by 4 washes in 0.4ml 
Binding Buffer, with centrifugation following each wash. 
 
The antigen (protein) sample was pre-cleared with Protein-L/G as described in 
section 2.11.1. 250µl was added to the gel/antibody complex, along with 250µl 
of Binding Buffer. This solution was incubated overnight at 4°C on a rocking 
platform. The following day, the sample was centrifuged, and excess solution 
discarded. The gel/antibody-antigen complex was then washed 3 times in 0.4ml 
Immunoprecipitation Buffer, with centrifugation after each wash. The antigen-
antibody complex was then cleaved with the addition of 200µl of an IgM/IgG 
Elution Buffer to the solution, followed by 5 minute incubation at room 
temperature. This was repeated twice more, with each 200µl fraction being 
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retained (the antigen should be eluted within the first 3 fractions). The high pH of 
the fractions was neutralised with the addition of 5µl of a Tris-HCl, pH 8.8, 
solution. The gel was then regenerated by washing, in triplicate, with 0.4ml 
Immunoprecipitation Buffer, centrifuging and discarding excess solution, 
between every wash. The gel was then stored at 4°C in 0.5ml Binding Buffer. 
The gel-antibody complex can be re-used up to 10 times without significant loss 
in binding capacity.  
 
Eluted fractions were prepared for Gel Electrophoresis using NuPAGE® LDS 
Sample Buffer (4X) (Invitrogen, NP0007), containing 10X NuPAGE® Sample 
Reducing Agent (Invitrogen, NP0009). All samples were made up to 1X 
concentration.   
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Figure 2: - Direct (Traditional) and Cross Linked Immunoprecipitation 
(www.piercenet.com) 
 
2.11.3  Gel Electrophoresis of Immunoprecipitated Proteins 
Immunoprecipitated proteins, along with unstained molecular weight markers 
(Invitrogen, LC5801), were separated on 4-12%, Bis-Tris, SDS-PAGE 
electrophoresis as described in section 2.10.3. Following gel electrophoresis, the 
gel was either stained using Brilliant blue G Colloidal Coomassie, or Western 
blot analysis was carried out as outlined in section 2.10.4.  
 
The Cross Linked IP Method 
Cross Linked 
IP product 
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2.11.4  Staining- Brilliant blue G Colloidal Coomassie and silver 
staining of gels for LC-MS Identification 
After electrophoresis, the gels were placed in a square petri dish (Sigma, 
Z617679) containing fixing solution (7% glacial acetic acid in 40% (v/v) 
methanol (ROMIL, HL109)) for at least 1 hour. During this step a 1X working 
solution of Brilliant Blue G colloidal Coomassie was prepared by adding 800ml 
UHP to the stock bottle. When the fixing step had nearly elapsed a solution 
containing 4 parts of 1X working colloidal Coomassie solution and 1 part 
methanol was made, mixed by vortexing for 30 seconds and then placed on top 
of the gels. The gels were left to stain for 2 hours. To destain, a solution 
containing 10% acetic acid in 25% methanol was poured over the shaking gels 
for 60 seconds. The gels were then rinsed with 25% methanol for 30 seconds and 
then destained with 25% methanol for 24 hours.  
 
Alternatively, gels were stained using a silver stain protocol. All buffers were 
prepared as outlined in Appendix I, Table 3: 
 
Gels were fixed for a minimum of 2 hours, followed by three 20 minute washes 
in 35% Ethanol. Gels were then sensitised for 2 minutes, and washed in UHP for 
5 minutes, in triplicate. Staining was then carried out, for 20 minutes with the 
Silver Nitrate solution, followed by two 1 minute washes in UHP. Gels were then 
developed until bands were visible to the naked eye. Staining was then stopped 
through a 5 minute wash with the stop solution.  
 
2.12  Protein Identification Using LC-MS/MS 
 
LC-MS/MS was performed on an Ultimate 3000 nanoLC system (Dionex), 
interfaced to an LTQ Orbitrap XL (Thermo Fisher Scientific). 
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Figure 2.1: - Standard workflow for protein identification based on tandem mass 
spectrometry. (1) and (2), protein sample complexity reduced using separation 
techniques; (3), proteins are enzymatically digested; (4), resulting peptides 
undergo tandem mass spectrometric analysis yielding a collection of MS/MS 
spectra; (5) Identification of peptides is achieved through correlation of the 
MS/MS spectra with theoretical peptides; (6), a list of identified proteins is 
produced (6) (Hernandez et al., 2005). 
Protein bands were excised from the Coomassie-stained gel and destained with a 
solution containing 50% methanol and 50 mM NH4HCO3. Samples were then 
dehydrated by the addition of 70% acetonitrile (ACN) and swelled by 
rehydration in a digestion buffer containing 40 mM NH4HCO3 and 12.5 ng/µL of 
trypsin (Promega, sequencing grade) at 37 °C overnight. Peptides were extracted 
with three changes of 50% ACN/ 0.1% formic acid (Fluka) and dried down in a 
vacuum centrifuge. Tryptic peptides were re-dissolved in 10µL of 0.1% formic 
acid. 5µL of sample was loaded onto a trapping column packed with C18, 
PepMAP100 (Dionex) at a flow rate of 20µL/min in 0.1% formic acid. After 5 
minutes of washing, peptides were eluted into a C18 PepMAP100 nanocolumn 
(15 cm×75µm ID, 3µm particles) (Dionex) at a flow rate of 350 nL/min. Peptides 
were separated using the mobile phase gradient: from 5 to 50% of solvent B in 
30 min, and from 50 to 90% B in 5 min. Solvent A was 98:2 H2O:ACN (v/v) 
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containing 0.1% formic acid; solvent B was 2:98 H2O:ACN (v/v) containing 
0.1% formic acid. 
LC-MS/MS data was acquired in data-dependent acquisition (DDA) mode 
controlled by Xcalibur 2.0.7 software (Thermo Fisher Scientific).  A typical 
DDA cycle consisted of an MS scan within m/z 300–2000 performed under the 
target mass resolution of 60,000 (full width at half maximum) followed by 
MS/MS fragmentation of the six most intense precursor ions under normalised 
collision energy of 35% in the linear trap.  
2.12.1  Bioinformatic Interpretation of Mass Spectrometry Data 
Bioinformatics is the application of computer science and statistics to the 
management of biological data such as genomics and proteomics. It allows for 
the determination of proteomic signatures responsible for important clinical-
pathological features, and the identification of proteins/antigens that may be 
significant candidates as biomarkers and therapeutic targets in a host of diseases.  
Database searches were performed using TurboSEQUEST software (Bioworks 
Browser version 3.3.1) (Thermo Fisher Scientific) using the human subset from 
the SWISS-PROT database. SWISS-PROT is a protein sequence database which 
provides a high level of annotations (such as the description of the function of a 
protein, its domains structure, post-translational modifications, variants, etc.), a 
minimal level of redundancy and high level of integration with other databases. It 
was established in 1986 by Amos Bairoch in the Department of Medical 
Biochemistry at the University of Geneva (Per Kraulis, 2001). The following 
filters were applied: for charge state 1, XCorr>1.5; for charge state 2, XCorr>2.5; 
for charge state 3, XCorr>3.5.  
LC-MS/MS analysis and bioinformatic interpretation of data was carried out with 
the help of Michael Henry and Dr. Paul Dowling.  
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2.13   Immunohistochemical Analysis 
 
All immunohistochemical studies on formalin-fixed paraffin-embedded tissue 
sections were performed following the method of Hsu et al., (1981) using an 
avidin-biotin horseradish peroxidase (HRP) conjugated kit (ABC) plus an 
appropriate secondary antibody. Formalin-fixed paraffin-embedded tissue was 
kindly provided by Tallaght Hospital (AMNCH), Mount Carmel Hospital, 
Beaumont Hospital, Royal Victoria Eye & Ear Hospital and St. Vincent’s 
Hospital, Dublin. 5µm sections of tissue blocks were cut using a microtome, 
mounted onto poly-l-lysine coated slides. Slides were stored at room temperature 
until required. 
 
All immunohistochemical staining was performed using the Dako Autostainer 
(Dako, S3800). Deparaffinisation and antigen retrieval was performed using 
Epitope Retrieval 3-in-1 Solution (pH 9) (Dako, S2375) and the PT Link system 
(Dako, PT101), whereby slides are heated to 97°C for 20 minutes, then cooled to 
65°C. The slides are then immersed in Wash buffer (Dako, S3006). On the 
Autostainer, slides were blocked for 10 minutes with 200µl HRP Block (Dako, 
S2023). Cells were washed with Wash buffer, and 200µl of MAb was added to 
the slides for 20 minutes. Slides were washed again with Wash buffer, and then 
incubated with 200µl Real EnVision DAB (Dako, K4065) for 30 minutes. Each 
slide was also run with Negative Control Reagent(1X TBS/0.05% Tween-20), to 
allow evaluation of non-specific staining and allow better interpretation of 
specific staining at the antigen site. Staining was performed using MAbs 
generated in this study. All slides were counterstained with haematoxylin for 5 
minutes, and rinsed with deionised water, followed by wash buffer. All slides 
were then dehydrated in graded alcohols (2 x 3 minutes each in 70% IMS, 90% 
IMS and 100% IMS), and cleared in xylene (2 x 5 minutes), and mounted with 
coverslips using DPX mountant (Sigma, 44581). 
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2.14  RNA interference (RNAi) 
 
RNAi using small interfering RNA's (siRNAs) was carried out to silence specific 
genes. The siRNAs used were chemically synthesised (Ambion Inc). These 
siRNAs were 21-23 bps in length and were introduced to the cells via reverse 
transfection with the transfection agent siPORTTM NeoFXTM (Ambion Inc., 
4511). 
 
2.14.1   Transfection optimisation 
In order to determine the optimal conditions for siRNA transfection, optimisation 
with kinesin siRNA (Ambion Inc., 16704) was carried out for each cell line. 
There were a number of different parameters that had to be determined to 
establish an optimised protocol for the siRNA transfection of MiaPaCa-2 and its 
single cell population clones. 
 
Cell suspensions were prepared at 1 X 105, 3 X 105 and 5 X 105 cells per ml. 
Solutions of negative control and kinesin siRNAs at a final concentration of 
30nM were prepared in optiMEM (GibcoTM, 31985047). NeoFX solutions at a 
range of concentrations were prepared in optiMEM in duplicate and incubated at 
room temperature for 10 minutes. After incubation, either negative control or 
kinesin siRNA solution was added to each neoFX concentration. These solutions 
were mixed well and incubated for a further 10 minutes at room temperature. 
100µl of the siRNA/neoFX solutions were added to each well of a 6-well plate. 1 
ml of the relevant cell concentrations were added to each well. The plates were 
mixed gently and incubated at 37°C for 24 hours. After 24 hours, the transfection 
mixture was removed from the cells and the plates were fed with fresh medium. 
The plates were assayed for changes in proliferation at 72 hours using the acid 
phosphatase assay (Section 2.4.1). Optimal conditions for siRNA transfection 
were determined as the combination of conditions, which gave the greatest 
reduction in cell number after kinesin siRNA transfection and also the least cell 
kill in the presence of transfection reagent. Western blot analysis was used to 
establish the optimum conditions for a siRNA transfection. The optimised 
conditions for the cell lines are shown in Table 2.16. 
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Cell Line Seeding 
Density per 
96-Well Plate 
Seeding Density 
per 6-Well Plate 
Volume 
NeoFX 
per 96 well 
(µl) 
 
Volume 
NeoFX 
per 6 well (µl) 
 
MiaPaCa-2 clone 3 2.5x103 3x105 0.2 2 
DLKP-M 2.5x103 3x105 0.2 2 
 
Table 2.14: - Optimised conditions for siRNA transfection 
 
2.14.2  siRNA functional analysis of targets identified in MiaPaCa-2 
clone 3 and DLKP-M 
Two - three pre-designed siRNAs were chosen for each of the protein/gene 
targets and transfected into cells. Two siRNAs were used if a validated siRNA 
was available. Validated siRNAs have been verified by real-time RT-PCR to 
reduce gene expression of >70% 48 hours post-transfection. For each set of 
siRNA transfections carried out, control, non-transfected cells and a scrambled 
(SCR) siRNA transfected control were used. Scrambled siRNA are sequences 
that do not have homology to any genomic sequence. The scrambled non-
targeting siRNA used in this study is commercially produced, and guarantees 
siRNA with a sequence that does not target any gene product. It has also been 
functionally proven to have no significant effects on cell proliferation, 
morphology and viability. For each set of experiments investigating the effect of 
siRNA, the cells transfected with target-specific siRNAs were compared to cells 
transfected with scrambled siRNA. This took account of any effects due to the 
siRNA transfection procedure, reagents, and also any random effects of the 
scrambled siRNA. Kinesin was used as a control to assess the efficiency of the 
siRNA transfection. Kinesin plays an important role in cell division; facilitating 
cellular mitosis. Therefore, transfection of siRNA kinesin resulted in cell cycle 
arrest and confirmed efficient transfection. Western blots (section 2.10.4) were 
used to determine if siRNA had an efficient knock-down effect at a Protein-
Level. (Appendix I, Table 5 outlines the list of siRNAs and IDs used in this 
thesis) 
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2.14.3  Proliferation assays on siRNA transfected cells 
As described in table 2.12, cells were seeded using 0.2µl NeoFX to transfect 
30nM siRNA in a cell density of 2.5 X 103 per well of a 96-well plate. After 24 
hrs, transfection medium was replaced with fresh media and cells were allowed 
to grow until they reached 80-90% confluency, a total of 5 days. Cell number 
was assessed using the acid phosphatase assay (section 2.4.1). All experiments 
were carried out independently at least three times. 
 
2.14.4   Invasion assays on siRNA transfected cells 
Using the optimised conditions in Table 2.16, each of the siRNAs was tested to 
see changes in invasion of the cells after transfection. Two-three separate 
siRNAs were used for each target gene (Appendix I, Table 5). All siRNAs were 
purchased from Ambion Inc. 
 
To assay for changes in invasive capacity, siRNA experiments in 6-well plates 
were set up using 2µl NeoFX to transfect 30nM siRNA at a cell density of 3 X 
105 per well of a 6-well plate. Transfection medium was removed after 24 hours 
and replaced with fresh growth medium. The transfected cells were assayed for 
changes in invasion capacity at 48 hours using the in vitro invasion assay 
described in Section 2.5.2. All experiments were carried out independently at 
least three times. 
 
2.14.5  Motility assays on siRNA transfected cells 
Motility assays were carried out as described in section 2.5.3 
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2.15   Statistical analysis 
 
Analysis of the difference of comparisons, as well as untreated versus siRNA 
treated mean invasion and motility counts, adherence absorbance, Anoikis and 
percentage survival calculated, were performed using a student t-test (two-tailed 
with equal variance), on Microsoft Excel. This t-test method was used because 
the 2 sample sizes are equal, and it is assumed that the two distributions have the 
same variance, e.g. SNB-19 invasion assay: 
 
Control (Hybridoma Media) MAb 7B7 G5 (2) 
31.5 28.9 
53.1 27.3 
37.2 27.4 
34.2 23.6 
21.2 15 
29 17.3 
25.9 16.9 
23.1 22.9 
25 22.3 
  
Table 2.15: - Mean cell counts from invasion assay of SNB-19 glioma cells n 
the presence of hybridoma media (control) and MAb 7B7 G5(2). Counts of 
inserts over  biological triplicates. 3 inserts per biological experiment 
 
Using Microsoft Excels T Test function with the above figures, a p value of 
0.029 is achieved, making it significant. The P value measures the probability 
that the differences between the control and test samples would be observed by 
chance 
 
*, A p value of ≤ 0.05 was deemed significant 
**, A p value ≤ 0.01 was deemed more significant 
***, A p value ≤ 0.005 was deemed highly significant 
 
n = 1 
n = 2 
n = 3 
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Error bars were plotted using plus and minus the standard deviation on triplicate 
inserts interexperimentally. 
 
In the siRNA experiments, siRNA scrambled transfected cells were used as 
control compared to siRNA treated samples. This was to ensure no ‘off-target’ 
effects of the siRNA transfection procedure. Non-treated controls were used to 
ensure scrambled siRNA was having no effect and to normalise data.  
 
Effects of less than 20% are taken as “little to no effect”, however, statistical 
analyses are still carried out, and therefore an experiment that shows little to no 
effect can still be significant or non-significant. 
   82 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
GENERATION OF MONOCLONAL ANTIBODIES 
DIRECTED AGAINST MIAPACA-2 CLONE 3 
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3.1  Background 
 
An initial primary immunisation, and 4 booster immunisations were carried out 
with  the pancreatic cell line, MiaPaCa-2 clone 3, an invasive variant of the 
MiaPaCa-2 parent cell line (Walsh et al., 2008), A final boost was carried out 3 
days prior to fusion. 
 
3.2  Fusion Results 
 
Following fusion with MiaPaCa-2 clone 3 cells, as described in section 2.3.3, 
335 hybridoma supernatants (77.5% fusion efficiency) were screened directly for 
any effect on the invasive capacity on MiaPaCa-2 clone 3 cells, and by live and 
fixed cell immunofluorescence. 
 
3.3  Preliminary Characterisation of Hybridoma Supernatants 
 
3.3.1  Screening Directly for Effects on Invasion 
 
All resulting hybridomas were screened using a newly developed 96-well 
invasion assay method (section 2.5.2.) against the parent cell line, MiaPaCa-2 
clone 3. Supernatants showing an increase or decrease in invasion levels were 
identified by three independent witnesses through microscopic evaluation. 
Controls comprised of cells with no antibody supernatant (hybridoma media 
added in place), with invasion levels in all cases being compared to this 
hybridoma medium control. 
 
25 supernatants (duplicate samples) were re-screened twice (96-well invasion 
assay). MAbs 8B3, 7B7, 1E5, 7C3, 7B7, 9D6, 5B1 & 6E2, which all exhibited a 
decrease in invasion, and MAbs 7C7 & 7B6, which both showed an increase in 
invasion, were then re-screened, in triplicate, using 24 well invasion assays, 
again on the invasive MiaPaCa-2 clone 3 and the low invasive MiaPaCa-2 clone 
8 cells. MAbs 7B7 and 6E2 appeared to have the most consistent inhibition of 
invasion, and were chosen for further characterisation. As can be seen in Figure 
3.3.1, MAb 7B7 supernatants harvested at various time points, from T25cm and 
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T75cm flasks, show a consistent inhibitive effect on invasion levels in invasive 
MiaPaCa-2 clone 3 cells. Preliminary results also indicated that MAb 7B7 
marginally decreased invasion (by observation only; not quantified) in MiaPaCa-
2 clone 8 cells, which exhibit very low levels of invasion (results not shown). 
 
MAbs 7B7 & 6E2 were then cloned out by limiting dilutions (section 2.3.6), and 
re-screened using both 96 and 24 well invasion assays (figure 3.3.2). Using 
invasive MiaPaCa-2 clone 3 pancreatic cells, clones G5 and G5 (2) exhibited a 
consistent inhibitive effect on invasion (figure 3.3.3). It was decided at this point 
that MAb 7B7 G5 (2) would be chosen for further characterisation. Significant 
inhibition of the 7B7 G5 (2) supernatant was observed (in triplicate, independent 
experiments) following the freezing down, and thawing back, of the hybridoma, 
indicating the stability of this MAb. Isotyping of MAb 7B7 G5 (2) determined it 
to be an IgM antibody (Figure 3.3). Isostrip analysis was carried out as described 
in section 2.3.7 
 
 
 
Figure 3.3: - Isostrip analysis of MAb 7B7 G5 (2), indicating that it is an IgM 
subclass antibody (Isostrip, Roche Diagnostics, GmbH, 1493027) 
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Figure 3.3.1: - Representative histogram showing inhibitory effects of MAbs 
6E2 and 7B7, harvested from T25cm3 and T75cm3 flasks over different dates, on 
MiaPaCa-2 clone 3 invasion after 48 hours. MAb 6E2 successfully inhibits 
invasion by 40%, while MAb 7B7 inhibits invasion by up to 86%. Error bars 
calculated using ± standard deviation. 
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Figure 3.3.2: - Representative histogram showing inhibitory effects of MAbs 
6E2 and 7B7 clones, on MiaPaCa-2 clone 3 invasion after 48 hours. Clone 6E2 
E7 successfully inhibits invasion by 39%, while 7B7 G5 (2) inhibits invasion by 
up to 77%. Error bars calculated using ± standard deviation. 
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Figure 3.3.3: - Representative photomicrographs showing invasion of MiaPaCa-
2 clone 3 cells after 48 hours with addition of (A) hybridoma media (Control – 
no MAb), (B) MAb 6E5 E7, (C) MAb 7B7 G5 (2) and (D) MAb 7B7 F5.  A 
decrease in invasion can be observed following addition of (B) MAb 6E5 clone 
E7 and (C) MAb 7B7 clone G5 (2) when compared to the control insert (A). No 
inhibition of invasion is observed with MAb 7B7 clone F5 (D). Magnification, 
100X. Scale Bar, 200µm 
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3.3.2  Immunofluorescence Assay 
 
Following 2 preliminary screenings, 22 hybridoma supernatants showing strong 
reactivity by immunofluorescence with MiaPaCa-2 clone 3 were chosen for 
repeat screenings. The cellular staining observed varied between strong 
membrane-like staining to more intracellular-like staining; some nuclear 
reactivity was also observed with a small number of hybridomas. Following 
repeated screenings, hybridomas 8F4, 3E2, 5B5, 1E5, 9D6 & 7B7 were chosen 
for further characterisation. Preliminary results using immunofluorescence 
indicated that MAbs 9D6 & 3E2 exhibited stronger reactivity with MiaPaCa-2 
clone 8 cells (low level invasive variant). MAbs 7B7 & 8F4 appeared to show 
stronger reactivity with clone 3 compared to clone 8. MAb 8F4 showed very 
strong membrane positivity, not observed with any of the other antibodies, 
indicating that this MAb was recognising a membrane epitope. Representative 
photomicrographs showing MAbs 3E2, 7B7, 8F4 & 9D6 reactivity in MiaPaCa-2 
clone 3 and clone 8 cells can be observed in Figure 3.3.4. Immunofluorescence 
assays were carried out as described in section 2.9.1 and 2.9.2 
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Figure 3.3.4: - Immunofluorescence analysis of MiaPaCa-2 clone 8 (A, C, E & 
G) and MiaPaCa-2 clone 3 (B, D, F & H) stained with MAbs 3E2 (A, B), 7B7 
(C, D), 8F4 (E, F) and 9D6 (G, H).  Magnification, 40X. Scale bar, 20µm.
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3.4 Investigation of Functional Effect of MAb 7B7 G5 (2) in 
Invasive Cancer Models In Vitro. 
 
MAb 7B7 G5 (2) underwent further testing to observe its effects on a number of 
cellular processes, including: 
 
• Proliferation: to observe what effect the MAb has on the cancer cells 
ability to grow.  
• Invasion & Motility: to assess the MAb’s effect on cellular 
invasion/motility 
• Adhesion: to assess the MAb’s impact on the adhesive abilities of a 
number of cell lines to ECM proteins  
• Anoikis: Anoikis is a specific form of apoptosis induced by the loss or 
alteration of cell-cell or cell-matrix anchorage. An in vitro anoikis assay 
was used to assess any impact this MAb has on anoikis resistance.  
• MMP activity: to observe what effect, if any, this MAb has on the activity 
of MMP-2 and MMP-9 in vitro. 
• Cell Morphology: to observe if incubation with this MAb affects the 
morphology of invasive cancer cells. Highly invasive cells usually 
display a spindle shaped elongated morphology. 
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3.4.1 MAb 7B7 G5 (2) Effect on Proliferation on the Invasive 
Pancreatic Cell Line MiaPaCa-2 clone 3 
 
The primary goal of this work was to examine the effects of MAb 7B7 G5 (2) on 
invasion and motility. To ensure that any changes observed in the assays were 
not secondary to effects on cell proliferation or survival, initial experiments were 
carried out to determine the effects MAb 7B7 G5 (2) had on 
proliferation/survival of the MiaPaCa-2 clone 3 cell line. Proliferation assays 
were carried out as described in section 2.4.  
 
Figure 3.4 shows that MAb 7B7 G5 (2) had no impact on MiaPaCa-2 clone 3 cell 
proliferation/survival after a 5 day growth assay. This suggests that the MAb has 
no toxic, growth inhibitory or stimulatory effect on this cell line over the course 
of the assay. 
 
Statistical analyses were carried out on the average absorbancy readings of the 
control Vs test wells, over biological triplicates. 
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Figure 3.4: - Histogram of MAb 7B7 G5 (2) showing negligible inhibition of 
proliferation compared to control hybridoma medium (no MAb) representing 
100% proliferation, after 96 hours. Statistics; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 
0.005, Student’s t-test. n = 3. Error bars calculated using ± standard deviation. 
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3.4.2 MAb 7B7 G5 (2) Effect on Invasion on Invasive Cancer Cell 
Lines  
 
In order to ascertain what effect MAb 7B7 G5 (2) has on cell invasion and 
motility, Invasion and Motility assays were carried out (as described in section 
2.5.2 & 2.5.3.) on a range of invasive cancer cell lines. Cells were incubated with 
the MAb, and after 24-48 hrs, depending on the cell line, levels of cellular 
invasion/motility were quantified.  
 
Figure 3.4.2 shows that MAb 7B7 G5 (2) significantly inhibited invasion in the 
MiaPaCa-2 clone 3 cell line. A dose response was also observed (MAb diluted 
1:2). However, no such inhibition was noted with the BxPc-3 cell line. 
Significant inhibition of invasion was also observed in the H1299 and DLKP-M 
lung cancer cell lines, the MiaPaCa-2 clone 3 pancreatic cell line, the MDA-231 
and SKBR-3 cell lines, the SNB-19 glioma cell line and the HCT-116 colon cell 
line. Inhibition of invasion was also observed in the Lox IMVI melanoma cell 
line, and the DLKP-I lung cancer cell line. No inhibition was observed in the 
MDA-MB-157 breast cell line, the BxPc-3 pancreatic cell line or the C/68 
prostate cell line. These results indicate that MAb 7B7 G5 (2) can successfully 
inhibit the invasion process in a number of cell types. 
 
Figure 3.4.3 shows that MAb 7B7 G5 (2) significantly reduces cell motility in 
the MiaPaCa-2 clone 3 cell line, by levels similar to those seen the invasion 
assay. A dose response is also observed in this assay. Motility assays carried out 
on the SNB-19 glioma cell line (Figure 3.4.8) show that MAb 7B7 G5 (2) does 
not significantly reduce motility in this cell line. This may indicate that the 
inhibition of invasion observed with this MAb is unrelated to inhibition of cell 
motility.  
 
Statistical analyses were carried out with the average cell counts of control Vs 
sample inserts over biological triplicates (section 2.15).  
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Figure 3.4.1: - Histogram of MAb 7B7 G5 (2) showing inhibition of invasion in 
MiaPaCa-2 clone 3, but little/no inhibition in BxPc-3 compared to control 
hybridoma medium (no MAb) representing 100% invasion, after 48 hours.  
 
A dose response inhibitive effect is also observed in the MiaPaCa-2 clone 3 cell 
line, with 1:2 dilutions of MAb inhibiting invasion by up to 28.7% compared to 
control hybridoma medium (no MAb). Statistics; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 
0.005, Student’s t-test. n = 3. Error bars calculated using ± standard deviation. 
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Figure 3.4.2: - Representative photomicrographs showing invasion status of 
MiaPaCa-2 clone 3 cells following incubation with MAb 7B7 G5 (2). A decrease 
in invasion can be observed following addition of MAb 7B7 G5 (2) (b) compared 
to control insert (a) (no antibody supernatant). Magnification, 100X. Scale Bar, 
200µm 
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3.4.3  MAb 7B7 G5 (2) Effect on Motility on the Pancreatic Cell 
Line MiaPaCa-2 clone 3 
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Figure 3.4.3 - Histogram and representative photomicrographs of MAb 7B7 G5 
(2) showing significant inhibition of motility compared to control hybridoma 
medium (no MAb) representing 100% motility, after 24 hours.  
 
A significant dose response inhibitive effect is also observed on all dates with 1:2 
dilutions of the MAb showing less inhibition compared to control hybridoma 
medium (no MAb). Statistics; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, Student’s t-
test. n = 3. Error bars calculated using ± standard deviation. Magnification, 
200X. Scale Bar, 200µm. 
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3.4.4 MAb 7B7 G5 (2) Effect on Invasion on the Large-Cell Lung 
Cancer Cell Line H1299 and Invasive Variants of NSCLC 
DLKP, DLKP-I & DLKP-M 
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Figure 3.4.4: - Histogram of MAb 7B7 G5 (2) showing inhibition of invasion in 
DLKP-I, DLKP-M and H1299 compared to control hybridoma medium (no 
MAb) representing 100% invasion after 24 hours. Inhibition of invasion 
observed in the DLKP-I cell line did not reach statistical significance. Statistics; 
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, Student’s t-test. n = 3. Error bars 
calculated using ± standard deviation. 
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Figure 3.4.5: - Representative photomicrographs showing invasion status of 
DLKP-I, DLKP-M and H1299 cells following incubation with MAb 7B7 G5 (2). 
A decrease in invasion can be observed following addition of MAb 7B7 G5 (2) 
(b) compared to control insert (a) (no antibody supernatant) in all three cell lines. 
Magnification, 100X. Scale Bar, 200µm. 
   98 
3.4.5 MAb 7B7 G5 (2) Effect on Invasion on the NSCLC DLKP-M: 
- Dose Response 
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Figure 3.4.6: - Histogram of MAb 7B7 G5 (2) showing significant inhibition of 
invasion compared to control hybridoma medium (no MAb) representing 100% 
invasion) after 24 hours. Statistics; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, 
Student’s t-test. n = 3. Error bars calculated using ± standard deviation. 
 
A dose response inhibitive effect is also observed with 1:2 and 1:10 dilutions of 
the MAb showing less inhibition compared to MAb 7B7 G5 (2). A slight dose 
response with concentrated MAb (concentrated 2x using Millipore Ultrafree-15 
centrifuge filter units) is also observed on one date (63.2% inhibition of invasion 
compared to control hybridoma medium (no MAb) representing 100% invasion). 
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3.4.6 MAb 7B7 G5 (2) Effect on Invasion on the Invasive, Triple 
Negative Breast cancer Cell Lines MDA-MB-231, MDA-MB-
157 and the HER-2 Over Expressing Breast Cell Line, SKBR-
3 
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Figure 3.4.7: - Histogram of MAb 7B7 G5 (2) showing inhibition of invasion in 
MDA-MB-231, SKBR-3, but an increase in invasion in MDA-MB-157, 
compared to control hybridoma medium (no MAb) representing 100% invasion, 
after 24 hours. Statistics; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, Student’s t-test. 
n = 3. Error bars calculated using ± standard deviation. 
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Figure 3.4.8: - Representative photomicrographs showing invasion status of 
MDA-MDA-231 MDA-MB-157 and SKBR-3 cells following incubation with 
MAb 7B7 G5 (2). A decrease in invasion can be observed following addition of 
MAb 7B7 G5 (2) (b) compared to control insert (a) (no antibody supernatant) in 
the MDA-MB-231 and SKBR-3 cell lines. However, a slight increase in invasion 
is observed in the MDA-MB-157 cell line.  Magnification, 100X. Scale Bar, 
200µm. 
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3.4.7 MAb 7B7 G5 (2) Effect on Invasion on the Invasive Glioma 
Cell Line SNB-19. 
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Figure 3.4.9: - Histogram and representative photomicrographs of MAb 7B7 G5 
(2) showing significant inhibition of invasion compared to control hybridoma 
medium (no MAb) representing 100% invasion, after 24 hours. Statistics; * p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.005, Student’s t-test. n = 3. Error bars calculated 
using ± standard deviation. Magnification, 100X. Scale Bar, 200µm. 
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3.4.8 MAb 7B7 G5 (2) Inhibition of Motility on Invasive Glioma 
Cell Line SNB-19 
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Figure 3.4.10 - Histogram and representative photomicrographs of MAb 7B7 G5 
(2) showing inhibition of motility compared to control hybridoma medium (no 
MAb) representing 100% motility, after 24 hours. Inhibitive effect did not reach 
statistical significance. Statistics; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, 
Student’s t-test. n = 3. Error bars calculated using ± standard deviation. 
Magnification, 100X. Scale Bar, 200µm.  
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3.4.9 MAb 7B7 G5 (2) Effect on Invasion on the Invasive Melanoma 
Cell Line Lox IMVI 
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Figure 3.4.11: - Histogram and and representative photomicrographs of MAb 
7B7 G5 (2) showing inhibition of invasion compared to control hybridoma 
medium (no MAb) representing 100% invasion, after 24 hours. Inhibitive effect 
did not reach statistical significance. Statistics; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 
0.005, Student’s t-test. n = 3. Error bars calculated using ± standard deviation. 
Magnification, 100X. Scale Bar, 200µm. 
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3.4.10 MAb 7B7 G5 (2) Effect on Invasion on the Invasive Prostate 
Cell line C/68 
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Figure 3.4.12: - Histogram and representative photomicrographs of MAb 7B7 
G5 (2) showing inhibition of invasion compared to control hybridoma medium 
(no MAb) representing 100% invasion, after 24 hours. Inhibitive effect did not 
reach statistical significance. Statistics; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, 
Student’s t-test. n = 3. Error bars calculated using ± standard deviation. 
Magnification, 100X. Scale Bar, 200µm. 
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3.4.11 MAb 7B7 G5 (2) Effect on Invasion on the Invasive Colorectal 
Cell line HCT-116 
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Figure 3.4.13: - Histogram and representative photomicrographs of MAb 7B7 
G5 (2) showing inhibition of invasion compared to control hybridoma medium 
(no MAb) representing 100% invasion, after 24 hours. Statistics; * p ≤ 0.05, ** p 
≤ 0.01, *** p ≤ 0.005, Student’s t-test. n = 3. Error bars calculated using ± 
standard deviation. Magnification, 100X. Scale Bar, 200µm. 
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Cancer Type Cell Line Mean Inhibition Levels  P value 
MDA-MB-157 11.4% increase 0.67 
MDA-MD-231 23% 0.16 
 
Breast 
SKBR-3 25.6% 0.22 
DLKP-I 12.9% 0.57 
DLKP-M 32.2% 0.22 
 
Lung 
H1299 30.6% 0.08 
MiaPaCa-2 clone 3 45.4% 0.33 Pancreatic 
BxPc-3 3.4% increase 0.64 
Melanoma Lox IMVI 18.47% 0.71 
Glioma SNB-19 27% 0.02 
Prostate C/68 11% 0.7 
Colon HCT-116 24.2% 0.11 
     
Table 3.4: - Effect of MAb 7B7 G5 (2) on invasion levels in a panel of cell lines. 
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3.4.12 MAb 7B7 G5 (2) Effect on Adhesion to Fibronectin & 
Matrigel on the Invasive Pancreatic Cancer Cell Line 
MiaPaCa-2 clone 3 
 
Adhesion assays were carried out in order to investigate what effect MAb 7B7 
G5 (2) had on the ability of cancer cells to attach to ECM proteins. Adhesion to 
ECM proteins, especially fibronectin represents an important step in metastasis 
(Shaw et al., 1996). The effect of the MAb on the ability of MiaPaCa-2 clone 3 
cells to adhere to fibronectin was investigated, as was the ability of DLKP-M 
cells to adhere to matrigel in the presence of the MAb. Adhesion assays were 
performed as described in section 2.5.4 
 
In Figure 3.4.12, MAb 7B7 G5 (2) reduced adhesion of MiaPaCa-2 clone 3 cells 
to fibronectin in vitro was observed. A significant decrease in adherence of 
DLKP-M cells to matrigel was also observed (Figure 3.4.13). These results 
indicate that MAb 7B7 G5 (2) can interfere with the ability of cancer cells to 
attach to components of the ECM.   
 
Statistical analyse were carried out on the average absorbancy reading of control 
Vs sample wells over biological triplicates. 
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Figure 3.4.14: - Adhesion of MiaPaCa-2 clone 3 to ECM protein, fibronectin. 
Results are expressed as percentage adhesion to fibronectin in the presence of 
MAb 7B7 G5 (2), compared to adhesion to fibronectin in the presence of control 
hybridoma medium (no MAb). Cells grown in the presence of MAb 7B7 G5 (2) 
for 24 hrs, showed a decrease in adhesion to fibronectin. Statistical significance 
was not achieved. Statistics; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, Student’s t-
test. n = 3. Error bars calculated using ± standard deviation. 
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Figure 3.4.15: - Adhesion of DLKP-M to extracellular matrix protein, matrigel. 
Results are expressed as percentage adhesion to matrigel in the presence of MAb 
7B7 G5 (2), compared to adhesion to matrigel in the presence of control 
hybridoma medium (no MAb). Cells grown in the presence of MAb 7B7 G5 (2) 
for 24 hrs, showed a significant decrease in adhesion to matrigel. Statistics; * p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.005, Student’s t-test. n = 3. Error bars calculated 
using ± standard deviation. 
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3.4.13 MAb 7B7 G5 (2) Effect on Anoikis on the Invasive Pancreatic 
Cancer Cell Line MiaPaCa-2 clone 3 and on the Invasive 
NSCLC DLKP-M Cell Line 
 
To determine whether MAb 7B7 G5 (2) effects anoikis resistance in vitro, 
Anoikis assays were carried out on the MiaPaCa-2 clone 3 and DLKP-M cell 
lines. Anoikis is a specific form of apoptosis induced by the loss or alteration of 
cell-cell or cell-matrix anchorage. MiaPaCa-2 clone 3 has been shown to have a 
high level of anoikis resistance (Walsh et al., 2009), while DLKP-M has been 
shown to be 50% resistant to anoikis (Dr. Keenan, NICB, unpublished results). In 
this study, the effect of MAb 7B7 G5 (2) on the above cell lines growing in 
anoikis-inducing conditions was investigated. Anoikis assays were carried out as 
described in section 2.6. 
 
Figure 3.4.14 shows that MAb 7B7 G5 (2) has little/no effect on the cells when 
there are growing in Anoikis-inducing conditions. The cells do not display any 
increased or decreased levels of anoikis resistance, indicating that MAb 7B7 G5 
(2) does not effect this cellular process.    
 
Statistical analyse were carried out on the average absorbancy reading of control 
Vs sample wells over biological triplicates. 
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Figure 3.4.16: - Representative histogram showing percentage survival of non-
adherent cells (24 hrs poly-HEMA treated plastic). The presence of MAb 7B7 
G5 (2) has a slight effect on cell survivability when compared to cells growing in 
the presence of hybridoma medium (no MAb). Statistical significance was not 
achieved in this experiment. Data shown is mean ± standard deviation (n = 3).  
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3.4.14 Morphological Change of MiaPaCa-2 clone 3 Cells Incubated 
with MAb 7B7 G5 (2) 
 
MiaPaCa-2 clone 3 cells display an elongated, splindle-like morphology, which 
is associated with an invasive phenotype. To investigate whether MAb 7B7 G5 
(2) effects cell morphology, MiaPaCa-2 clone 3 cells were incubated with the 
MAb for 24hrs, after which, cell morphology was observed. This assay was 
carried out as described in section 2.8.  
 
Figure 3.4.15 shows the effect MAb 7B7 G5 (2) has on the MiaPaCa-2 clone 3 
cells, compared to cells grown in the absence of the MAb. It is quite clear that 
the cells have lost their elongated, spindle-like shape, and exhibit a more rounded 
appearance, similar to the less invasive MiaPaCa-2 clone 8 cell morphology. As 
a spindle-like cell morphology has been linked to cell invasion (Yilmaz et al., 
2007), this change may indicate that the invasive capabilities of the MiaPaca-2 
clone 3 cells have been diminished following incubation with MAb 7B7 G5 (2).
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Figure 3.4.17: - Representative photomicrographs showing morphology of 
MiaPaCa-2 clone 3 cells following incubation with MAb 7B7 G5 (2). Cells 
incubated with MAb 7B7 G5 (2) (B) have lost their elongated, splindle-like 
morphology, which is associated with an invasive phenotype, and have become 
more rounded. Cells incubated with hybridoma media (A) retain their normal 
morphology. Magnification, 100X. Scale Bar, 200µm. 
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3.4.15 MAb 7B7 G5 (2) Effect on MMP Activity in the Invasive 
Breast Cancer Cell Line MDA-MB-231 
 
 
Zymography assays were carried out in order to investigate the effect of MAb 
7B7 G5 (2) has on MMP-9 expression. MMP-9 is involved in the degradation of 
proteins in the extracellular matrix and plays a crucial role in localised 
degradation of the basement membrane, and subsequent cellular invasion. MDA-
MB-231 was chosen for this study, as it is known to express MMP-9 (Hegedus et 
al., 2008). Conditioned media from cells incubated with the MAb was collected, 
as described in section 2.7.1. This was then separated on a zymography gel, 
which was then subsequently stained. The zymography assay was carried out as 
described in section 2.7.2.  
 
Figure 3.4.16 shows that MAb 7B7 G5 (2) greatly decreases the activity of active 
MMP-9 in the MDA-MB-231 cell line, when compared to cells grown in the 
absence of the MAb. This is also clearly observed in the zymography gel. This 
preliminary result indicates that MAb 7B7 G5 (2) inhibits the activity of MMP-9 
in vitro (see Appendix VI for complete zymograpgy gel).  
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Figure 3.4.18: - Graph and zymography gel showing effect of MAb 7B7 G5 (2) 
on MMP-9 activity in the MDA-MB-231 breast cell line. Cells incubated with 
MAb 7B7 G5 (2) show a decrease in the activity of MMP-9 when compared to 
control hybridoma medium (no MAb) representing normal MMP-9 activity.  
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3.5 Immunofluorescence Studies of MAb 7B7 G5 (2) In a Panel of 
Cancer Cell Lines 
 
 
 
 
A. B. 
  
 
C. D. 
  
 
 
 
Figure 3.5: - Immunofluorescence analysis of MAb 7B7 G5 (2) on MiaPaCa-2 
clone 3, clone 8 pancreatic cancer cells, and DLKP-SQ and a Mitoxantrone 
resistant variant, DLKP-Mitox-6p cancer cell lines (Joyce, H., unpublished). 
Cytoplasmic/membrane reactivity is observed in the invasive MiaPaCa-2 clone 3 
cells (A), while less intense positivity is observed in MiaPaCa-2 clone 8 cells 
(B), which exhibit low levels of invasion.  Intense reactivity with MAb 7B7 G5 
(2) is observed in the invasive DLKP-Mitox-6p cell line (D), compared to the 
parental DLKP-SQ cell line (C), which exhibits low levels of invasion. 
Magnification, 630X (A & B), 400X (C & D). Scale Bar, 10µm , 20µm. (D 
counter stained with Propidium Iodide).  
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3.6  Western Blotting Analysis 
 
Western blotting analysis of whole cell lysates of MiaPaCa-2 clone 3 cells, 
followed by probing with MAb 7B7 G5 (2) did not produce any specific reactive 
bands.  
 
3.7  Immunoprecipitation Studies 
 
In order to try and identify the target antigens, immunoprecipitation studies were 
carried out on a variety of cell lines. MiaPaCa-2 clone 3 was the primary cell line 
used, due to the initial invasion/motility assays carried out with that cell line. 
Protein-L agarose beads were used to pull out the reactive antigens from cell 
lysates of MiaPaCa-2 clone 3 cells for MAb 7B7 G5 (2). Following separation on 
4-12% Bis-Tris SDS-PAGE, a number of bands were identified (Figure 3.1.12). 
These were compared to bands pulled out using control mouse IgM, and those 
bands only present with the 7B7 G5 (2) MAb were identified through liquid 
chromatography mass spectrometry (LC-MS) analysis (Dionex Ultimate 3000 
LC system, LTQ-Orbitrap mass spectrometer), LC-MS sequencing using 
LCMS/LTQ mass spectrometry and TurboSEQUEST software using the human 
subset from the SWISS-PROT database.  
 
Two different methods of immunoprecipitation were carried out in order to 
facilitate identification of the antigen of interest. The first method, termed Direct 
IP (section 2.11.1.), involves incubating the antibody/cell lysates complex with 
Protein-L agarose beads, then separating the solution, containing both antigen 
and antibody fragments, on SDS-PAGE. In the second method, known as Cross-
Linked IP (section 2.11.2.), a purified form of the MAb (section 2.3.8) is 
covalently bound to the agarose beads, which is then incubated with the cell 
lysate. The antibody-antigen complex is then eluted leaving the antibody bound 
to the agarose beads, resulting in an antigen-only solution (i.e. no antibody 
interference). When separated on SDS-PAGE, any resulting bands will be free of 
antibody fragments, allowing for easier antigen identification through mass 
spectrometry. Controls for both immunoprecipitation methods consisted of 
control mouse IgG/IgM antibodies.  
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3.7.1 MAb 7B7 G5 (2) – Direct Immunoprecipitation Method 
 
 
 
 
 
  
 
 
 
 
 
Figure 3.7: - Direct Immunoprecipitation of cell lysates with 7B7 G5 (2) 
MAb and control mouse IgM. 
A representative SDS-PAGE gel of MiaPaCa-2 clone 3 and Lox IMVI cells 
immunoprecipitated with MAb 7B7 G5 (2) and separated on SDS-PAGE, and 
stained with 0.25% Coomassie Blue. Lane 1: molecular weight markers. Lane 2: 
MiaPaCa-2 clone 3 immunoprecipitated using control mouse IgM. Lane 3: 
MiaPaCa-2 clone 3 immunoprecipitated with MAb 7B7 G5 (2). Lane 4: Lox 
IMVI immunoprecipitated with MAb 7B7 G5 (2). Five bands of MAb 7B7 G5 
(2) target proteins are observed; at approx. 200 kDa, 160 kDa, 65 kDa, 45 kDa 
and 35 kDa. These 5 bands were not present in the control IgM, were observed in 
triplicate experiments, and in 3 different cell lines. Each band was excised, 
digested with trypsin and run through an LCMS/LTQ-Orbitrap Mass 
Spectrometer for identification (section 2.12). 
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3.7.2 Purification of MAb 7B7 G5 (2) 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
Figure 3.7.1: - Representative SDS-PAGE gel showing successful purification 
of 7B7 G5 (2) MAb, using the Pierce NAb Spin Purification Kit (section 2.3.8). 
Lane 1: Molecular Weight marker. Lane 2: Unpurified MAb 7B7 G5 (2). Lane 3: 
Concentrated, unpurified MAb 7B7 G5 (2). Lane 4: Purified MAb 7B7 G5 (2). 
Purified MAb is required for cross-linked immunoprecipitation. 
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3.7.3 MAb 7B7 G5 (2) - Cross Linked Immunoprecipitation Method 
 
 
 
 
 
   
 
 
 
 
 
 
 
Figure 3.7.2: - Immunoprecipitates of MiaPaCa-2 clone 3 cells separated by 
SDS-PAGE, and stained with 0.25% Coomassie Blue. Lane 1: molecular weight 
markers. Lane 2: Unbound MAb 7B7 G5 (2). Lane 3: MiaPaCa-2 clone 3 
immunoprecipitated with MAb 7B7 G5 (2). Three bands of antigen recognition 
and/or interacting proteins are observed; at approx. 100 kDa, 80 kDa, and 70 
kDa. No antibody heavy and light chains are present. Each band was excised and 
run through an LCMS/LTQ Mass Spectrometer for identification (section 2.12). 
Non-binding agarose beads were used as a control. 
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3.8 Western Blot Analysis of MAb 7B7 G5 (2) 
Immunoprecipitates   
 
Western blotting analysis was then carried with MAb 7B7 G5 (2) 
immunoprecipitates, in order to establish MAb reactivity, if any, with the 
antigens pulled out through the immunoprecipitation process.  No reactive bands 
were observed. 
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3.9 Mass Spectrometry Identification of MAb 7B7 G5 (2) Target 
Proteins 
 
Following separation of immunoprecipitates on 4-12% Bis-Tris SDS-PAGE, the 
gels were stained with 0.25% Coomassie Blue and destained accordingly. Bands 
of interest were excised from the gel, digested with trypsin, and subjected to LC-
MS analysis. Identification was achieved using the SWISS-PROT SEQUEST 
database (section 2.12.1). 
  
Positive identification was deemed valid if: 
 
• proteins were observed in duplicate or more, from 2 or more independent 
experiments 
• a minimum of 2 peptide sequences was obtained 
• molecular weight of protein matched molecular weight of band on gel  
• proteins achieved a high XC score, indicating excellent confidence in the 
identification (the minimum acceptable Xcorr for identified peptides was 
1.5 for 1+ peptides, 2.5 for 2+ peptides and 3.5 for 3+ peptides). 
• proteins were unique to MAb 7B7 G5 (2) (i.e. not found with other 
MAbs) 
 
 
Criteria for a valid identification is described in full in section 2.12.1 
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Protein Name Band Gene 
Symbol 
SWISSPROT  
Protein AC Number 
MW 
(kDa) 
ATP-dependent DNA helicase 2 
subunit 2 
2 
 (Cross Linked I.P.) 
XRCC5 P13010 82.65 
ATP-dependent DNA helicase 2 
subunit 1 
3 
 Cross Linked I.P.) 
XRCC6 P32807 69.79 
 
Table 3.9: - Proteins identified using the above criteria, from excised bands 
immunoprecipitated with MAb 7B7 G5 (2), through mass spectrometry. Band 
number refers to highlighted bands on gel represented in figures 3.7 and 3.7.2. 
 
Direct immunoprecipitation of MAb 7B7 G5 (2) only gave two positive results. 
The band at approx. 36 kDa was identified as Elongation Factor 1-Alpha 1. 
However, this protein was also immunoprecipitated out with another antibody 
(MAb 9E1 24 (6)).  All other bands were identified as Mouse IgM. In order to 
obtain a clear identification, it was necessary to remove the IgM components 
from the immunoprecipitates. This was achieved using the cross linked IP 
method, as described in section 2.11.2. A representative gel can be observed in 
Figure 3.7.2. From this, three bands of interest were observed. The top band 
(approx. 110 kDa), identified as Nucleolin, was also observed in a control IP, so 
was disregarded. The band at approx. 80 kDa was identified as ATP-dependent 
DNA helicase 2 subunit 2. The band at approx. 69 kDa was identified as ATP-
dependent DNA helicase 2 subunit 1. All proteomic data is included in Appendix 
II & III).  
 
All other bands observed were either identified as Mouse IgM, or were present in 
the control mouse IgM immunoprecipitates, and were thus disregarded. 
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3.9.1 Identification of MAb 7B7 G5 (2) Target Proteins by LC-MS 
Analysis of 7B7 G5 (2) Immunoprecipitates. 
 
ATP-dependent DNA helicase 2 subunit 1 
 
     P (pro) Score 
Scan(s) Peptide MH+ z Type P (pep) XC 
KU70_HUMAN RecName: Full=ATP-dependent DNA helicase 2 subunit 1; 
AltName: Full=ATP-dependent DNA helicase II 70 kDa subunit; AltName: 
Full=Lupus Ku autoantigen protein p70; Short=Ku70; AltName: Full=70 kDa 
subunit of Ku antigen; AltName: Full=Thyroid-lupu 
1.24E-09 50.24 
976 R.QIILEKEETEELKR.F 1757.96436 2 CID 4.76E-07 3.81 
1017 R.IM*LFTNEDNPHGNDSAK.A 1918.85997 2 CID 1.24E-09 4.77 
1244 R.TFNTSTGGLLLPSDTKR.S 1807.95483 2 CID 4.40E-08 3.71 
1540 K.KPGGFDISLFYR.D 1399.73682 2 CID 1.99E-06 3.39 
1650 R.DSLIFLVDASK.A 1207.65686 2 CID 3.27E-05 3.02 
 
Table 3.9.1: - Identification of Protein ATP-dependent DNA helicase 2 subunit 
1, obtained using SEQUEST Human protein database 
 
Peptides were identified using Bioworks 3.3.1 software. A representative results 
(experiments were carried out at least 3 times) is shown above, where 5 peptides 
corresponding to Human ATP-dependent DNA helicase 2 subunit 1 were 
identified. All 5 peptides showed high XC scores indicating excellent confidence 
in this identification. (Note: the minimum acceptable Xcorr for identified 
peptides was 1.5 for 1+ peptides, 2.5 for 2+ peptides and 3.5 for 3+ peptides). 
 
  
MSGWESYYKTEGDEEAEEEQEENLEASGDYKYSGRDSLIFLVDASKAMFESQSEDELTPFDMSIQCI
QSVYISKIISSDRDLLAVVFYGTEKDKNSVNFKNIYVLQELDNPGAKRILELDQFKGQQGQKRFQD
MMGHGSDYSLSEVLWVCANLFSDVQFKMSHKRIMLFTNEDNPHGNDSAKASRARTKAGDLRDT
GIFLDLMHLKKPGGFDISLFYRDIISIAEDEDLRVHFEESSKLEDLLRKVRAKETRKRALSRLKLKLN
KDIVISVGIYNLVQKALKPPPIKLYRETNEPVKTKTRTFNTSTGGLLLPSDTKRSQIYGSRQIILEKEET
EELKRFDDPGLMLMGFKPLVLLKKHHYLRPSLFVYPEESLVIGSSTLFSALLIKCLEKEVAALCRYT
PRRNIPPYFVALVPQEEELDDQKIQVTPPGFQLVFLPFADDKRKMPFTEKIMATPEQVGKMKAIVEK
LRFTYRSDSFENPVLQQHFRNLEALALDLMEPEQAVDLTLPKVEAMNKRLGSLVDEFKELVYPPDY
NPEGKVTKRKHDNEGSGSKRPKVEYSEEELKTHISKGTLGKFTVPMLKEACRAYGLKSGLKKQEL
LEALTKHFQD 
 
Figure 3.9: - Total amino acid sequence of Human ATP-dependent DNA 
helicase 2 subunit 1 protein presented above. Scan of 1017 peptide sequence, 
which shows the highest XC score (4.77) is highlighted  
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Figure 3.9.1: - The MS-MS spectrum for scan 1017 showing b (indicated in red) & y (indicated in blue) fragment ion series overlay. 
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ATP-dependent DNA helicase 2 subunit 2 
 
     P (pro) Score 
Scan(s) Peptide MH+ z Type P (pep) XC 
KU86_HUMAN RecName: Full=ATP-dependent DNA helicase 2 
subunit 2; AltName: Full=ATP-dependent DNA helicase II 80 kDa 
subunit; AltName: Full=Lupus Ku autoantigen protein p86; AltName: 
Full=86 kDa subunit of Ku antigen; AltName: Full=Ku86; AltName: 
Full=Ku80 
2.08E-07 30.21 
1257 R.YGSDIVPFSK.V 1112.56226 2 CID 9.87E-07 3.03 
1390 R.HIEIFTDLSSR.F 1317.67969 2 CID 2.08E-07 3.16 
1605 K.SQLDIIIHSLK.K 1266.74158 2 CID 5.48E-06 3.11 
 
Table 3.9.2: - Identification of Protein ATP-dependent DNA helicase 2 subunit 
2, obtained using SEQUEST Human protein database 
 
Peptides were identified using Bioworks 3.3.1 software. A representative result 
(experiments were carried out at least 3 times) is shown above, where 3 peptides 
corresponding to Human ATP-dependent DNA helicase 2 subunit 2 were 
identified. All 3 peptides showed high XC scores indicating excellent confidence 
in this identification.  
 
 
MVRSGNKAAVVLCMDVGFTMSNSIPGIESPFEQAKKVITMFVQRQVFAENKDEIALVLFGTDGTDN
PLSGGDQYQNITVHRHLMLPDFDLLEDIESKIQPGSQQADFLDALIVSMDVIQHETIGKKFEKRHIEI
FTDLSSRFSKSQLDIIIHSLKKCDISLQFFLPFSLGKEDGSGDRGDGPFRLGGHGPSFPLKGITEQQKE
GLEIVKMVMISLEGEDGLDEIYSFSESLRKLCVFKKIERHSIHWPCRLTIGSNLSIRIAAYKSILQERV
KKTWTVVDAKTLKKEDIQKETVYCLNDDDETEVLKEDIIQGFRYGSDIVPFSKVDEEQMKYKSEG
KCFSVLGFCKSSQVQRRFFMGNQVLKVFAARDDEAAAVALSSLIHALDDLDMVAIVRYAYDKRA
NPQVGVAFPHIKHNYECLVYVQLPFMEDLRQYMFSSLKNSKKYAPTEAQLNAVDALIDSMSLAKK
DEKTDTLEDLFPTTKIPNPRFQRLFQCLLHRALHPREPLPPIQQHIWNMLNPPAEVTTKSQIPLSKIKT
LFPLIEAKKKDQVTAQEIFQDNHEDGPTAKKLKTEQGGAHFSVSSLAEGSVTSVGSVNPAENFRVL
VKQKKASFEEASNQLINHIEQFLDTNETPYFMKSIDCIR 
 
 
 
Figure 3.9.2: - Total amino acid sequence of Human ATP-dependent DNA 
helicase 2 subunit 2 protein presented above. Scan of 1390 peptide sequence, 
which shows the highest XC score (3.16) is highlighted  
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Figure 3.9.3: - The MS-MS spectrum for scan 1390 showing b (indicated in red) & y (indicated in blue) fragment ion series overlay. 
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3.10  Western Blot Validation of MAb 7B7 G5 (2) Target Proteins 
 
 
 
 
 
 
 
 
 
 
A.   B. 
 
C.  D. 
 
 
 
 
 
 
 
 
Figure 3.10: - Western Blot analysis of (A) DLKP-A Cross Linked I.P. sample, 
and (B) MiaPaCa-2 clone 3 Cross Linked I.P. sample, separated by SDS-PAGE 
and probed with an ATP dependent DNA helicase 2 subunit 1 antibody (Ku80). 
A reactive band at the expected weight of 80 kDa is detected in all 
immunoprecipitates, confirming this protein band as ATP dependent DNA 
helicase 2 subunit 1.  n = 3. 
 
(C & D): Western Blot analysis of DLKP-A Cross Linked I.P. sample and 
MiaPaCa-2 clone 3 Cross Linked I.P. samples probed with ATP dependent DNA 
helicase 2 subunit 2 antibody (Ku70). A reactive band at the expected weight of 
70 kDa is detected in both immunoprecipitates, confirming this protein band as 
ATP dependent DNA helicase 2 subunit 2.  n = 3. 
 
80kDa Ku80 
70kDa Ku70 
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3.11 siRNA Functional Analysis of MAb 7B7 G5 (2) Target 
Proteins    
 
To investigate any functional role of the identified MAb 7B7 G5 (2) target 
proteins in cancer cell invasion, siRNA silencing of the respective targets was 
carried out using Ambion Inc. Silencer® Select siRNAs. Two or three (where 
available) siRNAs specific to each target were investigated.  
 
The conditions for siRNA transfection were optimised in 96- and 6-well plates 
using kinesin as a positive control, and scrambled siRNA as a siRNA 
transfection control (section 2.14.1). For each set of siRNA transfections carried 
out, a non-transfected cell line and a scrambled (SCR) siRNA transfected control 
were used. Kinesin (Kin) was used as a control for efficient transfection as Kin 
siRNA reduces proliferation in the cells.   
  
• 48hrs post-transfection, cells were lysed (RIPA), analysed by SDS-
PAGE, and probed with specific antibodies to respective targets to test 
effect of knockdown on Protein-Levels. 
 
• Proliferation assays (section 2.14.3) were carried out on transfected cells 
to assess the impact of knockdown on proliferation levels in the cells, to 
ensure that any inhibition in invasion was not just due to a decrease in the 
cell number. 
 
• Invasion assays (section 2.14.4) were carried out on transfected cells to 
confirm whether or not these targets were involved in invasion.  
 
• Motility assays (section 2.14.5) were carried out on transfected cells to 
confirm whether or not these targets were involved in motility.  
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3.11.1 Investigation of Ku70 in Cancer Cell Invasion  
 
Ku70 knockdown was carried out in the MiaPaCa-2 clone 3 and DLKP-M cell 
lines.  
 
Silencing of the Ku70 gene by two different siRNAs significantly reduced the 
invasive capacity of MiaPaCa-2 clone 3 and DLKP-M cells: 
 
• MiaPaCa-2 clone 3 invasion was significantly inhibited, by an average of 
37.4%, following siRNA transfection with Ku70A, and an average of 
24.9% following siRNA transfection by Ku70B. 
• DLKP-M invasion was inhibited by an average of 17.2% following 
siRNA transfection with Ku70A, and significantly inhibited by an 
average of 38.6% following siRNA transfection with Ku70B. 
 
Motility was also significantly inhibited in the MiaPaCa-2 clone 3 cell line 
following siRNA transfection with Ku70B, by an average of 35.7%  
 
No significant affect on proliferation in either the MiaPaCa-2 clone 3 or DLKP-
M cell lines was observed following transfection of siRNAs, indicating that the 
observed inhibition of invasion was not due to any reduced proliferative capacity 
of the cells. Protein knockdown was confirmed by Western Blot analysis 
(Figures 3.11 & 3.11.6).    
 
Statistical analyses for proliferation assays were carried out on the average 
absorbancy readings of the control Vs test wells, over biological triplicates. 
 
Statistical analyses for invasion assays were carried out with the average cell 
counts of control Vs sample inserts over biological triplicates (section 2.15).  
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Figure 3.11: - Western Blot analysis of whole cell (RIPA) lysates of MiaPaCa-2 
clone 3 transfected cells, separated on SDS-PAGE, and probed with an ATP-
dependent DNA helicase 2 subunit 2 antibody. A reduction in the levels of Ku70 
can be seen when compared to the control MiaPaCa-2 clone 3 cell lysate 
(untransfected). α-Tubulin  was used as a loading control. (15µg protein per lane 
loaded) n = 3. 
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• Effect of siRNA Ku70 on MiaPaCa-2 clone 3 Proliferation 
 
 
 
 
 
 
0
20
40
60
80
100
120
140
DMEM Scrambled kinesin Ku70 A Ku70 B
R
e
la
tiv
e 
Ce
ll 
Su
rv
iv
al
 
(%
)
n = 1
n = 2
n = 3
*
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11.1: - Histogram showing proliferation assay of MiaPaCa-2 clone 3 
scrambled, kinesin and transfected with siRNAs A, & B targeting Ku70. Results 
graphed as % survival relative to scrambled transfected cells (control). Loss of 
Ku70 did not affect proliferation in this cell line; therefore any inhibition of 
invasion is not due to cell kill. Statistics performed using student t-test compared 
to scrambled control; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, n = 3. 
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• Knockdown of Ku70 reduces invasion in MiaPaCa 2-clone 3 
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Figure 3.11.2: - Histogram showing effect of Ku70 knockdown on invasive 
behaviour of MiaPaCa-2 clone 3 cells. Forty-eight hours post-transfection with 
Ku70 siRNAs, invasion assays on MiaPaCa-2 clone 3 cells were performed. 
Ku70-A siRNA transfected cells show a significant decrease in invasion levels, 
while Ku70-B siRNA transfected cells also show a decrease in invasion levels, 
but not significantly so. Statistics performed using student t-test compared to 
scrambled control; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, n = 3. 
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Figure 3.11.3: - Representative photomicrographs showing invasion status of 
MiaPaCa-2 clone 3 cells after 48hrs, untreated (DMEM), transfected with 
scrambled siRNA (Control), transfected with Ku70-A siRNA and Ku70-B. A 
decrease in invasion can be observed following transfection with Ku70 siRNAs 
when compared to the control insert (scrambled).  Magnification, 100X, scale 
bar, 200 µm.  
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• Knockdown of Ku70 reduces motility in MiaPaCa 2-clone 3 
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Figure 3.11.4: - Histogram showing effect of Ku70 knockdown on motile 
behaviour of MiaPaCa-2 clone 3 cells. Forty-eight hours post-transfection with 
Ku70 siRNAs, motility assays on MiaPaCa-2 clone 3 cells were performed. 
Ku70 B siRNA transfected cells show a decrease in motility levels. Statistics 
performed using student t-test compared to scrambled control; * p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.005, n = 3. 
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Figure 3.11.5: - Representative photomicrographs showing motility status of 
MiaPaCa-2 clone 3 cells after 48hrs, untreated (DMEM), transfected with 
scrambled siRNA (Control), transfected with Ku70-A siRNA and Ku70-B. A 
decrease in motility can be observed following transfection with Ku70 siRNA B, 
but not A, when compared to the control insert (Scrambled). Magnification, 
100X, scale bar, 200 µm.  
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• Effect of Ku70 siRNA transfection in DLKP-M  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11.6: - Western Blot analysis of whole cell (RIPA) lysates of DLKP-M 
transfected cells, separated on SDS-PAGE, and probed with an ATP-dependent 
DNA helicase 2 subunit 2 antibody. A reduction in the levels of Ku70 can be 
seen when compared to the control DLKP-M cell lysate (untransfected). β-Actin 
was used as a loading control. (15µg protein per lane loaded) n = 3. 
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• Effect of siRNA Ku70 on DLKP-M Proliferation 
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Figure 3.11.7: - Histogram showing proliferation assay of DLKP-M scrambled, 
kinesin and transfected with siRNAs A, & B targeting Ku70. Results graphed as 
% survival relative to scrambled transfected cells (control). Loss of Ku70 did not 
affect proliferation in this cell line; therefore any inhibition of invasion is not due 
to cell kill. Statistics performed using student t-test compared to scrambled 
control; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, n = 3. 
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Knockdown of Ku70 reduces invasion in DLKP-M 
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Figure 3.11.8: - Histogram showing effect of Ku70 knockdown on invasive 
behaviour of DLKP-M cells. Forty-eight hours post-transfection with Ku70 
siRNAs, invasion assays on DLKP-M cells were performed. Ku70-A and Ku70-
B siRNA transfected cells show a decrease in invasion levels. Statistics 
performed using student t-test compared to scrambled control; * p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.005, n = 3. 
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Figure 3.11.9: - Representative photomicrographs showing invasion status of 
DLKP-M cells after 48hrs, untreated (DMEM), transfected with scrambled 
siRNA (Control), transfected with Ku70-A siRNA and Ku70-B. A decrease in 
invasion can be observed following transfection with Ku70 siRNA B, but not A, 
when compared to the control insert (Scrambled). Magnification, 100X, scale 
bar, 200 µm.  
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3.11.2 Investigation of Ku80 in Cancer Cell Invasion  
 
Ku80 knockdown was successfully carried out in the MiaPaCa-2 clone and 
DLKP-M cell lines.  
 
Silencing of the Ku80 gene by two different siRNAs significantly reduced the 
invasive capacity of the MiaPaCa-2 clone 3 and DLKP-M cells: 
 
• MiaPaCa-2 clone 3 invasion was significantly inhibited by an average of 
31.7% following siRNA transfection with Ku80A, and an average of 
50.8% following siRNA transfection by Ku80C 
• DLKP-M invasion was inhibited by an average of 16% following siRNA 
transfection with Ku70A, and an average of 38.4% following siRNA 
transfection with Ku80C 
 
Motility was also inhibited in the MiaPaCa-2 clone 3 cell line following siRNA 
transfection with Ku80A by an average of 21%, and significantly inhibited with 
Ku80C, by an average of 53.7%.  
 
No significant affect on proliferation in either the MiaPaCa-2 clone 3 or DLKP-
M cell lines was observed following transfection of both siRNAs, indicating that 
the observed inhibition of invasion was not due to any reduced proliferative 
capacity of the cells. Protein knockdown was confirmed by Western blot analysis 
(Figures 3.11.10 & 3.11.16) 
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• Effect of Ku80 siRNA transfection in MiaPaCa-2 clone 3  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11.10: - Western Blot analysis of whole cell (RIPA) lysates of 
MiaPaCa-2 clone 3 transfected cells, separated on SDS-PAGE, and probed with 
an ATP-dependent DNA helicase 2 subunit 1 antibody. A reduction in the levels 
of Ku80 can be seen when compared to the control MiaPaCa-2 clone 3 cell lysate 
(untransfected). α-Tubulin  was used as a loading control. (15µg protein per lane 
loaded) n = 3. 
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• Effect of siRNA Ku80 on MiaPaCa-2 clone 3 Proliferation 
 
 
 
 
 
 
0
20
40
60
80
100
120
140
DMEM Scrambled kinesin Ku80 A Ku80 B
R
el
at
iv
e 
Ce
ll 
Su
rv
iv
a
l (%
)
n = 1
n = 2
n = 3
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11.11: - Histogram showing proliferation assay of MiaPaCa-2 clone 3 
cells, scrambled, kinesin and transfected with siRNAs A, & B targeting Ku80. 
Results graphed as % survival relative to scrambled transfected cells (control). 
Loss of Ku80 did not affect proliferation in this cell line; therefore any inhibition 
of invasion is not due to cell kill. Statistics performed using student t-test 
compared to scrambled control; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, n = 3.
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• Knockdown of Ku80 reduces invasion in MiaPaCa-2 clone 3 
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Figure 3.11.12 - Histogram showing effect of Ku80 knockdown on invasive 
behaviour of MiaPaCa-2 clone 3 cells. Forty-eight hours post-transfection with 
Ku80 siRNAs, invasion assays on MiaPaCa-2 clone 3 cells were performed. 
Both Ku80-A and Ku80-C siRNA transfected cells show a significant decrease in 
invasion levels. Statistics performed using student t-test compared to scrambled 
control; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, n = 3. 
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Figure 3.11.13: - Representative photomicrographs showing invasion status of 
MiaPaCa-2 clone 3 cells after 48hrs untreated (DMEM), transfected with 
scrambled siRNA (Control), transfected with Ku80-A siRNA, transfected with 
Ku80-C siRNA. A decrease in invasion can be observed following transfection 
with Ku80 siRNAs  when compared to the control insert (Scrambled).  
Magnification, 100X, scale bar, 200 µm. 
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• Knockdown of Ku80 reduces Motility in MiaPaCa-2 clone 3 
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Figure 3.11.14: - Histogram showing effect of Ku80 knockdown on motile 
behaviour of MiaPaCa-2 clone 3 cells. Forty-eight hours post-transfection with 
Ku80 siRNAs, motility assays on MiaPaCa-2 clone 3 cells were performed. 
Ku80-A siRNA transfected cells show a decrease in motility levels while Ku80-
C siRNA transfected cells also show a significant decrease in motility levels. 
Statistics performed using student t-test compared to scrambled control; * p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.005, n = 3. 
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Figure 3.11.15: - Representative photomicrographs showing motility status of 
MiaPaCa-2 clone 3 cells after 24hrs, untreated (DMEM), transfected with 
scrambled siRNA (Control), transfected with Ku80-A siRNA, transfected with 
Ku80-C siRNA. A decrease in motility can be observed following transfection 
with Ku80 siRNAs  when compared to the control insert (Scrambled).  
Magnification, 100X, scale bar, 200 µm.  
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• Effect of Ku80 siRNA transfection in DLKP-M  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11.16: - Western Blot analysis of whole cell (RIPA) lysates of DLKP-
M transfected cells, separated on SDS-PAGE, and probed with an ATP-
dependent DNA helicase 2 subunit 1 antibody. A reduction in the levels of Ku80 
can be seen when compared to the control MiaPaCa-2 clone 3 cell lysate 
(untransfected). β-Actin was used as a loading control. (15µg protein per lane 
loaded) n = 3. 
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• Effect of siRNA Ku80 on DLKP-M Proliferation 
 
 
 
 
 
 
0
20
40
60
80
100
120
140
160
DMEM Scrambled Kinesin Ku80 A Ku80 C
R
el
at
iv
e 
Ce
ll 
Su
rv
iv
a
l (%
)
n = 1
n = 2
n = 3
*
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11.17: - Histogram showing proliferation assay of DLKP-M scrambled, 
kinesin and transfected with siRNAs A, & B targeting Ku80. Results graphed as 
% survival relative to scrambled transfected cells (control). Loss of Ku80 did not 
affect proliferation in this cell line; therefore any inhibition of invasion is not due 
to cell kill. Statistics performed using student t-test compared to scrambled 
control; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, n = 3. 
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• Knockdown of Ku80 reduces invasion in DLKP-M 
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Figure 3.11.18: - Histogram showing effect of Ku80 knockdown on invasive 
behaviour of DLKP-M cells. Forty-eight hours post-transfection with Ku80 
siRNAs, invasion assays on DLKP-M cells were performed. Ku80-A siRNA 
transfected cells show a small decrease in invasion levels, while Ku80-C siRNA 
transfected cells show a larger decrease in invasion levels. Statistics performed 
using student t-test compared to scrambled control; * p ≤ 0.05, ** p ≤ 0.01, *** p 
≤ 0.005, n = 3. 
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Figure 3.11.19: - Representative photomicrographs showing invasion status of 
DLKP-M cells after 48hrs, untreated (DMEM), transfected with scrambled 
siRNA (Control), transfected with Ku80-A siRNA and Ku80-C. A decrease in 
invasion can be observed following transfection with Ku80 siRNA C, but not A, 
when compared to the control insert (B). Magnification, 100X, scale bar, 200 
µm.  
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• Effect of Ku70 siRNA transfection on Ku80 Expression in MiaPaCa-2 
clone 3  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11.20: - Western Blot analysis of whole cell (RIPA) lysates of 
MiaPaCa-2 clone 3 transfected cells, separated by SDS-PAGE, probed with an 
ATP-dependent DNA helicase 2 subunit 2 antibody (Ku70). A reduction in the 
levels of Ku70 can be seen in cells transfected with siRNAs targeting Ku80, 
when compared to the control MiaPaCa-2 clone 3 cell lysate (untransfected). α-
Tubulin was used as a loading control. (15µg protein per lane loaded) n = 3. 
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• Effect of Ku80 siRNA transfection on Ku70 Expression in MiaPaCa-2 
clone 3  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11.21: - Western Blot analysis of whole cell (RIPA) lysates of 
MiaPaCa-2 clone 3 transfected cells, separated by SDS-PAGE, probed with an 
ATP-dependent DNA helicase 2 subunit 1 antibody (Ku80). A reduction in the 
levels of Ku80 can be seen in cells transfected with siRNAs targeting Ku80, 
when compared to the control MiaPaCa-2 clone 3 cell lysate (untransfected). α-
Tubulin was used as a loading control. (15µg protein per lane loaded) n = 3. 
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3.11.3 Expression of MAb 7B7 G5 (2) in MiaPaCa-2 clone 3 
Transfected with Ku70 & Ku80 siRNAs  
A.      B. 
    
 
C. D. 
   
 
E.     F. 
   
 
Figure 3.11.22: - Immunofluorescence analysis of MAb 7B7 G5 (2) of 
MiaPaCa-2 clone 3 pancreatic cancer cells (A) untransfected, (B) transfected 
with scrambled control, (C) transfected with Ku70A siRNA, (D) transfected with 
Ku70B siRNA, (E). transfected with Ku80A siRNA, (F) transfected with Ku80C 
siRNA. Reactivity is observed in the untransfected cells, scrambled control, and 
in cells transfected with Ku70 A and B (A, B, C & D), while little/no staining is 
observed in Ku80 transfected MiaPaCa-2 clone 3 cells (E & F).  Magnification, 
630X, A & B, 400X C & D. Scale Bar, 20µm 
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3.12 Western Blot Validation of MAb 7B7 G5 (2) Target Proteins 
in a Panel of Cell Lines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: - Western blot analysis of pancreatic cancer cell lines, MiaPaCa-2 
clone 3, MiaPaCa-2 clone 3 grown on Matrigel*, MiaPaCa-2 clone 8; Melanoma 
cell lines Lox IMVI, WM-115 (primary cancer), its metastatic counterpart, WM-
266-4, and SNB-19 glioma cell line probed with antibodies specific for Ku80 and 
Ku70. Ku80 shows strong expression in all cell lines, except for SNB-19 and 
WM-115, which show reduced levels of expression. Ku70 has lower expression 
in the MiaPaCa-2 clone 8 cell line, compared to both MiaPaCa-2 clone 3 lines. In 
the melanoma cell lines, Ku70 shows strong expression in Lox IMVI, while 
expression is stronger in the metastatic WM-266-4 cell line, compared to the 
WM-115 primary tumour cell line. No reactive band is observed in the SNB-19 
glioma cell line. n = 3. (See Appendix IV for representative coomassie stained 
gel showing equal loading). Cell lines in bold represent highly invasive 
phenotype.  
 
* MiaPaCa-2 clone 3 cells were grown on Matrigel in order to increae the 
expression of proteins involved in the invasion process. 
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Figure 3.12.1: - Western Blot analysis of lung cancer cell lines DLKP, DLKP-A, 
DLKP-I, DLKP-M, DLKP-SQ and H1299; C/68 Prostate cancer cell line and 
HCT-116 Colon cancer cell line probed with antibodies specific for Ku80 and 
Ku70. Ku80 is expressed to a lesser degree in the DLKP-M and DLKP-SQ cell 
lines compared to DLKP-I and H1299. C/68 also shows less expression of Ku80, 
while HCT-116 shows strong expression for Ku80. Levels of Ku70 expression 
are high in all cell lines, apart from C/68, where it is expressed to a lesser degree. 
n = 3. (See Appendix IV for representative coomassie stained gel showing equal 
loading). Cell lines in bold represent highly invasive phenotype.  
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Figure 3.12.2: - Western blot analysis of HER-2 over-expressing cell lines 
SKBR-3, BT474, MDA-MB-453, MDA-MB-361, probed with antibodies 
specific for Ku80 and Ku70. Ku80 shows strong expression in all cell lines. The 
triple negative MDA-MB-231 cell line shows higher expression of Ku70 
compared to HER2 positive cell lines. n = 3. (See Appendix IV for 
representative coomassie stained gel showing equal loading). Cell lines in bold 
represent highly invasive phenotype.  
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CHAPTER 4 
GENERATION OF MONOCLONAL ANTIBODIES 
DIRECTED AGAINST MDA-MB-435-SF 
   159 
4.1.  Background 
 
An initial primary immunisation, and 4 booster immunisations were carried out 
with MDA-MB-435-SF-Taxol10p4p-SI, a Taxol resistant variant of the parent 
cell line (Glynn, et al., 2004), followed by a further 2 immunisations with the 
parent MDA-MB-435-SF cell line. 
 
4.2  Fusion Results 
 
Following fusion with both MDA-MB-435-SF and the Taxol variant MDA-MB-
435-SF-Taxol10p4p-SI cells, as described in section 2.3.3, 436 supernatants 
(90.8% fusion efficiency) were screened directly for any effect on the invasive 
capacity on MDA-MB-435-SF cells by live and fixed cell immunofluorescence. 
 
4.3  Preliminary Characterisation Hybridoma Supernatants 
 
4.3.1  Screening Directly for Effects on Invasion 
 
All resulting antibodies were screened by 96 well invasion assay method (section 
2.5.2) against the parent cell line, MDA-MB-435-SF. Supernatants showing an 
increase or decrease in invasion levels were identified by three independent 
witnesses through microscopic evaluation. Controls comprised of cells with no 
antibody supernatant (hybridoma media added in place), with invasion levels in 
all cases being compared to this hybridoma medium control. 
 
Six supernatants were chosen on the basis of a slight increase in invasion 
observed in relation to invasion observed with the control cells (no supernatant 
added) (i.e. MDA-MB-435 SF), and six supernatants that appeared to have a 
slight reduction in invasion were also chosen. The levels of invasion observed in 
MDA-MB-435-SF cells were overall very low, which made it very difficult to 
observe any real reduction in invasion. 24 well invasion assays were then carried 
out on Lox-IMVI melanoma cells. An incubation step (antibody supernatant 
incubated with the cell suspension at 4°C for at least 20 minutes prior to addition 
to invasion insert) was included in all screenings, except for the initial assays 
   160 
carried out with 96-well plates. Quantification of inhibition levels of invasion 
was carried out through staining and counting, as described in section 2.5.2. Six 
antibodies that produced an inhibitory effect on cell invasion, MAbs 4E5, 3E2, 
9E1, 102C, 1D2 and 104D, were chosen for further screening and 
characterisation. 
 
Antibodies 4E5 & 9E1 were shown to have a consistent effect on invasion in the 
invasive Lox IMVI melanoma cell line (figures 4.3.1 & 4.3.2). Effects observed 
with MAbs 102C and 104D were not as consistent. Further analysis with MAb 
9E1 indicated that this MAb consistently inhibited invasion levels in a number of 
in vitro models (the invasive LOX-IMVI melanoma cell line & the highly 
invasive MiaPaCa-2 clone 3 pancreatic cell line). This MAb was chosen for 
further characterisation. 
 
MAb 9E1 was then cloned out by limiting dilutions (section 2.3.6), and re-
screened using both 96 and 24 well invasion assays Preliminary results with 
MiaPaCa-2 clone 3 cells showed that clone 24 (6) exhibited consistent inhibitive 
effects on invasion after 48 hours, and so was chosen for further characterisation. 
Isotyping of MAb 9E1 24 (6) determined it to be an IgG1 antibody. Isostrip 
analysis was carried out as described in section 2.3.7 
 
 
 
Figure 4.3: - Isostrip analysis of MAb 9E1 24 (26), indicating that it is an IgG1 
subclass antibody (Isostrip, Roche Diagnostics, GmbH, 1493027) 
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Figure 4.3.1: - Representative photomicrographs showing invasion status of 
LOX-IMVI melanoma cells following incubation with MAb 9E1. A decrease in 
invasion can be observed following incubation of cells with MAb (B) compared 
to control insert (A) (no MAb). A decrease in invasion is also observed following 
pre-incubation of cells for 5 hrs at 4°C with MAb 9E1 (C). Magnification, 100X. 
Scale Bar, 200µm 
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Figure 4.3.2: - Representative photomicrographs invasion status of LOX-IMVI 
melanoma cells following pre-incubation of cells (20 mins,  4°C) with test MAbs 
7F4 (B), 7E4 (C) & 4E5 (D). A decrease in invasion can be observed following 
incubation with MAb 4E5 (D) compared to control insert (A) (no MAb). MAb 
7F4 (B) did not appear to have any effect on invasion while there was possibly 
an increase in invasion following incubation with MAb 7E4 (C). Magnification, 
100X. Scale Bar, 200µm.  
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4.3.2  Immunofluorescence Assays 
 
Fifteen supernatants were selected on the basis of their reactivity with MDA-
MB-435 SF cells using live cell immunofluorescence (approx 50% of test 
supernatants showed some reactivity, chosen supernatants were representative of 
all observed staining patterns). This staining varied between intense staining 
localised to the membrane of cells to more intracellular like staining. A number 
of supernatants resulted in a “punctuation” type of staining associated with cells. 
From these 15 supernatants, 4 were chosen for further characterisation. MAbs 
4E5 & 7E4 showed positive staining to the inner plasma membrane on both live 
and fixed MDA-MB-435 SF cells. An intracellular like staining was observed, 
along with some inner plasma membrane positivity, on the same fixed cells with 
MAb 9E1, while MAb 104D showed intense membrane reactivity on 
preparations of live cells. Immunofluorescence analysis was carried out as 
described in section 2.9.1 & 2.9.2. 
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Figure 4.3.3: - Immunofluorescence analyses of MAb 4E5 reactivity on fixed 
(A) and live (B) MDA-MB-435-SF cells showing a positive staining localised to 
the inner plasma membrane. MAb 9E1 reactivity is also observed with MDA-
MB-435-SF (C) and MDA-MB-435-SF clone 10 (highly motile variant of the 
MDA-MB-435-SF cell line, Joyce, H., unpublished). Magnification, 40X, scale 
bar = 50µm.    
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4.4 Investigation of Functional Effect of MAb 9E1 24 (6) in 
Invasive Cancer Models In Vitro. 
 
MAb 9E1 24 (6) underwent further testing to observe its effects on a number of 
cellular processes, including: 
 
• Proliferation: to observe what effect the MAb has on the cancer cells 
ability to grow.  
• Invasion & Motility: to assess the MAb’s effect on cellular 
invasion/motility 
• Adhesion: to assess the MAb’s impact on the adhesive abilities of a 
number of cell lines to ECM proteins  
• Anoikis: Anoikis is a specific form of apoptosis induced by the loss or 
alteration of cell-cell or cell-matrix anchorage. An in vitro anoikis assay 
was used to assess any impact this MAb has on anoikis resistance.  
• MMP activity: to observe what effect, if any, this MAb has on the activity 
of MMP-2 and MMP-9 in vitro. 
• Cell Morphology: to observe if incubation with this MAb affects the 
morphology of invasive cancer cells. Highly invasive cells usually 
display a spindle shaped elongated morphology. 
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4.4.1 MAb 9E1 24 (6) Effect on Proliferation on the Invasive 
Pancreatic Cell Line MiaPaCa-2 clone 3 
 
The primary goal of this work was to examine the effects of MAb 9E1 24 (6) on 
invasion and motility. To ensure that any changes observed in the assays were 
not secondary to effects on cell proliferation or survival, initial experiments were 
carried out to determine the effects MAb 9E1 24 (6) had on proliferation/survival 
of the MiaPaCa-2 clone 3 cell line. Proliferation assays were carried out as 
described in section 2.4.  
 
Figure 4.4 shows that MAb 9E1 24 (6) had no impact on MiaPaCa-2 clone 3 cell 
proliferation/survival after a 5 day growth assay. This suggests that the MAb has 
no toxic, growth inhibitory or stimulatory effect on this cell line over the course 
of the assay. 
 
Statistical analyses were carried out on the average absorbancy readings of the 
control Vs test wells, over biological triplicates. 
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Figure 4.4: - Histogram of MAb 9E1 24 (6) showing little inhibition of 
proliferation in MiaPaCa-2 clone 3 compared to control hybridoma medium (no 
MAb) representing 100% proliferation after 96 hours. Statistics; * p ≤ 0.05, ** p 
≤ 0.01, *** p ≤ 0.005, Student’s t-test. n = 3. Error bars calculated using ± 
standard deviation. 
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4.4.2 MAb 9E1 24 (6) Effect on Invasion on Invasive Cancer Cell 
Lines  
 
In order to ascertain what effect MAb 9E1 24 (6) has on cell invasion and 
motility, Invasion and Motility assays were carried out (as described in section 
2.5.2 & 2.5.3.) on a range of invasive cancer cell lines. Cells were incubated with 
the MAb, and after 24-48 hrs, depending on the cell line, levels of cellular 
invasion/motility were quantified.  
 
Figure 4.4.2 shows that MAb 9E1 24 (6) significantly inhibited invasion in the 
MiaPaCa-2 clone 3 cell line. However, no such inhibition was noted with the 
BxPc-3 cell line. Significant inhibition of invasion was also observed in the 
DLKP-I, DLKP-M and H1299 lung cancer cell lines, the MDA-MD-231 breast 
cancer cell line, the Lox IMVI melanoma cell line and the c/68 prostate cell line. 
Inhibition of invasion was also observed in the SKBR-3 breast cancer cell line. 
No inhibition was observed in the SNB-19 glioma cell line or the BxPc-3 
pancreatic cell line. In the HCT-116 colon cancer cell line, a significant increase 
in cell invasion was observed upon exposure to MAb 9E1 24 (6). An increase in 
invasion was also observed in the MDA-MB-157 breast cancer cell line. These 
results indicate that MAb 9E1 24 (6) can successfully inhibit the invasion process 
in a number of cell types, but can also increase cell invasion in others. 
 
Figure 4.4.3 shows that MAb 9E1 24 (6) significantly reduces cell motility in the 
MiaPaCa-2 clone 3 cell line, by but to a lesser extent than those seen in the 
invasion assay.  
 
Statistical analyses were carried out with the average cell counts of control Vs 
sample inserts over biological triplicates (section 2.15).  
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Figure 4.4.1: - Histogram of MAb 9E1 24 (6) showing significant inhibition of 
invasion in MiaPaCa-2 clone 3, but no inhibition in BxPc-3, compared to control 
hybridoma medium (no MAb) representing 100% invasion, after 48 hours. 
Statistics; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, Student’s t-test. n = 3. Error 
bars calculated using ± standard deviation. 
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Figure 4.4.2: - Representative photomicrographs showing invasion status of 
MiaPaCa-2 clone 3 and BxPc-3 cells following incubation with MAb 9E1 24 (6) 
for 48 hours. A decrease in invasion can be observed in MiaPaCa-2 clone 3 
following addition of MAb 9E1 24 (6) (b) compared to control insert (a) (no 
antibody supernatant). No inhibitory effect is seen in BxPc-3. Magnification, 
100X. Scale Bar, 200µm. 
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4.4.3 MAb 9E1 24 (6) Inhibition of Motility on the Pancreatic Cell 
Line MiaPaCa-2 clone 3  
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Figure 4.4.3: - Histogram of MAb 9E1 24 (6) showing inhibition of motility in 
MiaPaCa-2 clone 3 compared to control hybridoma medium (no MAb) 
representing 100% motility after 24 hours. Statistics; * p ≤ 0.05, ** p ≤ 0.01, *** 
p ≤ 0.005, Student’s t-test. n = 3. Error bars calculated using ± standard 
deviation. 
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4.4.4 MAb 9E1 24 (6) Effect on Invasion on the Large-Cell Lung 
Cancer Cell Line H1299 and Invasive Variants of the NSCLC 
DLKP Cell Line DLKP-I & DLKP-M 
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Figure 4.4.4: - Histogram of MAb 9E1 24 (6) showing significant inhibition of 
invasion in DLKP-I and DLKP-M compared to control hybridoma medium (no 
MAb) representing 100% invasion after 24 hours. Inhibition of invasion 
observed in the H1299 cell line did not reach statistical significance. Statistics; * 
p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, Student’s t-test. n = 3. Error bars calculated 
using ± standard deviation. 
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Figure 4.4.5: - Representative photomicrographs showing invasion status of 
DLKP-I, DLKP-M and H1299 cells following 24hr incubation with MAb 9E1 
G5 (2). A decrease in invasion can be observed following addition of MAb 9E1 
24 (6) (b) compared to control insert (a) (no MAb) in all three cell lines. 
Magnification, DLKP-I & DLKP-M, 100X; H1299, 200X. Scale Bar, 200µm. 
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4.4.5 MAb 9E1 24 (6) Effect on Invasion on the DLKP-M Lung 
Cancer Cell Line: - Dose Response 
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Figure 4.4.6: - Histogram of MAb 9E1 24 (6) showing significant inhibition of 
invasion in DLKP-M compared to control hybridoma medium (no MAb) 
representing 100% invasion after 24 hours. Statistics; * p ≤ 0.05, Student’s t-test. 
n = 3. Error bars calculated using ± standard deviation. 
 
A dose response inhibitive effect is also observed with 1:2 and 1:5 dilutions of 
MAb showing less inhibition compared to neat MAb.  
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4.4.6 MAb 9E1 24 (6) Effect on Invasion on the Invasive, Triple 
Negative Breast cancer Cell Lines MDA-MB-231, MDA-MB-
157 and the HER-2 Over Expressing Breast Cell Line, SKBR-
3 
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Figure 4.4.7: - Histogram of MAb 9E1 24 (6) showing inhibition of invasion in 
MDA-MB-231, but an increase in invasion in MDA-MB-157, and inhibition of 
invasion in SKBR-3, compared to control hybridoma medium (no MAb) 
representing 100% invasion after 24 hours. Statistics; * p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.005, Student’s t-test. n = 3. Error bars calculated using ± standard 
deviation. 
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Figure 4.4.8: - Representative photomicrographs showing invasion status of 
MDA-MDA-231 and MDA-MB-157 cells following incubation with MAb 9E1 
24 (6). A decrease in invasion can be observed following addition of MAb 9E1 
24 (6) (b) compared to control insert (a) (no MAb) in the MDA-MB-231 and 
SKBR-3 cell lines. However, a slight increase in invasion is observed in the 
MDA-MB-157 cell line.  Magnification, 100X. Scale Bar, 200µm. 
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4.4.7 MAb 9E1 24 (6) Effect of Invasion in the Invasive Glioma Cell 
Line SNB-19 
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Figure 4.4.9: - Histogram and representative photomicrographs of MAb 9E1 24 
(6) showing no inhibition of invasion in SNB-19 compared to control hybridoma 
medium (no MAb) representing 100% invasion after 24 hours. Statistics; * p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.005, Student’s t-test. n = 3. Magnification, 100X. 
Scale Bar, 200µm. Error bars calculated using ± standard deviation. 
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4.4.8 MAb 9E1 24 (6) Effect of Invasion on the Invasive Melanoma 
Cell Line Lox IMVI 
 
 
0
20
40
60
80
100
120
Hybridoma Control MAb 9E1 24 (6)
Re
la
tiv
e 
Ce
ll 
In
v
as
io
n
 
(%
)
n = 1
n = 2
n = 3
 
 
 
Hybridoma Medium Control MAb 9E1 24 (6) 
  
 
Figure 4.4.10: - Histogram and representative photomicrographs of MAb 9E1 24 
(6) showing inhibition of invasion in Lox IMVI compared to control hybridoma 
medium (no MAb) representing 100% motility after 24hrs. Statistics; * p ≤ 0.05, 
** p ≤ 0.01, *** p ≤ 0.005, Student’s t-test. n = 3. Error bars calculated using ± 
standard deviation.  Magnification, 100X. Scale Bar, 200µm. 
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4.4.9 MAb 9E1 24 (6) Effect on Invasion on the Invasive Prostate 
Cell line C/68 
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Figure 4.4.11: - Histogram and representative photomicrographs of MAb 9E1 24 
(6) showing inhibition of invasion in C/68 compared to control hybridoma 
medium (no MAb) representing 100% invasion after 24 hours. Statistics; * p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.005, Student’s t-test. n = 3. Error bars calculated 
using ± standard deviation.  Magnification, 100X. Scale Bar, 200µm. 
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4.4.10 MAb 9E1 24 (6) Effect on Invasion on the Invasive Colorectal 
Cell line HCT-116 – Dose Response 
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Figure 4.4.12: - Representative representative histogram and photomicrographs 
of MAb 9E1 24 (6) showing a significant increase in invasion in HCT-116 
compared to control hybridoma medium (no MAb) representing 100% invasion 
after 24 hours. Statistics; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, Student’s t-test. 
n = 3. Error bars calculated using ± standard deviation. 
 
A dose response inhibitive effect is also observed on all dates with 1:2 dilutions 
of the MAb showing less inhibition compared to neat MAb. Magnification, 
100X. Scale Bar, 200µm. 
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Cancer Type Cell Line Mean Inhibition Levels  P value 
MDA-MB-157 22.6% increase 0.6 
MDA-MD-231 33% 0.19 
 
Breast 
SKBR-3 33% 0.22 
DLKP-I 50.8% 0.001 
DLKP-M 64% 0.02 
 
Lung 
H1299 24.6% 0.18 
MiaPaCa-2 clone 3 66% 0.01 Pancreatic 
BxPc-3 6.7% increase 0.64 
Melanoma Lox IMVI 36.9% 0.13 
Glioma SNB-19 0.7% 0.9 
Prostate C/68 39.3% 0.07 
Colon HCT-116 91.8% increase 0.0014 
 
Table 4.4: - Effect of MAb 9E1 24 (6) on invasion levels in a panel of cell lines. 
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4.4.12 MAb 9E1 24 (6) Effect on Adhesion to Matrigel on the 
Invasive Pancreatic Cancer Cell Line MiaPaCa-2 clone 3 and 
the Invasive NSCLC DLKP-M Cell Line 
 
Adhesion assays were carried out in order to investigate what effect MAb 9E1 24 
(6) had on the ability of cancer cells to attach to ECM proteins. The effect of the 
MAb on the ability of MiaPaCa-2 clone 3 and DLKP-M cells to adhere to 
matrigel was investigated. Adhesion assays were performed as described in 
section 2.5.4. 
 
In figure 4.4.13, MAb 9E1 24 (6) slightly reduced adhesion of MiaPaCa-2 clone 
3 cells to matrigel in vitro. A significant decrease in adherence of DLKP-M cells 
to matrigel was also observed (figure 4.4.14). These results indicate that MAb 
9E1 24 (6) can interfere with the ability of cancer cells to attach to components 
of the ECM. 
 
Statistical analyse were carried out on the average absorbancy reading of control 
Vs sample wells over biological triplicates. 
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Figure 4.4.13: - Adhesion of MiaPaCa-2 clone 3 to ECM protein, fibronectin. 
Results are expressed as percentage adhesion to fibronectin in the presence of 
MAb 9E1 24 (6), compared to adhesion to fibronectin in the presence of control 
hybridoma medium (no MAb). Cells grown in the presence of MAb 9E1 24 (6) 
for 24 hrs, showed a decrease in adhesion to fibronectin when compared to the 
control. Statistics; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, Student’s t-test. n = 3. 
Error bars calculated using ± standard deviation. 
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Figure 4.4.14: - Adhesion of DLKP-M to ECM protein, matrigel. Results are 
expressed as percentage adhesion to matrigel in the presence of MAb 9E1 24 (6), 
compared to adhesion to matrigel in the presence of control hybridoma medium 
(no MAb). Cells grown in the presence of MAb 9E1 24 (6) for 24 hrs, showed a 
significant decrease in adhesion to matrigel when compared to the control. 
Statistics; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, Student’s t-test. n = 3. Error 
bars calculated using ± standard deviation.  
 
 
   185 
4.4.13 MAb 9E1 24 (6) Effect on Anoikis on the Invasive Pancreatic 
Cancer Cell Line MiaPaCa-2 clone 3 and on the Invasive 
NSCLC DLKP-M Cell Line 
 
To determine whether MAb 9E1 24 (6) effects anoikis resistance in vitro, 
Anoikis assays were carried out, on the MiaPaCa-2 clone 3 and DLKP-M cell 
lines. Anoikis is a specific form of apoptosis induced by the loss or alteration of 
cell-cell or cell-matrix anchorage. MiaPaCa-2 clone 3 has been shown to have a 
high level of anoikis resistance (Walsh et al., 2007), while DLKP-M has been 
shown to be 50% resistant to anoikis (Dr. Keenan, NICB, unpublished results). In 
this study, the effect of MAb 9E1 24 (6) on the above cell lines growing in 
anoikis-inducing conditions was investigated. Anoikis assays were carried out as 
described in section 2.6. 
 
Figure 4.4.15 shows that MAb 9E1 24 (6) has no significant effect on the cells 
when there are growing in Anoikis-inducing conditions. The cells do not display 
any increased or decreased levels of anoikis resistance, indicating that MAb 9E1 
24 (6) does not effect this cellular process.    
 
Statistical analyse were carried out on the average absorbancy reading of control 
Vs sample wells over biological triplicates.  
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Figure 4.4.15: - Representative histogram showing percentage survival of non-
adherent cells (24 hrs poly-HEMA treated plastic) incubated in the presence of 
MAb 9E1 24 (6). No effect on cell survivability is observed when compared to 
cells growing in the presence of no MAb. Statistical significance was not 
achieved in this experiment. Data shown is mean ± standard deviation (n= 3).  
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4.4.14 Morphological Change of MiaPaCa-2 clone 3 Cells Incubated 
with MAb 9E1 24 (6) 
 
MiaPaCa-2 clone 3 cells display an elongated, splindle-like morphology, which 
is associated with an invasive phenotype. To investigate whether MAb 9E1 24 
(6) effects cell morphology, MiaPaCa-2 clone 3 cells were incubated with the 
MAb for 24hrs, after which, cell morphology was observed. This assay was 
carried out as described in section 2.8.  
 
Figure 4.4.16 shows the effect MAb 9E1 24 (6) has on the MiaPaCa-2 clone 3 
cells, compared to cells grown in the absence of the MAb. It is quite clear that 
the cells have lost their elongated, spindle-like shape, and exhibit a more rounded 
appearance, similar to the less invasive MiaPaCa-2 clone 8 cell morphology. As 
a spindle-like cell morphology has been linked to cell invasion (Yilmaz et al., 
2007), this change may indicate that the invasive capabilities of the MiaPaca-2 
clone 3 cells have been diminished following incubation with MAb 9E1 24 (6). 
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A. B. 
 
  
 
 
 
 
 
 
 
 
Figure 4.4.16: - Representative photomicrographs showing morphology of 
MiaPaCa-2 clone 3 cells following incubation with supernatant 9E1 24 (6) for 24 
hours. Cells incubated with MAb 9E1 24 (6) (B) have lost their elongated, 
spindle-like morphology, and have become more rounded. Cells incubated with 
hybridoma media (A) retain their normal morphology. Magnification, 100X. 
Scale Bar, 200µm. 
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4.4.15 MAb 9E1 24 (6) Effect on MMP-9 Activity in the Invasive 
Breast Cancer Cell Line MDA-MB-231 
 
 
Zymography assays were carried out in order to investigate the effect of MAb 
9E1 24 (6) has on MMP-9 expression. MMP-9 is involved in the degradation of 
proteins in the ECM and plays a crucial role in localised degradation of the 
basement membrane, and subsequent cellular invasion. MDA-MB-231 was 
chosen for this study, as it is known to express MMP-9 (Hegedus et al., 2008). 
Conditioned media from cells incubated with the MAb were collected, as 
described in section 2.7.1. This was then separated on a zymography gel, which 
was then subsequently stained. The zymography assay was carried out as 
described in section 2.7.2.  
 
Figure 4.4.17 shows that MAb 9E1 24 (6) decreases the activity of active MMP-
9 in the MDA-MB-231 cell line, when compared to cells grown in the absence of 
the MAb. This is also observed in the zymography gel. This preliminary result 
indicates that MAb 9E1 24 (6) inhibits the activity of MMP-9 in vitro (see 
Appendix VI for complete zymograpgy gel).  
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Figure 4.4.17: - Graph and zymography gel showing effect of MAb 9E1 24 (6) 
on MMP-9 activity in the MDA-MB-231 breast cell line. Cells incubated with 
MAb 9E1 24 (6) show a decrease in the activity of MMP-9 when compared to 
control hybridoma medium (no MAb) representing normal MMP-9 activity.  
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4.5 Immunofluorescence Studies of MAb 9E1 24 (6) in a Panel of 
Cancer Cell Lines 
 
 
 
 
A. B. 
  
 
C. D. 
  
 
 
 
 
 
Figure 4.5: - Immunofluorescence analysis of MAb 9E1 24 (6) on MiaPaCa-2 
clone 3 and clone 8 pancreatic cells. Positive staining, localised to the membrane, 
with some cytoplasmic reactivity, is observed in the invasive MiaPaCa-2 clone 3 
cells (A & C ), Staining in the poorly invasive MiaPaCa-2 clone 8 cells is slightly 
stronger compared to the invasive clone 3 (B & D). Magnification 400X, scale 
bar = 20µm. (A & B counter stained with Propidium Iodide). 
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Figure 4.5.1: - Immunofluorescence analysis of (A) SKBR-3 and (B) BT474 
HER-2 over expressing breast cancer cell lines; (C) DLKP-SQ and (D), DLPK-
SQ-Mitox 6p lung carcinoma cells. MAb 9E1 24 (6) shows punctuate type 
membrane, reactivity in SKBR-3, BT474 and DLKP-SQ-Mitox-6p cells. Weak 
reactivity is observed in DLKP-SQ cells. Magnification, 630X, scale bar 10µm. 
(C counter stained with Propidium Iodide). 
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4.6  Western Blotting Analysis with MAb 9E1 24 (6) 
 
Western blotting analysis was carried out on the MiaPaCa-2 clone 3 cell line (in 
which MAb 9E1 24 (6) showed a decrease in invasion) in order to establish the 
reactive antigen and its molecular weight. A selection of invasive and non-
invasive cell lines, of differing cancer cell types, was also included in the 
analysis. Immunoblotting with MAb 9E1 24 (6) MAb on a panel of cell lines 
identified a very strong reactive band at approx. 75 kDa (Figures 4.6 & 4.6.1). 
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Figure 4.6: - A. Western blot analysis of pancreatic cancer cell lines MiaPaCa-2 
clone 3, MiaPaCa-2 clone 3 grown on Matrigel, MiaPaCa-2 clone 8; Melanoma 
cell lines Lox IMVI, WM-115 tumour and its metastatic counterpart, WM-266-4; 
and SNB-19 glioma cell line probed MAb 9E1 24 (6). A reactive band at approx. 
76.5 kDa can be observed in all cell lines. Reactivity in the MiaPaCa-2 clone 3 
cell line is slightly stronger than in the clone 8 variant (agreeing with 
immunofluorescence results), while the strongest reactivity is observed in the 
SK-MEL-28 cell line. Very weak reactivity is observed in the WM-115, WM-
266-4 and SNB-19 cell lines.  
 
B. Western Blot analysis of lung cancer cell lines DLKP, DLKP-A, DLKP-I, 
DLKP-M, DLKP-SQ and H1299; C/68 Prostate cancer cell line and HCT-116 
Colon cancer cell line probed MAb 9E1 24 (6). A reactive band is observed at 
approx. 75 kDa in all cell lines. Strong reactivity can be seen in the DLKP-SQ 
cell line. n = 3. (See Appendix IV for representative coomassie stained gel 
showing equal loading). Cell lines in bold represent highly invasive phenotype.  
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Figure 4.6.1: - Western blot analysis of HER-2 over-expressing cell lines MDA-
MB-453, MDA-MB-361, SKBR-3 and BT474, and the Triple negative breast 
cancer cell line, MDA-MB-231; probed with MAb 9E1 24 (6). A strong reactive 
band can be observed at approx. 75 kDa in all cell lines, except for MDA-MB-
453, where no reactive band was visible. n = 3. (See Appendix IV for 
representative coomassie stained gel showing equal loading). Cell lines in bold 
represent highly invasive phenotype.  
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4.7  Immunoprecipitation Studies 
 
In order to try to identify the target antigens, immunoprecipitation studies were 
carried out on a panel of cell lines. MiaPaCa-2 clone 3 was the primary cell line 
used, due to the initial invasion/motility assays being carried out with that cell 
line. Protein-G agarose beads were used to pull out the reactive antigens from 
whole cell lysates of MiaPaCa-2 clone 3 cells for the 9E1 24 (6) MAb. Following 
separation on 4-12% Bis-Tris SDS-PAGE, a number of bands were identified out 
with this antibody (Figure 4.7). These were compared to bands pulled out using a 
control mouse IgG, and those bands only present with the 9E1 24 (6) MAb were 
identified through liquid chromatography mass spectrometry (LC-MS) analysis 
(Dionex Ultimate 3000 LC system, LTQ-Orbitrap mass spectrometer), LC-MS 
sequencing using LCMS/LTQ mass spectrometry and TurboSEQUEST software 
using the human subset from the SWISS-PROT database.  
 
The direct method of immunoprecipitation was carried out in order to facilitate 
identification of the antigen of interest. This method (section 2.11.1.) involves 
incubating the antibody/cell lysate complex with the agarose beads, then 
separating the solution, containing both the antigen and antibody fragments, on 
SDS-PAGE gels.  
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4.7.1  MAb 9E1 24 (6) – Direct Immunoprecipitation Method 
 
 
 
 
  
  
 
 
 
 
Figure 4.7: - Direct Immunoprecipitation of cell lysates with 9E1 24 (6) MAb 
and control mouse IgG. 
A representative SDS-PAGE gel of MiaPaCa-2 clone 3 and H1299 cells 
immunoprecipitated with MAb 9E1 24 (6) and separated on 4-12% Bis-Tris 
SDS-PAGE, and stained with 0.25% Coomassie Blue. Lane 1: molecular weight 
markers. Lane 2: MiaPaCa-2 clone 3 immunoprecipitated with MAb 9E1 24 (6). 
Five bands of MAb 9E1 24 (6) target proteins are observed; at approx. 170 kDa, 
155 kDa, 65 kDa, 42 kDa and 30 kDa. These 5 bands are not present in the 
control mouse IgG, have been observed in triplicate experiments, and in a 
number of cell lines. Each band was excised and run through an LCMS/LTQ 
mass spectrometer for identification. Lane 3: MiaPaCa-2 clone 3 
immunoprecipitated with control mouse IgG. Lane 4: H1299 immunoprecipitated 
with MAb 9E1 24 (6). 
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4.7.2  Purification of MAb 9E1 24 (6)  
 
 
 
 
 
 
     
  
 
 
 
 
 
 
 
Figure 4.7.1: - Representative SDS-PAGE gel showing successful purification 
of 9E1 24 (6) MAb, using the Pierce NAb Spin Purification Kit (section 2.3.8). 
Lane 1: Molecular Weight marker. Lane 2: Unpurified MAb 9E1 24 (6). Lane 3: 
Concentrated, unpurified MAb 9E1 24 (6). Lane 4: Purified MAb 9E1 24 (6). 
Purified MAb is required for cross linked immunoprecipitation. 
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4.8 Mass Spectrometry Identification of MAb 9e1 24 (6) Target 
Proteins 
 
Following separation of immunoprecipitates on 4-12% Bis-Tris SDS-PAGE, the 
gel was stained with 0.25% Coomassie Blue and destained accordingly. Bands of 
interest were excised from the gel, digested with trypsin, and subjected to LC-
MS analysis. Identification was achieved using the SWISS-PROT SEQUEST 
database (section 2.12.1). 
  
Positive identification was deemed valid if: 
 
• protein was observed in duplicate or more, from 2 or more independent 
experiments 
• a minimum of 2 peptide sequences was obtained 
• molecular weight of protein matched molecular weight of band on gel  
• molecular weight of protein matched the molecular weight of band 
excised from gel     
• protein achieved a high XC score, indicating excellent confidence in the 
identification  
• Proteins were unique to MAb 9E1 24 (6) (i.e. not found with other 
MAbs) 
 
Criteria for a valid identification is described in full in section 2.12.1. 
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Protein Name Band Gene Symbol SWISSPROT 
Protein AC 
Number 
MW (kDa) 
Annexin A6 3 ANXA6 P08133 75.87 
Prohibitin 5 PHB P35232 29.8 
Protein 14-3-3 epsilon 5 YWHAE P62258 29.1 
ADP/ATP Translocase 1 5 SLC25A4 P12235 33 
ADP/ATP Translocase 2 5 SLC25A5 P05141 32.87 
ADP/ATP Translocase 3 5 SLC25A6 P12236 32.84 
40S Ribosomal Protein 3 5 RS3 P23396 26.67 
40S Ribosomal Protein S4, Y isoform 1 5 RS4Y1 P22090 29.43 
40S Ribosomal Protein S4, Y isoform 2 5 RS4Y2 Q8TD47 29.27 
40S Ribosomal Protein S4, X isoform  5 RPS4X P62701 29.59 
 
Table 4.8: - Proteins identified using above criteria, from excised bands 
immunoprecipitated with MAb 9E1 24 (6), through mass spectrometry. Band 
number refers to highlighted bands on gel represented in figure 4.7. 
 
For MAb 9E1 24 (6), the band at approx. 75 kDa was identified as Annexin A6. 
The band at approx. 32 kDa was revealed to have a mixture of peptides; 
identified as Prohibitin, Protein 14-3-3 epsilon, and ADP-ATP Translocase 1, 2 
and 3. 40S Ribosomal proteins were not studied further due to budget constraints. 
  
All other bands observed in MAb 9E1 24 (6) were either identified as Mouse 
IgG, or were present in the control immunoprecipitation, and were thus 
disregarded. 
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Protein Name Gene Symbol SWISSPROT 
Protein AC 
Number 
MW (kDa) 
NAD(P)H dehydrogenase NQO1 P15559 30.86 
Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) 
G3P P04406 36 
Heat Shock Protein 90 kDa beta member 1 HSP90B1 Q96GW1 92.41 
Fructose-bisphosphate aldolase A ALDOA P04075 39.39 
 
Table 4.8.1: - Proteins identified only once, from excised bands 
immunoprecipitated with MAb 9E1 24 (6), through mass spectrometry. 
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4.8.1 Identification of MAb 9E1 24 (6) Target Proteins by LC-MS 
Analysis of 9E1 24 (6) Immunoprecipitates. 
 
• Annexin A6 
 
     P (pro) Score 
Scan(s) Peptide MH+ z Type P (pep) XC 
ANXA6_HUMAN RecName: Full=Annexin A6; AltName: Full=Annexin-6; 
AltName: Full=Annexin VI; AltName: Full=Lipocortin VI; AltName: 
Full=p68; AltName: Full=p70; AltName: Full=Protein III; AltName: 
Full=Chromobindin-20; AltName: Full=67 kDa calelectrin; AltName 
4.79E-06 60.17 
319 K.GAGTDEKTLTR.I 1148.59058 2 CID 4.97E-05 3.40 
408 R.AINEAYKEDYHK.S 1480.70667 2 CID 4.22E-05 3.01 
463 K.TTGKPIEASIR.G 1172.66333 2 CID 1.95E-02 2.61 
523 K.GTVRPANDFNPDADAK.A 1687.80347 2 CID 6.12E-03 3.46 
571 -.SEISGDLAR.- 947.47925 2 CID 1.77E-02 2.11 
1289 K.ALLALCGGED.- 1018.48743 1 CID 4.79E-06 2.06 
 
Table 4.9.2: - Identification of Protein Annexin A6, obtained using SEQUEST 
Human protein database 
 
Peptides were identified using Bioworks 3.3.1 software. A representative result 
(experiments were carried out at least 3 times) is shown above, where 6 peptides 
corresponding to Human Annexin A6 were identified. All 6 peptides showed 
high XC scores indicating excellent confidence in this identification. (Note: the 
minimum acceptable Xcorr for identified peptides was 1.5 for 1+ peptides, 2.5 
for 2+ peptides and 3.5 for 3+ peptides).  
 
QLVAAYKDAYERDLEADIIGDTSGHFQKMLVVLLQGTREEDDVVSEDLVQQDVQDLYEAGELKW
GTDEAQFIYILGNRSKQHLRLVFDEYLKTTGKPIEASIRGELSGDFEKLMLAVVKCIRSTPEYFAERL
FKAMKGLGTRDNTLIRIMVSRSELDMLDIREIFRTKYEKSLYSMIKNDTSGEYKKTLLKLSGGDDD
AAGQFFPEAAQVAYQMWELSAVARVELKGTVRPANDFNPDADAKALRKAMKGLGTDEDTIIDII
THRSNVQRQQIRQTFKSHFGRDLMTDLKSEISGDLARLILGLMMPPAHYDAKQLKKAMEGAGTDE
KALIEILATRTNAEIRAINEAYKEDYHKSLEDALSSDTSGHFRRILISLATGHREEGGENLDQAREDA
QVAAEILEIADTPSGDKTSLETRFMTILCTRSYPHLRRVFQEFIKMTNYDKGAGTDEKTLTRIMVSRS
EIDLLNIRREFIEKYDKSLHQAIEGDTSGDFLKALLALCGGED 
 
 
 
 
 
Figure 4.8: - Total amino acid sequence of Human Annexin A6 protein 
presented above. Scan of 523 peptide sequence, which shows the highest XC 
score (3.46) is highlighted. 
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Figure 4.8.1: - The MS-MS spectrum for scan 319 showing b (indicated in red) & y (indicated in blue) fragment ion series overlay.  
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• Prohibitin 
 
     P (pro) Score 
Scan(s) Peptide MH+ z Type P (pep) XC 
PHB_HUMAN RecName: Full=Prohibitin 
 1.76E-04 40.18 
583 K.AAIISAEGDSK.A 1061.54736 2 CID 1.00E-03 2.43 
1242 R.IFTSIGEDYDER.V 1444.65906 2 CID 7.83E-04 3.28 
1275 K.DLQNVNITLR.I 1185.65857 2 CID 1.91E-04 2.90 
1313 R.FDAGELITQR.E 1149.58984 2 CID 1.76E-04 3.57 
 
Table 4.8.3: - Identification of Protein Prohibitin, obtained using SEQUEST 
Human protein database. 
 
Peptides were identified using Bioworks 3.3.1 software. A representative result 
(experiments were carried out at least 3 times) is shown above, where 4 peptides 
corresponding to Human Prohibitin were identified. All 4 peptides showed high 
XC scores indicating excellent confidence in this identification.  
 
 
 
MAAKVFESIGKFGLALAVAGGVVNSALYNVDAGHRAVIFDRFRGVQDIVVGEGTHFLIP
WVQKPIIFDCRSRPRNVPVITGSKDLQNVNITLRILFRPVASQLPRIFTSIGEDYDERVLPSI
TTEILKSVVARFDAGELITQRELVSRQVSDDLTERAATFGLILDDVSLTHLTFGKEFTEA
VEAKQVAQQEAERARFVVEKAEQQKKAAIISAEGDSKAAELIANSLATAGDGLIELRKL
EAAEDIAYQLSRSRNITYLPAGQSVLLQLPQ 
 
 
 
 
 
 
 
 
Figure 4.8.2: - Total amino acid sequence of Human Prohibitin protein presented 
above. Scan of 1313 peptide sequence, which shows the highest XC score (3.57) 
is highlighted. 
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Figure 4.8.3: - The MS-MS spectrum for scan 1313 showing b (indicated in red) & y (indicated in blue) fragment ion series overlay. 
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• 14-3-3 protein epsilon 
 
     P (pro) Score 
Scan(s) Peptide MH+ z Type P (pep) XC 
1433E_HUMAN RecName: Full=14-3-3 protein epsilon; Short=14-3-3E 1.27E-09 30.21 
774 R.IISSIEQKEENK.G 1417.75330 2 CID 5.05E-05 3.44 
1138 K.VAGM*DVELTVEER.N 1463.70464 2 CID 1.27E-09 4.11 
1219 R.YLAEFATGNDR.K 1256.59058 2 CID 1.38E-05 2.75 
 
Table 4.8.4: - Identification of 14-3-3 protein epsilon, obtained using SEQUEST 
Human protein database. 
 
Peptides were identified using Bioworks 3.31 software. A representative result 
(experiments were carried out at least 3 times) is shown above, where 3 peptides 
corresponding to Human 14-3-3 protein epsilon were identified. All 3 peptides 
showed high XC scores indicating excellent confidence in this identification.  
 
 
 
 
MDDREDLVYQAKLAEQAERYDEMVESMKKVAGMDVELTVEERNLLSVAYKNVIGAR
RASWRIISSIEQKEENKGGEDKLKMIREYRQMVETELKLICCDILDVLDKHLIPAANTGES
KVFYYKMKGDYHRYLAEFATGNDRKEAAENSLVAYKAASDIAMTELPPTHPIRLGLAL
NFSVFYYEILNSPDRACRLAKAAFDDAIAELDTLSEESYKDSTLIMQLLRDNLTLWTSDM
QGDGEEQNKEALQDVEDENQ 
 
 
 
 
 
 
 
Figure 4.8.4: - Total amino acid sequence of Human 14-3-3 epsilon protein 
presented above. Scan of 1138 peptide sequence, which shows the highest XC 
score (4.11) is highlighted. 
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Figure 4.8.5: - The MS-MS spectrum for scan 1219 showing b (indicated in red) & y (indicated in blue) fragment ion series overlay. 
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4.9 Western Blot Validation of MAb 9E1 24 (6) Target Proteins  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: - Western Blot analysis of MiaPaCa-2 clone 3 I.P. samples, 
separated on SDS-PAGE, and probed with commercial Annexin A6 and Protein 
14-3-3 ε-specific antibodies. Reactive bands at the expected weights of 75 kDa 
(Annexin A6) and 29 kDa (14-3-3ε) are detected in all immunoprecipitates, 
confirming these protein bands as Annexin A6 and Protein 14-3-3 ε.  n = 3. 
 
 
 
 
 
75kDa (Annexin A6) 
29kDa (Protein 14-3-3 ε) 
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⇒ Prohibitin. 
 
 
 
 
  
 
 
 
 
 
 
Figure 4.9.5: - Western Blot Analysis of MiaPaCa-2 clone 3 I.P. sample, 
separated on SDS-PAGE, and probed with an Prohibitin antibody. A reactive 
band at the expected weight of 35 kDa is detected by the antibody in the 
immunoprecipitate, confirming this protein band as Prohibitin.  n = 2. 
35 kDa 
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⇒ Annexin A6 & MAb 9E1 24 (6). 
 
 
 
 
 
  
 
 
 
Figure 4.9.5: - Western Blot Analysis of MiaPaCa-2 clone 3 and SKBR-2 cancer 
cell lines, separated on SDS-PAGE, and probed with MAb 9E1 24 (6) and an 
Annexin A6 antibody. Reactive bands at approx. 75 kDa are detected by MAb 
9E1 24 (6), while reactive bands at the expected molecular weight of 75kDa are 
detected by the Annexin A6 antibody. Lanes 1: MiaPaCa-2 clone 3 probed with 
MAb 9E1 24 (6). Lane 2: SKBR-3 probed with MAb 9E1 24 (6). Lane 3: 
Molecular weight markers. Lane 4: MiaPaCa-2 clone 3 probed with an Annexin 
A6 antibody. Lane 5: SKBR-3 probed with an Annexin A6 antibody. These 
results suggest that the reactive antigen of MAb 9E1 24 (6) is Annexin A6.  n = 
3. 
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4.10 siRNA Functional Analysis of Targets Identified Through 
Immunoprecipitation  
 
After the targets for MAb 9E1 24 (6) were identified, siRNAs specific for the 
genes of interest were obtained, in order to see if silencing of the genes gave 
comparable inhibition in invasion levels to what was observed with the MAb. 
This would show whether the genes of interest play a role in the invasion 
process. The conditions for siRNA transfection were optimised in 96- and 6-well 
plates using kinesin as a positive control, and scrambled siRNA as a siRNA 
transfection control. Three siRNAs were selected for each of the targets chosen 
and transfected into cells (section 2.14.2). For each set of siRNA transfections 
carried out, a non-transfected cell line and a scrambled (SCR) siRNA transfected 
control were used. Kinesin (Kin) was used as a control for efficient transfection 
as Kin siRNA reduces proliferation in the cells.  
 
Three siRNAs were chosen for Annexin A6, each one targeting a different region 
of the gene. This was in order to maximise the chance of seeing an effect on 
invasion and proliferation levels. 
  
Proliferation assays (section 2.14.3) were carried out on transfected cells to 
assess the impact of gene silencing on proliferation levels in the cells, to ensure 
that any inhibition in invasion was not just due to a decrease in the cell number. 
 
Invasion assays (section 2.14.4) were carried out on transfected cells to confirm 
whether or not these targets played an important role in invasion, as suggested by 
proteomic analysis. 
 
Motility assays (section 2.14.5) were carried out on transfected cells to confirm 
whether or not these targets played an important role in motility, as suggested by 
proteomic analysis. 
   212 
4.10.1 Investigation of the Possible Role of Annexin A6 in Cancer 
Cell Invasion  
 
Annexin A6 knockdown was successfully carried out in the MiaPaCa-2 clone 3 
and DLKP-M cell lines.  
 
Silencing of the Annexin A6 gene by two different siRNAs significantly reduced 
the invasive capacity of the MiaPaCa-2 clone 3 and DLKP-M cells (the 3rd 
siRNA did not produce an effective knockdown of Annexin A6, and as such, 
invasion assays were not carried out on cells transfected with this siRNA): 
 
• MiaPaCa-2 clone 3 invasion was significantly inhibited, by an average of 
40% following siRNA transfection with Anx6A, and an average of 
28.2% following siRNA transfection by Anx6B. 
• DLKP-M invasion was inhibited by an average of 22% following siRNA 
transfection with Anx6A, and significantly inhibited by an average of 
36.6% following siRNA transfection with Anx6B. 
 
No significant affect on motility was observed in the MiaPaCa-2 clone 3 cell line 
following transfection with both siRNAs.  
 
No significant affect on proliferation in either the MiaPaCa-2 clone 3 or DLKP-
M cell lines was observed following transfection of both siRNAs, indicating that 
the observed inhibition of invasion was not due to any reduced proliferative 
capacity of the cells. Protein knockdown was confirmed by Western blot analysis 
(Figures 4.10 & 4.10.7). 
 
Statistical analyses for proliferation assays were carried out on the average 
absorbancy readings of the control Vs test wells, over biological triplicates. 
 
Statistical analyses for invasion assays were carried out with the average cell 
counts of control Vs sample inserts over biological triplicates (section 2.15).  
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Effect of Annexin A6 siRNA transfection in MiaPaCa-2 clone 3  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: - Western Blot analysis of whole cell (RIPA) lysates of MiaPaCa-2 
clone 3 transfected cells, separated on SDS-PAGE, and probed with an Annexin 
A6 antibody. A reduction in the levels of Annexin A6 (M.W. 75kDa) can be seen 
when compared to the control MiaPaCa-2 clone 3 cell lysate (untransfected). β-
actin was used as a loading control. (15µg protein per lane loaded) n = 3. 
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• Effect of siRNA Annexin A6 on MiaPaCa-2 clone 3 Proliferation 
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Figure 4.10.1: - Histogram showing proliferation assay of MiaPaCa-2 clone 3 
scrambled, kinesin and transfected with siRNAs A, & B targeting Annexin A6. 
Results graphed as % survival relative to scrambled transfected cells (control). 
Loss of Annexin A6 did not affect proliferation in this cell line; therefore any 
inhibition of invasion is not due to cell kill. Statistics performed using student t-
test compared to scrambled control; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, n = 3. 
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• Knockdown of Annexin A6 reduces invasion in MiaPaCa-2 clone 3 
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Figure 4.10.2: - Histogram showing effect of Annexin A6 knockdown on 
invasive behaviour of MiaPaCa-2 clone 3 cells. Forty-eight hours post-
transfection with Annexin A6 siRNAs, invasion assays on MiaPaCa-2 clone 3 
cells were performed. Annexin A6 siRNA A and B transfected cells show a 
significant decrease in invasion levels. Statistics performed using student t-test 
compared to scrambled control; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, n = 3.
 
   216 
 
 
 
DMEM Scrambled 
  
 
 
  
Anx6 A Anx6 B 
 
 
 
 
 
 
 
Figure 4.10.3: - Representative photomicrographs showing invasion status of 
MiaPaCa-2 clone 3 cells after 48hrs, untreated (DMEM), transfected with 
scrambled siRNA (Control), transfected with Anx6-A siRNA and Anx6-B. A 
decrease in invasion can be observed following transfection with both siRNAs 
when compared to the control insert (B). Magnification, 100X, scale bar, 200 
µm. 
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• Effect of siRNA Annexin A6 on MiaPaCa-2 clone 3 Motility 
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Figure 4.10.4: - Histogram showing effect of Annexin A6 knockdown on motile 
behaviour of MiaPaCa-2 clone 3 cells. Forty-eight hours post-transfection with 
Annexin A6 siRNAs, motility assays on MiaPaCa-2 clone 3 cells were 
performed. Annexin A6 siRNA A and B transfected cells show little decrease in 
motility levels. Statistics performed using student t-test compared to scrambled 
control; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, n = 3. 
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Figure 4.10.6: - Representative photomicrographs showing motility status of 
MiaPaCa-2 clone 3 cells after 24hrs, untreated (DMEM), transfected with 
scrambled siRNA (Control), transfected with Anx6-A siRNA and Anx6-B. No 
significant decrease in motility can be observed following transfection with both 
siRNAs when compared to the control insert (B). Magnification, 100X, scale bar, 
200 µm. 
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• Effect of Annexin A6 siRNA transfection in DLKP-M  
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
Figure 4.10.7: - Western Blot analysis of whole cell (RIPA) lysates of DLKP-M 
transfected cells, separated on SDS-PAGE, and probed with an Annexin A6 
antibody. A reduction in the levels of Annexin A6 (M.W. 75kDa) can be seen 
when compared to the control DLKP-M cell lysate (untransfected). β-actin was 
used as a loading control. (15µg protein per lane loaded) n = 3. 
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• Effect of siRNA Annexin A6 on DLKP-M Proliferation 
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Figure 4.10.8: - Histogram showing proliferation assay of MiaPaCa-2 clone 3 
scrambled, kinesin and transfected with siRNAs A, & B targeting Annexin A6. 
Results graphed as % survival relative to scrambled transfected cells (control). 
Loss of Annexin A6 did not affect proliferation in this cell line; therefore any 
inhibition of invasion is not due to cell kill. Statistics performed using student t-
test compared to scrambled control; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, n = 3. 
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• Knockdown of Annexin A6 reduces invasion in DLKP-M 
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Figure 4.10.9: - Histogram showing effect of Annexin A6 knockdown on 
invasive behaviour of DLKP-M cells. Forty-eight hours post-transfection with 
Annexin A6 siRNAs, invasion assays on DLKP-M cells were performed. 
Annexin A6 siRNA A shows a decrease in invasion levels, while Anx6B 
transfected cells show a significant decrease in invasion levels. Statistics 
performed using student t-test compared to scrambled control; * p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.005, n = 3. 
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Figure 4.10.10: - Representative photomicrographs showing invasion status of 
DLKP-M cells after 48hrs, untreated (DMEM), transfected with scrambled 
siRNA (Control), transfected with Anx6-A siRNA and Anx6-B. A decrease in 
invasion can be observed following transfection with both Anx6 siRNA A and B, 
when compared to the control insert (B). Magnification, 100X, scale bar, 200 
µm.  
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• Effect of Annexin A6 siRNA transfection on the expression of MAb 9E1 
24 (6) reactive antigen in MiaPaCa-2 clone 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10.11: - Western Blot analysis of whole cell (RIPA) lysates of 
MiaPaCa-2 clone 3 transfected cells, separated by SDS-PAGE, and probed with 
MAb 9E1 24 (6). A reduction in the levels of the reactive antigen of MAb 9E1 
24 (6) (M.W. 75kDa) can be seen when compared to the control MiaPaCa-2 
clone 3 cell lysate (untransfected), indicating that the reactive antigen is the 
Annexin A6 protein. α-tubulin was used as a loading control. (15µg protein per 
lane loaded) n = 3. 
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• Effect of Annexin A6 siRNA transfection on the expression of Protein 14-
3-3ε in DLKP-M 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10.12: - Western Blot analysis of whole cell (RIPA) lysates of DLKP-
M transfected cells, separated by SDS-PAGE, and probed with a commercial 
Protein 14-3-3ε antibody. No reduction in expression of Protein 14-3-3ε can be 
seen when compared to the control DLKP-M cell lysate (untransfected). β-actin 
was used as a loading control. (15µg protein per lane loaded) n = 3. 
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4.11 Western Blot Validation of MAb 9E1 24 (6) Target Proteins in 
a Panel of Cell Lines 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: - Western blot analysis of pancreatic cancer cell lines MiaPaCa-2 
clone 3, MiaPaCa-2 clone 3 grown on Matrigel, MiaPaCa-2 clone 8; Melanoma 
cell lines Lox IMVI, WM-115 primary cancer, and its metastatic counterpart 
WM-266-4 and SNB-19 glioma cell line probed with antibodies specific for 
Annexin A6 and Protein 14-3-3ε. Annexin A6 shows strong expression in both 
the MiaPaCa-2 clone 3 and MiaPaCa-2 clone 8 cell lines. Lox IMVI shows 
strong expression, but WM-115 and WM-266-4 show much weaker expression, 
while no expression is observed in SNB-19. All cell lines appear to show strong 
expression of Protein 14-3-3ε. n = 3. (See Appendix IV for representative 
coomassie stained gel showing equal loading). Cell lines in bold represent highly 
invasive phenotype.  
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Figure 4.11.1: - Western Blot analysis of lung cancer cell lines DLKP, DLKP-A, 
DLKP-I, DLKP-M, DLKP-SQ and H1299; C/68 Prostate cancer cell line and 
HCT-116 Colon cancer cell line probed with antibodies specific for Annexin A6 
and Protein 14-3-3ε. Annexin A6 expression is observed in all cell lines, apart 
from C/68. DLKP-SQ shows the strongest expression. Protein 14-3-3ε is 
expressed in all cell lines, with the strongest expression showing in the DLKP-
SQ and H1299 cell lines. n = 3. (See representative coomassie stained gel 
showing equal loading). (See Appendix IV for representative coomassie stained 
gel showing equal loading). Cell lines in bold represent highly invasive 
phenotype.  
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Figure 4.11.2: - Western blot analysis of HER-2 over expressing cell lines 
MDA-MB-453, MDA-MB-361, SKBR-3 and BT474, and the Triple negative 
breast cancer cell line, MDA-MB-231; probed with antibodies specific for 
Annexin A6 and Protein 14-3-3ε. Both Annexin A6 and Protein 14-3-3ε are 
weakly expressed in the MDA-MB-453 cell line, while strong expression is 
observed in all other cell lines. n =3. (See Appendix IV for representative 
coomassie stained gel showing equal loading). Cell lines in bold represent highly 
invasive phenotype.  
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4.12  MAb 9E1 24 (6) Expression in Normal and Malignant Tissues  
 
 
Normal Tissue Type No.  Reactivity (membrane, with some 
cytoplasmic positivity) 
Colon 2 + 
Prostate 1 + / - 
Liver 1 + / - 
Breast 2 + + 
 
Cancer Tissue Type No.  Reactivity (membrane, with some 
cytoplasmic positivity) 
Squamous Cell Carcinoma 2 + 
Glioma 8 + / - 
Colon Adenocarcinoma 1 + + + 
Pancreatic Adenocarcinoma 12 + + / + + + 
Breast Carcinoma 42* + / - → + + + 
Retinoblastoma 1 + + + 
Hodgkins Lymphoma 1 + + 
Malt Lymphoma (orbital tissue) 1 + + + 
B Cell Mantle Lymphoma 
(lacrimal gland) 
 + + + 
Basal Cell Carcinoma (eyelid) 1 + / - 
Parotid Tumour (Warthins 
[benign] tumour) 
1 + + 
 
Table 4.12: - Reactivity of MAb 9E1 24 (6) in a panel of normal and cancerous 
tissue sections.  
+++ Very intense staining; ++ Intense staining; + Weak staining; +/- Some very 
weak positivity. 
 
* A range of breast tumours, representing different sub-groups of disease – 
HER2 positive, Triple Negative, estrogen-receptor (ER) +/- and progesterone 
receptor (PR) +/-, were studied. MAb 9E1 24 (6) reactivity was observed in all 
tumour types studied, however, negative reactivity in various subtypes was also 
observed. 
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Figure 4.12: - A panel of normal, non-malignant tumour, and cancer tissues 
stained with MAb 9E1 24 (6). MAb shows membrane reactivity (some low level 
cytoplasmic reactivity also) in Hodgkins Lymphoma tissue (B), Retinoblastoma 
(F) and in a Warthins tumour (benign tumour of parotid gland) (E). Intense 9E1 
positivity is observed in  benign colon adenoma tumour (D) with weak positive 
staining observed in normal colon (C) and normal prostate tissue (A). 
Magnification, 200X, scale bar = 200µm (B) and (C). 400X, scale bar = 100µm 
(A), (D), (E) and (F). 
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Figure 4.23.1: - A panel of normal and cancer tissues stained with MAb 9E1 24 
(6). MAb positive staining is observed in pancreatic adenocarcinoma (A), B cell 
mantle lymphoma (C) and Malt lymphoma (orbital) tumour tissue (D). Very 
weak reactivity is observed in glioma (B). Normal breast tissue showing 9E1 
reactivity is observed in (E) and a HER2 over expressing breast tumour showing 
9E1 positivity (F). Magnification, 400X, scale bar, 100 µm, (A – E); 200X, scale 
bar, 200 µm (F). 
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4.13 Combination Studies Between MAb 7B7 G5 (2) & MAb 9E1 
24 (6)  
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Figure 4.13: - Representative histogram showing inhibitory effects of MAb 7B7 
G5 (2) and MAb 9E1 24 (6) individually, and in synergy, on MiaPaCa-2 clone 3 
invasion after 48 hours. Both 7B7 G5 (2) and 9E1 24 (6) hybridoma neat 
supernatant inhibits invasion compared to the control hybridoma medium (no 
MAb) representing 100% invasion. However, when combined, there is no 
increase in inhibition levels, indicating no synergy between the two MAbs. n = 3. 
Error bars calculated using ± standard deviation.  
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4.14. Combination Studies with MAb 9E1 24 (6) & 7B7 G5 (2) and 
a Panel of Statins 
 
Although MAbs have greatly enhanced cancer treatment, only a few are able to 
kill a sufficient number of malignant cells and cause tumour regression. 
Therefore, it is often necessary to use a combined treatment regime in order to 
enhance the efficacy of the anti-tumour activity.  
 
A number of recent studies have suggested that cancer incidence rates may be 
lower in patients receiving statin treatment for hypercholesterolemia. 
Examination of the effects of statin drugs in vitro, on migration and invasion 
levels of melanoma cells was carried out. The ability of Lovastatin, Mevastatin 
and Simvastatin to inhibit the melanoma migration and invasion were assessed 
using invasion and migration assays. These compounds were then used in 
combination with both MAb 7B7 G5 (2) and 9E1 24 (6), in order to determine if 
any synergistic effect occurs in relation to inhibition of invasion.  
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4.14.1 Effect of Statins on the Invasion & Motility Levels on a Panel 
of Melanoma Cell Lines: - Lovastatin 
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Figure 4.14: - Representative histogram of Lovastatin showing significant 
inhibition of HT144 cell motility at three different concentrations, compared to 
control (no Lovastatin) representing 100% motility, after 48hrs.  Statistics; * p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.005, Student’s t-test. n = 3. Error bars calculated 
using ± standard deviation.  
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Figure 4.14.1: - Representative histogram of Lovastatin showing significant 
inhibition of HT144 cell invasion at three different concentrations, compared to 
control (no Lovastatin) representing 100% motility, after 48hrs.  Statistics; * p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.005, Student’s t-test. n = 3. Error bars calculated 
using ± standard deviation.  
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Figure 4.14.2: - Representative histogram of Lovastatin showing significant 
inhibition of SK-MEL-28 cell motility at two different concentrations, compared 
to control (no Lovastatin) representing 100% motility, after 48hrs. No effect on 
motility was observed with 1.3µM Lovastatin. Statistics; * p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.005, Student’s t-test. n = 3. Error bars calculated using ± standard 
deviation.  
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Figure 4.14.3: - Representative histogram of Lovastatin showing significant 
inhibition of SK-MEL-28 cell invasion at two different concentrations, compared 
to control (no Lovastatin) representing 100% motility, after 48hrs.  No effect on 
invasion was observed with 1.3µM Lovastatin. Statistics; * p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.005, Student’s t-test. n = 3. Error bars calculated using ± standard 
deviation.  
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4.14.2   Mevastatin 
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Figure 4.14.4: - Representative histogram of Mevastatin showing significant 
inhibition of HT144 cell motility at three different concentrations, compared to 
control (no Mevastatin) representing 100% motility, after 48hrs.  Statistics; * p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.005, Student’s t-test. n = 3. Error bars calculated 
using ± standard deviation.  
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Figure 4.14.5: - Representative histogram of Mevastatin showing significant 
inhibition of HT144 cell invasion at two different concentrations, compared to 
control (no Mevastatin) representing 100% invasion, after 48hrs.  Invasion was 
only slightly inhibited with 2µM Mevastatin. Statistics; * p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.005, Student’s t-test. n = 3. Error bars calculated using ± standard 
deviation.  
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Figure 4.14.6: - Representative histogram of Mevastatin showing significant 
inhibition of SK-MEL-28 cell motility at three different concentrations, 
compared to control (no Mevastatin) representing 100% motility, after 48hrs.  
Statistics; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, Student’s t-test. n = 3. Error 
bars calculated using ± standard deviation.  
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Figure 4.14.7: - Representative histogram of Mevastatin showing significant 
inhibition of SK-MEL-28 cell invasion at three different concentrations, 
compared to control (no Mevastatin) representing 100% invasion, after 48hrs.  
Statistics; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, Student’s t-test. n = 3. Error 
bars calculated using ± standard deviation.  
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4.14.3   Simvastatin 
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Figure 4.14.8: - Representative histogram of Simvastatin showing inhibition of 
HT144 cell motility at 1.6µM concentration, and significant inhibition at 2.4µM 
concentration, compared to control (no Simvastatin) representing 100% motility, 
after 48hrs.  No effect on motility was observed with 0.8µM Simvastatin. 
Statistics; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, Student’s t-test. n = 3. Error 
bars calculated using ± standard deviation.  
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Figure 4.14.9: - Representative histogram of Simvastatin showing significant 
inhibition of HT144 cell invasion at two different concentrations, compared to 
control (no Simvastatin) representing 100% invasion, after 48hrs. Significance 
was not achieved with 2µM Mevastatin. Statistics; * p ≤ 0.05, ** p ≤ 0.01, *** p 
≤ 0.005, Student’s t-test. n = 3. Error bars calculated using ± standard deviation.
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Figure 4.14.10: - Representative histogram of Simvastatin showing significant 
inhibition of SK-MEL-28 cell motility at two different concentrations, compared 
to control (no Lovastatin) representing 100% motility, after 48hrs. 0.8µM 
Simvastatin shows little decrease in motility levels. Statistics; * p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.005, Student’s t-test. n = 3. Error bars calculated using ± 
standard deviation.  
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Figure 4.14.11: - Representative histogram of Simvastatin showing significant 
inhibition of SK-MEL-28 cell invasion at 2.4 µM concentration, compared to 
control (no Lovastatin) representing 100% invasion, after 48hrs. 0.8µM 
Simvastatin shows no decrease in invasion levels, while invasion is decreased 
with 1.6µM Simvastatin, but not significantly so. Statistics; * p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.005, Student’s t-test. n = 3. Error bars calculated using ± 
standard deviation.  
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4.14.4  Effect of Statins and MAbs on Cell Invasion   
 
4.14.4.1 MAb 7B7 G5 (2) 
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Figure 4.14.12: - Representative histogram showing significant inhibitory effects 
on MiaPaCa-2 clone 3 invasion by a panel of statins and MAb 7B7 G5 (2), 
working independently and synergistically of one another, compared to control 
hybridoma medium (no MAb or statins) representing 100% invasion after 48 
hours. No synergistic effect was observed. Error bars calculated using ± standard 
deviation.  
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4.14.4.2 MAb 9E1 24 (6) 
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Figure 4.14.13: - Representative histogram showing significant inhibitory effects 
on MiaPaCa-2 clone 3 invasion by a panel of statins and MAb 9E1 24 (6), 
working independently and synergistically of one another.  Independently, 
Simvastatin inhibits invasion by 75-80%, Lovastatin by 48-50%, and Mevastatin 
by 50-60%. When used in synergy with MAb 9E1 24 (6), there appears to be 
some synergy between the statins and MAb 9E1 24 (6). n = 2. Error bars 
calculated using ± standard deviation.  
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CHAPTER 5 
DISCUSSION 
   242 
The majority of deaths from cancer are due to metastatic disease. Metastasis is 
defined as the development of secondary tumours at a distance from a primary 
site of cancer. A critical step in metastatic progression is “invasion” – when 
cancer cells break through the ECM and enter the bloodstream/lymphatic system. 
While the malignant primary and secondary tumours can often be surgically 
removed, it is the invading cells circulating the body that cause the most harmful 
effects and prove to be the most difficult to target therapeutically. Successfully 
blocking or inhibiting these invading cells would greatly improve cancer 
treatment and patient prognosis. However, there are currently limited therapeutic 
treatments available that can successfully inhibit or prevent the invasion process.  
 
A number of early studies involving anti-metastatic agents were carried out, 
however these failed to produce any clinically relevant therapeutic treatments. 
Early investigations involving tumour-invasion-inhibiting-factor 2 (IIF-2), a 
polypeptide of 21 amino acids isolated from bovine liver, successfully inhibited 
invasion of rat mesothelial monolayers in vitro (Isoai et al., 1990). An albumin-
IIF-2 conjugate was then developed to increase the factor’s half-life, and 
subsequent in vivo testing successfully inhibited colonisation of various highly 
metastatic tumour cells, including murine melanoma, colon adenocarcinoma, 
squamous cell carcinoma, forestomach carcinoma, and human fibrosarcoma 
(Isoai et al., 1994). Its anti-invasive effects appeared to be related only to an 
impairment of cell motility, as no inhibition of cellular adhesion or degradation 
of the ECM was noted. While this agent showed promising anti-invasive 
potential, no further studies or clinical trials were pursued. 
 
Anti-invasion trials involving the use of MMP-inhibitors also failed to produce 
viable therapeutic strategies. A number of them did make it into Phase III trials, 
but were subsequently withdrawn. Tanamostat, an MMP-2, 3 and 9 inhibitor, 
was removed from Phase III trials due to patients with small cell lung cancer 
(SCLC) doing significantly worse than placebo-controlled patients. Prinomastat 
(MMP-2, 9, 13, & 14) failed to demonstrate any efficacy in any of the Phase III 
trials it was tested in (Fingleton, 2003). In vivo work carried out by Hoffman et 
al., on a new MMP inhibitor called cis-ACCP has shown good anti-invasion 
efficacy; however, it only targets MMP-2, and as such, will not be viable for a 
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wide range of tumour types e.g. NSCLC overexpress MMP-11 and 14 (Hoffman 
et al., 2008). 
 
MAb therapy has emerged as an important therapeutic modality for cancer, due 
to the high specificity, low systemic toxicity, predictable pharmacology, ability 
to recruit the body’s immune system and longer serum half-life of MAbs (Yan et 
al., 2008). There are a number of FDA-approved MAbs currently available for 
anti-tumour therapy, including Trastuzumab (Herceptin), the anti-HER2 MAb 
used in the treatment of HER2-overexpressing metastatic breast cancer (see 
Introduction – Table 1 for a full list of MAbs approved for the treatment of 
cancer). While these MAbs have constituted a tremendous success story for 
cancer treatment, they do not directly target tumour cells undergoing invasion. 
Some, like Trastuzumab, can limit cellular invasion, (blocking of HER2 by 
Trastuzumab reduced invasion in vitro, in the MDA-MB-435 breast cancer cell 
line (Sidera et al., 2008)); however, this is often only a side effect of their 
primary activity (e.g. promoting apoptosis, inhibiting cell 
proliferation/angiogenesis) - no MAbs are currently available that directly target 
the invasion process.  
 
A number of studies are now taking place, which investigate the possibility of 
increasing the limited anti-invasive effects that current clinical MAbs possess. 
Recent work carried out by Fischgräbe et al., (2010) used a combination therapy 
of Trastuzumab and atrasentan to study the effects on SKBR-3 cell invasion. 
Atrasentan is an endothelin receptor antagonist, selective for subtype A (ETA). 
Endothelin (ET) is a peptide containing 21 amino acids, and is involved in many 
normal physiological processes. They have also been shown to have a role in the 
growth and progression of several tumour types: in breast cancer, overexpression 
of ETAR and its ligand, ET-1, correlates with decreased survival and resistance to 
chemotherapy (Wulfing et al., 2003, 2004). The authors found that dual HER2-
ETAR targeting, utilising Trastuzumab and atrasentan, was superior to either 
agent alone in inhibiting invasion in the SKBR-3 breast cancer cell line. Apart 
from enhancing the anti-invasion effects of Trastuzumab, it was also found that 
atrasentan enhances its anti-proliferative effects. These results suggest that the 
anti-tumourigenic properties of Trastuzumab, including its limited inhibitive 
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effects on cellular invasion, can be increased through combination therapy with 
other anti-cancer agents (Fischgräbe et al., 2010).   
 
Another method for increasing the efficacy of current FDA-approved MAbs is to 
enhance their pharmacokinetic properties. Rituximab is generated in CHO 
(Chinese Hamster Ovary) cells, which express high levels of α1,6-
fucosyltransferase (FUT8). Reduction of fucose content in Rituximab 
oligosaccharides, achieved through gene knockdown of FUT8 in the host CHO 
cells, or by generating the antibodies in other cell lines with reduced fucosylation 
activity (e.g. rat YB2/0 cells), results in >100-fold enhancement of ADCC 
activity (Shinkawa et al., 2003). Furthermore, engineering of the Fc region of the 
antibody, to increase the efficacy of binding to the neonatal Fc receptor (FcRn) 
(which prevents IgG degradation), increases the serum half-life of MAbs (Beck 
et al., 2010).  
 
Studies have shown that targeting invasion-related proteins with MAbs (and 
other anti-cancer agents) can result in decreased cell invasion. A number of these 
MAbs are undergoing clinical trials (see section 1.8.5 for a comprehensive list), 
but as yet, none have received FDA approval.  
 
The research carried out in this study focused on a different approach in 
developing MAbs. Rather than pursuing a specific molecular target known to be 
involved in cancer invasion, generating MAbs against this target and checking 
whether they can block/inhibit invasion in vitro, the approach used here involved 
the screening of MAbs directed against highly invasive cancer cells directly for 
function. Using a 96-well Boyden chamber assay, we were able to assess large 
numbers of MAbs for their effect on cell invasion. Those of interest were cloned 
and re-tested, to ensure that their activity against cell invasion was stable. 
Following this, the target antigens of the MAbs were immunoprecipitated, and 
identified through mass spectrometry analysis. Confirmation of their role in the 
invasion process was obtained through siRNA silencing of the antigens. Using 
this method, we discovered two MAbs, designated 7B7 G5 (2) [7B7] and 9E1 24 
(6) [9E1], that directly target invasion-related proteins, and can successfully 
inhibit cell invasion in a number of cancer types. 
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5.1 Identification of MAbs That Can Block Cancer Invasion In 
Vitro 
MAb 7B7 was generated against the highly invasive pancreatic cell line 
MiaPaCa-2 clone 3 (Walsh et al., 2008). This cell line was chosen for 
immunisation because it is much more invasive than its parental cell line, 
displaying many differentially changed proteins, both up-regulated and down-
regulated. By using this cell line as an immunogen, it was hoped that MAbs 
would be generated that recognise novel proteins associated with the invasion 
process. A second clonal variant of MiaPaCa-2 (clone 8), has significantly lower 
invasion levels compared to its parent cell line. Having both an invasive and non-
invasive cell model available, MAbs produced could be tested to check for any 
increases or decreases in cell invasion. 
 
MAb 9E1 was generated against the highly invasive breast cancer cell line, 
MDA-MB-435S. This is a spindle shaped variant of the parental cell line MDA-
MB-435, which was isolated by Cailleau et al., (1978), from the pleural effusion 
of a 31-year old female with metastatic ductal adenocarcinoma of the breast. A 
clonal population of this variant named MDA-MB-435-SF was established here 
in the N.I.C.B (Glynn et al., 2004), which exhibited high levels of invasion. A 
Taxol resistant variant was then produced from this clonal variant through pulse 
selections, designated MDA-MB-435-SF-Taxol10p4p-SI. These two cell lines 
were chosen as immunogens due to their high levels of invasion and novel 
nature. It was hoped that any MAbs generated from this fusion would recognise 
new and unique proteins involved in the invasion process. However, 
characterisation work was not carried out with MDA-MB-435-SF, due to 
variations in invasion levels observed, and doubts about the origins of the 
parental cell line. 
 
In 2000, gene expression analysis carried out on the National Cancer Institute’s 
Developmental Therapeutics Program 60 (NCI60) cell line panel, found that 
MDA-MB-435 expressed a large number of melanoma-associated genes, and 
clustered with melanoma cell lines. It was proposed that the MDA-MB-435 cell 
line is of melanocyte origin and suggested that the patient, from whom the MDA-
MB-435 cell line was derived from a pleural effusion, may have had an 
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undiagnosed melanoma (Ross et al,. 2000). While credible, a more likely 
explanation is that the MDA-MB-435 cells were inadvertently lost due to 
switching with, or contamination by, another cell line, an occurance not limited 
to the above cell line (Masters, 2002). Rae and colleagues subsequently 
presented evidence that both the MDA-MB-435 cell line and the M14 melanoma 
cell line were essentially identical, and that ‘‘all currently available stocks of 
MDA-MB-435 cells are derived from the M14 melanoma cell line and can no 
longer be considered a model of breast cancer’’ (Rae et al., 2007). Due to the 
uncertainty surrounding the cell line, it was decided to characterise the 
hybridoma supernatants on different cell lines. Recently, however, Chambers 
(2009) has suggested that MDA-MB-435 and M14 are identical cell lines, but are 
both breast cancer cell lines. Although identical, M14 cells have been shown to 
express two X chromosomes, despite the fact that they were derived from a 
biopsy specimen from a male patient (Wong et al., 1988). This has also been 
suggested by Hollestelle et al., (2009). 
 
5.2  Functional Effects of MAbs 
Following on from the discovery of the two MAbs, it was decided to characterise 
their effects on a number of cellular processes. Proliferation assays carried out on 
invasive MiaPaCa-2 clone 3 cells showed that both MAbs had no effect on cell 
survival or growth, suggesting that their target antigens are not involved in cell 
growth/survival (sections 3.4.1 & 4.4.3). These results also suggest that the 
decreases observed in invasion levels were a direct result of inhibition of 
invasion. Invasion and motility assays were also carried out on MiaPaCa-2 clone 
3, resulting in significant inhibition of both processes following incubation with 
the MAbs. While MAb 9E1 reduced invasion levels in this cell line by up to 80% 
(section 4.4.2), inhibition of motility, while significant, was not as pronounced, 
with an average decrease of 23% observed (section 4.4.3). This suggests that the 
target antigen of 9E1 is playing a significant role in the invasion process, but less 
so in cell motility.  7B7 significantly reduced invasion, by up to 49% (section 
3.4.2), while similar levels of inhibition were observed in relation to motility 
(section 3.4.3), suggesting that this MAb’s target antigen is involved in both the 
invasion and motility process. However, at this stage, it was unclear whether the 
decrease in invasion levels observed in this cell line was due to a decline in 
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cellular motility. At this point, it was decided to expand the investigation of the 
functional effect of both MAbs to cover a wider range of human cancer cell lines. 
 
A panel of invasive breast cancer, lung cancer, and melanoma cell lines was 
investigated with 9E1 and 7B7, as were prostate, glioma and colon cancer cell 
lines. The levels of inhibition observed following incubation with the MAbs 
varied between the cell lines, with some showing little to no knockdown of 
invasion levels, while in some cell lines an unexpected increase in the levels of 
invasion was observed following MAb 9E1 incubation.  
 
Motility assays were also carried out on the glioma cell line SNB-19 in the 
presence of 7B7 (section 3.4.8). Results show a decrease in motility levels, by up 
to 14.3%, while invasion is inhibited, by up to 33.8%. This suggests that the 
inhibition of invasion is not completely due to a decrease in motility in this cell 
line.  
 
Cancer Type Cell Line MAb 7B7  
% Inhibition (up to..) 
MAb 9E1  
% Inhibition (up to..) 
MDA-MB-157 No Inhibition 50.9% Increase 
MDA-MD-231 32.9%* 37.4%* 
 
Breast 
SKBR-3 30.2%* 55.6% 
DLKP-I 35% 53.3%* 
DLKP-M 50%* 76.2%* 
 
Lung 
H1299 30.5%* 34.5%* 
MiaPaCa-2 clone 3 51.7%* 79.6% Pancreatic 
BxPc-3 16% No Inhibition 
Melanoma Lox 29.6% 50.6%* 
Glioma SNB-19 33.8%* No Inhibition 
Prostate C/68 20% 50.9%* 
Colon HCT-116 32%* 125.3% Increase* 
 
Table 5: - Effect of MAb 7B7 G5 (2) and 9E1 24 (6) on invasion levels in a 
panel of cell lines. * Significant result. 
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From the results obtained, it can be stated that 9E1 has a greater inhibitory effect 
on cell invasion than 7B7. However, no increases in invasion were observed 
following incubation with 7B7. Dose response studies were also carried out with 
both MAbs. With regard to 7B7, a corresponding drop in inhibition levels was 
observed in the MiaPaCa-2 clone 3 cell line, when the MAb was diluted (section 
3.4.2). Dose-response experiments with 9E1 in the DLKP-M cell line (section 
4.4.5) also showed that there was a corresponding decrease in invasion levels. 
However, surprisingly, at low levels of the MAb (1 in 5 dilution), invasion in 
DLKP-M was increased, by up to 62%.  
 
These results suggest that the target antigen(s) of 9E1 may be playing a dual role 
in the invasion process of a number of cell lines, acting as both a pro- and anti-
invasive protein(s). It would also appear that at low concentration, this MAb can 
stimulate invasion in a cell line where higher levels of the MAb decrease cell 
invasion.  
 
Cell invasion into the blood/lymph vessels depends on the interaction of the 
invading cells with components of the ECM and basement membrane, as does 
the penetration of the tumour cell into an organ at a secondary site. Adhesion 
assays were therefore carried out in order to observe whether the MAbs had any 
effect on the ability of cancer cells to adhere to matrigel and fibronectin (sections 
3.4.12 & 4.4.12). Adherence of MiaPaCa-2 clone 3 to fibronectin was reduced 
following incubation with 7B7 (up to 29%). A significant decrease in adhesion of 
DLKP-M lung cancer cells to matrigel (up to 35%) was also observed. 9E1 
slightly reduced adherence of MiaPaCa-2 clone 3 to fibronectin, while a 
significant decrease in adhesion of DLKP-M cells to matrigel (up to 42%) was 
observed. 
 
Anoikis assays were carried out to determine whether the MAbs affected the 
ability of cancer cells to survive in suspension (sections 3.4.13 & 4.4.13). When 
normal cells lose contact with the ECM, and become “unanchored”, they 
undergo a form of programmed cell death termed “anoikis”. Cancer cells often 
display a resistance to this form of cell death, allowing for their survival during 
systemic circulation, thereby facilitating secondary tumour formation in distant 
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organs (Douma et al., 2004). Both MiaPaCa-2 clone 3 and DLKP-M cells were 
incubated with 7B7 and 9E1 in conditions that induce anoikis (i.e. anchorage 
independent growth); however, no change in survival was observed, indicating 
that the MAbs do not affect anoikis.   
 
The effects of 7B7 and 9E1 on MMP activity were also investigated (sections 
3.4.15 & 4.4.15). MMPs are regarded as essential molecules for tumour cells 
undergoing metastasis. Early studies have shown that in cancer cells, there is a 
clear relationship between MMPs, ECM degradation and cancer cell invasion. 
Inhibition of MMPs corresponds to inhibition of cell invasion; conversely, up-
regulation of MMPs usually leads to increases in tumour cell invasion. These 
studies concluded that enhanced MMP levels result in increased tumour cell 
invasion (Liotta et al., 1980, 1986). The MDA-MB-231 breast cell line is known 
to have high expression levels of MMP-9 (Hegedus et al., 2008) and was 
therefore chosen for this study. We found that MDA-MB-231 cells incubated 
with 7B7 and 9E1 for 24hrs showed a marked decrease in MMP-9 activity, 
compared to MAb-free cells, suggesting that both MAbs can negatively affect 
MMP activity. However, it is still unclear if the decrease in MMP-9 activity is 
due to direct interaction of the MAb with MMP-9, or whether it is indirectly 
inactivated through inhibition of downstream signalling events. Western blot 
analysis of cell lysates incubated with the MAb, probed with an MMP-9 specific 
antibody will determine whether MMP activity is directly or indirectly affected.     
 
Incubation of MiaPaCa-2 clone 3 cells with the MAbs also produced a definite 
change in cell morphology (sections 3.4.14 & 4.4.14). Under normal conditions, 
MiaPaCa-2 clone 3 cells exhibit a fibroblast-like phenotype, with spindle shaped 
elongated cells, typical of highly invasive and motile cells. However, when 
grown in the presence of 7B7 and 9E1, the cells lose this spindle-shaped 
morphology, and start to display a more rounded appearance, similar to the 
morphology of the low invasive variant of the MiaPaCa-2 cell line, clone 8 
(Walsh et al., 2008). Loss of the spindle-shaped morphology might be expected 
in cells that have had their invasive capacity suppressed.  
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Preliminary immunofluorescence studies were initially carried out with both 
MAbs on the MiaPaCa-2 variants.  Staining in the MiaPaCa-2 clone 8 cell line 
with 7B7 was weaker than that observed in the clone 3 variant, suggesting that its 
target antigen is up-regulated in the highly invasive clone 3 cell line. This 
staining pattern was further demonstrated in the poorly invasive DLKP-SQ 
compared to the highly invasive DLKP-Mitox-6p variant. With regards to any 
association with invasion, conflicitng results were observed with MAb 9E1. 
MiaPaCa-2 clone 8 appeared to show stronger reactivity than that observed in the 
more invasive MiaPaCa-2 clone 3 variant, while staining in the DLKP-Mitox-6p 
variant was slightly stronger than the DLKP-SQ. MAb 7B7 showed membrane 
and cytoplasmic reactivity on MiaPaCa-2 clone 3 cells (figure 3.3.2), while MAb 
9E1 (figure 4.5) showed puntuated type, membrane staining on the same cell 
line. Some cytoplasmic reactivity was also observed. It would be likely to expect 
both MAbs to be reacting with a cell surface protein.  
 
Cell surface proteins are known to be involved in several key stages of 
metastasis, so their expression is of fundamental importance in cancer research, 
and may serve as potential therapeutic targets. For example, HER2 is 
overexpressed at the cell surface in a range of breast tumours, and its discovery 
led to the development of Trastuzumab (Slamon et al., 2001). Furthermore, 
growth factor receptors expressed on the cell surface have been linked to 
signalling and uncontrolled cell proliferation in many cancer types, (e.g. EGFR). 
This has led to the development of anticancer therapies that target specific 
components of the EGFR signal transduction pathway e.g. Cetuximab (Raymond 
et al., 2000).  
 
Western blot analyses were carried out in order to identify the molecular weights 
of the target antigens; however, 7B7 probing of a panel of cell lines did not 
produce any reactive bands. Therefore, we were unable to establish the molecular 
weights of 7B7’s potential reactive antigen(s). Analysis of 9E1 did reveal a 
strong reactive band of approximately 75 kDa in a number of cell lines, including 
MiaPaCa-2 clone 3, MiaPaCa-2 clone 8 and SKBR-3 (section 4.6), indicating 
that this MAb was recognising a target antigen of approximately 75kDa: 
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Cancer Type Cell Line Reactivity 
MiaPaCa-2 clone 3 + + + 
MiaPaCa-2 clone 3 
(Matrigel) 
+ + + 
 
Pancreatic 
MiaPaCa-2 clone 8 + + + 
Lox IMVI + + +  
SK-MEL-28 + + +  
WM-115 + / - 
 
Melanoma 
WM-226-4 + / - 
Glioma SNB-19 + / - 
DLKP + + 
DLKP-A + 
DLKP-I + + 
DLKP-M + + 
DLKP-SQ + + + 
Lung 
H1299 + + 
Prostate C/68 + + + 
Colon HCT-116 + + + 
Breast  
(Triple Negative) 
MDA-MB-231 + +  
MDA-MB-453 - 
MDA-MB-361 + +  
SKBR-3 + +  
Breast 
(HER2-Positive) 
BT474 + +  
  
Table 5.1: - Western blot analysis of MAb 9E1 in a panel of cancer cell lines. 
 
+++ Very Strong; ++ Strong; + Intermediate; +/- Weak 
 
Analyzing the levels of 9E1 expression in various cancer cell lines, it was found 
that expression in the metastatic WM-266-4 metastatic cell line was stronger than 
that observed in the WM-115 primary tumour. This pattern was also observed in 
the DLKP variants, with expression in the invasive I and M cell lines being 
stronger than that observed in the poorly invasive DLKP and less invasive 
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DLKP-A. However, the low invasive DLKP-SQ exhibited strong expression 
levels. (Immunofluorescence analysis showed more intense 9E1 reactivity in the 
DLKP-Mitox-6p cell line, compared to DLKP-SQ, however, no Western blot 
data is available for this cell line). SNB-19 showed little expression of the 
reactive antigen, which corresponds to the lack of inhibition of invasion observed 
in this cell line when incubated with 9E1. SKBR-3, MDA-MB-231, C/68, 
H1299, DLKP I and M, Lox IMVI and MiaPaCa-2 clone 3, all showed strong to 
very strong expression of the reactive antigen, and invasion in each was 
significantly inhibited following incubation with 9E1. HCT-116 also showed 
very strong expression. This assay shows that the main target antigen of 9E1 is 
expressed, to varying degrees, in a broad range of cancer cell types, both invasive 
and non-invasive.  
 
5.3  Proteomic Identification of MAb Target Antigens 
Immunoprecipitation studies were carried out in order to try to identify the 
reactive antigens of both MAbs. Immunoprecipitation is a technique which 
allows for the identification of a protein/antigen that reacts specifically with an 
antibody from a mixture of proteins so that its quantity or physical characteristics 
can be examined. In immunoprecipitation, the protein(s) from the cell or tissue 
homogenate is precipitated in an appropriate lysis buffer prior to addition of the 
antibody. An immune complex is then formed with the addition of the antibody 
to the cell lysate (which includes the antigen(s)). Once this antibody-antigen 
complex is formed, a protein A-, G-, or L-agarose conjugate (depending on the 
isoform of the antibody) is added, capturing the complex. Proteins that are bound 
to the antibody are precipitated, while those that are not are washed away; in 
order to ensure that the protein has not been non-specifically bound, an 
immunoprecipitation with a control antibody - mouse IgM/IgG, or an antibody 
with a known target protein - is run in parallel. Components of the bound 
immune complex are eluted from the beads, and the “immunoprecipitate” is 
separated according to molecular weight, using SDS-PAGE. Visualisation is 
achieved through colloidal blue or silver staining of the SDS-PAGE gel. The 
visible protein can now be excised and identified using mass spectrometry 
analysis. 
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As the MiaPaCa-2 clone 3 cell line showed the greatest inhibition of invasion 
following incubation with both MAbs, it was chosen to immunoprecipitate out 
the reactive antigens. However, subsequent immunoprecipitations were carried 
out on other cell lines (H1299, Lox IMVI, DLKP-I).  
 
Immunoprecipitations were carried out using Protein-L agarose beads to pull out 
the reactive antigens. Protein-L was chosen due to its ability to bind onto both 
the IgM and IgG antibody chains, through kappa light chain interactions without 
interfering with the antibody's antigen-binding site (Nilson et al., 1996). This 
approach was also used in a previous study by Larkin et al., (2005) to 
immunoprecipitate the target antigen of MAb 5C3. Crude cell lysates of the cells 
were prepared using three lysis buffers. Lysates prepared with NP/40 resulted in 
gels with numerous protein bands. RIPA, and finally lysis buffer C (see section 
2.10.1) produced gels with much sharper protein bands and low level background 
bands. (NP/40 buffer has a low denaturing level, while RIPA and lysis buffer C 
give lower backgrounds in immunoprecipitation, but can denature some 
proteins.) 
 
Following incubation of 9E1 with the cell lysate, the antigen was 
immunoprecipitated using Protein-L agarose beads, and separated on a 4-12% 
Bis tris SDS-PAGE gel. The gel was subsequently stained with Coomassie Blue, 
allowing for visualisation of the bands (section 4.7.1). Five bands of interest 
were observed following immunoprecipitation with 9E1, each of which were 
excised for mass spectrometry analysis. A number of these bands were identified, 
but subsequently disregarded, as the same proteins had also been identified with 
the control IgG antibody. 
 
Mass spectrometry (MS) is an analytical chemistry technique used for measuring 
mass-to-charge ratio (m/z) of gas-phase ions. It is the standard method used in the 
identification of proteins, by comparing MS data to gene and sequence databases. 
Basic MS instruments are comprised of three components: an ion source that 
confers electrical charge to the molecules, a mass analyser that separates 
resulting ions according to their m/z ratio, and a detector. In MS/MS, singly or 
multiply charged ions are selected according to their m/z in an initial mass 
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spectrometric stage. The selected precursor ions are then fragmented through 
collisions with an inert gas (such as helium or argon), in a process known as 
collisionally induced dissociation (CID). The fragmented ions formed are then 
mass analysed in a second mass spectrometric stage (Bonner et al., 2002). An 
MS/MS spectrum is then produced, which represents peptides as readable 
entities, allowing for their interpretation and correlation with theoretical peptide 
sequences found in protein or genomic databases.  
 
Extensive online searching of the peptide sequences obtained through MS/MS 
(section 4.9), using the SWISS-PROT database, indicated that the band excised 
at approx. 75 kDa was Annexin A6, with a molecular weight of 75.87 kDa. The 
lower band, excised at approx. 35 kDa consisted of a complex of proteins, 
identified as Prohibitin (M.W. = 29.8 kDa), protein 14-3-3ε (M.W. = 29.1 kDa) 
and 3 variants of ADP/ATP Translocase (1 – 3; M.W. = 33, 32.87, 32.84 kDa 
respectively). Variants of 40S Ribosomal protein were also identified. All 
identifications were obtained with multiple peptide sequences, matching the 
theoretical sequences in the protein database, high XC scores, and matching 
molecular weights (section 4.9.1). These criteria allowed us to accept that the 
identified proteins were immunoprecipitated out by the 9E1 MAb with a high 
degree of certainty. From this, it would appear that the MAb’s target antigen is 
Annexin A6, as the molecular weight of this protein matches that of the reactive 
band seen in the Western blot analysis on a panel of cell lines probed with MAb 
9E1, including MiaPaCa-2 clone 3, MiaPaCa-2 clone 8, BT474 and SKBR-3 (see 
figure 4.10.5). It is likely then that the other identified proteins may be 
interacting with this target protein. 
 
Western blot analysis of immunoprecipitated samples probed with commercial 
antibodies specific for Annexin A6, Prohibitin, and the 14-3-3ε protein (section 
4.10) showed a reactive band at the expected molecular weights, validating the 
identifications obtained through mass spectrometry analysis.  
 
Following immunoprecipitation studies with 7B7, six bands of interest were 
observed which were all excised for mass spectrometry analysis (section 3.7.1). 
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A number of these bands were identified, but disregarded, as the same proteins 
were immunoprecipitated out with the control IgM antibody. All of the other 
bands failed to produce a positive identification, as the IgM heavy chain was 
contaminating the proteins. Numerous methods were employed to overcome this, 
including varying the cell lysate concentration, antibody concentration, 
MAb/lysate incubation time, antibody/antigen/Protein-L complex, Protein-L 
volume, and varying the incubation and washing times. All this failed to produce 
a positive identification. In order to obtain a positive identification, the 
interfering IgM heavy chain would have to be removed. It was therefore decided 
to carry out a cross-linked immunoprecipitation. 
 
With cross-linked immunoprecipitation, the antibody is covalently immobilised 
to the agarose beads by cross-linking with disuccinmidyl suberate (DSS). The 
antibody/agarose complex is then added to the sample containing the antigen of 
interest, forming an antibody-antigen complex. As before, the bound antigens are 
precipitated, while those that are not are washed away. The antigen is then 
dissociated from the antibody, allowing the pure antigen sample to be separated 
on SDS-PAGE. With this method, the antigen can be identified through mass 
spectrometry without any interference from antibody fragments. 
 
Prior to cross-linked immunoprecipitation, the antibody needs to be purified and 
dialysed. This is due to the fact that any amines (e.g. Tris or glycine), gelatine or 
carrier proteins will compete for binding sites to the agarose beads, thus 
decreasing antigen binding (section 3.7.2).  
 
Following cross-linked immunoprecipitation (section 3.7.3), the antigen-only 
sample was separated on SDS-PAGE and bands were visualised with Coomassie 
Blue. This time, 3 bands were visible, at approx. 108 kDa, 80 kDa and 70 kDa. 
The 108 kDa band, identified as Nucleolin, was disregarded, as it was also 
identified with the control IgM antibody. The two remaining bands were excised, 
and analysed using a liquid chromatography- tandem mass spectrometer (LC-
MS/MS).  
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Database searching of the peptide sequences obtained through mass spectrometry 
(section 3.9), using the SWISS-PROT database, indicated that the protein excised 
at approx. 80 kDa was ATP-dependent DNA helicase 2 subunit 2 (Ku80), with a 
molecular weight of 82.65 kDa. The lower band was identified as ATP-
dependent DNA helicase 2 subunit 1 (Ku70), with a molecular weight of 69.79 
kDa. Both identifications were obtained, in triplicate, with multiple peptide 
sequences, matching the theoretical sequences in the protein database, high XC 
scores, and matching molecular weights. These criteria allowed us to accept that 
the identified proteins were immunoprecipitated by the 7B7 with a high degree of 
certainty. As no other proteins were identified, it would appear that the MAbs 
target antigen is the Ku heterodimer. It was therefore decided to carry out further 
investigations on the Ku70 and Ku80 proteins, including siRNA silencing.  
 
Western blot analysis of the immunoprecipitated samples with commercial 
antibodies targeting the Ku70 and Ku80 proteins showed a strong reactive band 
in both immunoprecipitates when probed with their corresponding antibody, thus 
validating the identifications obtained through mass spectrometry analysis 
(section 3.10).  
 
5.4  Investigation of Target Antigens of MAb 9E1 24 (6) 
Following identification of Annexin A6, and the strong indications that it is the 
target antigen of 9E1, the next step was to determine what role, if any, it plays in 
the invasion process. This was achieved by silencing the Annexin A6 gene using 
RNA interference (section 4.11). MiaPaCa-2 clone 3 and DLKP-M were chosen 
for this study. No other protein was chosen for siRNA silencing, due to the fact 
that only one reactive band was observed in Western blot analyses with 9E1, 
corresponding to the molecular weight of Annexin A6. 
 
Annexin A6 is a major cellular calcium and phospholipid binding protein, and 
has been suggested to have tumour suppressive effects, through its ability to 
cause the down-regulation of the cell proliferation pathways initiated by 
activated Ras (Monastyrskaya et al., 2009). However, limited information is 
available with regard to its specific role, if any, in the invasion process. 
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Annexin A6 was successfully knocked down in both cell lines as shown by 
Western blot analysis. In both MiaPaCa-2 clone 3 and DLKP-M, Annexin A6 
silencing did not affect cell proliferation, in agreement with proliferation results 
obtained with 9E1-incubated cells. (Kinesin transfected cells did however show a 
dramatic decrease in cell number, indicating that siRNA transfection was 
successful.) In relation to invasion, Annexin A6 knockdown by two siRNAs 
targeting the protein, significantly inhibited invasion in the MiaPaCa-2 clone 3 
cell line, while siRNA-B significantly inhibited DLKP-M invasion levels. In 
relation to motility, no significant reduction was observed in any of the cell lines. 
These results indicate that Annexin A6 is involved in the invasion process of 
both these cell lines.  
 
Western blot analysis on the same panel of cell lines previously probed with 9E1 
was carried out with a commercial Annexin A6 antibody (section 4.12). The 
expression pattern observed was almost identical to that seen with 9E1 (with no 
expression in the SNB-19 cell line observed). Western blot analysis of 9E1 on 
Annexin A6 silenced MiaPaCa-2 clone 3 cells showed a significant decrease in 
the expression of the reactive antigen. These results give further corroboration 
that the main target antigen of the MAb is indeed Annexin A6. Expression levels 
of Protein 14-3-3ε in the same panel of cell lines were also looked at. All cell 
lines showed strong expression of this protein, including the WM-114, WM-266-
4 and SNB-19 cell lines. Expression levels were somewhat stronger in the 
MiaPaCa-2 clone 8 and DLKP-SQ cell lines. Western blot analyses of Protein 
14-3-3ε on Annexin A6 silenced cells were also carried out; however, expression 
levels remained unchanged, indicating that this protein is unaffected by the loss 
of Annexin A6.  
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Cell Line Reactivity  Cell Line Reactivity 
MiaPaCa-2 clone 3 + + +   DLKP-M + + 
MiaPaCa-2 clone 3 
(Matrigel) 
+ + +  DLKP-SQ + + + 
MiaPaCa-2 clone 8 + + +  H1299 + 
Lox IMVI + + +   C/68 + + 
WM-115 + / -  HCT-116 + + + 
WM-226-4 +   MDA-MB-231 + + + 
SNB-19 -  MDA-MB-453 + 
DLKP +   MDA-MB-361 + + + 
DLKP-A + +  SKBR-3 + + + 
DLKP-I + +  BT474 + + + 
 
Table 5.2: - Western blot analysis of Annexin A6 in a panel of cancer cell 
lines. 
 
+++ Very Strong; ++ Strong; + Intermediate; +/- Weak 
 
The levels of Annexin A6 expression observed in this study are similar to 
previously published results. de Muga et al., (2009) carried out Western blot 
analyses of Annexin A6 expression on a range of normal and cancerous breast 
cell lines. Annexin A6 was highly expressed in the HER2 elevated breast cancer 
cell lines, BT474, SKBR-3 and MDA-MD-361, corresponding to results obtained 
in this study. However, MDA-MB-453 also showed strong expression of 
Annexin A6, contrary to our results. All ER-positive breast cancer cell lines 
tested also expressed high levels of Annexin A6, while half of ER-negative cell 
lines tested displayed reduced Annexin A6 expression, including MDA-MB-231 
and -157 (contrary to our observation with MDA-MB-231). Expression of 
Annexin A6 appeared to be lower in cell lines with EGFR amplification. 
However, it has also been suggested to play a tumour suppressor role in these 
cells, by reducing the activity of Ras (de Muga et al., 2009).  
   
In addition to Western blot analysis of the Annexin A6, further 
immunofluorescence assays (section 4.5) were carried out in order to further 
investigate 9E1 reactivity in various cancer cell types.  
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Cell Line Reactivity  Cell Line Reactivity 
MiaPaCa-2 clone 3 + +   C/68 + / - 
MiaPaCa-2 clone 8 + +   HCT-116 + +  
Lox IMVI +   MDA-MB-231 + +  
SNB-19 + / -  MDA-MB-435 + + 
DLKP-SQ + + +  SKBR-3 + + + 
DLKP-Mitox-4p 
(Matrigel) 
+ / -  BT474 + +  
DLKP-Mitox-6p 
(Matrigel) 
+ + +  MDA-MB-157 + + 
H1299 + +   
 
Table 5.3: - Immunofluorescence studies of MAb 9E1 24 (6) in a panel of 
cancer cell lines. 
 
+++ Very Strong; ++ Strong; + Intermediate; +/- Weak 
 
Levels of positive staining observed with 9E1 agreed broadly with expression 
levels as shown by Western blot analysis of both 9E1 and Annexin A6 
antibodies; strong staining and expression levels in the HER2-overexpressing 
breast cancer cell lines, SKBR-3, BT474; low reactivity and expression in the 
SNB-19 glioma cell line. Staining in the Lox and C/68, while detectable, was 
lower than expected, compared to the expression levels observed in Western blot 
analyses. Levels of expression did correspond with inhibition of invasion with 
9E1 in some cases: low reactivity and expression in SNB-19 cells correlates with 
the lack of inhibition of invasion observed in this cell line; strong reactivity and 
expression observed in MiaPaCa-2 clone 3, H1299, HCT-116, MDA-MB-231 all 
correlate with significant decreases (or increases) in invasion levels following 
incubation with 9E1.  
 
Immunohistochemical analysis was also carried out with 9E1 on a range of 
normal and tumour tissue types. In general, the normal tissues analysed with 
MAb 9E1 showed low levels of expression; however, some reactivity was 
observed in normal colon tissue, but this was much reduced compared to colon 
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tumour tissue. The normal breast tumour tissue analysed showed strong staining 
with 9E1. 
 
9E1 reactivity in tumour tissue sections varied between the tissue types. Glioma 
tissue samples were very weakly positive, in agreement with results obtained 
with the investigation of inhibition of invasion, Western blot and 
immunofluorescence studies. Very intense staining was observed in the colon 
adenocarcinoma, retinoblastoma, Malt lymphoma and B cell lymphoma tissue 
samples, while the basal cell carcinoma only showed some weak positivity. 
Staining was also observed in a Warthins tumour, a benign tumour of the parotid 
gland. These results indicate that Annexin A6 is associated with both invasive 
and non-invasive cancer phenotypes. A large number of breast cancer samples 
were also tested, including HER2, ER positive, ER negative, PR positive, PR 
negative and Triple negative samples, with 9E1 reactivity ranging from very 
weak positivity to very intense staining. Although these are only preliminary 
results, a number of HER2 positive tumours showed 9E1 reactivity, which does 
reflect Western blot and immunofluorescence results obtained in this study. 
However, in order to confirm this pattern, a much larger study would have to be 
carried out. 
 
In summary, immunoprecipitation, and mass spectrometry identification of the 
Annexin A6 protein, its matching molecular weight to the 9E1 reactive antigen, 
and the subsequent decrease of this reactive antigen in Annexin A6-silenced 
cells, strongly indicates that this protein is the main target antigen of MAb 9E1 
24 (6). This is further corroborated by the similar expression levels observed in a 
panel of cell lines, probed with both the 9E1 MAb, and a commercial Annexin 
A6 antibody. Immunofluorescence assays, and immunohistochemical analysis 
indicate that it is found in a variety of tumour types, both invasive, and non-
invasive, while invasion assay results suggest that it may act as both a pro- and 
anti-invasive protein.   
 
5.4.1  Annexin A6 
The Annexins are a family of calcium-and membrane-binding proteins 
characterised by their unique architecture of Ca2+-binding sites, which facilitates 
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their peripheral docking onto negatively charged membrane surfaces through 
their Ca2+-bound conformation, thus playing a critical role in linking the plasma 
membrane to the cytoskeleton (Bode et al., 2008). Annexins are described as 
ubiquitous proteins; that is, any single cell type appears to express a range of 
Annexins; however, no single Annexin is expressed in all cell types (Gerke et al., 
2002). Several of the Annexin genes are located in chromosomal regions that 
show high frequency of loss in specific types of cancer, indicating that these 
Annexins could have tumour suppressor capabilities. However, it has also been 
suggested that changes in the expression of some Annexins during 
tumourigenesis may be linked to resistance to chemotherapeutic agents 
(Mussunoor et al., 2008). Annexin A2 has been linked to the suppression of 
prostate cancer cell migration (Liu et al., 2003), while its inhibition is linked to a 
decrease in the invasive capacity of prostate cancer cells (Hastie et al., 2008). 
Proteomic and immunohistochemical analysis showed overexpression of 
Annexin A1, A2, A4 and A11 in colorectal cancer compared to normal colon, 
while decreased expression of Annexin A7 and A10 has been linked to prostate 
cancer and hepatocellular carcinoma respectively (Srivastava et al., 2001; Liu et 
al., 2002). These findings highlight the dichotomous role of Annexins in cancer. 
 
Annexin A6 is highly expressed in most mammalian tissues, including skeletal 
muscle, liver, heart, spleen and lymph nodes. High levels are also found in 
endothelial and endocrine cells, secretory cells and macrophages (Grewel et al., 
2010). Annexin A6 has the ability to interact simultaneously with membranes, 
proteins of the EGFR/Ras/mitogen-activated protein kinase (MAPK) pathway, 
endocytic machinery and the actin cytoskeleton. This enables it to provide a 
scaffold to (A) form membrane-bound multifactorial signalling complexes, (B) to 
regulate transient membrane-actin cytoskeleton interactions during endocytosis 
and (C) to stabilise the protein/lipid composition during membrane microdomain 
formation such as caveolae/membrane rafts (Grewal and Enrich, 2006, 2009).  
 
Expression of Annexin A6 at the cell surface has been reported in numerous 
studies; as a receptor for chondroitin sulfate chains (Takagi et al., 2001), in 
association with S100A8/A9 in the cytoplasm (Bode et al., 2008) and the serum 
adhesive protein, fetuin-A (Sakwe et al., 2010). This is in agreement with the 
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both immunofluorescence and immunohistochemistry results obtained in this 
study, showing strong 9E1 reactivity to the cell membrane.  
 
5.4.2  Annexin and Cell Proliferation 
It has been shown that Annexin A6 inhibits Ras signalling in breast cancer cells. 
The activated Ras protein significantly enhances several facets of the malignant 
phenotype, including the deregulation of tumour-cell growth (Shield et al., 
2000). At the cell surface, binding of EGF to EGFR leads to Ras activation, 
which in turn engages Raf and MAPK to propagate the signal. Ras inactivation is 
regulated by GTPase-activating proteins (GAPs). Vila de Muga and her 
colleagues have shown that in a panel of breast cancer cell lines, Annexin A6 
stimulates membrane recruitment of the p120GAP, in a calcium-dependent 
manner. By targeting p120GAP to the membrane, Annexin A6 stabilises the 
formation of Ras-p120GAP complexes at the plasma membrane, leading to a 
reduction of Ras in the cytoplasm, and therefore a decrease in activity of the Ras 
signalling pathway. Knockdown of Annexin A6 in MDA-MB-436 breast cancer 
cells resulted in increased Ras activity and cell proliferation (Vila de Muga et al., 
2009). This is contrary to results obtained in this study, where blocking of 
Annexin A6 with MAb 9E1, and silencing of its function through siRNA 
knockdown, did not produce any decreases in cell proliferation. This may be due 
to the fact that proliferation studies were only carried out with the MiaPaCa-2 
clone 3 pancreatic cell line, where Ras, and therefore Annexin A6, may not play 
a major in cell proliferation. Proliferation assays carried out on cancer cell lines 
that overexpress EGFR, in the presence of MAb 9E1, may help to shed more 
light on the role of Annexin A6 in this process. 
 
5.4.3  Annexin A6 and Cell Invasion 
Annexin A6 has been reported to be downregulated in the transition of a non-
metastatic to a metastatic phenotype in B16F10 mouse melanoma (Francia et al., 
1996); expressed in uveal melanoma, but absent in normal uveal melanocytes 
(van Ginkel et al., 1998) and absent in transformed human B lymphocytes 
compared to normal B lymphocytes (Barel et al., 1991). In a prostate cancer 
model, downregulation of Annexin A6 was observed during progression from a 
benign to a malignant state (Kopper et al., 2006). These findings suggest a 
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tumour suppressor role for Annexin A6 in malignant progression. Some results 
from this study do highlight the anti-tumourigenic effects of Annexin A6, as can 
be observed from the increases in cell invasion in the colorectal cancer cell line 
HCT-116, and the breast cancer cell line MDA-MB-157, upon incubation with 
MAb 9E1.   
 
However, it would appear that Annexin A6 can also act as a pro-invasive protein. 
In this study, inhibition of Annexin A6 using MAb 9E1 resulted in significant 
decreases in invasion levels in a number of cancer cell lines. siRNA knockdown 
experiments in the MiaPaCa-2 clone 3 pancreatic cell line, and in the DLKP-M 
lung cancer cell line, also showed a decrease in invasion levels upon silencing of 
the Annexin A6 gene, with motility levels remaining unaffected. This pro-
invasive role of Annexin A6 has not been previously described, and as such, its 
method of action remains undefined.  
 
One hypothetical mechanism for the role of Annexin A6 as a pro-invasive gene 
would be through the compartmentalisation of Caveolin-1. High levels of 
Annexin-A6 result in an accumulation of cholesterol in the late endocytic 
compartment, leading to reduced amounts of cholesterol in the Golgi and plasma 
membrane. This overall imbalance of cellular cholesterol is accompanied by an 
inhibition of Caveolin-1 export from the Golgi complex (Cubells et al., 2007, 
2008); therefore, inhibiting the function of Annexin A6 could result in the release 
of Caveolin-1 to the plasma membrane. Caveolin-1 has been linked to inhibition 
of invasion in a number of breast cancers. Cells expressing high levels of 
Caveolin-1 showed reduced capacity to invade matrigel, diminished response to 
laminin-1 stimulation and decreased metastasis to lung and bone, but no major 
changes in proliferative capacity (Sloan et al., 2004; Fiucci et al., 2002). 
Caveolin-1 is also integral to various cellular processes, including the formation 
of caveolae at the cell surface. A reduction in caveolae at the cell surface has 
been shown to enhance anchorage-independent growth, increase tumorigenicity, 
stimulate mitogen-activated protein kinase (MAPK) signalling, and drive cells to 
enter the cell cycle and become transformed (Galbiati et al., 1998; Lin et al., 
2005). Although in vitro data indicate that low Caveolin-1 expression 
corresponds to an increase in tumour growth, Caveolin-1 is highly expressed in 
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some solid-tumour types in vivo. Contrary to the in vitro findings, its expression 
has even been associated with increased tumour-cell survival, aggressiveness, 
metastatic potential and suppression of apoptosis (Tahir et al., 2001; Kato et al., 
2002) (although Bender et al., (2000), and Felley-Bosco et al., (2000) have 
published results disputing this). 
 
Furthermore, Caveolin-1 has been shown to facilitate secretion of the serine 
protease Kallikrein 6 (KLK6) in the colon cancer cell line HCT-116. KLK6 has 
been linked to ECM degradation and increased tumour cell invasiveness 
(Henkhaus et al., 2008), and above-average expression of it correlates with a 
poor prognosis in ovarian and uterine cancers (Diamandis et al., 2003; Santin et 
al., 2005). This may explain the significant increase in cell invasion observed in 
the HCT-116 cell line upon exposure to 9E1. The apparent dual role of Caveolin-
1 as an anti- and pro-invasion protein reflects the behaviour of 9E1 observed in 
this study.  
 
Another mechanism that may further clarify the role of Annexin A6 as a pro-
invasive protein is through the development of clathrin-coated pits. Lin et al., 
(1992) used an in vitro system to demonstrate that Annexin A6 is required for the 
Ca2+, and ATP-dependent budding of clathrin-coated pits from the cell 
membrane. It was also demonstrated that Annexin A6 is required for regulating 
the formation of coated vesicles. Furthermore, after stimulating endocytosis at 
the cell surface, Annexin VI remains bound to endocytic vesicles to regulate 
entry of ligands into the prelysosomal compartment (Grewal et al., 2000; Kamal 
et al., 1998). Inhibition of Annexin A6, and of ATP, through ADP/ATP 
translocase proteins, which was also identified as a possible interacting protein, 
(ATP/ADP translocases catalyse the highly specific transport of ATP across a 
membrane in an exchange mode with ADP (Schmitz-Esser et al., 2004)), by 9E1 
may impede clathrin-coated pit budding. One result of this would be the 
degradation of clathrin-mediated endocytosis (CME). CME regulates cell 
transduction, as well as morphogenetic aspects of normal physiology (e.g. cell 
adhesion). Receptor clustering in clathrin-coated pits is followed by membrane 
invagination and vesicle scission (Goldstein et al., 1979). Thereafter, cargos 
undergo sorting in the multi-vesicular body, either for degradation in lysosomes, 
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or for recycling. However, in tumour cells, this pathway presents multiple 
abnormalities. Tumour cells gain self-sufficiency in growth signals by delaying 
endocytosis-mediated inactivation of growth factor receptors (Orth et al., 2006), 
and adhesion molecules undergo enhanced recycling and re-distribution to propel 
invading protrusions (Balklava et al., 2007). However, this endocytic pathway is 
initiated at clathrin-coated invaginations of the plasma membrane (Mosesson et 
al., 2008). Disruption of the formation of clathrin-coated vesicles through 
inhibition of Annexin A6 may inhibit pro-tumourigenic signals further 
downstream. It must be stated however, that CME is only one pathway through 
which aberrant signalling can take place; endocytosis can be mediated by 
caveolae, and by clathrin and caveolae-independent pathways. Therefore 
inhibiting CME may not affect all endocytic tumour events. 
 
Although no previous studies have related Annexin A6, ADP/ATP translocase 
and 14-3-3 (another protein identified along with Annexin A6, through 
immunoprecipitation assays in this study) proteins to the same process, it is 
plausible that all three are involved in CME. As described, Annexin A6 and 
ADP/ATP translocase could function together to form clathrin-coated pits. 14-3-
3s were the first proteins to be identified that bind specifically to phosphorylated 
substrates. As endocytosis is regulated by phosphorylation, activity of these 
proteins at the membrane could have important functions (Shikano et al., 2006). 
Furthermore, 14-3-3 proteins form dimers that provide two binding sites for 
phosphoserine motifs in ligand proteins. They can therefore function as adaptor 
proteins, bringing two proteins that would not otherwise associate into close 
proximity (Hermeking, 2003). Inhibition of Annexin A6 as the main target 
antigen of 9E1 may be affecting these interacting proteins simultaneously.  
The increase in invasion levels observed in the DLKP-M cell line upon 
incubation with diluted 9E1 presents an intriguing situation. This result may 
indicate that a necessary concentration of the MAb is required in order to inhibit 
invasion. Lower levels may inhibit the function of Annexin A6 in relation to Ras 
signalling, thereby increasing invasion, while clathrin-coated vesicle driven 
invasion remains unperturbed. Further studies involving known concentration 
levels of 9E1 will need to be carried out, in order to determine the optimal 
concentration of MAb needed for inhibition of invasion.  
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5.4.4  Annexin A6 and Cellular Adhesion 
MiaPaCa-2 clone 3 pancreatic cells grown in the presence of MAb 9E1 showed 
significant decreases in adhesion to both fibronectin and matrigel, suggesting that 
Annexin A6 plays a role in cellular adhesion to these proteins. But what might 
this role be? Chondroitin sulfate proteoglycans (CSPGs) participate in the 
modulation of various cellular functions, including adhesion. Work carried out 
by Fthenou et al., (2009) showed that cleavage of cell-associated CS chains 
severely impaired Fibrosarcoma cell adhesion. Annexin A6 is known to facilitate 
attachment of cells to chondroitin sulphate chains (Takagi et al., 2002 – although 
in this study, they show that CSPGs are involved in anti-adhesive activity). 
Therefore, inhibiting the facilitory action of Annexin A6 may reduce cellular 
attachment to CS chains, and therefore reduce the level of cell adhesion.  
 
Additionally, Annexin A6 has been shown to facilitate adhesion of breast 
carcinoma cells to Fetuin-A in a calcium dependent manner, further illustrating 
the role of Annexin A6 in cell adhesion (Madappa et al., 2004). This may 
therefore explain the significant decreases observed in cancer cell adhesion in the 
presence of MAb 9E1. 
 
From the results obtained in this study, it would appear that Annexin A6 does 
have a hither-to unknown role to play as a pro-invasive protein, and that by 
blocking its function, it is possible to significantly reduce invasion levels in a 
number of cancer cell lines. However, further work will need to be carried out in 
order to fully elucidate its role in the invasion process.  
 
5.5  Investigation of MAb 7B7 Target Antigens 
Following identification of the target proteins of 7B7, the next step was to 
determine what role, if any, they play in the invasion process. This was achieved 
by carrying out siRNA knockdown of these proteins. MiaPaCa-2 clone 3 and 
DLKP-M were chosen for this study (section 3.11). 
 
The Ku heterodimer has been implicated in DNA double strand break repair, 
telomere maintenance and apoptosis, and as such, is thought to play a crucial role 
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in cell survival. Its overexpression has been linked to the promotion of oncogenic 
phenotypes, while low expression leads to genomic instability and 
tumourigenesis. These observations suggest that the Ku protein may act as either 
a tumour suppressor or an oncoprotein (Gullo et al., 2006). 
 
Ku70 was successfully knocked down in both cell lines, and reduction in protein 
levels was confirmed, as shown by Western blot analysis. In both MiaPaCa-2 
clone 3 and DLKP-M, Ku70 silencing did not affect cell proliferation. (Kinesin 
transfected cells did however show a dramatic decrease in cell number, 
indicating that siRNA transfection was successful.) This result corresponds with 
the proliferation assay results observed with 7B7. In relation to invasion, Ku70 
knockdown by both siRNAs significantly inhibited invasion in the MiaPaCa-2 
clone 3 cell line, while siRNA-B significantly inhibited DLKP-M invasion 
levels. In relation to motility, MiaPaCa-2 clone 3 siRNA-B transfected cells 
showed a significant decrease in levels.  
 
Ku80 silencing also gave similar results to those seen in Ku70-silenced cells. 
Both cell lines showed successful knockdown of Ku80; cell proliferation was 
unaffected, while invasion and motility was significantly decreased in the 
MiaPaCa-2 clone 3 cell line. Meanwhile, DLKP-M siRNA-C transfected cells 
showed a reduction in invasion levels. 
 
Furthermore, Ku70 expression was reduced in Ku80 silenced cells, and vice 
versa, suggesting that the two subunits of the Ku heterodimer work in tandem. 
This is in agreement with previous studies (Bertolini et al., 2007; Mayeur et al., 
2005). However, simultaneous silencing of both Ku70 and Ku80 did not produce 
a greater inhibitive effect on cell invasion - in fact, inhibition of invasion was 
greatly reduced. This may be due to the lack of optimisation for dual siRNA 
transfection: in order to maintain overall siRNA concentration levels, only half of 
the volume of each siRNA was used during transfection. This could explain the 
reduced inhibition levels observed.  
 
   268 
From the results obtained above, it would appear that the two subunits of the Ku 
protein play a role in cell invasion and motility, and that by blocking their 
function, both processes can be successfully inhibited.  
 
Due to the fact that Western blot analysis does not work with the 7B7 MAb, 
immunofluorescence assays were carried out on Ku70 and Ku80 silenced 
MiaPaCa-2 clone 3 cells. Strong staining was observed on both untransfected 
cells, and scrambled-siRNA transfected cells, which was taken as the control. 
Ku70 silenced cells did not display any reduced reactivity with 7B7, while Ku80 
silenced cells displayed a marked decrease in staining. While these results are 
only preliminary, it may suggest that the Ku80 subunit is the main target antigen 
for the 7B7 MAb, and that the Ku70 subunit is merely immunoprecipitated along 
with it. 
 
Western blot analysis was carried out in order to observe the expression levels of 
Ku70 and Ku80 in a panel of cancer cell lines. Ku80 showed strong expression in 
most of the cell lines tested; however, expression was weaker in the C/68 
prostate cell line, corresponding to the low inhibition of invasion observed 
following incubation with 7B7, while Ku70 expression is low in the SNB-19 
glioma cell line (possibly corresponding to the low inhibition of motility 
observed following incubation with 7B7). Expression was stronger in the 
MiaPaCa-2 clone 3 compared to the clone 8 variant, while expression was also 
stronger in the WM-266-4 metastatic cell line compared to the WM-115 primary 
cell line.  
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Cell Line Reactivity  Cell Line Reactivity 
 Ku70 Ku80   Ku70 Ku80 
MiaPaCa-2 clone 3 + +  + + + +  DLKP-M + + + + + 
MiaPaCa-2 clone 3 
(Matrigel) 
+ + + + + +  DLKP-SQ + +  + + 
MiaPaCa-2 clone 8 + +  + +  H1299 + + + + 
Lox IMVI + +  + + + +  C/68 +  + 
WM-115 + + -  HCT-116 + + + + + + 
WM-226-4 + + + + / -  MDA-MB-231 + +  + + + 
SNB-19 +  + /-  MDA-MB-453 + + + + 
DLKP + + +  MDA-MB-361 + +  + + 
DLKP-A + + + +  SKBR-3 + +  + 
DLKP-I + + + +  BT474 + +  + 
 
Table 5.4: - Levels of expression of Ku70 and Ku80 in a panel of cancer cell 
lines. 
 
+++ Very Strong; ++ Intermediate; + Weak; +/- Very Weak 
 
Ku70 expression levels were similar to those seen with Ku80 – stronger 
expression in the MiaPaCa-2 clone 3 compared to the clone 8 variant 
(corresponding to preliminary immunofluorescence assay results); stronger 
expression in the WM-266-4 metastatic tumour compared to the WM-115 
primary tumour. However, some differences are observed: Ku70 expression in 
the SNB-19 glioma cell line is negligible, there is slightly stronger expression in 
the DLKP-M cell line, compared to the other variants, while expression in the 
triple negative MDA-MB-231 breast cell line showed the strongest expression 
out of all the breast cancer cell lines. No data pertaining to expression levels in 
the triple negative MDA-MB-157 breast cancer cell line is available; therefore, 
any association of expression with triple negative cell lines cannot be confirmed. 
The differences between the expression of both proteins in the invasive and non-
invasive variants of cell lines correspond to results observed in 
immunofluorescence studies, with 7B7 giving stronger staining on invasive cell 
lines, compared to low/non-invasive cell lines. Furthermore, the weaker 
expression levels in the C/68 cell line may explain the relative lack of inhibition 
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observed in this cell line; however, as 7B7 did not work on Western blotting, no 
direct comparisons can be made with Ku70 and Ku80. Immunohistochemical 
analyses were also carried out, but 7B7 did not produce any staining.  
 
In work carried out by Nolens and his colleagues, Western blot analysis of 
nuclear and cytoplasmic Ku70 and Ku80 expression was carried out in a number 
of breast cell lines. Although our results only show whole cell expression of the 
Ku subunits, some results do correspond to Nolen’s et al., e.g. Ku70 expression 
is weaker than Ku80 in the HER2 positive BT474 and SKBR-3 breast cancer cell 
lines. However, these authors reported that the expression of Ku80 versus Ku70 
is weaker in the MDA-MB-231 cell line, contrary to the result obtained in this 
study. This discrepancy may be down to the fact that only whole cell expression 
of the subunits was looked at in our study (Nolens et al., 2009). 
 
Results observed in immunofluorescence assays carried out on a range of cell 
lines stained with 7B7, are in agreement with the expression levels of Ku70 and 
Ku80 obtained through Western blot analysis. Stronger staining was observed in 
the MiaPaCa-2 clone 3 cell line, when compared to the clone 8 variant; C/68 and 
SNB-19 reactivity was low, while low level staining was observed in the SKBR-
3 and BT474 cell lines, corresponding to the expression levels of Ku80.  These 
results also correlate with 7B7 inhibition of invasion, with significant decreases 
observed in MiaPaCa-2 clone 3 and SKBR-3, no significant inhibition of 
invasion in the C/68 prostate cell line, and no inhibition of SNB-19 motility.  
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Cell Line Reactivity  Cell Line Reactivity 
MiaPaCa-2 clone 3 + +  +  H1299 + + 
MiaPaCa-2 clone 8 + +   C/68 + / - 
Lox IMVI   MDA-MB-231 + +  
SNB-19 + / -  MDA-MB-435 +  
DLKP-SQ +  MDA-MB-157 + +  
DLKP-Mitox-4p 
(Matrigel) 
+ / -  SKBR-3 + +  
DLKP-Mitox-6p 
(Matrigel) 
++ / +++  BT474 + +  
 
Table 5.5: - Levels of immunofluorescence staining of MAb 9E1 24 (6) in a 
panel of cancer cell lines. 
 
+++ Very Strong; ++ Strong; + Intermediate; +/- Weak 
 
Positive identification and validation of the 7B7 immunoprecipitates as Ku70 and 
Ku80, along with the absence of any other identified proteins, indicates that the 
target antigens of this MAb are the subunits of the Ku heterodimer protein. 
Furthermore, reduced 7B7 reactivity on Ku80 siRNA-transfected cells observed 
in immunofluorescence assays suggests that this subunit is the main target 
antigen.  
 
5.5.1  Ku Heterodimer 
The Ku heterodimer consists of the two tightly associated sub-units, Ku70 and 
Ku80 (in S. cerevisiae) or Ku86 (in higher eukaryotes – the Ku80 designation is 
used in this study, due to the molecular weight of the identified band being 
80kDa). Located mainly in the nucleus, it is an abundant protein that plays a key 
role in the non-homologous end joining process, which is responsible for 
repairing a high percentage of DNA double strand breaks (DSBs) in somatic cells 
of all multicellular eukaryotes (Koike et al., 2008). Ku also recruits a 465-kDa 
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) to the DNA 
double-strand break sites stimulating the DNA-PKcs kinase activity. DNA-PKcs 
interacts with and phosphorylates a nuclear protein, XRCC4, which associates 
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with DNA ligase IV. DNA ligase IV is thought to catalyze DNA-end joining 
(Costantini et al., 2007). 
 
The Ku80 subunit of the heterodimer also exists as a truncated 69kDa protein 
variant in several human cell lines including B cells (Muller et al., 1998), the 
leukaemia cell line, HL60 (Han et al., 1996) and multiple myeloma cells (Tai et 
al., 2000). This variant differs from the full-length Ku80 protein through a 
truncated C terminus (Sallmyr et al., 2002). It is suggested that this variant is 
formed through post translational modification after Ku80 re-entry to the 
nucleus, where it is proteolytically cleaved into a smaller form (Gullo et al., 
2006). 
 
Apart from its essential role in DNA repair, Ku has also been implicated in a 
number of other cellular processes, including antigen receptor gene arrangements 
(e.g., Variable (Diversity) Joining {V(D)J} recombination), telomere 
maintenance and regulation of heat shock-induced responses. It has been 
observed to play a role in regulation of the G2 and M phases of the cell cycle 
(Gullo et al., 2006), and its binding to an apolipoprotein C-IV promoter 
stimulates the expression of the gene, facilitating the transport of lipids through 
the lymphatic and circulatory systems (Kim et al., 2008).  
 
Ku’s ability to regulate numerous intracellular functions suggests that it may be 
active at multiple locations within the cell. Ku proteins are primarily localised to 
the transcriptionally active regions of the nucleus. Furthermore, they are 
components of the nuclear matrix, and are diffusely distributed in the 
nucleoplasm (Yu et al., 1998). However, they have also been shown to relocate 
to extranuclear sites in the cells e.g. subcellular compartments including the 
cytoplasm and cell membranes of numerous cell types (Koike et al., 2008). 
Structurally, Ku does not contain a known plasma membrane localisation signal, 
but does contain a hydrophobic region, thus facilitating cell surface expression. 
(Zhang et al., 2001) As immunofluorescence studies have shown, MAb 7B7 has 
cytoplasmic and membrane reactivity in numerous cancer cell lines, suggesting 
that the MAb is binding to this subcellular Ku heterodimer.  
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Previous studies suggest that a delicate balance exists in Ku expression; 
overexpression of Ku proteins promotes oncogenic phenotypes, while low 
expression has been linked to genomic instability and tumourigenesis. Such 
studies indicate that the Ku proteins may have a role as either tumour suppressors 
or oncoproteins (Pucci et al., 2001; Gullo et al., 2006). 
 
5.5.2  Ku and Cell Proliferation 
The Ku heterodimer has been well documented as playing a crucial role in DNA 
double strand break repair (DSBR). Therefore, the presence of functional Ku 
proteins in the cell is necessary for the maintenance of genomic stability, and 
consequently, the survival and proliferation of cancer cells. It was shown that the 
hyperproliferation of cancerous gastric cells could be associated with both high 
expression and high nuclear levels of Ku70 and Ku86 (Lim et al., 2002).  
 
However, Uegaki et al., have shown that the Ku heterodimer is not essential for 
cell growth. They showed that inactivation of either Ku70 or Ku80 did not cause 
any defects in cellular proliferation (Uegaki et al., 2006). This agrees with the 
results seen in this study: the lack of inhibition of MiaPaCa-2 clone 3 
proliferation when incubated with 7B7 may be due to the fact that the MAb only 
targets cell surface Ku70 and 80, and that it is the nuclear Ku heterodimer that 
controls cell proliferation. Work carried out by Ajmani et al., (1995) showed that 
proliferating lymphocytes do not express cell surface Ku. However, siRNA 
silencing of both targets did not affect cell proliferation either, thus corroborating 
the results obtained by Uegaki and his colleagues.  
 
5.5.3  Ku and Cell Invasion/Motility 
From the results obtained in this study, targeting of the Ku70 and Ku80 proteins 
by 7B7 results in the inhibition of invasion and motility in a number of cell lines. 
The low levels of inhibition observed in the C/68 prostate cell line correspond to 
the low level of expression of both subunits of the Ku heterodimer observed in 
this cell line. Furthermore, inhibition of invasion was significantly decreased in 
the SNB-19 glioma cell line, while motility levels were relatively unchanged. 
Western blot analysis of this cell line showed that Ku80 was strongly expressed, 
while levels of Ku70 were greatly diminished. This may indicate that the 
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inhibitory effect 7B7 has on motility may depend on Ku70 having a role to play 
in the motility process, either individually or in concert with Ku80. In the 
MiaPaCa-2 clone 3 cell line, Ku70 expression is strong, which may correspond 
to the highly significant decrease in motility levels observed upon exposure to 
7B7. In the case of SNB-19, Ku70 may not be involved in cell motility, and 
therefore, 7B7 has no inhibitory effect. No data on Ku70/80 expression levels in 
the BxPc-3 pancreatic cell line, or the MDA-MB-157 breast cancer cell line is 
available, so it is unknown if the lack of inhibition of invasion observed in these 
cell lines is due to the absence of these proteins.   
 
Both Ku70 and Ku80 have been shown previously to play a role in cell invasion 
and motility. HER2 overexpression in breast cancers is correlated with poor 
patient outcome due to extensive metastatic progression. Nolens et al., (2009) 
have shown that the Ku heterodimer, through interaction with Activator protein-2 
(AP-2) α and AP-2γ transcription factors, contribute to HER2 gene 
overexpression in breast cancer (Nolen et al., 2009).  Furthermore, upregulation 
of the Ku protein has been shown to increase the ability of Kelly neuroblastoma 
and MCF-7 breast carcinoma cells to invade endothelial monolayers, and to 
enhance levels of cellular locomotion (Ginis et al., 2000). This is achieved 
through a specific interaction with MMP-9. 
 
MMP-9 is a Zn+2 dependent endopeptidase, synthesised and secreted in 
monomeric form as a zymogen. Its primary function is degradation of proteins in 
the extracellular matrix, proteolytically digesting decorin, elastin, fibrillin, 
laminin, gelatin (denatured collagen), and types IV, V, XI and XVI collagen. It 
also activates growth factors such as proTGFb and proTNFa 
(atlasgeneticsoncology.org). High serum levels of MMP-9 have been related to 
rapid progression, poor overall survival and secondary metastasis in cancer 
patients with melanoma (Nikkola et al., 2005). In an experimental model for 
spontaneous metastasis of rat mammary carcinoma, serum and plasma levels of 
MMP-9 were associated with the development of metastases in the lung and 
lymph nodes (Nakajima et al., 1993). 
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A number of studies have shown that secreted MMPs can localise at the cell 
surface through interactions with “docking” molecules (Stamenkovic, 2003), 
thereby allowing cells to concentrate, and activate these MMPs at the close 
interface between their plasma membrane and ECM, a stage essential for tumour 
cell invasion. In the case of cancer cells, this is a key event in promoting tumour 
invasion. The decrease in levels of activated MMP-9 following incubation with 
7B7 observed in this study suggests that the MAb is blocking the binding of this 
MMP to its “docking” molecule. Both forms of the Ku heterodimer have been 
shown to interact with MMP-9 at the cell surface (Monferran et al., 2004), thus 
suggesting that the Ku protein acts as the “docking” molecule for MMP-9. The 
presence of these MMP-binding proteins allows cells to concentrate and activate 
MMPs at the close interface between their plasma membrane and ECM and, in 
cancer cells, may be a key event in promoting tumour invasion and angiogenesis 
(Toth et al., 1997; Bourguignon et al., 1998; Olson et al., 1998; Yu and 
Stamenkovic, 1999, 2000). Therefore, the inhibitory effect seen with 7B7 could 
possibly be due to its blocking of the Ku protein, and its function as a docking 
molecule for MMP-9. MMP-9 remains inactive, and is unable to carry out its 
proteolytic activities. siRNA silencing of both Ku70 and Ku80 proteins resulted 
in inhibited levels of invasion similar to that seen with 7B7; however, whether 
this is due to the inability of the cells to bind to MMP-9 is unknown. 
Zymography assays carried out on the conditioned media of Ku70 and Ku80 
silenced cells would clarify this. 
 
Ku80 has also been implicated in cancer cell invasion through involvement with 
the tyrosine kinase receptor, TrkA. TrkA overexpression has been associated 
with increased breast cancer cell growth and invasion, as well as survival 
(Lagadec et al., 2009). In work carried out by Lagadec et al., (2010), they found 
an increase in membrane Ku80 and Ku70 levels in TrkA-overexpressing cells. 
Furthermore, inhibition of Ku80 through siRNA silencing, or antibody blocking, 
strongly reduced TrkA-stimulated invasion, thus indicating that Ku80 was 
involved in this process. Suppression of Ku70, however, had no effect on cell 
invasion. Interestingly, simultaneous inhibition of both Ku80 and Ku70 reduced 
cell invasion to a similar degree of that observed with Ku80 inhibition alone. 
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This would suggest that the Ku80 subunit, and not Ku70, mediates TrkA-
stimulated invasion (Lagadec et al., 2010). 
 
5.5.4  Ku and Cellular Adhesion 
Both Ku70 and Ku80 have also been shown to play a role in cell adhesion. Work 
carried out by Lynch et al., and Teoh et al., showed that a surface molecule 
induced by hypoxia and exposure to CD40 ligand was identified as Ku80. The 
role of Ku in both homotypic (same cell type) and heterotypic (different cell 
types) adhesion was further demonstrated by these two groups using functional 
antibodies directed against both subunits of the Ku protein.  It was shown that Ku 
is involved in heterotypic adhesion of leukocytes to endothelial cells and of 
myeloma cells to bone marrow stroma; in the homotypic adhesion of myeloma 
cells and in the adhesion of fibroblasts and myeloma cells on fibronectin and 
collagen IV; all these phenomena are mediated by Ku upon CD40L stimulation 
(Lynch et al., 2001; Teoh et al., 1998).  
  
So how might Ku contribute to increase cell adhesion on Fibronectin? Monferran 
and her colleagues showed that both Ku70 and Ku80 present a structural 
relationship with Integrin I domains, and the A1 and A3 domains of von 
Willebrand factor (VWA), domains known to be involved in cell adhesion to 
ECM proteins, including Fibronectin (Monferran et al., 2004). Results obtained 
in this study show that 7B7 MAb reduces cellular adhesion to both Fibronectin 
and Matrigel by around 30%. The possibility exists that this MAb may be 
blocking this Ku/VWA interaction, thus reducing cell adhesion to Fibronectin.  
 
5.5.5  Ku and Anoikis Resistance 
From the Greek word meaning “homelessness”, anoikis is an apoptotic process 
induced by the absence of a surface for cell adhesion. Cells that have undergone 
anoikis usually display nuclear fragmentation and membrane blebbing, resulting 
from the activation of caspase proteases, all features observed during anoikis. 
Caspase activation in most cells requires permeabilisation of the outer 
mitochondrial membrane. This releases into the cytosol a host of factors, whose 
combined effect is caspase activation (Valentijn et al., 2004). One such factor in 
this caspase activation pathway is Bax. Bax is a member of the pro-apoptotic 
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Bcl-2 family of proteins and is localised in a physiologically inactive form in the 
cytoplasm (Fan et al., 2005). After apoptotic stimuli, Bax is translocated into the 
mitochondria and promotes the release of cytochrome c, leading to protein 
degradation, nuclear fragmentation, and eventual cell apoptosis. However, 
association between the C-terminus of Ku70 and the N-terminus of Bax in the 
cytoplasm results in the inactivation of Bax, thus suppressing Bax translocation 
to the mitochondria and eventual cell death (Sawada et al., 2003). This mediation 
between Ku70 and Bax does not require the co-operative effects of Ku80. 
Therefore, inhibiting Ku70 should increase the level of anoikis seen in cells, and 
this has been observed in numerous studies. Sawada et al., (2003) showed that 
overexpression of Ku70 suppressed the mitochondrial translocation of Bax, and 
increased the relative proportion of Bax in the cytosol. Ku70 deficient mouse 
embryonic fibroblasts also showed increased sensitivity to apoptotic stimuli.  
 
Anoikis assays set up with 7B7 did not show an increase in cell death, or a 
decrease in the number of anoikis-resistant cells. There are a number of possible 
reasons for this. One could be that the concentration of antibody was not 
sufficient in order to produce an observable effect. Another possibility was that 
Ku70 was successfully blocked, but that Bax translocation to the mitochondria 
did not take place. Sawada et al., (2003) have shown that even in Ku70-deficient 
cells, a substantial amount of Bax remained in the cytosol. This suggests that 
there is a multitude of steps involved in Bax activation, in addition to the 
dissociation of Ku70. The presence of a Bax inhibitor protein (e.g. Bax Inhibitor 
I) may also be acting as an anti-apoptotic agent. It is also possible that the pool of 
Ku70/80 available to 7B7 (primarily on the outside of the plasma membrane) 
does not play a role in intracellular events leading to apoptosis. One final 
possibility for the lack of any effect observed in relation to anoikis with 7B7 is 
that the Ku70-Bax association is not involved in anoikis in the DLKP-M and 
MiaPaCa-2 clone 3 cell lines. Other signalling pathways may be involved in 
Anoikis resistance in these cells, which are unaffected by 7B7, therefore no 
changes (within errors) would be seen in cell number when compared to the 
hybridoma media control.     
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5.5.6  Anti-Ku MAbs 
There have been a number of studies carried out, using MAbs that specifically 
target the subunits of the Ku heterodimer. Wang et al., (1994) used an MAb, 
designated 162, to investigate the assembly of Ku70 and Ku80, and their 
interaction with DNA. Immunofluorescence assays carried out with this MAb 
indicated that it interacted with both subunits of the Ku heterodimer, but not with 
each individual subunit. MAb 162 also immunoprecipitated the Ku heterodimer 
from cells infected with a Ku70 & 80 vaccine, but did not immunoprecipitate the 
individual subunits from cells coinfected with only a single subunit vaccine. 
Furthermore, the MAb stabilised the Ku heterodimer under conditions that 
normally dissociate Ku70 from Ku80 (Wang et al., 1994).   
 
Luk et al., (2005) generated a MAb, designated CLD3, through immunisation of 
BALB/c mice with cancerous tissue lysates from hepatocellular carcinoma 
(HCC) patients. Hybridomas were subsequently screened against the 
homologous antigens by ELISA, producing MAb CLD3. Immunofluorescence 
and immunohistochemistry assays were carried out to characterise the location of 
reactivity of the MAb in tumourigenic HCC cell lines. Immunoprecipitation 
assays indicated that the target antigen was the Ku heterodimer, and this was then 
confirmed through Western blot analysis. This antibody was able to react with 
the Ku70 and Ku80 subunits individually, as well as the heterodimer as a whole 
(Luk et al., 2005).   
 
A MAb generated against multiple myeloma (MM) cells was found to recognise 
the Ku80 subunit only. Designated 5E2, this MAb was found to inhibit MM cell 
adhesion to bone marrow stromal cells. Immunoprecipitations carried out with 
this MAb showed that the Ku70 subunit was co-immunoprecipitated out along 
with the Ku80 subunit, even though the MAb did not react specifically with Ku-
70 protein, as shown by Western blot. This study reveals that it is possible to 
immunoprecipitate out the Ku heterodimer as a whole, with a MAb that only 
targets one specific subunit (Teoh et al., 1997). 
 
Immunofluorescence assays carried out on Ku transfected cells with 7B7 
suggests that this MAb is targeting the Ku80 subunit of the heterodimer. 
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Simultaneous siRNA transfection with the two different subunits did not produce 
levels of inhibition greater than those observed when each subunit was targeted 
individually, but this may be due to lack of optimisation of dual siRNA 
transfection.  However, previous studies have suggested that each subunit of Ku 
protein is required to stabilize the other. Therefore, targeting one subunit should 
be sufficient to block the activity of the complete heterodimer at the membrane 
(Monferran et al., 2004; Satoh et al., 1995; Li et al., 2002).  
 
5.6  Combination Studies of MAb 7B7 & 9E1  
The Ku heterodimer and Annexin A6 share common targets in different 
signalling pathways, leading to potential co-operative effects. For example, Ku70 
and 80 form a complex with poly (ADP-ribose) polymerase (PARP-1), driving 
expression of the stress-specific S100A9 gene (Grote et al., 2006); expression of 
this gene has been associated to inflammation, and its up-regulation in various 
types of tumours suggests that it has a possible role in inflammation-associated 
cancer (Gebhardt et al., 2006). S100A8/A9 is also connected to Annexin A6, 
since both proteins are exposed on the cell surface of SKBR-3 cells upon calcium 
influx (Bode et al., 2008). Therefore, both of the MAbs generated in this study 
could have a possible synergistic effect. In order to investigate this, invasion 
assays were carried out on the MiaPaCa-2 clone 3 cell line, with a combination 
of the two MAbs.  
 
Initially, there did not appear to be any further increase in the inhibition of 
invasion above that observed with each MAb acting individually. However, it 
should be noted that only half the volume of each antibody was used in the assay, 
(i.e. 50µl of each MAb, giving a total volume of 100µl). We have seen that our 
MAbs present a dose-dependent response; 9E1 at a 1 in 2 dilution gave an 
average inhibition of 22% in the DLKP-M cell line, while the same dilution of 
MAb 7B7 gave an average of 20% inhibition in the same cell line. When used in 
combination in the MiaPaCa-2 clone 3 cell line, invasion was inhibited by an 
average of 42%, suggesting that an additive effect had been achieved, rather than 
a synergistic one.  
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While invasion was significantly inhibited by both MAbs in various cancer cell 
lines, the effects observed differed between them. For example, 9E1 significantly 
inhibited invasion in the C/68 prostate cancer cell line, while 7B7 had little 
effect. Conversely, SNB-19 invasion was significantly reduced in the presence of 
7B7, while 9E1 had no impact on invasion levels. In many cases, these 
differences between the MAbs can be attributed to the expression of their 
respective target antigens in the given cell lines. The effects of both MAbs on 
HCT-116 invasion highlight their differing mechanisms of actions. MAb 7B7’s 
significant decrease in invasion levels may possibly be due to its disruption of 
the proteolytic action of MMP-9, while the increases observed upon incubation 
with MAb 9E1 may be due to the action of caveolin-1 facilitating KLK6 
secretion, and thus increased ECM degradation and cell invasion. Interestingly, 
both MAbs had no effect on the BxPc-3 pancreatic cancer cell line.   
 
Significant inhibition of cell motility was observed with both MAbs; however, 
7B7 gave a much more pronounced decrease, with levels comparable to that 
observed in inhibition of invasion. Again, this may be as a result of its target 
antigens having a more central role in cellular motility, than Annexin A6. 
Cellular adhesion to matrigel was significantly decreased upon incubation with 
the MAbs, while adhesion to fibronectin was also inhibited. However, 7B7 gave 
more consistent results in relation to the former ECM protein. Similar 
morphological changes were observed following exposure to the MAbs, and 
MMP-9 activity was also decreased. The similarity in results obtained in these 
experiments is not unexpected, as inhibition of cellular invasion is likely to affect 
these cellular processes. Therefore, two separate and distinct anti-invasive agents 
can elicit similar responses. The absence of effect in anoikis observed with both 
MAbs is likely due to the complex nature of this cellular process. It is highly 
unlikely that a single pathway regulates anoikis. Many signals are affected 
depending on whether or not cells commit to an apoptotic fate, and it is an 
accumulation of all these pathways that decides the cell fate.  
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5.7  Combination Studies with MAb 9E1 24 (6) & 7B7 G5 (2)  
 and Lovastatin, Mevastatin and Simvastatin 
 
Although both MAbs significantly inhibited invasion in numerous cancer cell 
types, neither one gave complete inhibition. This is not unexpected, as it is highly 
unlikely that only one protein would control cell invasion. One of the reasons 
why cancer is such a difficult disease to treat is due to the multiple mechanisms it 
employs in order to continue with proliferation and colonisation. Therefore, any 
successful therapeutic treatments will likely involve various anti-cancer agents, 
working in synergy, against a myriad of targets. For this reason, combination 
studies were carried out in order to investigate the possibility of increasing the 
inhibitive effects of both MAbs. As mentioned earlier (section 1.2.7.1) statin 
drugs have shown some anti-tumourigenic properties in relation to melanoma, 
therefore it was decided to test Simvastatin, Lovastatin, and Mevastatin to 
observe their effects on melanoma cell invasion and migration in vitro. All three 
statins were found to inhibit melanoma cell invasion and cell motility, in vitro, in 
the two melanoma cell lines tested, at non-toxic concentrations, in a dose-
dependant manner (section 4.14). These results reflect results obtained by 
Collisson et al., (2003), who described atorvastatin inhibition of invasion of the 
melanoma cell lines A375M, CHL, SK-MEL-28, and WM 166-4 in a dose-
dependant manner, with A375M invasion being inhibited at non-toxic 
concentrations. Farina et al., (2003) described the metastatic inhibition of F311 
mammary carcinoma cells in BALB/c mice following pre-treatment with a non-
cytotoxic concentration of Lovastatin. 
 
The results observed suggest that the standard doses used for cholesterol 
treatment may not be sufficient to directly inhibit melanoma cell invasion (the 
peak plasma concentration of Simvastatin achieved in patients receiving a 40mg 
per day does is approximately 3ng/ml (7.2nM) (Najib et al., 2003). Therefore, 
statins are unlikely to be beneficial for prevention of melanoma. However, statin 
treatment at higher doses may be beneficial as an adjuvant therapy to inhibit 
melanoma cell invasion and metastasis. Synergistic interactions have been 
observed between statins and several chemotherapy agents in vitro (Sleijfer et 
al., 2005).  
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Once the anti-invasion and anti-motility effects of the statins were established, 
synergy studies were conducted between the 9E1 and 7B7 MAbs, and 
Simvastatin, Lovastatin and Mevastatin. However, no increase in inhibition of 
invasion in the MiaPaCa-2 clone 3 cell line was observed. Incubation of both 
MAbs with Lovastatin and Mevastatin did not produce any noticeable synergistic 
effect, with inhibition of invasion remaining at levels achieved with the statins 
alone. Incubation of MAb 7B7 G5 (2) with Simvastatin did increase inhibition 
levels slightly; however, these decreases remained within experimental error. 
Although no apparent synergy was observed between the MAbs and the statins 
tested, further studies should be carried out, not only on a wider range of statins, 
but also on other anti-cancer agents, such as MMP inhibitors. Future cancer 
therapies will inevitably involve multi-drug treatments, targeting different 
processes, including metastasis, and as such, information on compatibility and 
synergy will be essential.  
 
5.8  MAb 9E1 & 7B7: From Bench to Bedside 
 
The research presented in this thesis is proof of principle of how MAbs can be 
successfully generated that specifically target invasion-related proteins, and can 
block cancer invasion in vitro. Both 9E1 and 7B7 have shown significant anti-
invasion activity in vitro in a number of cancer models; however, if they are to be 
considered as future therapeutic agents for the treatment of cancer, a lengthy 
development process has to be initiated to produce a final product suitable for 
testing in humans. While in vitro systems of testing can offer a wide range of 
data pertaining to the mechanisms of action of the MAbs, they are not 
sufficiently complex to study the entire metastatic process: metastasis, as 
discussed in section 1.1, is much more than invasion, adhesion, and growth rate 
(Mendoza et al., 2010). The use of animal models (in vivo) allows for the testing 
of MAbs in a highly complex environment.  
 
In order to investigate the effects our MAbs would have on the invasion process 
in vivo, an orthotopic mouse model would have to be used. With this model, 
tumour cells are implanted in their original tissue, allowing for the development 
of tumours that are comparable to human tumours, and leading to the emergence 
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of metastasis in a few weeks. In these models, bioluminescence imaging allows 
for the characterisation of tumour burden, and consequently, determination of the 
effect of the MAbs on the metastatic process (Pastuskovas et al., 2010; 
Engebraaten et al., 2009).  
 
Another method of animal testing involves ex vivo modelling. This involves 
experimenting on animal tissues outside of the organism under controlled 
conditions, but with minimal changes to its natural environment. Recently, 
Mendoza et al., have developed an ex vivo pulmonary metastasis assay (PuMa) in 
which GFP-expressing cancer cells proliferate and progress in lung tissue, 
allowing for the assessment of metastatic progression up to, and beyond, a 21-
day observation period. Furthermore, this assay validated in vivo behaviour of 
high- and low-metastatic human and mouse cancer cell lines (Mendoza et al., 
2010). This method offers a simple way to study the process of metastatic 
progression at a secondary site, while recapturing the cellular and 
microenvironmental complexity of in vivo systems. If the MAbs show the same 
anti-invasion effect in vivo, or ex vivo, as was observed in vitro, then they could 
be considered for possible testing in pre-clinical trials. However, a number of 
factors must be considered before testing commences 
 
As with the MAbs developed during this study, the majority of clinically 
interesting antibodies were raised in mice and prepared from hybridoma cells. 
This gave rise to the problem of immunogenicity of murine MAbs in humans, 
and the inevitable generation of HAMA (Human-Anti-Mouse-Antibodies). 
Therefore, murine-origin MAbs must undergo re-engineering to enhance their 
clinical utility i.e. to increase their immunogenicity. The most commonly used 
re-engineering techniques are chimerisation and humanisation (see section 1.8.2 - 
Qu et al., 2005). (However, murine MAbs can still be used in clinical settings 
e.g. lymphoma patients who are immunosuppressed rarely develop HAMAs, 
which interfere with repeated therapeutic MAb administration (Leonard et al., 
2005).) Furthermore, a fully human antibody can be made against a specific 
target, in this case Annexin A6 and the Ku heterodimer. 
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Another point of consideration involves the IgM nature of 7B7. Historically, IgM 
monoclonal antibodies have been underrepresented in human therapeutic 
development due to problems with low affinity and cross reactivity (Brändlein et 
al., 2002), and their large size means they have a limited utility for therapeutics 
(Reichert et al., 2006). Although IgM is the most effective isotype for 
complement activation, it does not readily extravasate from vascular structures 
(Adams et al., 2005). Therefore, when choosing MAbs for clinical testing, many 
companies tend to shy away from those with an IgM subclass. However, Irie et 
al., (2004) have hypothesized that IgM MAbs may be more effective against 
cancer cells in vivo, due to the correlation between prolonged survival and high 
serum levels of IgM, but not IgG, anti-tumour antibodies in patients with 
metastatic melanoma, and the complete or partial regression of skin metastases of 
melanoma following intra-tumoural injection of human IgM antibodies. 
Furthermore, a number of IgM MAbs have undergone clinical trials (Azuma et 
al., 2007; Irie et al., 2004), highlighting the therapeutic potential of IgM-type 
MAbs.   
 
There is also a hierarchy among IgG MAbs when effecting ADCC; IgG1 and 
IgG3 have high ADCC effector function, while IgG2 and IgG4 have low 
function (Lin, M.Z., et al., 2005). This is probably due to their differential 
affinities for Fc receptors (Nimmerjahn et al., 2005).  
 
If it is decided to either make chimeric or humanised antibodies from our MAbs, 
or to make fully human antibodies against their targets, these will then have to 
undergo rigorous testing before they can obtain FDA or EMA approval.  Pre-
clinical in vivo characterisation must take place, in order to investigate the 
pharmaceutical properties, pharmacokinetics and pharmacodynamics of the 
administered drug. Distribution studies provide preliminary data on routes of 
metabolism and excretion, target organs for toxicity, and drug sanctuary sites 
(DeVita et al., 2008). Animal models for cancer drug development should 
include features relevant to human cancer, such as the representation of 
molecular targets, microenvironment, tumour natural history, angiogenesis, and 
metastasis (Gitler et al., 2004). Mice are the most commonly used vertebrate 
species for in vivo testing, due to their size, low cost, ease of handling, fast 
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reproduction rate, and similarity to human physiology (they share 99% of their 
genes with humans) (Rosenthal et al., 2007).  
 
Dosing studies will be essential when testing (the chimeric/humanised/fully 
human) 9E1 and 7B7 in vivo, both in animal models and in clinical trials. As 
observed in the DLKP-M cell line, incubation of the cells with diluted 9E1 
resulted in an increase in invasion levels. Concentrated 7B7 was also observed to 
increase invasion levels in the MiaPaCa-2 clone 3 cell line (results not shown). 
Varying dilutions of the MAbs will need to be administered in order to determine 
the optimal antibody concentration required for successful inhibition of invasion. 
 
Side effects of the MAbs, both positive and negative, will also be a critical 
feature to investigate when conducting in vivo trials. The proposed target antigen 
of 9E1 is Annexin A6. This protein is the most abundant Annexin in the heart, 
and has been localised in various cell types, including muscle cells (myocytes). 
Overexpression of Annexin A6 has resulted in physiological alterations in 
contractile mechanics, leading to dilation and weakening of the heart, whereas its 
absence has been found to induce faster changes in Ca2+ removal from myocytes 
and increased contractility, suggesting a negative role for Annexin A6 in cardio-
muscle contraction (Camors et al., 2005). Annexin A6 has also been implicated 
in regulation of the secretory process in plasma cells (Bode et al., 2008; Tiacci et 
al., 2005). This presents a situation where the administration of 9E1 could affect 
other physiological functions, unrelated to cancer, where Annexin A6 is 
involved.  
 
Cell surface Ku proteins has been implicated in the invasion processes of cancer 
cells in this, and many other studies, but they are also involved in invasion of 
normal cells such as monocytes during recruitment to tissues, a crucial event 
during inflammatory responses. Inflammation is known to play a decisive role at 
different stages of tumour development, including initiation, promotion, 
malignant conversion, invasion, and metastasis (Grivennikov et al., 2010). 
Therefore, an anti-Ku antibody may have further anti-cancer effects than those 
identified in this study. However, the Ku heterodimer is involved in many other 
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cellular processes, and its inhibition could have negative side effects that could 
greatly influence regular physiological activities.  
 
As undesired as they are, any negative side effects observed with either MAb in 
vivo may not necessarily result in the abandonment of clinical trials. Although 
animal models are designed to represent events occurring in humans, sometimes 
metabolic and physiological differences result in the appearance of side effects in 
animals which later do not materialize in humans. Even so, most therapeutic 
drugs available to clinicians elicit unwanted side effects. For example, 
Trastuzumab is linked with cardiac toxicity. In a clinical trial of Trastuzumab in 
HER2-positive metastatic cancer patients, an increased incidence of serious 
cardiac events was observed, notably when Trastuzumab was administered in 
combination with anthracyclines. In addition to its expression in tumour cells, the 
HER2 receptor is also expressed on cardiomyocytes, where it exerts a protective 
effect on cardiac function; therefore, interference with HER2-signaling may 
block this protective effect (Perez, 2008). However, if it is deemed that any 
beneficial effects observed with a new drug outweigh the negative side effects, or 
if the side effects can be managed or even reversed with standard therapy, then it 
may be decided that clinical trials can begin. 
Clinical trials of prospective agents for cancer treatment undergo 5 phases of 
testing: phase 0, which establishes whether the drug or agent behaves in human 
subjects as was expected from preclinical studies (Lancet, 2009), through to 
phase IV, which involves the safety surveillance and technical support of a drug 
after it has been granted a license (Ebbesen et al., 2008). However, clinical trials 
involving anti-metastatic agents present a number of problems. These include the 
high numbers of patients required, due to the necessity to assess recurrence of 
metastatic disease. Measuring response rates beyond stable disease will further 
increase the number of patients needed.   
Over the past 20 years, there has been a dramatic shift in MAbs undergoing 
clinical development. From the period 1990-1991, humanised MAbs accounted 
for 45% of all MAbs in clinical development; 30% were murine, 13.5% were 
chimeric while 11.5% were fully human. However, from 2000-2008, these 
   287 
figures changed dramatically, with 45% of MAbs in clinical development being 
fully human, 39% humanised, 9% chimeric, and 7% murine (Nelson et al., 
2010). This trend highlights the growing development of fully human MAbs in 
clinical trials. Furthermore, between 1997 and 2008, 131 human MAbs entered 
clinical trials. Of these, 30 were in Phase I, 51 in Phase II and 7 in Phase III, and 
a total of 7 were approved for marketing by the FDA (33 were discontinued). 
Among the FDA approved MAbs were Panitumumab, an anti-EGFR antibody 
approved for the treatment of metastatic colorectal carcinoma, and Ofatumumab, 
a CD20-specific MAb approved for the treatment of chronic lymphocytic 
leukaemia (Nelson et al., 2010).  
 
In 2009, MAb-mediated cancer therapy generated total revenues of over 
US$18bn worldwide. From 2010, that sector will benefit from new drugs, new 
targets and expanding indications for existing products. With cancer incidence 
and prevalence rising worldwide (studies reveal that incidence rates will rise by 
up to 40% by 2025) the treatment of cancer will be a priority for healthcare 
providers, with high demand for effective and well-tolerated therapies 
(Visiongain, 2010). The lack of MAbs directed against invading cancer cells is a 
major market niche that is waiting to be exploited, and with the current trends in 
revenues generated by MAb based therapy, the rewards are there for anyone 
willing to commit resources into the development of anti-metastatic MAbs.  
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1. By screening directly for function, two Mabs were identified that can 
significantly block cancer invasion in vitro. 
 
2. MAb 7B7 was generated against the highly invasive pancreatic cell line 
MiaPaCa-2 clone 3. Incubation with this MAb significantly reduced 
invasion in the MDA-MB-231 and SKBR-3 breast cancer cell lines; the 
DLKP-M NSCLC and H1299 ling cancer cell lines; the SNB-19 glioma 
cell line and the HCT-116 colon cell line. Inhibition of invasion was also 
observed in the Lox IMVI melanoma cell line, but significance was not 
reached. Invasion levels in the pancreatic cell line BxPc-3 and the 
prostate cell line C/68 were only slightly inhibited. MAb 7B7 also 
significantly inhibited motility in the MiaPaCa-2 clone 3 cell line 
following incubation with MAb 7B7, but not SNB-19 motility. This MAb 
also decreased MiaPaCa-2 clone 3 adhesion to fibronectin, and DLKP-M 
adhesion to matrigel. MMP-9 activity in the MDA-MB-231 breast cancer 
cell line was also decreased following incubation with MAb 7B7.  
 
3. Immunofluorescence analysis of MAb 7B7 on MiaPaCa-2 clone 3 cells 
revealed membrane and cytoplasmic reactivity. Stronger reactivity was 
observed in cells exhibiting a more invasive phenotype compared to less 
invasive cells (MiaPaCa clone 3 versus clone 8; DLKP-Mitox-6p versus 
DLKP-SQ).  
 
4. Cross-linked immunoprecipitation studies, followed by LC-MS/MS 
analysis, revealed the Ku70 and Ku80 subunits of the Ku heterodimer as 
the target proteins of 7B7. These identifications were validated through 
Western blot analysis using commercial antibodies directed against Ku70 
and Ku80. 
 
5. Confirmation of the role of Ku70 and Ku80 in invasion and motility was 
confirmed through siRNA silencing of both subunits, which resulted in 
significant inhibition of both of these processes.  
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6. Western blot analysis of Ku70 and Ku80 produced a similar pattern of 
expression to that observed in the immunofluorescence studies. 
Expression was stronger in the invasive (MiaPaca-2 clone 3, WM-266-4) 
versus non-invasive (MiaPaCa-2 clone 8, WM-115) cell lines. Expression 
levels also corresponded to invasion assay results e.g. low expression and 
inhibtion was observed in the SNB-19 glioma and C/68 prostate cell 
lines. 
 
7. Immunofluorescence assays carried out on Ku70 and Ku80 siRNA-
transfected cells revealed that 7B7 reactivity was decreased in Ku80 
silenced cells, while reactivity was unchanged with Ku70 silenced cells. 
This suggests that the Ku80 subunit is the main target antigen of MAb 
7B7.  
 
8. MAb 9E1 was generated against the highly invasive melanoma cell line 
MDA-MB-435-SF. This MAb was shown to significantly inhibit cell 
invasion in the MiaPaCa-2 clone 3 pancreatic cancer cell line; the MDA-
MB-231 breast cancer cell line; the DLKP-I, DLKP-M and H1299 
NSCLC cell lines; the Lox IMVI melanoma cell line and the C/68 
prostate cancer cell line. Inhibition of invasion was also observed in the 
SKBR-3 breast cancer cell line, but significance was not reached. 
Surprisingly, invasion was increased in the MDA-MB-157 breast cancer 
cell line, and in the HCT-116 colon cancer cell line. These results suggest 
that the target antigen(s) of this MAb can act as both a pro- and anti-
invasive protein. MAb 9E1 also significantly inhibited cell motility in the 
MiaPaCa-2 clone 3 cell line, but to a lesser extent. Other invasion-related 
processes, including MiaPaCa-2 clone 3 adhesion to fibronectin, DLKP-
M adhesion to matrigel, and MMP-9 activity in the MDA-MB-231, were 
also decreased following incubation with 9E1. 
 
9. Immunofluorescence analysis of MAb 9E1 showed membrane 
“punctuate” type staining, along with some cytoplasmic reactivity, in 
MiaPaCa-2 clone 3 cells. Reactivity was observed in invasive and anon-
invasive cancer cell types. Western blot analysis indicated that the target 
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antigen of 9E1 is expressed in a wide variety of cancer cell types 
(melanoma, lung, pancreatic, breast, and colon) and in both non-invasive 
and invasive tumour cell lines.  
 
10. Immunohistochemical analysis showed that the target antigen was 
expresssed, to varying degrees, in a range of breast cancer sub-types 
(HER-2 overexpressing, triple negative, ER +/-, PR +/-), strong reactivity 
was observed in a number of HER-2 overexpressing tumours. 9E1 
reactivity was also observed in normal breast tissue; normal liver & 
prostate tissue. 9E1 reactivity was also observed in Malt lymphoma 
(orbital tissue), Retinoblastoma, Hodgkins Lymphoma, B-Cell Mantle 
lymphoma and B-Cell lymphoma tumour tissues and in a number of 
pancreatic tumours. Very weak expression was bserved in Glioma tumour 
tissues; 9E1 expression was also observed in a Warthins Tumour, a 
benign parotid tumour.  
 
11. Western blot analysis indicated that the target antigen of MAb 9E1 is a 
75kDa protein. This matches the molecular weight of Annexin A6, which 
was identified through immunoprecipitation and mass spectrometry 
analysis. This indicates that Annexin A6 is the target antigen of MAb 
9E1. A number of possible interacting proteins were also identified 
through immunoprecipitation studies, namely, Protein 14-3-3ε, Prohibitin 
and ADP/ATP translocase 1, 2 and 3.  
 
12. siRNA silencing of Annexin A6 in MiaPaCa-2 clone 3 and DLKP-M cell 
lines, resulted in significant reduction of invasion in these cell lines. 
These results confirmed the role of Annexin A6 in cellular invasion. 
However, the increases in invasion observed in the HCT-116 colon 
cancer cell line indicate that Annexin A6 may also have an anti-invasive 
effect. 
 
13. Western blot analysis of a commercial Annexin A6 antibody produced a 
similar pattern of expression to that observed with MAb 9E1. 
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Furthermore, Western blot analysis on Annexin A6-silenced cells with 
the 9E1 MAb revealed strongly reduced expression levels of the reactive 
band. These results further supports that the target antigen of 9E1 is the 
Annexin A6 protein. 
 
14. Lovastatin, Mevastatin and Simvastatin all significantly decreased 
invasion and motility in the HT144 and SK-MEL-28 cell lines, indicating 
that they do have therapeutic effects against melanomas. Although the 
concentrations used in this study were at higher doses that those currently 
used for statin treatment, higher doses may be beneficial as an adjuvant 
therapy to inhibit melanoma cell invasion and metastasis. 
 
15. Synergy studies carried out between the MAbs and Lovastatin, 
Mevastatin and Simvastain, did not produce any increase in inhibition. 
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Future Work Suggested 
 
1. In order to gather more information on the MAbs (particularly MAb 7B7) 
effects on cancer cell motility, motility assays will have to be carried out on a 
wider range of cell types. This will help to determine if the inhibitory effects 
on invasion of the MAbs are a result of reduced cellular motility, or if the two 
processes are inhibited by differing mechanisms.  
 
2. Investigate the effects of both MAbs on normal cells that are invasive e.g. 
HUVEC, melanocytes. 
 
3. siRNA functional analysis studies of Prohibitin,  Protein 14-3-3ε, ADP/ATP 
translocase 1-3 and the 40S ribosomal proteins will need to be carried out in 
order to investigate their role in the invasion process. If they are found to 
play a role in the invasion process, their expression in invasive versus non-
invasive cancer cell lines will be looked at. Their role as interacting proteins 
will also need to be established. This will be carried out through 
immunoprecipitation studies using a commercial antibody targeting Annexin 
A6, to see if the same interacting proteins are identified. 
 
4. More detailed localisation studies could be carried out through labelling of 
the MAbs. 
 
5. The role of the identified target antigens could be looked at in other cellular 
processes e.g. adhesion, anoikis, MMP activity, and angiogenesis, through 
siRNA silencing of the identified proteins.  
 
6. In order to further investigate if the Ku heterodimer in involved in activating 
MMP-9, zymography assays will be carried on Ku70 and Ku80 silenced 
cells. 
 
7. While both MAbs significantly inhibit cancer invasion and motility, they do 
not fully inhibit both processes. Therefore, a wider investigation of any 
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possible synergistic effect between the MAbs and a range of anti-cancer 
agents, including MMP inhibitors, on invasion and motility, will be carried 
out.  
 
8. Further confirmation that Annexin A6 is the main target antigen of MAb 9E1 
can be determined though a competition assay. Western blots of cell lysates 
would be initially probed with MAb 9E1. Following treatment with this 
MAb, the blots would then be washed, and treated with a commercial 
Annexin A6 antibody. In theory, if the antibodies are recognising the same 
binding site (i.e. Annexin A6), this site will have been occupied following 
incubation of the blot with MAb 9E1. An appropriate 2° antibody against the 
commercial Annexin A6 antibody, (which does not react to MAb 9E1 24 (6)) 
theoretically should have little/no primary antibody to bind onto. 
Development of the blots should therefore reveal a much-reduced reactive 
band, if any, thus confirming that Annexin A6 is the target antigen of MAb 
9E1 24.  
 
9. Immunofluorescence assays involving MAb 7B7 competing with commercial 
anti-Ku antibodies for binding sites may also confirm if the Ku subunits are 
the target antigens for this MAb.  
 
10. To obtain a more complete understanding of the mechanisms of actions of 
each MAb (and exactly how they are blocking invasion), and their interacting 
proteins, it will be necessary to carry out a human phospho-kinase assay. This 
involves analysing the phosphorylation profiles of kinases and their protein 
substrates of cells, following treatment with 7B7 & 9E1. A Human Phospho-
Kinase Array Kit is available from R&D systems (Cat #: ARY003), which 
can detect the relative site-specific phosphorylation of 46 proteins.  
 
11. Immunoprecipitation assays using a commercial Annexin A6 antibody would 
determine if the prohibitin, Protein 14-3-3ε, ADT/ATP Translocases and 40S 
Ribosomal proteins are interacting with Annexin A6. 
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12. A wider immunohistochemical study of triple negative, HER2 positive, ER 
positive, ER negative, invasive and non-invasive breast tumours, should be 
carried out, in order to fully ascertain the expression pattern of Annexin A6 
in breast cancers, and to investigate any asociation with particular subsets of 
breast tumours (preliminary findings presented in this study in relation to 
HER2). The strong expression in colon and pancreatic tumours will need to 
be further investigated; the range of tumour types will have to be extended, 
and more extensive testing will need to be carried out on a range of normal 
tissues.  
 
13. Immunohistochemical studies and antigen retrieval techniques, with 7B7 will 
need to be optimised in order to investigate the expression levels of its target 
antigens in a panel of normal and tumour tissues.   
 
14. Levels of nuclear, versus cytoplasmic, Caveolin-1 in Annexin A6-silenced 
cells could be investigated, in order to test the hypothesis that incubation with 
MAb 9E1 results in de-compartmentalisation of caveolin-1 from the golgi 
complex. If this is found to be the case, then invasion assays on Caveolin-1 
silenced cells, in the presence of this MAb, could allow us to determine if the 
anti-invasive effects of 9E1 are a result of the release of caveolin-1.  
 
15. In vitro angiogenesis assays should be carried out in order to ascertain what 
effect, if any, both 7B7 and 9E1 have on the ability of cells to form new 
capillary blood vessels. HUVEC endothelial cells are standard model to use 
for this assay.  
 
16. The effects of both MAbs will need to be investigated in in vivo mouse 
models. Implanted tumours will be established with a fluorescent tag, and an 
in vivo fluorescent imager will follow the growth and metastatic spread of the 
cells. Other in vivo processes will be observed, such as angiogenesis, CDC 
and ADCC.  
 
   296 
17. MAbs that expressed strong reactivity with cancer cells in 
immunofluorescence assays, but gave no inhibition of invasion, could be 
investigated further as to any potential diagnostic use. 
 
18. As MAb 9E1 can inhibit the pro-invasive capability of Annexin A6 in 
numerous cell lines, it should prove useful in further defining its role in the 
invasion process. This MAb may also be useful in ascertaining if certain 
cancer types contain a pro- or anti-invasive copy of the Annexin A6 protein. 
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Appendix I 
 
1.  Ultrapure water 
 
Ultrapure water (UHP) was used in the preparation of all media and solutions. 
This water was purified to a standard of 12-18 MΩ/cm resistance by a reverse 
osmosis system (Millipore Mill-RO 10 Plus, Elastat UHP). 
 
2.  Glassware 
 
The solutions used in the various stages of cell culture were stored in sterile glass 
bottles. All sterile bottles and other glassware required for cell culture related 
applications were prepared as follows: glassware and lids were soaked in a 2% 
RBS- 25 (AGB Scientific) for 1 hour. After this time, they were cleansed and 
washed in an industrial dishwasher, using Neodisher detergent and rinsed twice 
with UHP. The resulting materials were sterilised by autoclaving. 
 
3.  Sterilisation procedures 
 
All thermostable solutions, water and glassware were sterilised by autoclaving at 
121°C for 20 minutes at 15 p.s.i. Thermolabile solutions were filtered through 
0.22 µm sterile filters (Millipore, Millex-GV SLGV025BS). Larger volumes (up 
to 10 litres) of thermolabile solutions were filter sterilised through a micro-
culture bell filter (Gelman, 12158). 
 
4.  Preparation of cell culture media 
 
Basal media used during cell culture was prepared as followed: 10X media 
(DMEM (Sigma, D5648) was added to sterile UHP water, buffered with HEPES 
and NaHCO3 as required and adjusted to a pH of 7.45-7.55 using sterile 1.5M 
HCl. The medium was then filtered through a sterile 0.22µm bell filters (Gelman, 
12158) and stored in sterile 500ml bottles at 4°C. Basal media were stored at 4°C 
for up to three months. The HEPES buffer was prepared by dissolving 23.8g of 
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HEPES in 80ml UHP water and this solution was then sterilised by autoclaving. 
Then 5ml sterile 5M NaOH was added to give a final volume autoclaving. 
Complete media was then prepared as described in Materials & Methods, Table 
2.2: supplements of 2mM l-glutamine (Gibco, 11140-0350) and 100mM sodium 
pyruvate (Gibco, 11360-035) were added as required. Complete media was 
stored for a maximum of one month. 
 
Sources of other types of media: 
• DMEM/Ham’s F12 1:1 = represented by ATCC in this project and 
produced in house 
• RPMI-1640 (made in house) 
• McCoy5A (Lonza; 12-688F) 
• Keratinocyte (Gibco, 17005) and supplements: 
o EGF (Epidermal Growth Factor supplement supplied as 25 µg 
stock (Gibco, 10450-013) 
o BPE (Bovine Pituitary Extract) supplement supplied as 25mg 
stock (Gibco, 13028-014) 
 
Hybridoma and SP2/O-Ag14 myeloma cells were grown in a basic basal medium 
of commercially available DMEM, DMEM with Glutamax I (Glutamax is L-
Amyl-L-Glutamine, high glucose concentration – 4.5mg (Gibco, 61965-026) 
supplemented with 10% heat inactivated FCS (Myoclone, Gibco, 10082-147). 
This was further supplemented for hybridoma growth and hybridoma cloning 
with 1% penicillin streptomycin and 5% briclone (Archport Ltd.). Briclone is a 
conditioned medium collected from a human cell line, for use in post fusion 
stages of hybridoma production and cloning, replacing the function of feeder 
cells. Sterility checks were performed on all bottles of media by inoculation of 
media samples on to Colombia blood agar (Oxoid, CM217), Sabauraud dextrose 
(Oxoid, CM217) and Thioglycolate broth (Oxoid, CM173). All sterility checks 
were then incubated at both 25°C and 37°C. These tests facilitated the detection 
of bacterial, yeast and fungal contamination. 
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5.  Monitoring of sterility of cell culture solutions 
 
Sterility testing was performed on all cell culture media and related culturing 
solutions. Samples of prepared basal media were incubated at 37°C for a period 
of seven days. This ensured that no bacterial or fungal contamination was present 
in the media. 
 
6.  Indirect staining procedure for Mycoplasma analysis. 
 
Mycoplasma-negative NRK (Normal rat kidney fibroblast) cells were used as 
indicator cells for this analysis. The cells were incubated with a sample volume 
of supernatant from the cell lines in question and the examined for mycoplasma 
contamination. A fluorescent Hoechst stain was used in the analysis. The stain 
binds specifically to DNA and so stains the nucleus of the cells in addition to any 
mycoplasma present. Mycoplasma infection was indicated by fluorescent bodies 
in the cytoplasm of the NRK cells. 
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Table 1: - NP/40 Lysis Buffer for immunopecipitation studies 
(Total Volume, 500mls; pH 8.5): 
  
Components Final Conc. 
425ml UHP - 
0.5% NP/40 2.5ml NP-40 
150mM NaCl 15ml 5M NaCl 
50mM Tris-HCl 25ml 1M Tris-HCL 
 
 
Table 2: - Lysis Buffer C for immunoprecipitation studies 
(Total Volume, 40mls; pH 8.5): 
 
Components Quantity 
7M Urea 16.8ml 
2M Thiourea 6g 
4% CHAPS 1.6g 
30mM Tris 0.1g 
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Table 3: - Buffers used for Silver Staining Procedure 
 
Buffer Component Volume 
MeOH  50ml 
24ml Glacial Acetic Acid 12ml 
Formalin 50µl 
Fixer (100ml) 
UHP 38ml 
EtOH 36ml Wash (100ml) 
UHP 64ml 
Na2S2O3 0.02g Sensitising (100ml) 
UHP 100ml 
AgNO3 0.2g 
Formalin 76µl 
Silver Nitrate (100ml) 
UHP 100ml 
Na2CO3 12g 
Formalin 100µl 
Sensitising Buffer 4ml 
Developer (200ml) 
UHP 196ml 
MeOH 50ml 
Glacial Acetic Acid 12ml 
Stop Solution 
UHP 38ml 
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Table 4.: - Antibodies used during the course of this work 
 
Primary Antibody Dilution  
β-actin (Monoclonal) 
 
1:10,000 A5441, Sigma 
α-Tubulin (Monoclonal) 1/1000 T6199, Sigma 
Annexin A6 (Polyclonal) 1/5000 ab52221, Abcam 
Ku70 (Polyclonal) 1/5000 ab10878, Abcam 
Ku80 (Monoclonal) 1/12,000 ab80592, Abcam 
Prohibitin (Monoclonal) 1/400 - 1/800 CP34, Calbiochem 
Protein 14-3-3 ε  
(Polyclonal) 
 NBP1-32695, Novis Biologicals 
Secondary Antibody Dilution  
Swine Anti-Rabbit HRP 1/2000 P0399, Dako 
Goat Anti-Mouse HRP 1/2000 P0447, Dako 
Goat Anti-Rabbit HRP 1/2000 P0448, Dako 
Swine Anti-Rabbit FITC 1/40 F0054, Dako 
Rabbit Anti-Mouse FITC 1/40 F0261, Dako 
 
Table 5: - List of siRNAs used during the course of this work 
 
Target Name Ambion Product I.D. 
Scrambled 4390843 
Kinesin AM4639 
Annexin A6 #1 s1397 
Annexin A6 #2 s1396 
Annexin A6 #3 s1395 
ATP dependent DNA Helicase 2 subunit 2 #1 s5455 
ATP dependent DNA Helicase 2 subunit 2 #2 s52594 
ATP dependent DNA Helicase 2 subunit 1 #1 s14952 
ATP dependent DNA Helicase 2 subunit 1 #2 s14953 
ATP dependent DNA Helicase 2 subunit 1 #3 s14954 
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Appendix II 
 
Protein Identification Results obtained with MAb 7B7 G5 (2) 
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P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
KU70_HUMAN RecName: Full=ATP-dependent DNA helicase 2 subunit 1;  
AltName: Full=ATP-dependent DNA helicase II 70 kDa subunit;  
AltName: Full=Lupus Ku autoantigen protein p70; Short=Ku70; AltName: Full=70 kDa subunit 
of Ku antigen; AltName: Full=Thyroid-lupu 1.23526E-09 50.23 5 (50000) 
 
 
 
69799.2 
976 R.QIILEKEETEELKR.F 1757.964355 0.002733136 2 CID 4.75974E-07 3.80 20/26 438.5 
1017 R.IM*LFTNEDNPHGNDSAK.A 1918.859967 0.001774869 2 CID 1.23526E-09 4.77 23/32 886.2 
1244 R.TFNTSTGGLLLPSDTKR.S 1807.954834 0.001512432 2 CID 4.40144E-08 3.71 18/32 620.9 
1540 K.KPGGFDISLFYR.D 1399.736816 4.75888E-05 2 CID 1.98974E-06 3.38 17/22 767.7 
1650 R.DSLIFLVDASK.A 1207.65686 -0.000318622 2 CID 3.27486E-05 3.02 17/20 1130.4 
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P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
KU70_HUMAN RecName: Full=ATP-dependent DNA helicase 2 subunit 1;  
AltName: Full=ATP-dependent DNA helicase II 70 kDa subunit;  
AltName: Full=Lupus Ku autoantigen protein p70; Short=Ku70; AltName: Full=70 kDa 
subunit of Ku antigen; AltName: Full=Thyroid-lupu 
2.33E-14 200.26 20 (20 0 0 0 0) 69799.2 
893 K.VEYSEEELKTHISK.G 1691.84863 0.00139 2 CID 3.00E-05 3.43 18/26 874.0 
1005 K.TEGDEEAEEEQEENLEASGDYK.
Y 
2500.99585 0.00273 2 CID 5.27E-12 4.10 23/42 473.2 
1011 R.QIILEKEETEELKR.F 1757.96436 -0.00192 3 CID 7.71E-09 3.11 23/52 704.4 
1038 R.IM*LFTNEDNPHGNDSAK.A 1918.85997 -0.00018 2 CID 1.37E-11 4.87 24/32 1119.8 
1249 R.TFNTSTGGLLLPSDTKR.S 1807.95483 -0.00020 2 CID 3.37E-09 4.14 18/32 651.6 
1282 R.SDSFENPVLQQHFR.N 1703.81360 0.00017 2 CID 1.23E-06 3.78 17/26 940.8 
1385 R.TFNTSTGGLLLPSDTK.R 1651.85376 -0.00081 2 CID 2.16E-07 4.06 24/30 1533.6 
1551 K.NIYVLQELDNPGAK.R 1573.82202 -0.00068 2 CID 1.22E-07 4.24 20/26 2294.1 
1576 R.DIISIAEDEDLR.V 1388.69031 -0.00142 2 CID 3.14E-07 3.36 19/22 1381.8 
1627 K.KPGGFDISLFYR.D 1399.73682 -0.00032 2 CID 3.01E-07 3.46 20/22 1649.4 
1651 R.DTGIFLDLM*HLK.K 1418.73481 -0.00039 2 CID 4.04E-06 3.25 18/22 1133.2 
1783 K.IISSDRDLLAVVFYGTEKDK.N 2269.20752 -0.00033 3 CID 5.96E-09 5.26 33/76 1804.4 
1836 R.NIPPYFVALVPQEEELDDQK.I 2344.17065 0.00151 2 CID 8.98E-07 2.77 20/38 339.4 
1844 R.DLLAVVFYGTEKDK.N 1597.84717 -0.00007 2 CID 1.02E-09 3.62 18/26 926.8 
1858 R.FDDPGLM*LM*GFKPLVLLK.K 2066.10647 0.00124 2 CID 1.53E-06 2.95 17/34 301.1 
1880 K.IISSDRDLLAVVFYGTEK.D 2026.08557 0.00078 2 CID 1.03E-09 4.43 24/34 2031.6 
1990 R.DLLAVVFYGTEK.D 1354.72534 -0.00056 2 CID 1.85E-07 3.09 18/22 1392.7 
1998 K.IQVTPPGFQLVFLPFADDKR.K 2288.24365 0.00273 2 CID 2.33E-14 4.55 23/38 919.0 
2003 R.NLEALALDLM*EPEQAVDLTLPK.V 2439.26872 0.00428 2 CID 2.01E-12 4.92 27/42 1185.2 
2133 K.IQVTPPGFQLVFLPFADDK.R 2132.14258 0.00249 2 CID 1.27E-13 4.71 28/36 1997.8 
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P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
KU70_HUMAN RecName: Full=ATP-dependent DNA helicase 2 subunit 1; AltName: Full=ATP-
dependent DNA helicase II 70 kDa subunit; AltName: Full=Lupus Ku autoantigen protein p70; 
Short=Ku70; AltName: Full=70 kDa subunit of Ku antigen; AltName: Full=Thyroid-lupu 
3.33E-10 130.21 13 (13 0 0 0 0) 69799.2 
275 K.IM*ATPEQVGK.M 1089.56087 -0.00016 2 CID 1.70E-04 2.64 14/18 698.9 
452 K.VEYSEEELKTHISK.G 1691.84863 0.00127 2 CID 6.30E-07 3.90 19/26 1433.5 
518 R.QIILEKEETEELKR.F 1757.96436 0.00151 2 CID 6.87E-08 3.69 16/26 394.4 
607 R.IM*LFTNEDNPHGNDSAK.A 1918.85997 -0.00019 3 CID 4.87E-05 3.83 27/64 607.5 
700 R.ILELDQFKGQQGQK.R 1631.87512 0.00249 2 CID 2.84E-06 3.54 19/26 1141.8 
738 K.KQELLEALTK.H 1172.68848 -0.00020 2 CID 3.82E-03 2.58 14/18 931.2 
772 R.TFNTSTGGLLLPSDTKR.S 1807.95483 0.00188 2 CID 2.71E-08 4.20 19/32 752.4 
783 R.SDSFENPVLQQHFR.N 1703.81360 0.00078 2 CID 3.33E-10 3.96 17/26 875.1 
961 R.ILELDQFK.G 1005.56152 -0.00056 2 CID 4.55E-04 2.47 12/14 502.7 
1039 K.NIYVLQELDNPGAK.R 1573.82202 0.00139 2 CID 1.33E-03 2.74 17/26 712.0 
1085 K.KPGGFDISLFYR.D 1399.73682 0.00066 2 CID 5.20E-06 3.01 17/22 744.6 
1120 R.DTGIFLDLM*HLK.K 1418.73481 0.00144 2 CID 8.57E-05 2.84 15/22 713.0 
1213 R.DSLIFLVDASK.A 1207.65686 0.00029 2 CID 8.85E-08 3.13 16/20 812.6 
527 R.YGSDIVPFSK.V 1112.56226 0.00005 2 CID 1.30E-05 2.27 15/18 781.7 
543 -.LTIGSNLSIR.- 1073.63135 -0.00020 2 CID 6.99E-05 2.18 13/18 357.0 
553 R.HIEIFTDLSSR.F 1317.67969 0.00078 2 CID 9.96E-05 3.56 17/20 980.2 
561 K.KDEKTDTLEDLFPTTK.I 1880.94873 0.00162 3 CID 2.07E-05 4.73 29/60 1671.5 
703 K.CFSVLGFCK.S 1117.51697 -0.00081 2 CID 2.10E-04 2.13 12/16 565.9 
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P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
KU86_HUMAN RecName: Full=ATP-dependent DNA helicase 2 subunit 2;  
AltName: Full=ATP-dependent DNA helicase II 80 kDa subunit;  
AltName: Full=Lupus Ku autoantigen protein p86; AltName: Full=86 kDa subunit of Ku 
antigen; AltName: Full=Ku86; AltName: Full=Ku80 
2.08E-07 30.21 3 (3 0 0 0 0) 82652.4 
1257 R.YGSDIVPFSK.V 1112.56226 0.00017 2 CID 9.87E-07 3.03 15/18 995.1 
1390 R.HIEIFTDLSSR.F 1317.67969 0.00066 2 CID 2.08E-07 3.16 17/20 1220.9 
1605 K.SQLDIIIHSLK.K 1266.74158 0.00066 2 CID 5.48E-06 3.11 16/20 1158.0 
 
 
      
P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
KU86_HUMAN RecName: Full=ATP-dependent DNA helicase 2 subunit 2;  
AltName: Full=ATP-dependent DNA helicase II 80 kDa subunit; 
 AltName: Full=Lupus Ku autoantigen protein p86;  
AltName: Full=86 kDa subunit of Ku antigen; AltName: Full=Ku86; AltName: Full=Ku80 
4.31E-12 90.25 9 (9 0 0 0 0) 125731 
445 K.EEASGSSVTAEEAKK.F 1522.72314 0.00102 2 CID 2.75E-08 3.84 19/28 1 
504 K.EEASGSSVTAEEAK.K 1394.62817 0.00041 2 CID 3.10E-08 3.53 23/26 1 
992 K.KKDQVTAQEIFQDNHEDGPTAK.K 2499.21094 0.00107 3 CID 4.31E-12 4.39 35/84 1 
1155 K.DQVTAQEIFQDNHEDGPTAK.K 2243.02100 0.00151 2 CID 5.76E-09 4.93 22/38 1 
1394 R.HIEIFTDLSSR.F 1317.67969 -0.00142 2 CID 3.13E-08 3.27 18/20 1 
1596 K.SQLDIIIHSLK.K 1266.74158 -0.00105 2 CID 1.14E-05 3.43 17/20 1 
1604 K.TDTLEDLFPTTK.I 1380.68933 -0.00044 2 CID 8.20E-07 3.37 18/22 1 
1694 K.KYAPTEAQLNAVDALIDSM*SLAK.K 2465.25922 -0.00265 3 CID 3.78E-07 4.04 30/88 1 
1816 K.YAPTEAQLNAVDALIDSM*SLAK.K 2337.16425 0.00132 2 CID 3.30E-11 4.54 25/42 1 
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P (pro) Score MW Peptide (Hits) 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Sp Ions 
KU86_HUMAN ATP-dependent DNA helicase 2 subunit 2 (ATP-dependent DNA helicase 
II 80 kDa subunit) (Lupus Ku autoantigen protein p86) (86 kDa subunit of Ku antigen) 
(Ku86) (Ku80) (Thyroid-lupus autoantigen) (TLAA) (CTC box-binding factor 85 kDa 
subunit) (CT 
1.11E-15 180.26 82652.4 18 (18 0 0 0 0) 
215 -.AFREEAIK.- 963.52582 -0.00014 2 CID 7.19E-03 2.60 617.6 12/14 
249 K.ALQEKVEIK.Q 1057.62524 -0.00068 2 CID 3.42E-03 2.89 780.5 13/16 
250 -.SQIPLSK.- 772.45636 0.00079 1 CID 9.09E-03 1.87 342.2 9/12 
263 R.HSIHWPCR.L 1092.51563 0.00005 2 CID 8.50E-06 2.55 606.5 13/14 
313 K.KVITM@FVQR.Q 1137.64488 0.00129 2 CID 9.30E-05 2.72 786.2 14/16 
318 K.KKDQVTAQEIFQDNHEDGPTAK.K 2499.21094 0.00455 3 CID 1.11E-15 5.20 1824.1 37/84 
324 -.KKDQVTAQEIFQDNHEDGPTAK.- 2499.21094 0.00112 4 CID 3.20E-05 4.10 750.2 41/126 
379 K.GITEQQKEGLEIVK.M 1571.86389 0.00188 2 CID 9.71E-07 3.96 1311.0 18/26 
396 R.LGGHGPSFPLK.G 1109.61023 -0.00020 2 CID 4.08E-05 2.85 693.7 15/20 
403 -.VITM@FVQR.- 1009.54991 -0.00061 2 CID 7.65E-04 2.23 468.1 12/14 
440 -.TWTVVDAK.- 919.48834 0.00092 1 CID 9.36E-03 1.91 337.6 10/14 
477 R.ANPQVGVAFPHIK.H 1377.76379 -0.00056 2 CID 8.46E-07 3.33 583.3 15/24 
523 R.LFQCLLHR.A 1086.58777 0.00005 2 CID 4.62E-03 2.45 911.8 12/14 
527 R.YGSDIVPFSK.V 1112.56226 0.00005 2 CID 1.30E-05 2.27 781.7 15/18 
543 -.LTIGSNLSIR.- 1073.63135 -0.00020 2 CID 6.99E-05 2.18 357.0 13/18 
553 R.HIEIFTDLSSR.F 1317.67969 0.00078 2 CID 9.96E-05 3.56 980.2 17/20 
561 K.KDEKTDTLEDLFPTTK.I 1880.94873 0.00162 3 CID 2.07E-05 4.73 1671.5 29/60 
703 K.CFSVLGFCK.S 1117.51697 -0.00081 2 CID 2.10E-04 2.13 565.9 12/16 
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P (pro) Score MW Peptide (Hits) 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Sp Ions 
ANXA6_HUMAN Annexin A6 (Annexin-6) (Annexin VI) (Lipocortin VI) (P68) (P70) (Protein III) 
(Chromobindin-20) (67 kDa calelectrin) (Calphobindin-II) (CPB-II) [MA 
3.41E-12 70.26 75825.7 7 (7 0 0 0 0) 
807 R.TNEQMHQLVAAYK.D 1532.75256 0.26384 2 CID 1.52E-08 4.11 1520.8 20/24 
1283 K.SLEDALSSDTSGHFR.R 1621.74524 1.40398 2 CID 4.16E-10 3.87 1413.0 21/28 
1623 -.SEIDLLNIR.- 1072.59973 -0.16138 1 CID 5.73E-04 1.83 230.5 9/16 
1627 R.DAFVAIVQSVK.N 1176.66235 1.24712 2 CID 3.50E-05 4.15 1849.3 17/20 
1667 R.DLEADIIGDTSGHFQK.M 1745.83411 0.36785 2 CID 3.41E-12 4.41 1629.3 23/30 
1874 - 1875 R.EDAQVAAEILEIADTPSGDK.T 2072.00293 0.49822 2 CID 1.28E-11 5.16 1648.1 23/38 
2055 K.WGTDEAQFIYILGNR.S 1782.88098 1.11882 2 CID 9.23E-10 4.66 2842.8 24/28 
 
 
      
P (pro) Score MW Peptide (Hits) 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Sp Ions 
ANXA6_HUMAN RecName: Full=Annexin A6; AltName: Full=Annexin-6; AltName: Full=Annexin 
VI; AltName: Full=Lipocortin VI; AltName: Full=p68; AltName: Full=p70; AltName: Full=Protein 
III; AltName: Full=Chromobindin-20; AltName: Full=67 kDa calelectrin; AltName 
4.79E-06 40.17 75825.7 4 (4 0 0 0 0) 
319 K.GAGTDEKTLTR.I 1148.59058 0.00066 2 CID 4.97E-05 3.40 755.1 16/20 
408 R.AINEAYKEDYHK.S 1480.70667 0.00176 2 CID 4.22E-05 3.01 499.6 14/22 
523 K.GTVRPANDFNPDADAK.A 1687.80347 0.00237 2 CID 6.12E-03 3.46 1099.6 19/30 
1289 K.ALLALCGGED.- 1018.48743 0.00079 1 CID 4.79E-06 2.06 386.0 10/18 
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P (pro) Score MW Peptide (Hits) 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Sp Ions 
ANXA6_HUMAN RecName: Full=Annexin A6; AltName: Full=Annexin-6; AltName: Full=Annexin 
VI; AltName: Full=Lipocortin VI; AltName: Full=p68; AltName: Full=p70; AltName: Full=Protein III; 
AltName: Full=Chromobindin-20; AltName: Full=67 kDa calelectrin; AltName 
1.10E-09 200.22 75825.7 20 (20 0 0 0 0) 
344 R.QRQEVCQSYK.S 1325.62671 0.00005 2 CID 6.62E-06 3.07 353.0 15/18 
358 K.GAGTDEKTLTR.I 1148.59058 0.00005 2 CID 6.28E-03 2.86 520.4 15/20 
495 R.AINEAYKEDYHK.S 1480.70667 0.00115 2 CID 1.04E-04 3.04 861.0 16/22 
544 K.M*TNYDVEHTIKK.E 1494.72571 0.00115 2 CID 1.76E-04 3.46 919.1 18/22 
579 K.TTGKPIEASIR.G 1172.66333 -0.00044 2 CID 6.05E-04 2.37 377.2 15/20 
629 K.MTNYDVEHTIKK.E 1478.73083 0.00090 2 CID 7.91E-04 3.39 1264.9 18/22 
669 K.M*TNYDVEHTIK.K 1366.63074 0.00090 2 CID 1.87E-05 3.32 561.2 15/20 
672 R.TNEQM*HQLVAAYK.D 1548.74750 0.00071 2 CID 9.82E-05 3.39 741.0 18/24 
676 K.GTVRPANDFNPDADAK.A 1687.80347 0.00115 2 CID 4.25E-07 3.95 1199.9 20/30 
889 K.EIKDAISGIGTDEK.C 1475.75879 0.00090 2 CID 2.14E-06 2.64 378.2 16/26 
1141 R.LIVGLM*RPPAYCDAK.E 1719.89210 0.00175 2 CID 3.91E-04 2.66 163.8 13/28 
1196 K.SLHQAIEGDTSGDFLK.A 1717.83911 0.00078 2 CID 5.52E-07 4.44 1614.1 21/30 
1213 K.SLEDALSSDTSGHFR.R 1621.74524 0.00090 2 CID 1.10E-09 3.72 1378.0 21/28 
1282 R.SELDM*LDIR.E 1107.53505 -0.00034 2 CID 4.81E-03 3.23 1173.3 14/16 
1409 K.DLIADLK.Y 787.45599 0.00031 1 CID 2.30E-03 2.42 584.9 10/12 
1559 K.ALLALCGGED.- 1018.48743 0.00079 1 CID 5.33E-07 3.09 550.0 12/18 
1605 -.LVFDEYLK.- 1026.55066 0.00110 1 CID 2.44E-03 2.10 803.8 10/14 
1629 -.SEIDLLNIR.- 1072.59973 -0.00068 2 CID 9.03E-03 2.58 514.2 13/16 
1670 R.DAFVAIVQSVK.N 1176.66235 0.00017 2 CID 9.89E-06 3.48 1540.5 16/20 
1698 K.ALIEILATR.T 999.61969 -0.00081 2 CID 1.96E-03 2.75 850.5 14/16 
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P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
1433E_HUMAN RecName: Full=14-3-3 protein epsilon; Short=14-3-
3E 
  3.80E-07 20.17 2 (2 0 0 0 0) 29155.4 
1198 R.YLAEFATGNDRK.E 1384.68555 -0.00020 2 CID 3.80E-07 3.13 17/22 1095.8 
1300 K.VAGM*DVELTVEER.N 1463.70464 0.00073 2 CID 1.67E-05 3.39 19/24 1194.0 
 
 
      
P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
1433B_PONAB 14-3-3 protein beta/alpha 
    1.14E-08 28.21 3 (2 1 0 0 0) 28064.8 
450 K.AVTEQGHELSNEER.N 1598.74048 -0.00020 2 CID 1.14E-08 4.24 19/26 1464.2 
517 -.VISSIEQK.- 903.51459 -0.00024 1 CID 2.48E-04 1.74 10/14 423.0 
621 R.YLSEVASGDNK.Q 1182.56372 -0.00166 2 CID 3.19E-04 2.93 16/20 770.8 
 
 
      
P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
gi|52000883|sp|P63102.1|1433Z_RAT RecName: Full=14-3-3 protein zeta/delta; 
AltName: Full=Protein kinase C inhibitor protein 1; Short=KCIP-1; AltName: 
Full=Mitochondrial import stimulation factor S1 subunit 
3.68E-06 20.17 2 (2 0 0 0 0) 27753.7 
984 R.YLAEVAAGDDKK.G 1279.65283 -0.00068 2 CID 8.11E-06 3.33 18/22 1408.6 
1006 K.SVTEQGAELSNEER.N 1548.71362 0.00041 2 CID 3.68E-06 3.22 18/26 1104.1 
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P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
1433E_HUMAN RecName: Full=14-3-3 protein epsilon; Short=14-3-
3E 
  1.27E-09 30.21 3 (3 0 0 0 0) 29155.4 
774 R.IISSIEQKEENK.G 1417.75330 0.00054 2 CID 5.05E-05 3.44 18/22 1146.8 
1138 K.VAGM*DVELTVEER.N 1463.70464 -0.00085 2 CID 1.27E-09 4.11 18/24 1397.6 
1219 R.YLAEFATGNDR.K 1256.59058 -0.00081 2 CID 1.38E-05 2.75 15/20 896.4 
 
 
 
      
P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
1433E_HUMAN 14-3-3 protein epsilon (14-3-3E)    1.15E-06 10.19 1 (1 0 0 0 0) 29155.4 
1390 K.VAGM*DVELTVEER.N 1463.70464 0.00147 2 CID 1.15E-06 3.87 20/24 1797.9 
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P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
ADT1_HUMAN ADP/ATP translocase 1 (Adenine nucleotide translocator 1) (ANT 1) 
(ADP,ATP carrier protein 1) (Solute carrier family 25 member 4) (ADP,ATP carrier protein, 
heart/skeletal muscle isoform T1)  
4.21E-07 20.14 2 (2 0 0 0 0) 33043.2 
1246 K.LLLQVQHASK.Q 1136.67859 -0.00032 2 CID 9.33E-04 2.80 15/18 1134.7 
1597 R.AAYFGVYDTAK.G 1205.58374 -0.00154 2 CID 4.21E-07 2.63 16/20 1040.1 
 
ADT2_HUMAN RecName: Full=ADP/ATP translocase 2; AltName:  
Full=Adenine nucleotide translocator 2;  
Short=ANT 2; AltName: Full=ADP,ATP carrier protein 2;  
AltName: Full=Solute carrier family 25 member 5;  
AltName: Full=ADP,ATP carrier protein, fibroblast isofo 
8.53E-07 30.21 3 (3 0 0 0 0) 32874.2 
1246 K.LLLQVQHASK.Q 1136.67859 -0.00032 2 CID 9.33E-04 2.80 15/18 1134.7 
1691  R.AAYFGIYDTAK.G 1219.59937 -0.00056 2 CID 1.55E-04 2.66 16/20 1124.9 
1897  K.DFLAGGVAAAISK.T 1219.66809 -0.00032 2 CID 8.53E-07 4.14 21/24 2681.7 
 
ADT3_HUMAN RecName: Full=ADP/ATP translocase 3; AltName:  
Full=Adenine nucleotide translocator 2;  
AltName: Full=ANT 3; AltName: Full=ADP,ATP carrier protein 3;  
AltName: Full=Solute carrier family 25 member 6;  
AltName: Full=ADP,ATP carrier protein, isoform  
4.21E-07 20.14 2 (2 0 0 0 0) 32845.2 
1246 K.LLLQVQHASK.Q 1136.67859 -0.00032 2 CID 9.33E-04 2.80 15/18 1134.7 
1597 R.AAYFGVYDTAK.G 1205.58374 -0.00154 2 CID 4.21E-07 2.63 16/20 1040.1 
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P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
ADT1_HUMAN ADP/ATP translocase 1 (Adenine nucleotide translocator 1) (ANT 1) 
(ADP,ATP carrier protein 1) (Solute carrier family 25 member 4) (ADP,ATP carrier protein, 
heart/skeletal muscle isoform T1)  
6.20E-09 20.16 2 (2 0 0 0 0) 33043.2 
868 K.LLLQVQHASK.Q 1136.67859 -0.00068 2 CID 1.79E-04 2.66 13/18 695.0 
1769 R.YFPTQALNFAFK.D 1446.74158 0.00005 2 CID 6.20E-09 3.29 19/22 842.7 
ADT2_HUMAN RecName: Full=ADP/ATP translocase 2; AltName: Full=Adenine nucleotide 
translocator 2; Short=ANT 2; AltName: Full=ADP,ATP carrier protein 2; AltName: 
Full=Solute carrier family 25 member 5; AltName: Full=ADP,ATP carrier protein, fibroblast 
isofo 
6.20E-09 20.16 2 (2 0 0 0 0) 32874.2 
868 K.LLLQVQHASK.Q 1136.67859 -0.00068 2 CID 1.79E-04 2.66 13/18 695.0 
1769 R.YFPTQALNFAFK.D 1446.74158 0.00005 2 CID 6.20E-09 3.29 19/22 842.7 
ADT3_HUMAN RecName: Full=ADP/ATP translocase 3; AltName: Full=Adenine nucleotide 
translocator 2; AltName: Full=ANT 3; AltName: Full=ADP,ATP carrier protein 3; AltName: 
Full=Solute carrier family 25 member 6; AltName: Full=ADP,ATP carrier protein, isoform  
6.20E-09 20.16 2 (2 0 0 0 0) 32845.2 
868 K.LLLQVQHASK.Q 1136.67859 -0.00068 2 CID 1.79E-04 2.66 13/18 695.0 
1769 R.YFPTQALNFAFK.D 1446.74158 0.00005 2 CID 6.20E-09 3.29 19/22 842.7 
 
 
      
P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
gi|113459|sp|P05141.6|ADT2_HUMAN RecName: Full=ADP/ATP translocase 2; AltName: 
Full=Adenine nucleotide translocator 2 
8.53E-07 30.21 3 (3 0 0 0 0) 32874.2 
1246 K.LLLQVQHASK.Q 1136.67859 -0.00032 2 CID 9.33E-04 2.80 15/18 1134.7 
1691 R.AAYFGIYDTAK.G 1219.59937 -0.00056 2 CID 1.55E-04 2.66 16/20 1124.9 
1897 K.DFLAGGVAAAISK.T 1219.66809 -0.00032 2 CID 8.53E-07 4.14 21/24 2681.7 
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P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
ADT1_HUMAN RecName: Full=ADP/ATP translocase 1; AltName: Full=Adenine nucleotide 
translocator 1; Short=ANT 1; AltName: Full=ADP,ATP carrier protein 1; AltName: 
Full=Solute carrier family 25 member 4; AltName: Full=ADP,ATP carrier protein, 
heart/skeletal m 
4.74E-09 28.19 3 (2 1 0 0 0) 33043.2 
1467 R.AAYFGVYDTAK.G 1205.58374 -0.00178 2 CID 2.64E-06 2.58 16/20 1155.2 
2017 R.YFPTQALNFAFK.D 1446.74158 -0.00056 2 CID 4.74E-09 2.93 18/22 740.2 
2111 -.GM*GGAFVLVLYDEIKK.- 1755.93497 0.00001 2 CID 3.64E-07 3.74 18/30 855.5 
          
ADT3_HUMAN RecName: Full=ADP/ATP translocase 3; AltName: Full=Adenine nucleotide 
translocator 2; AltName: Full=ANT 3; AltName: Full=ADP,ATP carrier protein 3; AltName: 
Full=Solute carrier family 25 member 6; AltName: Full=ADP,ATP carrier protein, isoform  
3.64E-07 20.19 2 (2 0 0 0 0) 32845.2 
1932 K.DFLAGGIAAAISK.T 1233.68372 -0.00056 2 CID 1.41E-05 3.45 20/24 2304.9 
2111 R.GM*GGAFVLVLYDELKK.V 1755.93497 0.00001 2 CID 3.64E-07 3.74 18/30 855.5 
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P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
gi|464371|sp|P35232|PHB_HUMAN Prohibitin    5.12E-10 70.25 7 (7 0 0 0 0) 29785.9 
1053 R.NVPVITGSK.D 914.53058 0.00067 1 CID 5.35E-04 1.82 11/16 401.6 
1601 R.IFTSIGEDYDER.V 1444.65906 -0.00020 2 CID 2.72E-08 3.11 19/22 1095.5 
1609 K.DLQNVNITLR.I 1185.65857 -0.00081 2 CID 6.93E-05 3.31 16/18 1429.0 
1662 R.FDAGELITQR.E 1149.58984 -0.00239 2 CID 1.44E-06 3.36 17/18 1993.8 
1704 R.ILFRPVASQLPR.I 1396.84229 -0.00100 3 CID 5.41E-04 3.11 21/44 382.3 
1785 R.KLEAAEDIAYQLSR.S 1606.84351 -0.00166 2 CID 5.12E-10 5.10 23/26 3017.1 
2349 K.FGLALAVAGGVVNSALYN
VDAGHR.A 
2371.25171 0.00107 3 CID 9.54E-08 4.84 34/92 982.0 
 
 
 
 
      
P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
gi|464371|sp|P35232.1|PHB_HUMAN RecName: Full=Prohibitin   3.01E-11 60.28 6 (6 0 0 0 0) 29785.9 
944 K.AAIISAEGDSK.A 1061.54736 0.95806 2 CID 1.29E-06 2.73 15/20 661.4 
1027 R.NVPVITGSK.D 914.53058 0.00061 1 CID 4.92E-04 2.10 12/16 472.6 
1581 K.DLQNVNITLR.I 1185.65857 -0.00081 2 CID 1.22E-04 3.11 15/18 1113.5 
1614 R.FDAGELITQR.E 1149.58984 -0.00252 2 CID 4.16E-07 3.30 16/18 1550.6 
1752 R.KLEAAEDIAYQLSR.S 1606.84351 0.00054 2 CID 5.86E-08 5.56 24/26 3424.7 
2191 K.FGLALAVAGGVVNSALYN
VDAGHR.A 
2371.25171 0.00016 3 CID 3.01E-11 4.68 35/92 1251.8 
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P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
PHB_HUMAN RecName: Full=Prohibitin     2.27E-07 20.18 2 (2 0 0 0 0) 29785.9 
846 K.AAIISAEGDSK.A 1061.54736 -0.00012 1 CID 2.27E-07 2.00 11/20 176.7 
1551 R.FDAGELITQR.E 1149.58984 -0.00130 2 CID 4.59E-06 3.51 17/18 1764.5 
 
      
P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
PHB_HUMAN Prohibitin     5.12E-10 70.25 7 (7 0 0 0 0) 29785.9 
1053,  R.NVPVITGSK.D 914.53058 0.00067 1 CID 5.35E-04 1.82 11/16 401.6 
1601,  R.IFTSIGEDYDER.V 1444.65906 -0.00020 2 CID 2.72E-08 3.11 19/22 1095.5 
1609,  K.DLQNVNITLR.I 1185.65857 -0.00081 2 CID 6.93E-05 3.31 16/18 1429.0 
1662,  R.FDAGELITQR.E 1149.58984 -0.00239 2 CID 1.44E-06 3.36 17/18 1993.8 
1704,  R.ILFRPVASQLPR.I 1396.84229 -0.00100 3 CID 5.41E-04 3.11 21/44 382.3 
1785,  R.KLEAAEDIAYQLSR.S 1606.84351 -0.00166 2 CID 5.12E-10 5.10 23/26 3017.1 
2349,  K.FGLALAVAGGVVNSALYNV
DAGHR.A 
2371.25171 0.00107 3 CID 9.54E-08 4.84 34/92 982.0 
 
      
P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
PHB_HUMAN RecName: Full=Prohibitin     1.27E-10 60.26 6 (6 0 0 0 0) 29785.9 
892 R.NVPVITGSK.D 914.53058 0.00012 1 CID 8.56E-05 2.22 12/16 522.2 
1466 R.IFTSIGEDYDER.V 1444.65906 -0.00191 2 CID 6.82E-09 3.14 19/22 1123.3 
1525 R.FDAGELITQR.E 1149.58984 -0.00154 2 CID 8.86E-06 3.21 16/18 1634.3 
1659 R.KLEAAEDIAYQLSR.S 1606.84351 -0.00252 2 CID 1.27E-10 5.10 23/26 3066.7 
2089 K.AAELIANSLATAGDGLIELR.K 1998.08655 0.00054 2 CID 7.58E-09 5.03 27/38 2354.4 
2149 R.NITYLPAGQSVLLQLPQ.- 1855.03235 0.00041 2 CID 9.63E-05 3.33 17/32 688.4 
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P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
gi|50401474|sp|Q76MY1|RS4X_MACFU 40S ribosomal protein S4, X isoform 1.29E-12 70.20 7 (7 0 0 0 0) 29579.1 
827 K.DANGNSFATR.L 1052.47559 0.98406 2 CID 2.80E-05 2.21 15/18 853.7 
968 K.YALTGDEVKK.I 1123.59937 -0.00130 2 CID 1.03E-05 2.69 15/18 1086.0 
1130 K.GIPHLVTHDAR.T 1215.65930 -0.00032 2 CID 8.27E-07 2.51 15/20 648.4 
1203 R.ERHPGSFDVVHVK.D 1506.78113 0.00139 2 CID 3.73E-06 2.95 15/24 377.7 
1620 K.VNDTIQIDLETGK.I 1445.74817 -0.00056 2 CID 2.85E-06 4.00 19/24 1638.1 
1838 R.LSNIFVIGK.G 990.59827 -0.00026 2 CID 2.15E-05 3.36 14/16 1340.0 
1974 R.TDITYPAGFM*DVISIDK.T 1901.92011 0.00133 2 CID 1.29E-12 3.63 22/32 740.8 
 
gi|133948|sp|P22090|RS4Y1_HUMAN 40S ribosomal protein S4, Y isoform 1  8.27E-07 40.20 4 (4 0 0 0 0) 29437.0 
827 K.DANGNSFATR.L 1052.47559 0.98406 2 CID 2.80E-05 2.21 15/18 853.7 
968 K.YALTGDEVKK.I 1123.59937 -0.00130 2 CID 1.03E-05 2.69 15/18 1086.0 
1130 K.GIPHLVTHDAR.T 1215.65930 -0.00032 2 CID 8.27E-07 2.51 15/20 648.4 
1203 R.ERHPGSFDVVHVK.D 1506.78113 0.00139 2 CID 3.73E-06 2.95 15/24 377.7 
 
gi|27805713|sp|Q8TD47|RS4Y2_HUMAN 40S ribosomal protein S4, Y isoform 2  8.27E-07 30.13 3 (3 0 0 0 0) 29276.9 
827 K.DANGNSFATR.L 1052.47559 0.98406 2 CID 2.80E-05 2.21 15/18 853.7 
968 K.YALTGDEVKK.I 1123.59937 -0.00130 2 CID 1.03E-05 2.69 15/18 1086.0 
1130 K.GIPHLVTHDAR.T 1215.65930 -0.00032 2 CID 8.27E-07 2.51 15/20 648.4 
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P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
gi|417719|sp|P23396.2|RS3_HUMAN RecName: Full=40S ribosomal protein S3 1.75E-07 30.16 3 (3 0 0 0 0) 26671.4 
1062 K.GGKPEPPAM*PQPVPTA.- 1589.79920 0.00004 2 CID 7.45E-04 3.09 15/30 358.4 
1231 K.KPLPDHVSIVEPK.D 1458.83154 0.00005 2 CID 6.03E-06 3.19 19/24 1101.0 
1518 K.DEILPTTPISEQK.G 1470.76868 -0.00044 2 CID 1.75E-07 2.75 19/24 684.8 
 
 
 
      
P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
RS4Y1_HUMAN 40S ribosomal protein S4, Y isoform 1   8.27E-07 40.20 4 (4 0 0 0 0) 29437.0 
827,  K.DANGNSFATR.L 1052.47559 0.98406 2 CID 2.80E-05 2.21 15/18 853.7 
968,  K.YALTGDEVKK.I 1123.59937 -0.00130 2 CID 1.03E-05 2.69 15/18 1086.0 
1130,  K.GIPHLVTHDAR.T 1215.65930 -0.00032 2 CID 8.27E-07 2.51 15/20 648.4 
1203,  R.ERHPGSFDVVHVK.D 1506.78113 0.00139 2 CID 3.73E-06 2.95 15/24 377.7 
          
RS4Y2_HUMAN 40S ribosomal protein S4, Y isoform 2   8.27E-07 30.13 3 (3 0 0 0 0) 29276.9 
827,  K.DANGNSFATR.L 1052.47559 0.98406 2 CID 2.80E-05 2.21 15/18 853.7 
968,  K.YALTGDEVKK.I 1123.59937 -0.00130 2 CID 1.03E-05 2.69 15/18 1086.0 
1130,  K.GIPHLVTHDAR.T 1215.65930 -0.00032 2 CID 8.27E-07 2.51 15/20 648.4 
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P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
RS3_HUMAN RecName: Full=40S ribosomal protein S3  4.96E-13 60.26 6 (6 0 0 0 0) 26671.4 
1077 K.KPLPDHVSIVEPK.D 1458.83154 -0.00178 2 CID 3.03E-07 3.40 19/24 1029.1 
1215 R.ELAEDGYSGVEVR.V 1423.66992 0.00005 2 CID 1.24E-08 3.41 20/24 2014.6 
1396 K.DEILPTTPISEQK.G 1470.76868 -0.00203 2 CID 6.85E-06 2.73 20/24 839.3 
1495 K.KPLPDHVSIVEPKDEILPTTPISEQK.G 2910.58228 -0.00076 3 CID 2.41E-11 4.84 30/100 786.2 
1790 K.FVDGLM*IHSGDPVNYYVDTAVR.H 2484.18639 -0.00093 3 CID 4.96E-13 5.13 36/84 1552.0 
1799 R.FGFPEGSVELYAEK.V 1572.75806 -0.00142 2 CID 6.32E-12 3.07 20/26 860.0 
RS4X_MACFU RecName: Full=40S ribosomal protein S4, X isoform 3.16E-12 20.18 2 (2 0 0 0 0) 29579.1 
1041 R.ERHPGSFDVVHVK.D 1506.78113 -0.00093 2 CID 1.58E-07 3.13 16/24 435.0 
1862 R.TDITYPAGFM*DVISIDK.T 1901.92011 0.00157 2 CID 3.16E-12 3.67 24/32 947.5 
 
 
      
P (pro) Score Peptide (Hits) MW 
Scan(s) Peptide MH+ DeltaM z Type P (pep) XC Ions Sp 
RS4X_MACFU RecName: Full=40S ribosomal protein S4, X isoform 4.56E-05 20.14 2 (2 0 0 0 0) 29579.1 
800 K.YALTGDEVKK.I 1123.59937 -0.00130 2 CID 3.12E-04 2.19 16/18 1098.4 
1691 R.TDITYPAGFM*DVISIDK.T 1901.92011 0.00084 2 CID 4.56E-05 2.87 17/32 385.2 
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Protein Name Gene 
Symbol 
Protein AC 
Number 
MW 
(kDa) 
Myosin 10 MYH10 gi| 215274129| 228.9 
Myosin 11 MYH11 gi| 13432177| 228 
Myosin 9 MYH9 gi| 6166599| 226.5 
Heat Shock 90, Beta HSP90AB1 gi| 39644662| 83.26 
Lamin A/C LMNA gi| 55957499| 79.39 
Heat Shock 70, Protein 5 HSPA5 gi| 86577744| 72.33 
Heat Shock 70, Protein 8 HSPA8 gi| 48257068| 70.89 
Annexin A1 ANXA1 gi| 197692503| 69.97 
HnRP Q SYNCRIP gi| 56204904| 69.63 
Elongation factor 1-alpha 1 EF1A1 gi| 55584035| 50.1 
Annexin A2 ANXA2 gi| 62202495| 50.1 
HnRP G RBMX gi| 14279350| 42.33 
Actin - α ACTA1 gi| 49456549| 42 
Β - Actin ACTB gi| 4501885| 41.73 
HnRP A1  HNRPA1L3 gi| 190360152| 38.74 
HnRP A2/B1 HNRPA2B1 gi| 14043072| 37.43 
60S Ribosomal Protein-L7 RPL7 gi|133021| 29.22 
Filaggrin-2 FLG2 gi| 62122917| 24.8 
Histone H1.5 HIST1H1B gi| 19856407| 22.58 
Histone H1.3 HIST1H1D gi| 121925| 22.35 
Histone H1.1 HIST1H1A gi| 18202479| 21.84 
S100-A9 S100A9 gi| 49457442| 13.24 
 
Table 6: - Proteins identified from excised bands immunoprecipitated with 
MAb 7B7 G5 (2), MAb 9E1 24 (6), and the IgG and IgM negative controls, 
through mass spectrometry. The above proteins were as such disregarded 
for further characterisation.  
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Appendix IV 
 
Densitometry Histograms of Western Blot Analysis of siRNA transfected Cells 
 
 
 
 
Figure 1: - A representative SDS-PAGE gel showing equal loading of cell 
lysates (10µg loaded per lane).  
 
A. MiaPaCa-2 clone 3;    B. MiaPaCa-2 clone 3 Matrigel; 
C. MiaPaCa-2 clone 3 Membrane;   D. MiaPaCa-2 clone 8;  
E. MiaPaCa-2 clone 8 Membrane;   F. Lox IMVI;  
G. MDA-MB-435 Membrane;   H. SK-Mel 28 Membrane;  
I. WM-115;      J. WM-266-4;  
A B C D E F G H I J 
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Figure 2: - A representative SDS-PAGE gel showing equal loading of cell 
lysates (10µg loaded per lane).  
 
K. DLKP;      L. DLKP-A;  
M. DLKP-SQ;     N. DLKP-I;  
O. DLKP-M;      P. H1299;  
Q. SNB-19;      R. C/68;  
S. HCT-116;      T. HCT-116 (20ug) 
K L M N O P Q R S T 
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Appendix V 
 
Densitometry Histograms of Western Blot Analysis of siRNA transfected Cells 
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Figure 3: - Representative histogram showing the level of Annexin A6 
knockdown in MiaPaCa-2 clone 3 cells following transfection by a nonsense 
control siRNA (Scrambled), and 2 siRNAs targeting the Annexin A6 protein 
(Anx6 A & Anx6 B). Expression levels were normalised with α-tubulin (not 
shown). Data shown is mean ± standard deviation (n = 3). 
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Figure 4: - Representative histogram showing the level of Annexin A6 
knockdown in DLKP-M cells following transfection by a nonsense control 
siRNA (Scrambled), and 2 siRNAs targeting the Annexin A6 protein (Anx6 A & 
Anx6 B). Expression levels were normalised with α-tubulin (not shown). Data 
shown is mean ± standard deviation (n = 3). 
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Figure 5: - Representative histogram showing the level of Ku70 knockdown in 
MiaPaCa-2 clone 3  cells following transfection by a nonsense control siRNA 
(Scrambled), and 2 siRNAs targeting the Ku70 protein (Ku70 A & Ku70 B). 
Expression levels were normalised with α-tubulin (not shown). Data shown is 
mean ± standard deviation (n = 3). 
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Figure 6: - Representative histogram showing the level of Ku70 knockdown in 
DLKP-M cells following transfection by a nonsense control siRNA (Scrambled), 
and 2 siRNAs targeting the Ku70 protein (Ku70 A & Ku70 B). Expression levels 
were normalised with α-tubulin (not shown). Data shown is mean ± standard 
deviation (n = 3). 
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Figure 7: - Representative histogram showing the level of Ku80 knockdown in 
MiaPaCa-2 clone 3  cells following transfection by a nonsense control siRNA 
(Scrambled), and 2 siRNAs targeting the Ku80 protein (Ku80 A & Ku80 C). 
Expression levels were normalised with α-tubulin (not shown). Data shown is 
mean ± standard deviation (n = 3). 
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Figure 8: - Representative histogram showing the level of Ku80 knockdown in 
DLKP-M  cells following transfection by a nonsense control siRNA 
(Scrambled), and 2 siRNAs targeting the Ku80 protein (Ku80 A & Ku80 C). 
Expression levels were normalised with α-tubulin (not shown). Data shown is 
mean ± standard deviation (n = 3). 
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Appendix VI 
 
Complete Zymograpgy Gel showing effect of MAbs on MMP-9 activity in the 
MDA-MB-231 breast cell line. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: - Graph and zymography gel showing effect of MAb 7B7 G5 (2) and 
MAb 9E1 24 (6) on MMP-9 activity in the MDA-MB-231 breast cell line. Cells 
incubated with both MAbs show a decrease in the activity of MMP-9 when 
compared to control hybridoma medium (no MAb) representing normal MMP-9 
activity.  
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